ANTICANCER RESEARCH
International Journal of Cancer Research and Treatment
ISSN (print): 0250-7005; ISSN (online): 1791-7530

VOLUME 31
2011

Editorial Board

B. B. Aggarwal	Cytokine Research Laboratory, Department of Experimental Therapeutics, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA
J. P. Armand	Institut Claudius Regaud, Toulouse, France
V. I. Avramis	Division of Hematology/Oncology, Childrens Hospital, Los Angeles, CA, USA
R. C. Bast	Department of Translational Research, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA
G. Bauer	Abteilung Virologie, Institut für Medizinische Mikrobiologie und Hygiene, Universität Freiburg, Germany
E. E. Baulieu	INSERM U488 and College de France, Le Kremlin-Bicetre, France
Y. Becker	Department of Biochemistry, Faculty of Medicine, Hebrew University of Jerusalem, Ein Kerem, Jerusalem, Israel
E. J. Benz, Jr.	Dana-Farber Cancer Institute, Boston, MA, USA
J. Bergh	Department of Clinical and Molecular Medicine, Radiumhemmet, Karolinska Institute, Stockholm, Sweden
D. D. Bigner	Department of Pathology, Duke University Medical Center, Durham, NC, USA
A. Böcking	Institute for Cytopathology, University of Düsseldorf, Germany
G. Bonadonna	Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano, Italy
F. T. Bosman	Institute of Pathology, University of Lausanne, Switzerland
G. Broich	Gruppo Policlinico di Monza, Monza, Italy
J. M. Brown	Department of Radiation Oncology, Stanford Medical Center, Stanford, CA, USA
Ø. S. Bruland	Department of Medical Oncology-Radiotherapy, Norwegian Radium Hospital, Oslo, Norway
M. M. Burger	Novartis, Basel, Switzerland
M. Carbone	Cancer Research Center of Hawaii, Honolulu, HI, USA
J. Carlsson	Department of Biomedical Radiation Sciences, Uppsala University, Sweden
A. F. Chambers	Department of Oncology, London Regional Cancer Center, London, Ontario, Canada
P. Chandra	Abt. für Molekularbiologie, Klinikum Wolfgang Goethe-Universität, Frankfurt am Main, Germany
L. Cheng	Department of Pathology, Indiana University School of Medicine, Indianapolis, IN, USA
J.-G. Chung	Department of Biological Science and Technology, China Medical University, Taichung, Taiwan, ROC
E. De Clercq	Rega Institute for Medical Research, Katholieke Universiteit Leuven, Belgium
W. De Loecker	Department of Biochemistry, Katholieke Universiteit Leuven, Belgium
W. Den Otter	VUMC, Department of Urology, Amsterdam, The Netherlands
E. P. Diamandis	Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada
G. Th. Diamandopoulos	Department of Pathology, Harvard Medical School, Boston, MA, USA
W. Ebert	Thoraxclinic HD-Rohrbach, Heidelberg, Germany
J. A. Fernandez-Pol	Metalloproteomics, LLC, Chesterfield, MO, USA
I. J. Fidler	Department of Cancer Biology, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA
G. Gabbiani	Department of Pathology, University of Geneva, Switzerland
R. Ganapathi	Department of Clinical Pharmacology, Taussing Cancer Center, Cleveland Clinic Foundation, Cleveland, OH, USA
A. F. Gazdar	Hamon Center for Therapeutic Oncology Research, University of Texas Southeastern Medical Center, Dallas, TX, USA
A. Giordano	Sbarro Institute for Cancer Research, Temple University, Philadelphia, PA, USA
G. Gitsch	Department of Gynecology and Obstetrics, University of Freiburg, Germany
R. H. Goldfarb	Sopherion Therapeutics, Inc., Princeton, NJ, USA
J. W. Gorrod	Toxicology Unit, John Tabor Laboratories, University of Essex, Colchester, Essex, UK
S. Hammarström	Department of Immunology, University of Umeä, Sweden
I. Hart	Centre for Tumour Biology, Institute of Cancer and CR-UK Clinical Centre, Bart's and The London, Queen Mary's School of Medicine and Dentistry, London, UK
I. Hellström	Harborview Medical Center, Seattle, WA, USA
L. Helson	Sign Path Pharma, Inc., Quakertown, PA, USA
R. B. Herberman	Intrexon Corporation, Germantown, MD, USA
R. M. Hoffman	Department of Surgery, University of California, San Diego, CA, USA

C. G. Ioannides	Department of Gynecology, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA
S. C. Jhanwar	Laboratory of Solid Tumor Genetics, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
J. V. Johannessen	Department of Pathology, The Norwegian Radium Hospital, Oslo, Norway
B. Kaina	Institute of Toxicology, University of Mainz, Germany
B. K. Keppler	School of Medicine, University of Vienna, Austria
D. G. Kieback	Department of Obstetrics and Gynecology, Elblandklinikum Riesa, Riesa (Dresden), Germany
R. Klapdor	Medical Clinic, University of Hamburg, Germany
U. R. Kleeberg	Hämatologisch - Onkologisch - Praxis Altona, Hamburg, Germany
P. Kleihues	Department of Pathology, University Hospital Zürich, Switzerland
E. Klein	Department of Tumor Biology, Karolinska Institute, Stockholm, Sweden
S. von Kleist	Institut für Immunologie der Universität der Freiburg, Germany
S. D. Kottaridis	Department of Virology, Hellenic Anticancer Institute, Athens, Greece
G. R. F. Krueger	Center of Anatomy II, University of Cologne Medical School, Cologne, Germany
D. W. Kufe	Division of Medicine, Dana-Farber Cancer Institute, Boston, MA, USA
Pat M. Kumar	Department of Biological Sciences, Manchester Metropolitan University, Manchester, UK
Shant Kumar	Department Pathology, University of Manchester Medical School, Manchester, UK
M. Kuroki	Department of Biochemistry, Fukuoka University School of Medicine, Fukuoka, Japan
O. D. Laerum	Department of Pathology, The Gade Institute, University of Bergen, Norway
F. J. Lejeune	Fondation du Centre Pluridisciplinaire d' Oncologie, CHUV, Lausanne, Switzerland
L. F. Liu	Department of Pharmacology, UMD of New Jersey, Piscataway, NJ, USA
D. M. Lopez	Department of Microbiology and Immunology, University of Miami School of Medicine, Miami, FL, USA
E. Lundgren	Unit of Applied Cell and Molecular Biology, University of Umeä, Sweden
H. T. Lynch	Department of Preventive Medicine and Public Health, Creighton University, Omaha, NE, USA
J. Marescaux	IRCAD, University of Strasbourg, France
J. Mark	Department of Pathology, Kärnsjukhuset, Skövde, Sweden
J. F. Marshall	Centre for Tumour Biology, Institute of Cancer and CR-UK Clinical Centre, Bart's and The London, Queen Mary's School of Medicine and Dentistry, London, UK
D. Medina	Department of Cell Biology, Baylor College of Medicine, Houston, TX, USA
S. Mitra	Sealy Center for Molecular Science, University of Texas Medical Branch, Galveston, TX, USA
M. Mueller	Research Group of Tumor and Microenvironment (A101), German Cancer Research Center (DKFZ), Heidelberg, Germany
F. M. Muggia	New York University Cancer Institute, School of Medicine, NY, USA
M. J. Murphy, Jr.	Hipple Cancer Research Center, Dayton, OH, USA
R. Narayanan	Department of Biological Sciences, Florida Atlantic University, Boca Raton, FL, USA
K. Nilsson	Rudbeck Laboratory, Department of Genetics and Pathology, Uppsala University Hospital, Sweden
J. F. Novak	Department of Biology, Bucknell University, Lewisburg, PA, USA
S. Pathak	Department of Cell Biology, University of Texas, Houston, TX, USA
S. Pestka	Department of Molecular Genetics and Microbiology, University of Medicine and Dentistry of New Jersey, Piscataway, NJ, USA
G. J. Pilkington	Department of Cellular and Molecules Neurooncology, School of Pharmacy and Biomedical Sciences, University of Portsmouth, UK
C. D. Platsoucas	College of Sciences, Old Dominion University, Norfolk, VA, USA
F. Podo	Laboratory of Cell Biology, Istituto Superione di Sanità, Rome, Italy
A. Polliack	Department of Haematology, Hadassah University Hospital and Medical School, Jerusalem, Israel
M. F. Rajewsky	Institute of Cell Biology, University of Essen Medical School, Essen, Germany
G. Rebel	IRCAD, Hopitaux Universitaires, Strasbourg, France
M. Rigaud	Laboratory Biochimie et Génétique Molecules, Faculté de Médecine de Limoges, France
U. Ringborg	Department of General Oncology, Karolinska Hospital, Stockholm, Sweden

M. Roselli	Department of Medical Oncology, University of Rome "Tor Vergata", Italy
A. Schauer	Zentrum Pathologie, Georg-August Universität, Göttingen, Germany
M. Schneider	Department of Organic Chemistry, Bergische University, Wuppertal, Germany
A. Seth	Laboratory of Molecular Pathology, Sunnybrook Research Institute and University of Toronto, Ontario, Canada
G. V. Sherbet	Cancer Research Unit, University of Newcastle-upon-Tyne, UK
G.-I. Soma	Institute for Health Sciences, Tokushima Bunri University, Tokushima, Japan
G. S. Stein	Department of Cell Biology, University of Massachusetts Medical Center, Worcester, MA, USA
T. Stigbrand	Department of Immunology, Umeä University, Umeä, Sweden
D. Tarin	University of California at San Diego, Cancer Center, La Jolla, CA, USA
T. M. Theophanides	Department of Chemistry, Technical University of Athens, Greece
B. Toth	The Eppley Institute for Research in Cancer and Allied Diseases, Omaha, NE, USA
P. M. Ueland	Clinical Pharmacolocy Unit, Department of Pharmacology, University of Bergen, Norway
P. T. Vihko	Department of Clinical Chemistry, University of Oulu, Finland
M. Volm	German Cancer Research Center, Heidelberg, Germany
G. Weber	Laboratory of Experimental Oncology, Indiana University, Indianapolis, IN, USA
B. Westermark	Rudbecklaboratoriet, Department of Genetics and Pathology, University of Uppsala, Sweden
B. Zumoff	Division of Endocrinology and Metabolism, Beth Israel Medical Center, New York, NY, USA

Acknowledgements

The following Organisations supported many of the works published in Anticancer Research, Volume 31, 2011.

Aaltonen foundation, Helsinki, Finland
Academia Sinica, Taipei, Taiwan, R.O.C.
Academy of Finland, Finland
Aichi Cancer Research Foundation, Nagoya, Japan
Albert Einstein College of Medicine, Bronx, NY, U.S.A.

Albert Hung Foundation, U.K.
Alberta Cancer Board, Alberta , Canada
Alberta Heritage Foundation for Medical Research, Canada
Albertinen-Stiftung, Hamburg, Germany
Alfred und Ursula Kulemann Stiftung, Philipps University, Marburg, Germany
Alma Toorock Memorial for Cancer Research, Brooklyn, NY, U.S.A.
American Cancer Society, Atlanta, GA, U.S.A.
American Heart Association, Dallas, TX, U.S.A.
AmpliMed Corporation, Tucson, AZ, U.S.A.
Animal Care Resource Centre, BC Cancer Agency's Vancouver Research Centre, Vancouver, Canada
Ar.Ger.on onlus, Italy
ARIAD Pharmaceuticals Inc., Cambridge, MA, U.S.A.
Artemisia BioMedical Inc (AB), Newcastle, WA, U.S.A.
Asan Institute for Life Science, Seoul, Republic of Korea
Association for International Cancer Research, UK
Association for the Promotion of Research in Arteriosclerosis, Thrombosis and Vascular Biology, U.S.A.
Associazione gli Amici di Marco, La Spezia, Italy
Associazione Italiana Contro le Leucemie/Linfoma e Mieloma, AIL, Sezione Francesca Lanzone, La Spezia, Italy
AstraZeneca, Wilmington, NC, U.S.A.
Australian Catholic University, Brisbane, Australia
Australian Department of Education, Employment and Workplace Relations (DEEWR), Australia
Australian Nuclear Science and Technology Organisation, Australia
Australian Orthopaedic Association, Australia
Avanti Polar Lipids, Alabaster, AL, U.S.A.
Avon Foundation, New York, NY, U.S.A.

Bernard O'Brien Institute of Medical Research, Fitzroy, Australia
Biomedical Laboratory Research and Development, Washington, DC, U.S.A.
Biomedical Research Laboratory, Kureha Chemical Industry, Japan
Biomedicum Helsinki Foundation, Helsinki, Finland
BioMolecular Products, Newburyport, MA, U.S.A.
Björnsson Foundation, Sweden
Boehringer-Ingelheim, Ingelheim am Rhein, Germany
Bristol-Myers Squibb, New York, U.S.A.
Bruce Meyers Associates LP, New York, NY, U.S.A.
Bruker Daltonics, Germany
Bundesministerium für Bildung und Forschung, Germany

Canadian Breast Cancer Foundation-Prairies/NWT, Canada
Canadian Breast Cancer Research Alliance, Canada
Canadian Cancer Society Research Institute, Canada
Canadian Institutes of Health Research (CIHR), Canada
Cancer Association of South Africa, Johannesburg, South Africa
Cancer Assosciation North Rhine Westphalia(Krebsgesellschaft Nordrhein-Westfalen e.V.), Germany
Cancer Center Research, National Cancer Institute (NCI), NIH, Bethesda, MD, U.S.A.
Cancer Coordinating Committee, University of California, San Fransisco, CA, U.S.A.
Cancer Institute, University of Mississippi Medical Center, Jackson, MS, U.S.A.
Cancer Research Wales, Wales, U.K.
Cancer Vaccine Institute, Selborne, U.K.
Cardiovascular Institute, University of Pittsburg, Pittsburg, PA, U.S.A.
Celgene Corporation, Summit, NJ, U.S.A.
CellTrend, GmbH, Luckenwalde, Germany
Center for Development and Commercialization of Anti-Cancer Therapeutics, Ministry of Health and Welfare, Republic of Korea.
Centre for Medical Research (ZMF), Medical University of Graz, Graz, Austria
Centro de Terapia Celular/Fundação Hemocentro de Ribeirão Preto (CTC/FUNDHERP), Sao Paolo, Brazil
Chang Gung Medical Research Council, P.R. China
Chang Gung Memorial Hospital, Kaohsiung, Taiwan, R.O.C.
Chang-Hua Hospital, Taiwan, R.O.C.
Charles River Laboratories, Ann Arbor, MI, U.S.A.
Childrens Hospital Los Angeles, Los Angeles, CA, U.S.A.

China Medical University and Hospital, Taichung City, Taiwan, R.O.C.
China Postdoctoral Science Foundation, P.R. China
China Scholarship Council, Beijing, P.R. China
Chinese Ministry of Education, P.R. China
Chinese National Natural Science Foundation, P.R. China
Chulabhorn Research Institute, Bangkok, Thailand
CIRRO, The Lundbeck Foundation Center for Interventional Research in Radiation Oncology, Denmark
CNRS, Paris, France
College of Medicine, Chang Gung University, Taiwan, R.O.C.
Commission of Higher Education, Thailand
Company and Cutting Image Histology, Ann Arbor, MI, U.S.A.
Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Brazil
Core Genomics Facility, Gothenburg, Sweden
Cotton Inc., Cary, NC, U.S.A.
Cure Foundation, Montreal, Canada
CVMNAH Center of Excellence Tuskegee, U.S.A.

Daiichi Sankyo Co. Ltd., Tokyo, Japan
Dental Society Apollonia, Helsinki, Finland
Department of Biotechnology, Ministry of Science, India
Department of Dermatology, Hamamatsu University School of Medicine, Shizuoka, Japan
Department of Environmental and Occupational Health, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, U.S.A.
Department of Environmental Medicine, School of Medicine, New York University, Tuxedo, NY, U.S.A.
Department of Health, China Medical University Hospital Cancer Research of Excellence, Taichung, Taiwan, R.O.C.
Department of International Medical Communications of Tokyo Medical University, Tokyo, Japan
Department of Medicine, University of California, Los Angeles, CA, U.S.A.
Department of Obstetrics and Gynecology, Ashiya Municipal Hospital, Ashiya, Japan
Department of Obstetrics and Gynecology, Inamino Hospital, Kakogawa, Japan
Department of Obstetrics and Gynecology, Izumi Municipal Hospital, Osaka, Japan
Department of Otorhinolaryngology, Head and Neck Surgery, University of Heidelberg, Heidelberg, Germany
Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Giessen and Marburg, Marburg, Germany
Department of Pathology and Cell Biology, University of South Florida College of Medicine, Tampa, FL, U.S.A.
Department of Pathology, Shizuoka Cancer Center, Shizuoka, Japan
Department of Pharmaceutical Biology, Institute of Pharmacy and Biochemistry, University of Mainz, Mainz, Germany
Department of Radiology, Breast Imaging Center, Ullevaal University Hospital, Oslo, Norway
Department of Radiotherapy, Charité University Medicine of Berlin, Berlin, Germany
Department of Stem Cell Biology, Institute for Frontier Medical Sciences, Kyoto University, Kyoto, Japan
Department of Surgical Pathology, University of Foggia, Foggia, Italy
Department of Surgical Sciences, Medical Faculty Uppsala University, Uppsala, Sweden
Department of Urology, Albertinen-Krankenhaus, Hamburg, Germany
Department of Veterans Affairs, Washington, DC, U.S.A.
Desirée and Niels Yde Foundation, Denmark
Deutsche Forschungsgemeinschaft (DFG), Bonn, Germany
Deutsche Krebshilfe, Bonn, Germany
Division of Cancer Epidemiology and Prevention, National Cancer Institute, NIH, Bethesda, MD, U.S.A.
Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, Bethesda, MD, U.S.A.
Dr. Mildred Scheel Stiftung für Krebsforschung, Germany
Duke University GI Oncology, Durham, NC, U.S.A.
Duodecim Foundation, Helsinki, Finland
Dutch Cancer Foundation, the Netherlands

Eli Lilly, Indianapolis, IN, U.S.A.
Epidemiological & Clinical Research Information Network (ECRIN)
Erik, Karin and Gösta Selenders Foundation, Sweden

F. Hoffmann-La Roche Ltd., Basel, Switzerland
Faculty Research and Publications Board, UNC, Greeley, CO, U.S.A.
Far Eastern Memorial Hospital, Taiwan, R.O.C.
Feinberg School of Medicine, Northwestern University, Chicago, IL, U.S.A.
Felix Mindus Foundation, Stockholm, Sweden
Finnish Cancer Organizations, Helsinki, Finland
Finnish Cancer Society, Finland
Finnish Cultural Foundation, Helsinki, Finland
Finnish Medical Society Duodecim, Helsinki, Finland

Finnish Society for Therapeutic Radiology and Oncology, Finland
Flow Cytometry Laboratory, Medical School, University of Illinois, Chicago, U.S.A.
Fondation Andreas P. Naef pour la Chirurgie Thoracique, Lausanne, Switzerland
Fondation pour la Recherche et l'Enseignement en Pharmacologie Clinique, Lausanne, Switzerland
Fondazione CARIPUGLIA, Bari, Italy
Fondazione Ente Cassa di Risparmio di Firenze, Florence, Italy
Fondazione per il Diabete, Endocrinologia e Metabolismo (DEM), Rome, Italy
Fondazione per la Ricerca Oncologica (FO.R.O.-onlus), Italy
Fonds der Chemischen Industrie (FCI), Frankfurt, Germany
Fonds voor Wetenschappelijk Onderzoek Vlaanderen, Brussel, Belgium
Fong Family Foundation, San Francisco, CA, U.S.A.
Foundation for Promotion of Cancer Research, Japan
French Ministry of Health, France
Friedrich-Baur-Stiftung, Munich, Germany
Fukuoka OBGYN Researcher's Charity Foundation, Fukuoka, Japan
Fundação de Amparo à Pesquisa do Estado de Minas Gerais, Sao Paolo, Brazil
Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP), Sao Paolo, Brazil
Fundação para a Ciência e Tecnologia, Ministério da Ciência e Ensino Superior, Portugal
Fundación Mutua Madrileña, Madrid, Spain
Fundamental Research Department, Fujirebio Inc., Yoshiwa, Japan

Genesis Pharma SA, Athens, Greece
Genzyme, Japan
German Cancer Research Center (DKFZ), Heidelberg, Germany
German Jose Carreras Leukemia Foundation, Germany
Gesellschaft zur Förderung Kynologischer Forschung e.V., Bonn, Germany
GmbH, Berlin, Germany.
Gothenburg Medical Association, Gothenburg, Sweden
Gothenburg University, Gothenburg, Sweden
Graduate Institute of Biomedical Sciences, Chang Gung University, Taoyuan, Taiwan, R.O.C.
Grand Forks Human Nutrition Research Center, Grand Forks, ND, U.S.A.
Greek Ministry of Education, Athens, Greece
Guangxi Ministry of Science and Technology, P.R. China
Guangxi Provincial Science Foundation for Young Scientists, P.R. China

Harbin Institute of Technology, Heilongjiang, P.R. China
Harry S. Truman Memorial Veterans' Hospital, Columbia, MO, U.S.A.
Harvard Catalyst, The Harvard Clinical and Translational Science Center, Boston, MA, U.S.A.
Health Service Center, University of Tokushima, Tokushima, Japan
Helsinki University Central Hospital Research Foundation, Helsinki, Finland
Helsinki University Central Hospital, Helsinki, Finland
HighTech.NRW (ForSaTum), Germany
Hilleroed Hospital Research Foundation, Denmark
Histology Section of the Tissue Core and the Analytic Microscopy Core at the Moffitt Cancer Center and Research Institute, Tampa, FL, U.S.A.
Huazhong University of Science and Technology Foundation, P.R. China
Hungarian Science and Technology Foundation, Budapest, Hungary
Hunter New England Pathology, Tamworth Base Hospital, Australia

Imperial College, London, U.K.
Independent Innovation Foundation of Shandong University (IIFSDU), P.R. China
inScience Communications, Yardley, PA, U.S.A.
INSERM, Paris-Diderot University, Paris, France
Institut National du Cancer (INCa), Boulogne Billancourt, France
Institute for Medical Informatics, Statistics and Epidemiology, Leipzig, Germany
Institute for Molecular Biology and Tumor Research, Philipps University, Marburg, Germany
Institute of Biology, Demokritos, Athens, Greece
Institute of Biomedical Informatics, Medical Faculty, Ljubljana, Slovenia
Institute of Biomedical Science of Academia Sinica, Taiwan, R.O.C.
Institute Paoli-Calmettes, Marseille, France
Instituto de Ciencia y Tecnología del D.F., Mexico
Instituto Nacional de Ciencias Médicas y Nutrición, Mexico
International Myeloma Foundation, Japan
Irish Cancer Society, Dublin, Ireland
Istanbul University, Istanbul, Turkey

Jan M & Eugenia Krol Charitable Foundation Inc,Barnegat, NJ, U.S.A.
Japan Society for the Promotion of Science (JSPS), Tokyo, Japan
Japan Society for the Promotion of Science, Japan
Japanese Ministry of Health, Welfare and Labor, Japan
Japanese Society for the Promotion of Science (JSPS), Tokyo, Japan
Jarislowsky Foundation, Canada
Jennifer Hunter Yates Sarcoma Foundation, Hudson, MA, U.S.A.
Juvenile Diabetes Research Foundation, New York, NY, U.S.A.

Kakihara Science and Technology Foundation, Fukuoka, Japan
Kansas State University, Manhattan, KS, U.S.A.
Kaohsiung Chang Gung Memorial Hospital, College of Medicine, Chang Gung University, Taiwan, R.O.C.
Kaohsiung Medical University Hospital, P.R. China
Karolinska Institute, Huddinge, Sweden
Karolinska Institutet, Stockholm, Sweden
Kentucky Lung Cancer Foundation, U.S.A.
Khulna University, Bangladesh
King Abdulaziz City for Science and Technology (KACST), Riyadh, Saudi Arabia
King Gustaf the Vths Jubilee Foundation, Sweeden
Kinki University, Osaka, Japan
Knut and Alice Wallenberg Foundation, Sweden
Korea Healthcare Technology R&D Project, Ministry for Health & Welfare Affairs, Republic of Korea
Krebs- und Scharlachforschung Foundation, University of Heidelberg, Heidelberg, Germany
Kreitz-Stiftung, Germany
Kuopio University Hospital, Kuopio, Finland
Kureha Corporation, Tokyo, Japan
Kyowa Hakko Kirin Co. Ltd., Tokyo, Japan
Kyung Hee University, Seoul, Republic of Korea

Laboratory of Clinical Chemistry, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland
Laboratory of Experiment Pathology, Vrije Universiteit Brussel, Brussels, Belgium
Laboratory of Genomic Studies, São Paulo State University, Sao Paulo, Brazil
Laboratory of Molecular Oncology, Vrije Universiteit Brussel, Brussels, Belgium
Laboratory of Tumor Biology, Department of Obstetrics and Gynaecology, Ludwig Maximilians University of Munich, Munich, Germany
Les Amis de l'Institut Bordet, Brussels, Belgium
Ligue Contre le Cancer, France
Limoges Teaching Hospital, Limoges, France
Lithuanian State Science and Studies Foundation, Lithuania
Lloyd-Carr Harris Foundation, Canada
Ludwig Boltzmann Cluster for Cardiovascular Research, Vienna, Austria
Lundberg Foundation, Sweden

M.D. Anderson Cancer Center, Houston, TX, U.S.A.
Mackay Memorial Hospital, Taiwan, R.O.C.
Manitoba Health Research Council, Winnipeg, Canada
Maryland Technology Corporation, Ellicott City, MD, U.S.A.
Mass Spectrometry Unit, Department of Chemistry, University of Florida, Gainesville, FL, U.S.A.
Maud Kuistila Memorial Foundation (EK), Finland
Maud Kuistila Memorial Foundation, Helsinki, Finland
Max Eder Stiftung, Deutsche Krebshilfe, Bonn, Germany
Max-Planck Institute für experimentelle Medizin, Göttingen, Germany
Medical Faculty, University of Heidelberg, Heidelberg, Germany
Medical University of Lublin, Poland
Merck GesmbH, Vienna, Austria
Merkel Technologies Ltd., Israel
Metastasis and Angiogenesis Research Group, Cardiff, U.K.
Methodist Research Institute, Indiana University Health, U.S.A.
Michael J. Fox Foundation for Parkinson's Disease Research, New York, NY, U.S.A.
Microbiology Department, UCC, Cork, Ireland
Ministero dell'Università e della Ricerca Scientifica e Tecnologica (MIUR), Rome, Italy
Ministry for Health, Welfare & Family Affairs, Republic of Korea
Ministry of Education, Culture, Sports, Science and Technology, Japan
Ministry of Education, Youth and Sports, Czech Republic
Ministry of Health and Welfare, Republic of Korea
Ministry of Health, Czech Republic
Ministry of Health, Labor and Welfare of Japan, Japan
Ministry of Science and Technology, Israel
MiUR, Diagnostica molecolare in Oncologia and Banco di Sardegna, Italy
Monika Kutzner Stiftung, Germany

Nagono Medical Foundation, Nagoya, Japan
Nagoya City University, Nagoya, Japan
National Cancer Institute of Canada, Toronto, Canada

National Cancer Institute Tumor Repository, National Cancer Institute, Frederick, MD, U.S.A.
National Cerebral & Cardiovascular Center Research Institute, Osaka, Japan
National Hospital Organization Policy Based Medical Services.
National Institute of Health, Bethesda, MD, U.S.A.
National Institute of Radiological Sciences, Chiba, Japan
National Natural Science Foundation, Guangdong, P.R. China
National Research Council of Thailand (NRCT), Bangkok, Thailand
National Research Foundation of Korea (NRF), Republic of Korea
National Research Foundation of Korea, Republic of Korea
National Science Council, Taipei, Taiwan, R.O.C.
National Science Foundation of China, P.R. China
National Yang-Ming University, P.R. China
Natural Science Foundation of Guangdong Province, P.R. China
Necropsy Unit, Southwest National Primate Research Center, San Antonio, TX, U.S.A.
New Energy and Industrial Technology Development Organization, Japan
Nippon Kayaku Co., Ltd., Tokyo, Japan
Nord Chemicals Ltd., Ningbo, P.R. China
Northern Norway Regional Health Authority, Norway
Norwegian Cancer Society, Norway
Norwegian Research Council, Oslo, Norway
Novartis Pharma AG, Basel, Switzerland
Novartis Pharma, Vilvoorde, Belgium
Novartis, Spain

Office of Research Affairs (ORA), King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia
Oklahoma Center for the Advancement of Science and Technology, Oklahoma City, OK, U.S.A.
ORTON, Helsinki, Finland
Osaka Medical College, Osaka, Japan
Oslo Breast Cancer Micrometastasis Project, Oslo, Norway

Paavo Koistinen Foundation, Finland
Pancreatic Cancer Action Network-AACR, Manhattan Beach, CA, U.S.A.
Pathology Department, Mercy University Hospital, Cork, Ireland
Pathology Service, Hospital de Base de São José do Rio Preto, Sao Paulo, Brazil
Paul Blümel Stiftung, Hannover, Germany
Pfizer, Inc, New York, U.S.A.
Pfizer, Inc., France
Pfizer, Inc., Vienna, Austria
Pharmacia & Upjohn, Dübendorf, Switzerland
Pierre Fabre Pharma, New Jersey, U.S.A.
Polish State Committee for Scientific Research, Poland
Port Macquarie Private Hospital, Australia
Presbyterian Health Foundation, Oklahoma City, OK, U.S.A.
Provincial Research Project Funding of Guangxi, P.R. China

Rappaport Research Institute, Haifa, Israel
REHAU AG & Co., Germany
Research Center Administration, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia
Research Council of Lithuania, Lithuania
Research Network for Tissue Engineering and Rapid Prototyping (Forschungsverbund FORTEPRO), Bavarian Research Foundation (Bayerische Forschungsstiftung), Germany
Research Reactor Institute, Kyoto University, Kyoto, Japan
RHL Comprehensive Cancer Center, Northwestern University, Chicago, IL, U.S.A.
Riley Children's Foundation, Indiana, U.S.A.
Roche Hellas SA, Athens, Greece
Romanian Ministry of Education and Research, Romania
Rowett Institute for Nutrition, Aberdeen, Scotland
Rudolf Bartling Stiftung, Germany
Rural and Environmental Research and Analysis Directorate, Scotland
Rural Development Administration, Republic of Korea

SAIC-Frederick, Inc, Maryland, U.S.A.
Sanofi S.A., Paris, France
Sarcoma Foundation of America, Damascus, MD, U.S.A.
Science and Technology Commission Foundation of Guangxi Province, P.R. China
Scientific Research Foundation, Heilongjiang, P.R. China
Seidel Family Trust, California, U.S.A.
Seta Clinic Group, Japan
Shimane University, Shimane, Japan
Sigrid Juselius Foundation, Helsinki, Finland
SNFK, Amsterdam, the Netherlands
Society of Nuclear Medicine, Reston, VA, U.S.A.
Soochow University Medical Development Foundation, P.R. China
Southwest Finland Cancer Society, Turku, Finland
Sterix Ltd, London, U.K.
Stockholm Cancer Society, Stockholm, Sweden
Stockholm City Council, Stockholm, Sweden

Sukuseura Lindgren, Helsinki, Finland
Surgical Department, South Infirmary Victoria University Hospital, Cork, Ireland
Swedish Cancer Foundation, Stockholm, Sweden
Swedish Cancer Society, Sweden
Swedish Children's Cancer Foundation, Stockholm , Sweden
Swedish Larynx Foundation, Stockholm, Sweden
Swedish Match AB, Stockholm, Sweden
Swedish Research Council, Stockholm, Sweden
Swiss Cancer League, Switzerland
Swiss National Science Foundation
Sydney Medical School, University of Sydney, Sydney, Australia
Szeged Foundation for Cancer Research, Szeged, Hungary

Taiwan Department of Health Clinical Trial and Research Center of Excellence, Taiwan, R.O.C.
Tampere University Hospital, Tampere, Finland
Terry Fox Cancer Research Foundation, National Science Council, Canada
Texas AgriLife, College Station, TX, U.S.A.
Texas Health Harris Methodist Foundation, Fort Worth, TX, U.S.A.
The Cancer Society in Stockholm, Stockholm, Sweden
The Chinese Scholarship Council, P.R. China
The Delta State University Foundation, Cleveland, MS, U.S.A.
The Institute of Medical Science, Tokyo, Japan
The King Gustav V Jubilee Fund, Stockholm, Sweden
The Sallie Astor Burdine Breast Foundation, Baton Rouge, LA, U.S.A.
The Swedish Cancer Society, Stockholm, Sweden
The Third Affiliated Hospital, Soochow University, Changzhou, P.R. China
The University of Tokyo, Tokyo, Japan
Third Faculty of Medicine, Charles University, Prague, Czech Republic
Tissue Bank and Lung Cancer Registry, Thoraxklinik, University of Heidelberg, Heidelberg, Germany
Tissue Bank, China Medical University, Taichung City, Taiwan, R.O.C.
Tissue Bank, National Center for Tumor Diseases, University of Heidelberg, Heidelberg, Germany
Tohoku University, Sendai, Japan
Translational Research Informatics Center, Kobe, Japan
Turku University, Turku, Finland

Università degli Studi di Milano, Milan, Italy
University Hospitals Trust, Bristol, U.K.
University of Bristol, Bristol, U.K.
University of Maryland School of Medicine, Baltimore, MD, U.S.A.
University of Melbourne, Melbourne, Australia
University of Nebraska Medical Center, Omaha, NE, U.S.A.
University of the Basque Country (UPV/EHU), Bilbao, Spain
University Research Council and the College of Liberal Arts and Sciences, DePaul University, Chigago, U.S.A.
Uppsala University Hospital, Uppsala, Sweden.
USC Norris Comprehensive Cancer Center, Los Angeles, CA, U.S.A.

Vanderes Foundation, Breda, the Netherlands
Verein für Tumorforschung Innsbruck, Innsbruck, Austria
VGH & UBC Hospital Foundation, Vancouver, Canada
Vrije Universiteit Brussel (VUB), Brussels, Belgium

Weill Cornell Medical College, New York, U.S.A.
Wetenschappelijk Fonds Willy Gepts, UZ Brussel, Brussels, Belgium
Wroclaw Research Centre, EIT+, Wrocław, Poland

Yokohama City University, Yokohama, Japan

Zentrum für Medizinische Forschung, Universitätsklinikum Tübingen, Germany

Contents, Volume 31, 2011

Number 1

Experimental Studies

Inhibition of Tumor Cellular Proteasome Activity by Triptolide Extracted from the Chinese Medicinal Plant 'Thunder God Vine'. L. LU, J. KANWAR, S. SCHMITT, Q.C. CUI, C. ZHANG, C. ZHAO, Q. PING DOU *(Guangdong, China; Detroit, MI, USA)* 1

Frequent Absence of Tumor Suppressor FUS1 Protein Expression in Human Bone and Soft Tissue Sarcomas. G. LI, H. KAWASHIMA, L. JI, A. OGOSE, T. ARIIZUMI, H. UMEZU, Y. XU, T. HOTTA, N. ENDO *(Niigata, Japan; Heilongjiang, PR China; Houston, TX, USA)* 11

Measuring IGF-1, ER-α and EGFR Expression Can Predict Tamoxifen-resistance in ER-positive Breast Cancer. K. CHONG, A. SUBRAMANIAN, A. SHARMA, K. MOKBEL *(London, UK)* 23

Human Lymphoma Cells Develop Resistance to Radiation in the Presence of Astrocytes *In Vitro*. M. KOTO, H. CHO, O. RIESTERER, U. GIRI, M.D. STORY, C.S. HA, U. RAJU *(Sendai, Japan; Pusan, South Korea; Zurich, Switzerland; Houston; Dallas; San Antonio, TX, USA)* 33

Apoptosis of SAS Cells Induced by Sonodynamic Therapy Using 5-Aminolevulinic Acid Sonosensitizer. W. SONG, H. CUI, R. ZHANG, J. ZHENG, W. CAO *(Heilongjiang, PR China; University Park, PA, USA)* 39

Procathepsin D and Cytokines Influence the Proliferation of Lung Cancer Cells. V. VETVICKA, J. VETVICKOVA *(Louisville, KY, USA)* 47

Feulgen Staining Remains the Gold Standard for Precise DNA Image Cytometry. S. BIESTERFELD, S. BECKERS, M. DEL CARMEN VILLA CADENAS, M. SCHRAMM *(Düsseldorf, Germany)* 53

EGFR Codon 497 Polymorphism – Implications for Receptor Sensitivity to Inhibitors in HNSCC Cell Lines. V. KROHN, S. WIEGAND, J.A. WERNER, R. MANDIC *(Marburg, Germany)* 59

Overexpression of Interleukin-6 Suppresses Cisplatin-induced Cytotoxicity in Esophageal Squamous Cell Carcinoma Cells. K. SUCHI, H. FUJIWARA, S. OKAMURA, H. OKAMURA, S. UMEHARA, M. TODO, A. FURUTANI, M. YONEDA, A. SHIOZAKI, T. KUBOTA, D. ICHIKAWA, K. OKAMOTO, E. OTSUJI *(Kyoto, Japan)* 67

TIP60 as a Potential Marker for the Malignancy of Gastric Cancer. K. SAKURABA, K. YOKOMIZO, A. SHIRAHATA, T. GOTO, M. SAITO, K. ISHIBASHI, G. KIGAWA, H. NEMOTO, K. HIBI *(Yokohama, Japan)* 77

Cytotoxicity of *Thymus vulgaris* Essential Oil Towards Human Oral Cavity Squamous Cell Carcinoma. S. SERTEL, T. EICHHORN, P.K. PLINKERT, T. EFFERTH *(Heidelberg; Mainz, Germany)* 81

Thyroid Hormones (T3 and T4): Dual Effect on Human Cancer Cell Proliferation. G. MORIGGI, C. VERGA FALZACAPPA, C. MANGIALARDO, S. MICHIENZI, A. STIGLIANO, E. BRUNETTI, V. TOSCANO, S. MISITI *(Rome, Italy)* 89

Prognostic Value of Mitotic Counts in Breast Cancer of Saudi Arabian Patients. A. BUHMEIDA, J. AL-MAGHRABI, A. MERDAD, F. AL-THUBAITY, A. CHAUDHARY, M. GARI, A. ABUZENADAH, Y. COLLAN, K. SYRJÄNEN, M. AL-QAHTANI *(Jeddah, Saudi Arabia; Turku, Finland)* 97

NK4 Gene Therapy Combined with Cisplatin Inhibits Tumour Growth and Metastasis of Squamous Cell Carcinoma. G. MATSUMOTO, Y. OMI, U. LEE, E. KUBOTA, Y. TABATA *(Kanagawa; Kyoto, Japan)* 105

Constitutively Active *FGFR3* with Lys650Glu Mutation Enhances Bortezomib Sensitivity in Plasma Cell Malignancy. M. OTSUKA, M. MIZUKI, J. FUJITA, S. KANG, Y. KANAKURA *(Osaka, Japan; Atlanta, GA, USA)* 113

The Tumor Suppressive Effect of Angiotensin II Type 1 Receptor Antagonist in a Murine Osteosarcoma Model. J. WASA, H. SUGIURA, E. KOZAWA, K. KOHYAMA, K. YAMADA, O. TAGUCHI *(Nagoya, Japan)* 123

New Sarcomatoid Cancer Cell Line SAR-HCV Established from a Hepatitis C Virus-related Liver Tumour Lesion. D.-I. TAI, Y.-J. SHEN, W.-H. WENG, H.-W. CHEN, C.-C. KANG, T.-C. CHEN, S.-K. LIAO *(Taoyuan; Taipei, Taiwan, ROC)* 129

Oncogramme, A New Promising Method for Individualized Breast Tumour Response Testing for Cancer Treatment. S. GIRAUD, E. LOUM, B. BESSETTE, V. FERMEAUX, C. LAUTRETT*E (Limoges Cedex, France)* 139

Hepatic Arterial Infusion in the Treatment of Liver Metastases with PEG Liposomes in Combination with Degradable Starch Microspheres (DSM) Increases Tumor 5-FU Concentration. An Animal Study in CC-531 Liver Tumor-bearing Rats. U. POHLEN, R. RESZKA, H.J. BUHR, G. BERGER *(Berlin, Germany)* 147

Improvement of Biodistribution with PEGylated Liposomes Containing Docetaxel with Degradable Starch Microspheres for Hepatic Arterial Infusion in the Treatment of Liver Metastases: A Study in CC-531 Liver Tumor-bearing WAG RIJ Rats. U. POHLEN, H.J. BUHR, G. BERGER *(Berlin, Germany)* 153

Neem Leaf Extract Induces Radiosensitization in Human Neuroblastoma Xenograft Through Modulation of Apoptotic Pathway. J. VEERARAGHAVAN, S. ARAVINDAN, M. NATARAJAN, V. AWASTHI, T.S. HERMAN, N. ARAVINDAN *(Oklahoma City, OK; San Antonio, TX, USA)* 161

MAGE Expressions Mediated by Demethylation of *MAGE* Promoters Induce Progression of Non-small Cell Lung Cancer. N. YANAGAWA, G. TAMURA, H. OIZUMI, M. ENDOH, T. MOTOYAMA *(Yamagata, Japan)* 171

Oleic Acid Is the Active Component in the Mushroom *Daedalea gibbosa* Inhibiting Bcr-Abl Kinase Autophosphorylation Activity. H. KHAMAISIE, S. SUSSAN, M. TAL, Y. NAJAJREH, M. RUTHARDT, J. MAHAJNA *(Kiryat Shmona; Ness-Ziona, Israel; Jerusalem-Abu Dies, Palestine; Frankfurt, Germany)* 177

Chemical Composition and Antiproliferative Activity of Essential Oil from the Leaves of a Medicinal Herb, *Levisticum officinale,* against UMSCC1 Head and Neck Squamous Carcinoma Cells. S. SERTEL, T. EICHHORN, P.K. PLINKERT, T. EFFERTH *(Heidelberg; Mainz, Germany)* 185

Anticancer and Antimetastatic Activities of Renieramycin M, a Marine Tetrahydroisoquinoline Alkaloid, in Human Non-small Cell Lung Cancer Cells. H. HALIM, P. CHUNHACHA, K. SUWANBORIRUX, P. CHANVORACHOTE *(Bangkok, Thailand)* 193

ATM/ATR and SMAD3 Pathways Contribute to 3-Indole-induced G_1 Arrest in Cancer Cells and Xenograft Models. S.-M. HUANG, K.-T. LU, Y.-C. WANG *(Taipei; Tainan, Taiwan, ROC)* 203

Effect of Genistein on p90RSK Phosphorylation and Cell Proliferation in T47D Breast Cancer Cells. J. GWIN, N. DREWS, S. ALI, J. STAMSCHROR, M. SORENSON, T.T. RAJAH *(Chicago, IL, USA)* 209

Increased Efficacy and Reduced Cardiotoxicity of Metronomic Treatment with Cyclophosphamide in Rat Breast Cancer. V.K. TODOROVA, Y. KAUFMANN, V.S. KLIMBERG *(Little Rock, AR, USA)* 215

Association of Cyclooxygenase 2 Polymorphic Genotypes with Prostate Cancer in Taiwan. H.-C. WU, C.-H. CHANG, H.-L. KE, W.-S. CHANG, H.-N. CHENG, H.-H. LIN, C.-Y. WU, C.-W. TSAI, R.-Y. TSAI, W.-C. LO, D.-T. BAU *(Taichung; Kaohsiung; Chang-Hua, Taiwan, ROC)* 221

Significant Association of Cyclin D1 Single Nucleotide Polymorphisms with Oral Cancer in Taiwan. M.-H. TSAI, C.-W. TSAI, Y.-A. TSOU, C.-H. HUA, C.-F. HSU, D.-T. BAU *(Taichung; Chang-Hua, Taiwan, ROC)* 227

Ruta graveolens Extract Induces DNA Damage Pathways and Blocks Akt Activation to Inhibit Cancer Cell Proliferation and Survival. K. FADLALLA, A. WATSON, T. YEHUALAESHET, T. TURNER, T. SAMUEL *(Tuskegee, AL, USA)* 233

Clinical Studies

Detection and Significance of Parametrial Micrometastases in Early-stage Cervical Cancer. P.C. BRADY, X. CHEN, W.M. BURKE, I. DEUTSCH, X. SUN, T.J. HERZOG, J.D. WRIGHT *(New York, NY, USA)* 243

Phase II Study of Saracatinib (AZD0530) for Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC). M.G. FURY, S. BAXI, R. SHEN, K.W. KELLY, B.L. LIPSON, D. CARLSON, H. STAMBUK, S. HAQUE, D.G. PFISTER *(New York, NY, USA)* 249

A Phase II Study of Capecitabine, Oxaliplatin, Bevacizumab and Cetuximab in the Treatment of Metastatic Colorectal Cancer. N.S. WONG, N.H. FERNANDO, A.B. NIXON, S. CUSHMAN, M. AKLILU, J.C. BENDELL, M.A. MORSE, G.C. BLOBE, J. ASHTON, H. PANG, H.I. HURWITZ *(Durham; Winston-Salem, NC, USA)* 255

Expression of LGR5, an Intestinal Stem Cell Marker, During Each Stage of Colorectal Tumorigenesis. K. TAKEDA, I. KINOSHITA, Y. SHIMIZU, Y. MATSUNO, T. SHICHINOHE, H. DOSAKA-AKITA *(Sapporo, Japan)* 263

* Short Review: The Role of Pelvic Lymph Node Dissection During Radical Cystectomy for Bladder Cancer. E. BRUNOCILLA, R. PERNETTI, G. MARTORANA *(Bologna, Italy)* 271

Two Cases with a Long-term Survival Following Multidisciplinary Treatment for Recurrent Breast Cancer After Surgery. H. URAMOTO, T. HANAGIRI *(Kitakyushu, Japan)* 277

C-erbB-3 Expression in Non-small Cell Lung Cancer (NSCLC) Patients Treated by Erlotinib. I. CsTOTH, G. ANTHOINE, T. BERGHMANS, C. MASCAUX, M. PAESMANS, J.-P. SCULIER, A.-P. MEERT *(Brussels, Belgium)* 281

A Phase II Study of Weekly Paclitaxel and Doxifluridine Combination Chemotherapy for Advanced/Recurrent Gastric Cancer. I. TAKEYOSHI, F. MAKITA, Y. TANAHASHI, S. IWAZAKI, T. OGAWA, N. TOMIZAWA, S. NAKAMURA, H. ISHIKAWA, T. OHYA, S. KAKINUMA, K. NAKAGAMI, Y. SATO, T. KOYANO, T. ROPPONGI, M. IZUMI, J. KOBAYASHI, S. KAWATE, Y. SUNOSE, M. KOBAYASHI, T. YAMADA, I. SAKAMOTO *(Maebashi; Shibukawa; Tatebayashi; Takasaki; Ota; Numata; Annaka, Gunma; Yamanashi, Yamanashi; Ojiya, Niigata; Shimada, Shizuoka; Saitama, Saitama, Japan)* 287

Cortactin in Breast Cancer: Analysis with Tissue Microarray. S.-M. SHEEN-CHEN, C.-Y. HUANG, Y.-Y. LIU, C.-C. HUANG, R.-P. TANG *(Kaohsiung, Taiwan, ROC; Xiamen, PR China)* 293

Successful S-1 Monotherapy for Chemorefractory Thymic Carcinoma. T. KOIZUMI, T. AGATSUMA, Y. KOMATSU, K. KUBO *(Matsumoto, Nagano, Japan)* 299

Prognostic Value of the Human Antigen R (HuR) in Human Breast Cancer: High Level Predicts a Favourable Prognosis. Z. YUAN, A.J. SANDERS, LI. YE, Y. WANG, W.G. JIANG *(Cardiff, UK; Beijing, PR China)* 303

Pronounced Tumour Regression after Radiotherapy is Associated with Negative/Weak Glucose Transporter-1 Expression in Rectal Cancer. E. KORKEILA, P.M. JAAKKOLA, K. SYRJÄNEN, S. PYRHÖNEN, J. SUNDSTRÖM *(Turku, Finland)* 311

Randomized Phase II Study of Paclitaxel and Carboplatin or Vinorelbine in Advanced Non-small Cell Lung Cancer. K. JAHNKE, U. KEILHOLZ, D. LÜFTNER, E. THIEL, A. SCHMITTEL *(Berlin, Germany)* 317

Clinical Significance of *STC1* Gene Expression in Patients with Colorectal Cancer. S. TAMURA, T. OSHIMA, K. YOSHIHARA, A. KANAZAWA, T. YAMADA, D. INAGAKI, T. SATO, N. YAMAMOTO, M. SHIOZAWA, S. MORINAGA, M. AKAIKE, C. KUNISAKI, K. TANAKA, M. MASUDA, T. IMADA *(Kanagawa-ken, Japan)* 325

Temsirolimus in Metastatic Chromophobe Renal Cell Carcinoma after Interferon and Sorafenib Therapy. B. PAULE, N. BRION *(Creteil; Le Chesnay; Guyancourt, France)* 331

5-FU-induced Hyperammonemic Encephalopathy in a Case of Metastatic Rectal Adenocarcinoid Successfully Rechallenged with the Fluoropyrimidine Analog, Capecitabine. P.P. ADVANI, M.G. FAKIH *(Buffalo, NY, USA)* ... 335

Predictive Value of Serum Biomarkers in Patients After Portal Vein Embolization (PVE): A Pilot Study. V. TRESKA, O. TOPOLCAN, J. VRZALOVA, T. SKALICKY, A. SUTNAR, V. LISKA, J. FICHTL, A. NARSANSKA, J. FERDA, I. TRESKOVA, H. MIRKA, B. KREUZBERG *(Pilsen, Czech Republic)* 339

The Dynamics of Serum Tumor Markers in Predicting Metastatic Uveal Melanoma (Part 1). V. BARAK, I. KAISERMAN, S. FRENKEL, K. HENDLER, I. KALICKMAN, J. PE'ER *(Ashkelon; Jerusalem, Israel)*..... 345

Trends in Liver Function Tests: A Comparison with Serum Tumor Markers in Metastatic Uveal Melanoma (Part 2). K. HENDLER, J. PE'ER, I. KAISERMAN, R. BARUCH, I. KALICKMAN, V. BARAK, S. FRENKEL *(Jerusalem; Ashkelon, Israel)* 351

Pharmacogenetic Tailoring of Irinotecan-based First-line Chemotherapy in Metastatic Colorectal Cancer: Results of a Pilot Study. G. FREYER, A. DURET, G. MILANO, E. CHATELUT, C. REBISCHUNG, J.-P. DELORD, Y. MERROUCHE, G. LLEDO, M.-C. ETIENNE, C. FALANDRY *(Pierre-Bénite; Nice; Grenoble; Saint-Priest-en-Jarez; Lyon, France)* 359

Risk of Ipsilateral Breast Tumor Recurrence in Patients Treated with Tamoxifen or Anastrozole Following Breast-conserving Surgery with or without Radiotherapy. M. ISHITOBI, S. NAKAHARA, Y. KOMOIKE, K. MOTOMURA, H. KOYAMA, H. INAJI *(Osaka, Japan)* 367

Parameters of Biological Activity in Colorectal Cancer. S. SVOBODOVA, O. TOPOLCAN, L. HOLUBEC Jr., M. LEVY, L. PECEN, S. SVACINA *(Prague, Czech Republic)* 373

* Review (page 271)

Number 2

Experimental Studies

Apurinic/Apyrimidinic Endonuclease 1 Regulates Inflammatory Response in Macrophages. A. JEDINAK, S. DUDHGAONKAR, M.R. KELLEY, D. SLIVA *(Indianapolis, IN, USA)* 379

Magnetic Resonance and Fluorescence–Protein Imaging of the Anti-angiogenic and Anti-tumor Efficacy of Selenium in an Orthotopic Model of Human Colon Cancer. A. BHATTACHARYA, S.G TUROWSKI, I.D. SAN MARTIN, A. RAJPUT, Y.M. RUSTUM, R.M. HOFFMAN, M. SESHADRI *(Buffalo, NY; Albuquerque, NM; San Diego, CA, USA)* 387

Four Cardiac Hormones Cause Death of Human Cancer Cells but Not of Healthy Cells. W.P. SKELTON IV, G.E. PI, D.L. VESELY *(Durham, NC; Notre Dame, IN; Tampa, FL, USA)* 395

miR-221 Is Down-regulated in *TMPRSS2:ERG* Fusion-positive Prostate Cancer. A. GORDANPOUR, A. STANIMIROVIC, R.K. NAM, C.S. MORENO, C. SHERMAN, L. SUGAR, A. SETH *(Atlanta, GA, USA, Toronto, ON, Canada)* 403

Increased Tumor Uptake of Chemotherapeutics and Improved Chemoresponse by Novel Non-anticoagulant Low Molecular Weight Heparin. P.G. PHILLIPS, M. YALCIN, H. CUI, H. ABDEL-NABI, M. SAJJAD, R. BERNACKI, J. VEITH, S.A. MOUSA *(Rensselaer; Buffalo, NY, USA; Bursa, Turkey; Riyadh, Saudi Arabia)* 411

Addition of 2-Deoxyglucose Enhances Growth Inhibition But Reverses Acidification in Colon Cancer Cells Treated with Phenformin. M.A. LEA, J. CHACKO, S. BOLIKAL, J.Y. HONG, R. CHUNG, A. ORTEGA, C. desBORDES *(Newark, NJ; Brooklyn, NY, USA)* 421

A New Device for Rapid Isolation by Size and Characterization of Rare Circulating Tumor Cells. I. DESITTER, B.S. GUERROUAHEN, N. BENALI-FURET, J. WECHSLER, P.A. JÄNNE, Y. KUANG, M. YANAGITA, L. WANG, J.A. BERKOWITZ, R.J. DISTEL, Y.E. CAYRE *(Paris, France; Boston, MA, USA)* 427

The Prognostic Value of the Orphan Nuclear Receptor DAX-1 (NROB1) in Node-negative Breast Cancer. H. ZHANG, A. SLEWA, E. JANSSEN, I. SKALAND, Y. YU, E. GUDLAUGSSON, W. FENG, K. KJELLEVOLD, H. SØILAND, J.P.A. BAAK *(Stavanger; Bergen, Norway; Houston, TX, USA; Shanghai, PR China)* 443

Expression of Mucin-1, Galectin-1 and Galectin-3 in Human Leiomyosarcoma in Comparison to Leiomyoma and Myometrium. T. WEISSENBACHER, C. KUHN, D. MAYR, R. PAVLIK, K. FRIESE, C. SCHOLZ, U. JESCHKE, N. DITSCH, D. DIAN *(Munich, Germany)* 451

Oxidative Stress Reduces Na^+/H^+ Exchange (NHE) Activity in a Biliary Epithelial Cancer Cell Line (Mz-Cha-1). C. ELSING, A. VOSS, T. HERRMANN, I. KAISER, C.A. HUEBNER, T. SCHLENKER *(Dorsten; Heidelberg; Idar-Oberstein; Jena, Germany)* 459

HAVcR-1 Reduces the Integrity of Human Endothelial Tight Junctions. T.A. MARTIN, G.M. HARRISON, M.D. MASON, W.G. JIANG *(Cardiff, UK)* 467

Natural Killer Cell Line YT Exerts Cytotoxicity Against $CD86^+$ Myeloma Cells. U. HARNACK, H. JOHNEN, G. PECHER *(Berlin, Germany)* 475

Serum Derived from Zeranol-implanted ACI Rats Promotes the Growth of Human Breast Cancer Cells *In Vitro*. S. ZHONG, W.-P. YE, E. FENG, S.-H. LIN, J.-Y. LIU, J. LEONG, C. MA, Y.C. LIN *(Beijing, PR China; Columbus, OH, USA)* 481

The Effect of Normoxia and Hypoxia on a Prostate (PC-3) CD44/CD41 Cell Side Fraction. K.M. ANDERSON, P. GUINAN, M. RUBENSTEIN *(Chicago, IL, USA)* 487

Expression of Cancer Stem Cell Markers CD133 and CD44 in Locoregional Recurrence of Rectal Cancer. T. NAGATA, C. SAKAKURA, S. KOMIYAMA, A. MIYASHITA, M. NISHIO, Y. MURAYAMA, S. KOMATSU, A. SHIOZAKI, Y. KURIU, H. IKOMA, M. NAKANISHI, D. ICHIKAWA, H. FUJIWARA, K. OKAMOTO, T. OCHIAI, Y. KOKUBA, T. SONOYAMA, E. OTSUJI *(Kyoto, Japan)* 495

Sonodynamically-induced Antitumor Effect of Mono-l-aspartyl Chlorin e6 (NPe6). N. YUMITA, Y. IWASE, K. NISHI, T. IKEDA, H. KOMATSU, T. FUKAI, K. ONODERA, H. NISHI, K. TAKEDA, S.-I. UMEMURA, K. OKUDAIRA, Y. MOMOSE *(Yokohama, Kanagawa; Sendai; Funabashi, Chiba, Japan)* 501

Hypoxia-inducible Adrenomedullin in Colorectal Cancer. M. UEMURA, H. YAMAMOTO, I. TAKEMASA, K. MIMORI, T. MIZUSHIMA, M. IKEDA, M. SEKIMOTO, Y. DOKI, M. MORI *(Osaka; Beppu, Japan)*.... 507

Quantitative Structure–Cytotoxicity Relationship of Newly Synthesised Trihaloacetylazulenes Determined by a Semi-Empirical Molecular-Orbital Method (PM5). M. ISHIHARA, H. WAKABAYASHI, N. MOTOHASHI, H. SAKAGAMI *(Saitama; Tokyo, Japan)*..... 515

Reassessment of Estrogen Receptor Expression in Human Breast Cancer Cell Lines. C.H.J. FORD, M. AL-BADER, B. AL-AYADHI, I. FRANCIS *(Safat, Kuwait)*..... 521

Binding of Lactoferrin to IGBP1 Triggers Apoptosis in a Lung Adenocarcinoma Cell Line. D. LI, S. SAKASHITA, Y. MORISHITA, J. KANO, A. SHIBA, T. SATO, M. NOGUCHI *(Tsukuba, Ibaraki, Japan)*..... 529

Sustained Aberrant Localization of KL-6 Mucin and β-Catenin at the Invasion Front of Human Gastric Cancer Cells. Y. INAGAKI, W. TANG, H. XU, M. NAKATA, K.-I. MAFUNE, T. KONISHI, Y. SETO, N. KOKUDO *(Tokyo; Kanagawa, Japan)*..... 535

Mutations and Aberrant Transcriptions of *Stk11 (Lkb1)* Gene in Rat Liver Tumors. N. WAKABAYASHI, K. OKABE, M. HAYASHI, K. HONOKI, T. TSUJIUCHI *(Higashiosaka, Osaka; Kashihara, Nara, Japan)*..... 543

The Role of MAPK Pathway in Bone and Soft Tissue Tumors. K. SASAKI, T. HITORA, O. NAKAMURA, R. KONO, T. YAMAMOTO *(Kagawa, Japan)*..... 549

Tissue Expression of Glycated Apolipoprotein B in Colorectal Adenoma and Cancer. R. REDDAVIDE, G. MISCIAGNA, M.G. CARUSO, M. NOTARNICOLA, R. ARMENTANO, M.L. CARUSO, M. PIRRELLI, A.M. VALENTINI *(Castellana Grotte, Italy)*..... 555

Late Residual γ-H2AX Foci in Murine Spinal Cord Might Facilitate Development of Response-modifying Strategies: A Research Hypothesis. N. ANDRATSCHKE, T. BLAU, S. SCHILL, C. NIEDER *(Munich; Cologne, Germany; Bodø; Tromsø, Norway)*..... 561

Glutamate Receptors in Laryngeal Cancer Cells. A. STEPULAK, H. LUKSCH, O. UCKERMANN, M. SIFRINGER, W. RZESKI, K. POLBERG, K. KUPISZ, J. KLATKA, M. KIEŁBUS, A. GRABARSKA, J. MARZAHN, L. TURSKI, C. IKONOMIDOU *(Lublin, Poland; Dresden; Berlin, Germany; Weesp, Netherlands; Madison, WI, USA)*..... 565

Associations between Single Nucleotide Polymorphisms of *MMP2, VEGF,* and *HIF1A* Genes and the Risk of Developing Colorectal Cancer. M.-J. KANG, S.-A. JUNG, J.M. JUNG, S.-E. KIM, H.-K. JUNG, T.-H. KIM, K.-N. SHIM, S.Y. YI, K. YOO, I.H. MOON *(Seoul, South Korea)*..... 575

Clinical Studies

Implementation of Molecular Intra-operative Assessment of Sentinel Lymph Node in Breast Cancer. A. KHADDAGE, S.-A. BERREMILA, F. FOREST, A. CLEMENSON, C. BOUTEILLE, P. SEFFERT, M. PEOC'H *(St. Etienne, France)*..... 585

Osseous Changes in Meningioma En Plaque. J. MATSCHKE, J. ADDO, C. BERNREUTHER, J. ZUSTIN *(Hamburg, Germany)*..... 591

Clinical Significance and Predictive Value of Prostaglandin E2 Receptors (EPR) 1 – 4 in Patients with Renal Cell Carcinoma. K. OHBA, Y. MIYATA, S.-I. WATANABE, T. HAYASHI, H. KANETAKE, S. KANDA, H. SAKAI *(Nagasaki, Japan)*..... 597

Vitamin D Supplement Doses and Serum 25-Hydroxyvitamin D in the Range Associated with Cancer Prevention. C.F. GARLAND, C.B. FRENCH, L.L. BAGGERLY, R.P. HEANEY *(La Jolla, CA; Omaha, NE, USA)*..... 607

Low Number of Detectable Circulating Tumor Cells in Non-metastatic Colon Cancer. M. THORSTEINSSON, G. SÖLETORMOS, P. JESS *(Roskilde; Hilleroed, Denmark)* 613

The Development of Bronchopleural Fistula in Lung Cancer Patients after Major Surgery: 31 Years of Experience with 19 Cases. H. URAMOTO, T. HANAGIRI *(Kitakyushu, Japan)* 619

A Phase I Study Evaluating the Effect of CDHP as a Component of S-1 on the Pharmacokinetics of 5-Fluorouracil. M.W. SAIF, L.S. ROSEN, K. SAITO, C. ZERGEBEL, L. RAVAGE-MASS, D.S. MENDELSON *(New York, NY; Santa Monica, CA; Princeton, NJ; Scottsdale, AZ, USA)* 625

Phase II Study of Combined Chemotherapy with Docetaxel, CDDP and 5-FU for Highly Advanced Esophageal Cancer. Y. OSAKA, M. SHINOHARA, S. HOSHINO, T. OGATA, Y. TAKAGI, A. TSUCHIDA, T. AOKI *(Tokyo, Japan)* 633

* Review: Prediction of Response in Cancer Immunotherapy. D. CHARACIEJUS, J.J.L. JACOBS, V. PAŠUKONIENĖ, N. KAZLAUSKAITĖ, V. DANILEVIČIŪTĖ, M. MAURICAS, W. DEN OTTER *(Vilnius, Lithuania; Amsterdam, Netherlands)* 639

* Review: The Need for Third-line Treatment in Non-small Cell Lung Cancer: An Overview of New Options. K.N. SYRIGOS, M.W. SAIF, E.M. KARAPANAGIOTOU, G. OIKONOMOPOULOS, F. DE MARINIS *(Athens, Greece; New Haven, CT; New York, NY, USA; Rome, Italy)* 649

Pediatric Neuro-oncology in Small Centers – Quality Control of Network Support: The HIT-GBM Experience. J.E.A. WOLFF, P.H. DRIEVER, B. WOLFF, C.M. KRAMM, R.-D. KORTMANN, T. PIETSCH, S. RUTKOWSKI, A. GNEKOW *(Houston, TX, USA; Berlin; Halle; Leipzig; Bonn; Hamburg; Augsburg, Germany)* 661

Heterogeneity of Primary Site Biopsies in Head and Neck Squamous Cell Carcinoma. S. MOERTEL, H. ACKERMANN, M. BAGHI, A. ECKARDT, J. WAGENBLAST, T. STÖVER, M. HAMBEK *(Frankfurt am Main, Germany)* 665

Premenopausal Hormone-responsive Breast Cancer with Extensive Axillary Nodes Involvement: Total Estrogen Blockade and Chemotherapy. F. RECCHIA, G. CANDELORO, S. NECOZIONE, G. DESIDERI, C.O.C. RECCHIA, J. PIAZZE, S. REA *(Avezzano; Rome; L'Aquila, Italy)* 671

Alcohol-dehydrogenase (*ADH1B*) Arg48His Polymorphism in Basque Country Patients with Oral and Laryngeal Cancer: Preliminary Study. X. MARICHALAR-MENDIA, A. ACHA-SAGREDO, M.J. RODRIGUEZ-TOJO, N. REY-BARJA, M. HERNANDO-RODRIGUEZ, J.I. AGUIRREGAVIRIA, J.M. AGUIRRE-URIZAR *(Leioa; San Sebastian, Spain)* 677

Gastric Cancer in a Pregnant Woman Presenting with Low Back Pain and Bilateral Erythematous Breast Hypertrophy Mimicking Primary Inflammatory Breast Carcinoma. V.D. MANDATO, D. PIRILLO, M.C. GELLI, M. CAVINA, G.B LA SALA *(Reggio Emilia, Italy)* 681

Clinical Application of Determining Serum AFP-IgM Complexes for Diagnosis of Small Hepatocellular Carcinoma. J. JIANG, C. WU, Y. SHEN, B. XU, X. ZHENG, X. LI, N. XU *(Changzhou; Suzhou, PR China; Lund, Sweden)* 687

Axillary Node Sampling in Conjunction with Sentinel Node Biopsy in Patients with Breast Cancer. A Prospective Preliminary Study. F. LUMACHI, L. NORBERTO, S. ZANELLA, F. MARINO, S.M.M. BASSO, U. BASSO, A. BRUNELLO, A. FASSINA *(Padova; Pordenone, Italy)* 693

Prognostic Significance of Peripheral Blood $CD8^{high}CD57^{+}$ Lymphocytes in Bladder Carcinoma Patients After Intravesical IL-2. D. CHARACIEJUS, V. PAŠUKONIENĖ, J.J.L. JACOBS, R. EIDUKEVIČIUS, F. JANKEVIČIUS, N. DOBROVOLSKIENĖ, M. MAURICAS, R.J. VAN MOORSELAAR, W. DEN OTTER *(Vilnius, Lithuania; Amsterdam, Netherlands)* 699

Effect of Genetic Polymorphisms Related to DNA Repair and the Xenobiotic Pathway on the Prognosis and Survival of Gastric Cancer Patients. T. TAHARA, T. SHIBATA, M. NAKAMURA, H. YAMASHITA, D. YOSHIOKA, M. OKUBO, J. YONEMURA, T. ISHIZUKA, N. MARUYAMA, T. KAMANO, Y. KAMIYA, H. FUJITA, Y. NAKAGAWA, M. NAGASAKA, M. IWATA, H. YAMADA, I. HIRATA, T. ARISAWA *(Toyoake; Ishikawa, Japan)* 705

Loss of Estrogen Receptor Beta Expression Correlates with Shorter Overall Survival and Lack of Clinical Response to Chemotherapy in Ovarian Cancer Patients. A. HALON, E. NOWAK-MARKWITZ, A. MACIEJCZYK, M. PUDELKO, T. GANSUKH, B. GYÖRFFY, P. DONIZY, D. MURAWA, R. MATKOWSKI, M. SPACZYNSKI, H. LAGE, P. SUROWIAK *(Wroclaw; Poznan, Poland; Ulan Bator, Mongolia; Budapest, Hungary; Berlin, Germany)* 711

Hemangiopericytoma/Solitary Fibrous Tumor of the Oral Cavity. F. ANGIERO, A. SIGNORE, S. BENEDICENTI *(Milan; Genoa, Italy)* 719

* Review: Influencing the Wnt Signaling Pathway in Multiple Myeloma. Y. KIM, G. REIFENBERGER, D. LU, T. ENDO, D.A. CARSON, S.-M. GAST, K. MESCHENMOSER, M. NOWAK, I.G.H. SCHMIDT-WOLF *(Bonn; Duesseldorf, Germany; La Jolla, CA, USA; Sapporo, Hokkaido, Japan)* 725

Expression of the Vascular Endothelial Growth Factor (*VEGF*) Gene in Epithelial Ovarian Cancer: An Approach to Anti-VEGF Therapy. K. HATA, Y. WATANABE, H. NAKAI, T. HATA, H. HOSHIAI *(Takamastu; Osaka-Sayama; Kagawa, Japan)* 731

Forsen Psychological Risk Inventory for Breast Cancer Patients: A Prospective Case–Control Study with Special Reference to the Use of Psychiatric Medications. M. ESKELINEN, P. OLLONEN *(Kuopio, Finland)* 739

Significant Association of Caveolin-1 (*CAV1*) Genotypes with Prostate Cancer Susceptibility in Taiwan. H.-C. WU, C.-H. CHANG, Y.-A. TSOU, C.-W. TSAI, C.-C. LIN, D.-T. BAU *(Taichung, Taiwan, ROC)* 745

* Reviews (pages 639, 649, 725)

Number 3

Experimental Studies

HMGA2 and p14^{Arf}: Major Roles in Cellular Senescence of Fibroids and Therapeutic Implications. D.N. MARKOWSKI, B.M. HELMKE, G. BELGE, R. NIMZYK, S. BARTNITZKE, U. DEICHERT, J. BULLERDIEK *(Bremen; Heidelberg; Cuxhaven, Hannover, Germany)* 753

Anticancer Effects of Novel Photodynamic Therapy with Glycoconjugated Chlorin for Gastric and Colon Cancer. M. TANAKA, H. KATAOKA, M. MABUCHI, S. SAKUMA, S. TAKAHASHI, R. TUJII, H. AKASHI, H. OHI, S. YANO, A. MORITA, T. JOH *(Nagoya; Okayama; Kyoto; Nara, Japan)* 763

Microfluidic Assembly of Lipid-based Oligonucleotide Nanoparticles. B. YU, J. ZHU, W. XUE, Y. WU, X. HUANG, L.J. LEE, R.J. LEE *(Columbus, OH, USA; Xian, PR China)* 771

MACC 1 as a Marker for Vascular Invasive Hepatocellular Carcinoma. A. SHIRAHATA, W. FAN, K. SAKURABA, K. YOKOMIZO, T. GOTO, H. MIZUKAMI, M. SAITO, K. ISHIBASHI, G. KIGAWA, H. NEMOTO, Y. SANADA, K. HIBI *(Yokohama, Japan)* 777

Promotion of the Self-renewal Capacity of Human Leukemia Cells by Sonic Hedgehog Protein. N. KAWAGUCHI-IHARA, Y. OKUHASHI, M. ITOH, I. MUROHASHI, N. NARA, S. TOHDA *(Tokyo; Saitama, Japan)* 781

The Min Mouse on FVB Background: Susceptibility to Spontaneous and Carcinogen-induced Intestinal Tumourigenesis. C. SVENDSEN, J. ALEXANDER, H.K. KNUTSEN, T. HUSØY *(Oslo, Norway)* 785

Inhibition of c-ABL Sensitizes Breast Cancer Cells to the Dual ErbB Receptor Tyrosine Kinase Inhibitor Lapatinib (GW572016). Y.-H. LO, P.-C. HO, H. ZHAO, S.-C. WANG *(Cincinnati, OH, USA)*..... 789

Citrate Induces Apoptotic Cell Death: A Promising Way to Treat Gastric Carcinoma? Y. LU, X. ZHANG, H. ZHANG, J. LAN, G. HUANG, E. VARIN, H. LINCET, L. POULAIN, P. ICARD *(Guangxi, PRC; Caen, France)* 797

Identification of the M541L Sequence Variation of the Transmembrane KIT domain in Merkel Cell Carcinoma. K. KRASAGAKIS, M. METAXARI, M. ZERVOU, E.N. STATHOPOULOS, J. EBERLE, J. KANITAKIS, V. GEORGOULIAS, S. KRÜGER-KRASAGAKIS, N. TAVERNARAKIS, A.D. TOSCA *(Heraklion, Greece; Berlin, Germany; Lyon, France)* 807

The PPARγ Antagonist T0070907 Suppresses Breast Cancer Cell Proliferation and Motility *via* Both PPARγ-dependent and -independent Mechanisms. Y.Y. ZAYTSEVA, N.K. WALLIS, R.C. SOUTHARD, M.W. KILGORE *(Lexington, KY, USA)* 813

Cytotoxicity of Ferrocenyl–Ethynyl Phosphine Metal Complexes of Gold and Platinum. E. FOURIE, E. ERASMUS, J.C. SWARTS, A. JAKOB, H. LANG, G. K. JOONE, C.E.J. VAN RENSBURG *(Bloemfontein; Pretoria, Republic of South Africa; Chemnitz, Germany)* 825

In Silico/*In Vitro* Study of Hybrid D-modified Steroidal Alkylator Anticancer Activity Using Uridine Phosphorylase as Target Protein. G.D. GEROMICHALOS, E. GEROMICHALOU, C. CAMOUTSIS, M. KONTOS, P. DALEZIS, A. PAPAGEORGIOU, A.A. GRIVAS, C. TSIGRIS, D.T. TRAFALIS *(Thessaloniki; Ioannina; Patras; Piraeus, Greece)* 831

Co-localization of Prothrombin Fragment F1+2 and VEGF-R2-Bound VEGF in Human Colon Cancer. E. SIERKO, M.Z. WOJTUKIEWICZ, L. ZIMNOCH, P.E. THORPE, R.A. BREKKEN, W. KISIEL *(Bialystok, Poland; Dallas, TX; Seattle, WA; Albuquerque, NM, USA)* 843

The Dual PI3K/mTOR Inhibitor BEZ235 Is Effective in Lung Cancer Cell Lines. V. ARRIAS-HERRERA, E. ZEINDL-EBERHART, A. JUNG, R.M. HUBER, A. BERGNER *(Munich, Germany)* 849

Lack of Direct Association between *EGFR* Mutations and ER Beta Expression in Lung Cancer. T. ONITSUKA, H. URAMOTO, F. TANAKA *(Kitakyushu, Japan)* 855

The Endothelin Axis in the Metastatic Process of Colon Carcinoma. L.A. SØRBY, C.R. KLEIVELAND, S.N. ANDERSEN, I.R. BUKHOLM, M.B. JACOBSEN *(Fredrikstad; Ås; Lørenskog; Oslo, Norway)* 861

Novel Quinuclidinone Derivative 8a Induced Apoptosis in Human MCF-7 Breast Cancer Cell Lines. A. MALKI, S.C. BERGMEIER *(Athens, OH, USA; Alexandria, Egypt)* 871

Insoluble Fraction of Tumor Cell Homogenate Is a Useful Material for Eliciting Cytotoxic T Lymphocytes: A Unique Method for Protein Solubilization. E. KUWADA, K. KAMBARA, T. TADAKI, K. NOGUCHI *(Tokyo, Japan)* 881

Effects of Combination of Notch Inhibitor plus Hedgehog Inhibitor or Wnt Inhibitor on Growth of Leukemia Cells. Y. OKUHASHI, M. ITOH, N. NARA, S. TOHDA *(Tokyo, Japan)* 893

Biotinylated PAMAM Dendrimers for Intracellular Delivery of Cisplatin to Ovarian Cancer: Role of SMVT. V.K. YELLEPEDDI, A. KUMAR, D.M. MAHER, S.C. CHAUHAN, K.K. VANGARA, S. PALAKURTHI *(Kingsville, TX; Sioux Falls, SD, USA)* 897

Differential Distribution of Intravenous Curcumin Formulations in the Rat Brain. S.S. CHIU, E. LUI, M. MAJEED, J.K. VISHWANATHA, A.P. RANJAN, A. MAITRA, D. PRAMANIK, J.A. SMITH, L. HELSON *(London, ON, Canada; Princeton, NJ; Baltimore, MD; Houston; Fort Worth, TX; Quakertown, PA, USA; Bangalore, India)* 907

Measles Virus Antigens in Breast Cancer. S. ARIAD, N. MILK, A. BOLOTIN, J. GOPAS, N. SION-VARDY, D. BENHAROCH *(Beer Sheva, Israel)* 913

Overcoming Multidrug Resistance in Human Lung Cancer with Novel Benzo[*a*]quinolizin-4-ones. Y. KANINTRONKUL, R. WORAYUTHAKARN, N. THASANA, P. WINAYANUWATTIKUN, K. PATTANAPANYASAT, R. SURARIT, S. RUCHIRAWAT, J. SVASTI *(Bangkok, Thailand)* 921

Instillation of Mitomycin C after Transurethral Resection of Bladder Cancer Impairs Wound Healing: An Animal Model. J.C.-T. HOU, S. LANDAS, C.Y. WANG, O. SHAPIRO *(Syracuse, NY, USA)* 929

Host Genetic Factors, Related to Inflammatory Response, Influence the CpG Island Methylation Status in Colonic Mucosa in Ulcerative Colitis. T. TAHARA, T. SHIBATA, M. NAKAMURA, M. OKUBO, H. YAMASHITA, D. YOSHIOKA, J. YONEMURA, Y. KMIYA, T. ISHIZUKA, H. FUJITA, M. NAGASAKA, H. YAMADA, I. HIRATA, T. ARISAWA *(Toyoake; Ishikawa, Japan)* 933

Clinical Studies

* Review: Full Myeloablative Conditioning and an Unrelated HLA Mismatched Donor Increase the Risk for BK Virus-positive Hemorrhagic Cystitis in Allogeneic Hematopoetic Stem Cell Transplanted Patients. T. DALIANIS, P. LJUNGMAN *(Stockholm, Sweden)* 939

Fascin and CK4 as Biomarkers for Esophageal Squamous Cell Carcinoma. M. TAKIKITA, N. HU, J.-Z. SHOU, C. GIFFEN, Q.-H. WANG, C. WANG, S.M. HEWITT, P.R. TAYLOR *(Bethesda; Silver Spring, MD, USA; Beijing; Shanxi; PR China)* 945

Immunohistochemical Analyses of α1 and α3 Na^+/K^+-ATPase Subunit Expression in Medulloblastomas. M. SUÑOL, V. CUSI, O. CRUZ, R. KISS, F. LEFRANC *(Barcelona, Spain; Brussels, Belgium)* 953

No Circulating Cytomegalovirus in Five Patients with Glioblastoma Multiforme. S. LEHRER, V. LABOMBARDI, S. GREEN, M.S. PESSIN-MINSLEY, I.M. GERMANO, K.E. ROSENZWEIG *(New York, NY, USA)* 959

Phase I Trial of Fenretinide Lym-X-Sorb Oral Powder in Adults with Solid Tumors and Lymphomas. S. KUMMAR, M.E. GUTIERREZ, B.J. MAURER, C.P. REYNOLDS, M. KANG, H. SINGH, S. CRANDON, A.J. MURGO, J.H. DOROSHOW *(Bethesda, MD; Lubbock, TX, USA)* 961

High-fidelity of Five Quasimonomorphic Mononucleotide Repeats to High-frequency Microsatellite Instability Distribution in Early-stage Adenocarcinoma of the Colon. K. SØREIDE *(Stavanger; Bergen, Norway)* 967

Prolonged Response to Early Docetaxel in a Patient with Biochemical Relapse after Primary Therapy for Prostate Cancer and Incomplete Response to Androgen Suppression Therapy. C.M. BARNETT, J.F. FLAMIATOS, T.M. BEER *(Portland, OR, USA)* 973

First-line Cisplatin Plus Etoposide in High-grade Metastatic Neuroendocrine Tumors of Colon and Rectum (MCRC NET): Review of 8 Cases. A. PATTA, M. FAKIH *(Buffalo, NY, USA)* 975

Changing Levels of Circulating Tumor Cells in Monitoring Chemotherapy Response in Patients with Metastatic Breast Cancer. A.D. HARTKOPF, P. WAGNER, D. WALLWIENER, T. FEHM, R. ROTHMUND *(Tuebingen, Germany)* 979

15-Year Survival Rates after Transurethral Resection and Radiochemotherapy or Radiation in Bladder Cancer Treatment. F.S. KRAUSE, B. WALTER, O.J. OTT, L. HÄBERLE, C. WEISS, C. RÖDEL, B. WULLICH, R. SAUER *(Erlangen; Frankfurt, Germany; Linz, Austria)* 985

Clinical Significance of Wnt-induced Secreted Protein-1 (WISP-1/CCN4) in Esophageal Squamous Cell Carcinoma. Y. NAGAI, M. WATANABE, S. ISHIKAWA, R. KARASHIMA, J. KURASHIGE, S. IWAGAMI, M. IWATSUKI, Y. BABA, Y. IMAMURA, N. HAYASHI, H. BABA *(Kumamoto, Japan)* 991

Is Class III β-Tubulin a True Predictive Marker of Sensitivity to Vinorelbine in Non-small Cell Lung Cancer? Chemosensitivity Data Evidence. Y. HIRAI, T. YOSHIMASU, S. OURA, F. OTA, K. NAITO, H. NISHIGUCHI, S. HASHIMOTO, Y. OKAMURA *(Wakayama, Japan)* 999

Interphase FISH Does Not Improve the Detection of DEL(5q) and DEL(20q) in Myelodysplastic Syndromes. N. DOUET-GUILBERT, A. HERRY, M.-J. LE BRIS, N. GUÉGANIC, C. BOVO, F. MOREL, M. DE BRAEKELEER *(Brest, France)* 1007

The Evaluation of *MSX2* mRNA Expression Level in Biliary Brush Cytological Specimens. H. ITO, K. SATOH, S. HAMADA, M. HIROTA, A. KANNO, K. ISHIDA, J. UNNO, A. MASAMUNE, Y. KATAYOSE, M. UNNO, T. SHIMOSEGAWA *(Sendai, Miyagi, Japan)* 1011

A Case of Complete Response to S-1 plus CDDP in Early-Stage Mucosal Esophageal Cancer. Y. TAKAYAMA, M. KOCHI, M. FUJII, N. KANAMORI, T. KAIGA, Y. MIHARA, T. MIYAZAKI, H. TAMEGAI, M. WATANABE, T. TAKAYAMA *(Tokyo, Japan)* 1019

Response to Temozolomide in Supratentorial Multifocal Recurrence of Malignant Ependymoma. C.F. FREYSCHLAG, J. TUETTENBERG, F. LOHR, C. THOMÉ, K. SCHMIEDER, M. SEIZ *(Heidelberg; Idar-Oberstein, Germany; Innsbruck, Austria)* 1023

A New Indicator of Favorable Prognosis in Locally Advanced Renal Cell Carcinomas: γδ T-Cells in Peripheral Blood. H. KOBAYASHI, Y. TANAKA, H. NAKAZAWA, J. YAGI, N. MINATO, K. TANABE *(Tokyo-to; Kyoto, Japan)* 1027

Effective Panitumumab Treatment in Patients with Heavily Pre-treated Metastatic Colorectal Cancer: A Case Series. A.A. TZOVARAS, A. KARAGIANNIS, C. MARGARI, G. BARLA, A. ARDAVANIS *(Athens, Greece)* 1033

Does Erlotinib Restore Chemosensitivity to Chemotherapy in Pancreatic Cancer? A Case Series. M.W. SAIF *(New York, NY, USA)* 1039

CCND1 1722 Polymorphism and Potential Relevance to Upper Tract Urothelial Cancer. H.-H. LIN, H.-L. KE, K.-H. HSIAO, C.-W. TSAI, W.-J. WU, D.-T. BAU, L.-L. CHANG *(Kaohsiung; Taichung, Taiwan, ROC)* 1043

Efficacy of Surgery for Lung Metastases from Colorectal Cancer Synchronous to or Following that for Liver Metastases. K. NOJIRI, K. TANAKA, Y. NAGANO, M. UEDA, K. MATSUO, M. OTA, Y. ICHIKAWA, H. SHIMADA, I. ENDO *(Yokohama, Japan)* 1049

The Influence of Viral Hepatitis Status on Long-term HCC Outcome in Patients with Non-cirrhotic Livers. K. NOJIRI, Y. NAGANO, K. TANAKA, M. UEDA, K. TAKEDA, T. KUMAMOTO, S. FUJII, C. KUNISAKI, I. ENDO *(Yokohama, Japan)* 1055

Human Mammaglobin Transcript Amplification for Differential Diagnosis in a Breast Cancer Metastatic to Dura Mater. M. DONO, P. FERRO, M.C. FRANCESCHINI, P. DESSANTI, B. BACIGALUPO, E. CIBEI, C. CAPELLINI, D. AMOROSO, A. CAMERINI, F. FEDELI, S. RONCELLA *(Genova; La Spezia; Lido di Camaiore, Italy)* 1061

Montgomery-Asberg Depression Rating Scale (MADRS) in Healthy Study Subjects, in Patients with Breast Disease and Breast Cancer: A Prospective Case–Control Study. M. ESKELINEN, P. OLLONEN *(Kuopio, Finland)* 1065

Investigative Clinical Study on Prostate Cancer Part V: Luteinizing Hormone and the Pituitary-Testicular-Prostate Axis at the Time of Initial Diagnosis and Subsequent Cluster Selection of the Patient Population. A.B. PORCARO, A. PETROZZIELLO, F. MIGLIORINI, B. CARUSO, C. COCCO, T. SAVA, C. GHIMENTON, M. ROMANO, C. MONACO, L. COMUNALE *(Verona, Italy)* 1071

Capecitabine after Anthracycline and Taxane Exposure in HER2-negative Metastatic Breast Cancer Patients: Response, Survival and Prognostic Factors. M. GILABERT, F. BERTUCCI, B. ESTERNI, A. MADROSZYK, C. TARPIN, J. JACQUEMIER, J.-M. EXTRA, P. VIENS, A. GONÇALVES *(Marseille, France)* 1079

Book Reviews 1087

Announcements 1091

* Review (page 939)

Number 4

Experimental Studies

Synergistic Activity of Histone Deacetylase and Proteasome Inhibition Against Pancreatic and Hepatocellular Cancer Cell Lines. J.L. SPRATLIN, T.M. PITTS, G.N. KULIKOWSKI, M.P. MORELLI, J.J. TENTLER, N.J. SERKOVA, S.G. ECKHARDT *(Aurora, CO, USA; Edmonton, AB, Canada)* 1093

* Review: Targeting Notch to Eradicate Pancreatic Cancer Stem Cells for Cancer Therapy. Z. WANG, A. AHMAD, Y. LI, A.S. AZMI, L. MIELE, F.H. SARKAR *(Detroit, MI; Jackson, MS, USA)* 1105

Histone Deacetylase Inhibitor PCI-24781 Enhances Chemotherapy-induced Apoptosis in Multidrug-resistant Sarcoma Cell Lines. C. YANG, E. CHOY, F.J. HORNICEK, K.B. WOOD, J.H. SCHWAB, X. LIU, H. MANKIN, Z. DUAN *(Wuhan, China; Boston, MA, USA)* 1115

Fractionated Irradiation of Five Human Lung Cancer Cell Lines and Prediction of Survival According to a Radiobiology Model. M. HEDMAN, M. BERGQVIST, D. BRATTSTRÖM, O. BRODIN *(Stockholm; Uppsala, Sweden)* 1125

Synergism from Sequenced Combinations of Curcumin and Epigallocatechin-3-gallate with Cisplatin in the Killing of Human Ovarian Cancer Cells. N.M. YUNOS, P. BEALE, J.Q. YU, F. HUQ *(Lidcombe; Sydney, NSW, Australia; Kepong, Malaysia)* 1131

Molecular Diagnosis of MACC1 Status in Lung Adenocarcinoma by Immunohistochemical Analysis. G. CHUNDONG, H. URAMOTO, T. ONITSUKA, H. SHIMOKAWA, T. IWANAMI, M. NAKAGAWA, T. OYAMA, F. TANAKA *(Dalian, China; Kitakyushu, Japan)* 1141

Ras/Raf/MEK/ERK Pathway Is Associated with Lung Metastasis of Osteosarcoma in an Orthotopic Mouse Model. Y. YU, F. LUK, J.-L. YANG, W.R. WALSH *(Sydney, NSW, Australia)* 1147

The Effect of PTEN on Serotonin Synthesis and Secretion from the Carcinoid Cell Line BON. S.R. SILVA, Y.Y. ZAYTSEVA, L.N. JACKSON, E.Y. LEE, H.L. WEISS, K.A. BOWEN, C.M. TOWNSEND JR., B.M. EVERS *(Lexington, KY; Galveston, TX, USA)* 1153

* Review: Body Fluid Biomarkers for Early Detection of Head and Neck Squamous Cell Carcinomas. K.-D. LEE, H.-S. LEE, C.-H. JEON *(Busan; Daegu, South Korea)* 1161

Beta-(1-3),(1-6)-D-glucan Enhances the Effect of Low-dose Cyclophosphamide Treatment on A20 Lymphoma in Mice. U. HARNACK, K. ECKERT, G. PECHER *(Berlin, Germany)* 1169

Pigment Epithelial-derived Factor Inhibits c-FLIP Expression and Assists Ciglitazone-induced Apoptosis in Hepatocellular Carcinoma. L.-J. LAI, T.-C. HO *(Chia-Yi; Tao-Yuan; Taipei, Taiwan, ROC)* 1173

MT477 Acts in Tumor Cells as an AURKA Inhibitor and Strongly Induces NRF-2 Signaling. P. JASINSKI, P. ZWOLAK, K. TERAI, R.I. VOGEL, D. BORJA-CACHO, A.Z. DUDEK *(Minneapolis, MN, USA; Vienna, Austria)* 1181

Quantitative Comparison of Erythropoietin Receptor Levels in the Epithelial *versus* Endothelial Fractions of Primary Breast Tumors. C.P. MILLER, N. URBAN, C.A. BLAU *(Seattle, WA, USA)* 1189

Antitumor Effect of Novel HSP90 Inhibitor NVP-AUY922 against Oral Squamous Cell Carcinoma. T. OKUI, T. SHIMO, N.M. HASSAN, T. FUKAZAWA, N. KURIO, M. TAKAOKA, Y. NAOMOTO, A. SASAKI *(Okayama, Japan)* 1197

EMMPRIN Expression in Oral SCC Is Regulated by FYN Kinase. D.M. RAMOS, D. DANG *(San Francisco, CA, USA)* 1205

Inverse Correlation between *EGFR* Mutation and *FHIT, RASSF1A* and *RUNX3* Methylation in Lung Adenocarcinoma: Relation with Smoking Status. N. YANAGAWA, G. TAMURA, H. OIZUMI, M. ENDOH, M. SADAHIRO, T. MOTOYAMA *(Yamagata, Japan)* 1211

Increased Apoptosis of Host Cells and Tumor Cells in the Invasion Front of Colorectal Liver Metastases. O.R. BANDAPALLI, N. HARIRI, S. MACHER-GÖPPINGER, C. KAHLERT, P. SCHIRMACHER, K. BRAND *(Heidelberg, Germany)* 1215

Sunitinib Suppresses Tumor Growth and Metastases in a Highly Metastatic Mouse Mammary Cancer Model. Y. TANAKA, M.-A. SHIBATA, J. MORIMOTO, Y. OTSUKI *(Osaka, Japan)* 1225

Revitalization of Human Bone after Extracorporeal High Hydrostatic Pressure Treatment. J. SCHAUWECKER, R. VON EISENHART-ROTHE, R. BURGKART, J. TUEBEL, M. SCHMITT, W. MITTELMEIER, P. DIEHL *(Munich; Rostock, Germany)* 1235

Enhancement of Dectin-2 Gene Expression by Lignin–Carbohydrate Complex from *Lentinus edodes* Mycelia Extract (LEM) in a Mouse Macrophage-like Cell Line. T. KUSHIDA, T. MAKINO, M. TOMOMURA, A. TOMOMURA, H. SAKAGAMI *(Tokyo; Saitama, Japan)* 1241

* Review: Potential Tumor-tropic Effect of Genetically Engineered Stem Cells Expressing Suicide Enzymes to Selectively Target Invasive Cancer in Animal Models. S.U. KIM, E.-B. JEUNG, Y.-B. KIM, M.-H. CHO, K.-C. CHOI *(Vancouver, BC, Canada; Chungbuk; Seoul, South Korea)* 1249

Two-dimensional Gel Electrophoresis Using Immobilized pH Gradient Strips and Flamingo™ Fluorescent Gel Stain Identified Non-nuclear Proteins Possibly Related to Malignant Tumour Progression. Y. KURAMITSU, E. HAYASHI, F. OKADA, X. ZHANG, Y. UEYAMA, K. NAKAMURA *(Ube; Yonago, Japan)* 1259

Human EAG1 Potassium Channels in the Epithelial-to-Mesenchymal Transition in Lung Cancer Cells. I. RESTREPO-ANGULO, C. SÁNCHEZ-TORRES, J. CAMACHO *(Mexico City, Mexico)* 1265

Claudin-4: A Potential Therapeutic Target in Chemotherapy-resistant Ovarian Cancer. H. YOSHIDA, T. SUMI, X. ZHI, T. YASUI, K.-I. HONDA, O. ISHIKO *(Osaka, Japan)* 1271

Adenoviral Therapy Is More Effective in Gemcitabine-resistant Pancreatic Cancer than in Gemcitabine-sensitive Cells. T. YASUI, K. OHUCHIDA, M. ZHAO, L. CUI, M. ONIMARU, T. EGAMI, H. FUJITA, T. OHTSUKA, K. MIZUMOTO, K. MATSUMOTO, M. TANAKA *(Fukuoka; Kanazawa, Japan)* 1279

Aberrant Methylation of the *Vimentin* Gene in Hepatocellular Carcinoma. Y. KITAMURA, A. SHIRAHATA, K. SAKURABA, T. GOTO, H. MIZUKAMI, M. SAITO, K. ISHIBASHI, G. KIGAWA, H. NEMOTO, Y. SANADA, K. HIBI *(Yokohama, Japan)* 1289

Methylation of *OSMR* Gene Is Frequently Observed in Non-invasive Colorectal Cancer. K. HIBI, T. GOTO, K. SAKURABA, A. SHIRAHATA, M. SAITO, K. ISHIBASHI, G. KIGAWA, H. NEMOTO, Y. SANADA *(Yokohama, Japan)* 1293

Involvement of Cancer Biomarker C7orf24 in the Growth of Human Osteosarcoma. D. UEJIMA, K. NISHIJO, Y. KAJITA, T. ISHIBE, T. AOYAMA, S. KAGEYAMA, H. IWAKI, T. NAKAMURA, H. IIDA, T. YOSHIKI, J. TOGUCHIDA *(Kyoto; Osaka; Shiga, Japan)* 1297

Induction of MMP-13 Expression in Bone-metastasizing Cancer Cells by Type I Collagen through Integrin α1β1 and α2β1-p38 MAPK Signaling. S. IBARAGI, T. SHIMO, N.M. HASSAN, S. ISOWA, N. KURIO, H. MANDAI, S. KODAMA, A. SASAKI *(Okayama, Japan)* 1307

Prognostic Impact of CD133 Immunoexpression in Node-negative Invasive Breast Carcinomas. A. IENI, G. GIUFFRÈ, V. ADAMO, G. TUCCARI *(Messina, Italy)* 1315

Chitosan Derivatives Inhibit Cell Proliferation and Induce Apoptosis in Breast Cancer Cells. M. JIANG, H. OUYANG, P. RUAN, H. ZHAO, Z. PI, S. HUANG, P. YI, M. CREPIN *(Wuhan; Guangzhou; Shiyan, PR China; Bobigny, France)* 1321

Tumour-derived Microvesicles Contain Interleukin-8 and Modulate Production of Chemokines by Human Monocytes. M. BAJ-KRZYWORZEKA, K. WĘGLARCZYK, B. MYTAR, R. SZATANEK, J. BARAN, M. ZEMBALA *(Cracow, Poland)* 1329

Abnormal Methylation of Histone Deacetylase Genes: Implications on Etiology and Epigenetic Therapy of Astrocytomas. M.V. GOMES, K.S. BORGES, D.A. MORENO, R.G. QUEIROZ, H.R. MACHADO, C.G. CARLOTTI JR., C.A. SCRIDELI, L.G. TONE *(Londrina, PR; Ribeirão Preto, SP, Brazil)* 1337

Differential Apoptotic Effects of Novel Quinuclidinone Analogs 8a and 8b in Normal and Lung Cancer Cell Lines. A. MALKI, S. BERGMEIER *(Athens, OH, USA; Alexandria, Egypt)* 1345

Polymorphisms of the *CYP1A1, CYP2E1* and *XRCC1* Genes and Cancer Risk in a Southern Italian Population: A Case–Control Study. G. BIANCHINO, A. CITTADINI, V. GRIECO, A. TRAFICANTE, A. ZUPA, G. IMPROTA, M. AIETA, A. SGAMBATO *(Potenza; Rome, Italy)* 1359

Clinical Studies

Effect of Tamoxifen or Anastrozole on Steroid Sulfatase Activity and Serum Androgen Concentrations in Postmenopausal Women with Breast Cancer. S.J. STANWAY, C. PALMIERI, F.Z. STANCZYK, E.J. FOLKERD, M. DOWSETT, R. WARD, R.C. COOMBES, M.J. REED, A. PUROHIT *(London, UK; Los Angeles, CA, USA)* 1367

Single Nucleotide Polymorphisms of Integrin Alpha-2 and Beta-3 Genes Are not Associated with Relapse-free and Overall Survival in Colorectal Cancer Patients. G. HOFMANN, U. LANGSENLEHNER, T. LANGSENLEHNER, M. GLEHR, A. GERGER, G. ABSENGER, J. SZKANDERA, F. FUERST, H. SAMONIGG, P. KRIPPL, W. RENNER *(Graz; Fuerstenfeld, Austria)* 1373

Combined *KRAS* and *TP53* Mutation Status Is not Predictive in CAPOX-treated Metastatic Colorectal Cancer. M.T. DE BRUIJN, D.A.E. RAATS, J. TOL, J. HINRICHS, S. TEERENSTRA, C.J.A. PUNT, I.H.M. BOREL RINKES, O. KRANENBURG *(Utrecht; Nijmegen, Netherlands)* 1379

* Review: The Involvement of Retroperitoneal Lymph Nodes in Primary Serous-papillary Peritoneal Carcinoma. A Systematic Review of the Literature. P.R. STEINHAGEN, J. SEHOULI *(Berlin, Germany)* 1387

The Expression of Sialic Fibronectin Correlates with Lymph Node Metastasis of Thyroid Malignant Neoplasmas. H. TAKEYAMA, S. KYODA, T. OKAMOTO, Y. MANOME, M. WATANABE, S. KINOSHITA, K. UCHIDA, A. SAKAMOTO, T. MORIKAWA *(Tokyo, Japan)* 1395

PCA3 Urinary Test *Versus* ^{1}H-MRSI and DCEMR in the Detection of Prostate Cancer Foci in Patients with Biochemical Alterations. V. PANEBIANCO, A. SCIARRA, E. DE BERARDINIS, G.M. BUSETTO, D. LISI, V. BUONOCORE, V. GENTILE, F. DI SILVERIO, R. PASSARIELLO *(Rome, Italy)* 1399

Nonadherence to Imatinib Treatment in Patients with Gastrointestinal Stromal Tumors: The ADAGIO Study. F. MAZZEO, L. DUCK, E. JOOSENS, L. DIRIX, C. FOCAN, F. FORGET, S. DE GEEST, K. MUERMANS, M.-A. VAN LIERDE, K. MACDONALD, I. ABRAHAM, J. DE GRÈVE *(Brussels; Ottignies; Antwerp; Liège; Libramont; Vilvoorde, Belgium; Basel; Switzerland; Earlysville, VA; Tucson, AZ, USA)* 1407

Elevated Serum 8-OHdG Is Associated with Poor Prognosis in Epithelial Ovarian Cancer. M. PYLVÄS, U. PUISTOLA, L. LAATIO, S. KAUPPILA, P. KARIHTALA *(Oulu, Finland)* 1411

Evidence for the Efficacy of Iniparib, a PARP-1 Inhibitor, in BRCA2-associated Pancreatic Cancer. D.R. FOGELMAN, R.A. WOLFF, S. KOPETZ, M. JAVLE, C. BRADLEY, I. MOK, F. CABANILLAS, J.L. ABBRUZZESE *(Houston, TX; Francisco, CA, USA; San Juan, Puerto Rico)* 1417

The Value and Limitations of Contrast-enhanced Ultrasound in Detection of Prostate Cancer. A. STRAZDIŅA, G. KRŪMIŅA, M. SPERGA *(Riga, Latvia)* 1421

Impact of Renal Failure on the Tumor Markers of Mesothelioma, N-ERC/Mesothelin and Osteopontin. K. SHIOMI, S. SHIOMI, Y. ISHINAGA, M. SAKURABA, Y. HAGIWARA, K. MIYASHITA, M. MAEDA, K. SUZUKI, K. TAKAHASHI, O. HINO *(Tokyo; Gunma, Japan)* 1427

Roles of BCL-2 and MDR1 Expression in the Efficacy of Paclitaxel-based Lung Cancer Chemoradiation. A. MARÁZ, J. FURÁK, R. PÁLFÖLDI, J. ELLER, E. SZÁNTÓ, Z. KAHÁN, L. THURZÓ, J. MOLNÁR, L. TISZLAVICZ, K. HIDEGHÉTY *(Szeged, Hungary)* 1431

High-risk Group for Locoregional Recurrence in Patients with Stage IB-IIB Squamous Cell Carcinoma of the Cervix Treated with Concurrent Chemoradiotherapy. M. HIRAKAWA, Y. NAGAI, T. TOITA, W. KUDAKA, M. INAMINE, K. OGAWA, S. MURAYAMA, Y. AOKI *(Okinawa, Japan)* 1437

Sentinel Lymph Node Biopsy for Squamous Cell Carcinoma of the Extremities: Case Report and Review of the Literature. Y.Y. LIU, W.M. ROZEN, R. RAHDON *(Geelong, VIC, Australia)* 1443

Evaluation of Tumour Markers as Differential Diagnostic Tool in Patients with Suspicion of Liver Metastases from Breast Cancer. V. LISKA, L. HOLUBEC JR., V. TRESKA, J. VRZALOVA, T. SKALICKY, A. SUTNAR, S. KORMUNDA, J. BRUHA, O. VYCITAL, J. FINEK, M. PESTA, L. PECEN, O. TOPOLCAN *(Prague, Czech Republic)* 1447

Prognostic Value of Persistent Peripheral Blood and Bone Marrow Lymphoblasts on Day 15 of Therapy in Childhood Acute Lymphoblastic Leukemia as Detected by Flow Cytometry. A. JAWORSKA-POSADZY, J. STYCZYNSKI, M. KUBICKA, R. DEBSKI, B. RAFINSKA-KURYLO, B. KOLODZIEJ, M. POGORZALA, M. WYSOCKI *(Bydgoszcz, Poland)* 1453

Association between Genetic Polymorphisms Related to DNA Repair or Xenobiotic Pathways and Gastric Premalignant Conditions. T. TAHARA, T. SHIBATA, M. NAKAMURA, H. YAMASHITA, D. YOSHIOKA, M. OKUBO, J. YONEMURA, Y. KAMIYA, T. ISHIZUKA, Y. NAKAGAWA, M. NAGASAKA, M. IWATA, I. HIRATA, T. ARISAWA *(Toyoake; Ishikawa, Japan)* 1459

Concomitant Diagnosis of Myeloproliferative Neoplasm and Non-Hodgkin's Lymphoma in a Patient with Portal Vein Thrombosis. M.-V. PAPAGEORGIOU, A. ALEXOPOULOU, F. KONTOPIDOU, A. FILIOTOU, J. KOSKINAS, D. PECTASIDES *(Athens, Greece)* 1467

Continuous Saline Bladder Irrigation after Transurethral Resection Is a Prophylactic Treatment Choice for Non-muscle Invasive Bladder Tumor. T. ONISHI, T. SASAKI, A. HOSHINA, T. YABANA *(Ise; Mie, Japan)* 1471

Time to Castration Resistance Is an Independent Predictor of Castration-resistant Prostate Cancer Survival. E. BOURNAKIS, E. EFSTATHIOU, A. VARKARIS, S. WEN, M. CHRISOFOS, C. DELIVELIOTIS, C. ALAMANIS, I. ANASTASIOU, C. CONSTANTINIDES, A. BAMIAS, M.A. DIMOPOULOS *(Athens, Greece; Houston, TX, USA)* 1475

Phase II Trial of Preoperative Chemotherapy for Breast Cancer: Japan Breast Cancer Research Network (JBCRN)-02 Trial. S. IWASE, D. YAMAMOTO, Y. KURODA1, T. KAWAGUCHI, K. KITAMURA, H. ODAGIRI, S. TERAMOTO, K. AKAZAWA, Y. NAGUMO *(Tokyo; Hirakata, Osaka; Fukuoka; Hirosaki; Niigata, Japan)* 1483

ABSTRACTS OF THE 4TH INTERNATIONAL SYMPOSIUM ON VITAMIN D AND ANALOGS IN CANCER PREVENTION AND THERAPY, Homburg/Saar, Germany, 20-21 May, 2011 1489

Erratum 1513

* Review (page 1105, 1161, 1249, 1387)

Number 5

Experimental Studies

* Review: An Epidemic of Oropharyngeal Squamous Cell Carcinoma (OSCC) Due to Human Papillomavirus (HPV) Infection and Aspects of Treatment and Prevention. T. RAMQVIST, T. DALIANIS *(Stockholm, Sweden)* 1515

Synthesis and Evaluation of a Novel Lipophilic Folate Receptor Targeting Ligand. Y. LIU, S. XU, L. TENG, B. YUNG, J. ZHU, H. DING, R.J. LEE *(Wuhan; Changchun, China; Columbus, OH, USA)* 1521

Direct Effects of Pure Nicotine, Cigarette Smoke Extract, Swedish-type Smokeless Tobacco (Snus) Extract and Ethanol on Human Normal Endothelial Cells and Fibroblasts. N. LAYTRAGOON-LEWIN, F. BAHRAM, L.E. RUTQVIST, I. TURESSON, F. LEWIN *(Jönköping; Uppsala; Stockholm, Sweden)* 1527

Circulating Human Prostate Cancer Cells from an Orthotopic Mouse Model Rapidly Captured by Immunomagnetic Beads and Imaged by GFP Expression. K. KOLOSTOVA, D. PINTEROVA, R.M. HOFFMAN, V. BOBEK *(Prague, Czech Republic; San Diego, CA, USA)* 1535

Quantitative PCR and Immunohistochemical Analyses of HMGB1 and RAGE Expression in Canine Disseminated Histiocytic Sarcoma (Malignant Histiocytosis). K.A. STERENCZAK, S. KLEINSCHMIDT, P. WEFSTAEDT, N. EBERLE, M. HEWICKER-TRAUTWEIN, J. BULLERDIEK, I. NOLTE, H.M. ESCOBAR *(Hannover; Bremen, Germany)* 1541

Anticancer Effect of Dihydroartemisinin (DHA) in a Pancreatic Tumor Model Evaluated by Conventional Methods and Optical Imaging. W. AUNG, C. SOGAWA, T. FURUKAWA, T. SAGA *(Chiba, Japan)* 1549

Pretreatment HIF-1α and GLUT-1 Expressions Do Not Correlate with Outcome after Preoperative Chemoradiotherapy in Rectal Cancer. B.M. HAVELUND, F.B. SØRENSEN, J. LINDEBJERG, K.-L.G. SPINDLER, A. JAKOBSEN *(Vejle, Denmark)* 1559

Heterogeneity of Metalloproteinase Expression in Colorectal Cancer – Relation of Molecular Findings to Basic Morphology. Y. KAJIWARA, H. UENO, Y. HASHIGUCHI, E. SHINTO, H. SHIMAZAKI, H. MOCHIZUKI, K. HASE *(Saitama, Japan)* 1567

Overexpression of the TXNDC5 Protein in Non-small Cell Lung Carcinoma. E.E. VINCENT, D.J.E. ELDER, L. PHILLIPS, K.J. HEESOM, J. PAWADE, M. LUCKETT, M. SOHAIL, M.T. MAY, M.R. HETZEL, J.M. TAVARÉ *(Bristol, UK)* 1577

Effect of Hyperthermia on Liver Cell Lines: Important Findings for Thermal Therapy in Hepatocellular Carcinoma. U. MAYRHAUSER, P. STIEGLER, V. STADLBAUER, S. KOESTENBAUER, B. LEBER, K. KONRAD, F. IBERER, R.H. PORTUGALLER, K. TSCHELIESSNIGG *(Graz, Austria)* 1583

Lectin Histochemistry of Metastasizing and Non-metastasizing Breast and Colon Cancer Cells. B. SCHNEGELSBERG, U. SCHUMACHER, U. VALENTINER *(Hamburg, Germany)* 1589

Structural Rearrangements of Trisomies Are a Risk Marker of Clinical Progression in Hyperdiploid Multiple Myeloma. R. ALFARO, J. ROSELL, M.A. DURÁN, G. PUGET, J. BESALDUCH, P. GALÁN, A. VALLÉS, M. BERNUÉS *(Mallorca; Menorca, Spain)* 1599

Correlation and Coexpression of HIFs and NOTCH Markers in NSCLC. S. ANDERSEN, T. DONNEM, S. AL-SAAD, K. AL-SHIBLI, H. STENVOLD, L.-T. BUSUND, R.M. BREMNES *(Tromsø; Bodo, Norway)* 1603

NF-κB Activation by Peroxynitrite through IκBα-dependent Phosphorylation *versus* Nitration in Colon Cancer Cells. E. GOCHMAN, J. MAHAJNA, A.Z. REZNICK *(Haifa; Kiryat Shmona, Israel)* 1607

Efficient Down-regulation of *CDK4* by Novel Lipid Nanoparticle mediated siRNA Delivery. X. WANG, B. YU, Y. WU, R.J. LEE, L.J. LEE *(Beijing, PR China; Columbus, OH, USA)* 1619

Targeting of Breast Metastases Using a Viral Gene Vector with Tumour-selective Transcription. S. RAJENDRAN, S. COLLINS, J.P. VAN PIJKEREN, D. O'HANLON, G.C. O'SULLIVAN, M. TANGNEY *(Cork, Ireland)* 1627

Experimental Study of the Anticancer Effect of Gemcitabine Combined with Sirolimus on Chemically Induced Urothelial Lesions. C. VASCONCELOS-NÓBREGA, A. COLAÇO, L. SANTOS, H. VALA, L.F. PALOMINO, C. LOPES, P.A. OLIVEIRA *(Viseu; Vila Real; Porto, Portugal; Lugo, Spain)* 1637

$p16^{INK4a}$ Methylation in Serum as a Follow-up Marker for Recurrence of Colorectal Cancer. G. NAKAYAMA, Y. KODERA, N. OHASHI, M. KOIKE, M. FUJIWARA, A. NAKAO *(Nagoya; Aichi, Japan)* 1643

Barley Low Molecular Weight β-Glucan Potently Induces Maturation of Mouse Dendritic Cells. A. TANIOKA, W.-W. AN, T. KUGE, K. TSUBAKI, K. NAKAYA *(Tokyo; Niigata, Japan)* 1647

The Effect of PTEN on Proliferation and Drug-, and Radio-sensitivity in Malignant Glioma Cells. N. INABA, M. KIMURA, K. FUJIOKA, K. IKEDA, H. SOMURA, K. AKIYOSHI, Y. INOUE, M. NOMURA, Y. SAITO, H. SAITO, Y. MANOME *(Tokyo, Japan)* 1653

Zeranol Induces Cell Proliferation and Protein Disulfide Isomerase Expression in Mammary Gland of ACI Rat. S. ZHONG, W. YE, S.-H. LIN, J.-Y. LIU, J. LEONG, C. MA, Y.C. LIN *(Beijing, PR China; Columbus, OH, USA)* 1659

Zanthoxylum ailanthoides Sieb and Zucc. Extract Inhibits Growth and Induces Cell Death through G_2/M-phase Arrest and Activation of Apoptotic Signals in Colo 205 Human Colon Adenocarcinoma Cells. S.-T. CHOU, H.-Y. PENG, C.-T. CHANG, J.-S. YANG, H.-K. CHUNG, S.-T. YANG, W. GIBSON WOOD, J.-G. CHUNG *(Taichung, Taiwan, ROC; Minneapolis, MN, USA)* 1667

Association of FOXP3 Expression with Non-small Cell Lung Cancer. F.-I.D. DIMITRAKOPOULOS, H. PAPADAKI, A.G. ANTONACOPOULOU, A. KOTTOROU, A.D. GOTSIS, C. SCOPA, H.P. KALOFONOS, A. MOUZAKI *(Patras, Greece)* 1677

Gene Mutations and Polymorphisms of *TP53* and *FHIT* in Chronic Esophagitis and Esophageal Carcinoma. A.P.F. SILVEIRA, F. MANOEL-CAETANO, S. AOKI, L.H.T. YAMASAKI, P. RAHAL, A.E. SILVA *(São José do Rio Preto, SP, Brazil)* 1685

Phenethyl Isothiocyanate (PEITC) Promotes G_2/M Phase Arrest *via* p53 Expression and Induces Apoptosis through Caspase- and Mitochondria-dependent Signaling Pathways in Human Prostate Cancer DU 145 Cells. N.-Y. TANG, Y.-T. HUANG, C.-S. YU, Y.-C. KO, S.-H. WU, B.-C. JI, J.-S. YANG, J.-L. YANG, T.-C. HSIA, Y.-Y. CHEN, J.-G. CHUNG *(Taichung; Chiayi; Changhua, Taiwan, ROC)* 1691

Potential Prognostic Value of Repulsive Guidance Molecules in Breast Cancer. J. LI, L. YE, R.E. MANSEL, W.G. JIANG *(Cardiff, UK)* 1703

Prognostic Effects and Regulation of Activin A, Maspin, and the Androgen Receptor in Upper Urinary Tract Urothelial Carcinoma. K.-M. RAU, Y.-J. CHEN, M.-T. SUN, H.-Y. KANG *(Kaohsiung, Taiwan, ROC)* 1713

Response of Medulloblastoma Cells to Vincristine and Lomustine: Role of TRKC, CTNNB1 and STK15. Z. SHINWARI, H. AL-HINDI, E. AL-SHAIL, Y. KHAFAGA, A. AL-KOFIDE, N. EL-KUM, A. ABOUSSEKHRA *(Riyadh, Saudi Arabia)* 1721

Clinical Studies

Impact of Common Medications on Serum Total Prostate-specific Antigen Levels and Risk Group Assignment in Patients with Prostate Cancer. C. NIEDER, J. NORUM, H. GEINITZ *(Bodo; Tromsø, Norway; Munich, Germany)* 1735

Iron Chelation Therapy with Deferasirox Induced Complete Remission in a Patient with Chemotherapy-resistant Acute Monocytic Leukemia. T. FUKUSHIMA, H. KAWABATA, T. NAKAMURA, H. IWAO, A. NAKAJIMA, M. MIKI, T. SAKAI, T. SAWAKI, Y. FUJITA, M. TANAKA, Y. MASAKI, Y. HIROSE, H. UMEHARA *(Ishikawa; Kyoto, Japan)* 1741

Treatment of Low-risk Prostate Cancer with Radical Hypofractionated Accelerated Radiotherapy with Cytoprotection (HypoARC): An Interim Analysis of Toxicity and Efficacy. M.I. KOUKOURAKIS, G. KYRGIAS, A. PAPADOPOULOU, M. PANTELIADOU, A. GIATROMANOLAKI, E. SIVRIDIS, S. MAVROPOULOU, K. KALOGERIS, P. NASSOS, N. MILIOUDIS, S. TOULOUPIDIS *(Alexandroupolis; Larissa; Xanthi, Greece)* 1745

Pemetrexed-induced Hyperpigmentation of the Skin. D. SCHALLIER, L. DECOSTER, J. DE GREVE *(Brussels, Belgium)* 1753

Lymphatic Microvessel Density, VEGF-C, and VEGFR-3 Expression in Different Molecular Types of Breast Cancer. M. RAICA, A.M. CIMPEAN, R. CEAUSU, D. RIBATTI *(Timisoara, Romania; Bari, Italy)* 1757

Off-label Use of Oxaliplatin in Patients with Metastatic Breast Cancer. A. DELPEUCH, D. LEVEQUE, L. ROB, J.-P. BERGERAT *(Strasbourg, France)* 1765

Correlation between Tumor-associated Proteins and Response to Neoadjuvant Treatment in Patients with Advanced Squamous-cell Esophageal Cancer. R. FARKAS, E. POZSGAI, S. BELLYEI, L. CSEKE, A. SZIGETI, A. VERECZKEI, S. MARTON, L. MANGEL, O.P. HORVATH, A. PAPP *(Pécs, Hungary)* 1769

Bevacizumab in First-line Therapy of Metastatic Colorectal Cancer: A Retrospective Comparison of FOLFIRI and XELIRI. J. OCVIRK, M. REBERSEK, M. BOC *(Ljubljana, Slovenia)* 1777

Differences in Breast Carcinoma *In Situ* Between Menopausal and Premenopausal Women. C. PRADIER, M. CORNUAU, J. NORCA, H. MESBAH, P. POREE, G. BODY, J.-M. CLASSE, J. LEVEQUE *(Rennes; Tours; Nantes, France)* 1783

Fundic Gland Polyps. C.A. RUBIO, G. NESI *(Stockholm, Sweden)* 1789

* Short Review: Current Concepts in the Non-operative Management of Rectal Cancer after Neoadjuvant Chemoradiation. G. SINGH-RANGER, D. KUMAR *(London, UK)* 1795

Assessment of General Anxiety in Patients with Breast Disease and Breast Cancer Using the Spielberger STAI Self Evaluation Test: A Prospective Case-Control Study in Finland. M. ESKELINEN, P. OLLONEN *(Kuopio, Finland)* 1801

ABSTRACTS OF THE 21st ANNUAL MEETING OF THE ITALIAN SOCIETY OF URO-ONCOLOGY (SIUrO), Naples, Italy, 22-24 June, 2011 1807

ABSTRACTS OF THE 15th INTERNATIONAL HAMBURG SYMPOSIUM ON TUMOR MARKERS, Hamburg, Germany, 29-31 May, 2011 1957

* Reviews (pages 1515, 1795)

Number 6

Experimental Studies

Cytotoxic Activity of New Acetoxycoumarin Derivatives in Cancer Cell Lines. M.A. MUSA, V.L.D. BADISA, L.M. LATINWO, J. COOPERWOOD, A. SINCLAIR, A. ABDULLAH *(Tallahassee, FL, USA)* 2017

Characterization of the Effect of *In Vivo* Doxorubicin Treatment on Skeletal Muscle Function in the Rat. D.S. HYDOCK, C.-Y. LIEN, B.T. JENSEN, C.M. SCHNEIDER, R. HAYWARD *(Greeley, CO, USA)* 2023

LLL12 Inhibits Endogenous and Exogenous Interleukin-6-induced STAT3 Phosphorylation in Human Pancreatic Cancer Cells. A. LIU, Y. LIU, P.-K. LI, C. LI, J. LIN *(Columbus, OH, USA; Wuhan, PR China)* 2029

Overexpression of κ-Actin Alters Growth Properties of Hepatoma Cells and Predicts Poor Postoperative Prognosis. K.-W. CHANG, A. CHOU, C.-C. LEE, C. YEH, M.-W. LAI, T.-S. YEH, T.-C. CHEN, K.-H. LIANG, C.-T. YEH *(Taoyuan; Taipei, Taiwan, ROC; Palo Alto; Los Angeles, CA; Milwaukee, WI, USA)* 2037

Predicting Response to Benzamide Riboside Chemotherapy in Hepatocellular Carcinoma Using Apparent Diffusion Coefficient of Water. A.M. BABSKY, S. JU, B. GEORGE, S. BENNETT, M. HUANG, H.N. JAYARAM, G. MCLENNAN, N. BANSAL *(Indianapolis, IN, USA)* 2045

* Review: Disseminated and Circulating Tumor Cells for Monitoring Chemotherapy in Urological Tumors. S. KRUCK, G. GAKIS, A. STENZL *(Tuebingen, Germany)* 2053

Identification of Differentially Expressed Proteins in Tumour Necrosis Factor-alpha-resistant and -sensitive Rat Hepatoma Cells. Y. KURAMITSU, X. ZHANG, Y. WANG, K. NAKAMURA *(Ube, Japan)* 2059

The Therapeutic Effects of R8-Liposome-BCG-CWS on BBN-Induced Rat Urinary Bladder Carcinoma. J. MIYAZAKI, H. NISHIYAMA, I. YANO, A. NAKAYA, H. KOHAMA, K. KAWAI, A. JORAKU, T. NAKAMURA, H. HARASHIMA, H. AKAZA *(Tsukuba, Ibaraki; Kiyose; Tokyo, Tokyo; Sapporo, Hokkaido, Japan)* 2065

Ischemic Time Impacts Biological Integrity of Phospho-proteins in PI3K/Akt, Erk/MAPK, and p38 MAPK Signaling Networks. T.R. HOLZER, A.D. FULFORD, A.M. ARKINS, J.M. GRONDIN, C.W. MUNDY, A. NASIR, A.E. SCHADE *(Indianapolis, IN, USA)* 2073

Bioactivity of Synthetic 2-Halo-3-aryl-4(3*H*)-quinazoliniminium Halides in L1210 Leukemia and SK-BR-3 Mammary Tumor Cells *In Vitro*. J.-P. H. PERCHELLET, A. M. WATERS, E.M. PERCHELLET, V.K. NAGANABOINA, K.L. CHANDRA, J. DESPER, S. RAYAT *(Manhattan, KS, USA)* 2083

Associations of HSP90 Client Proteins in Human Breast Cancer. C. SHIPP, K. WATSON, G.L. JONES *(Armidale, NSW, Australia)* 2095

Proteomic Differential Display Analysis for TS-1-resistant and -sensitive Pancreatic Cancer Cells Using Two-dimensional Gel Electrophoresis and Mass Spectrometry. K. YOSHIDA, Y. KURAMITSU, K. MURAKAMI, S. RYOZAWA, K. TABA, S. KAINO, X. ZHANG, I. SAKAIDA, K. NAKAMURA *(Ube, Yamaguchi, Japan)* 2103

Response of Thyroglobulin to Radioiodine Therapy in Thyroglobulin-elevated Negative Iodine Scintigraphy (TENIS) Syndrome. P. SINHA, G.R. CONRAD, H.C. WEST *(Lexington, KY, USA)* 2109

Dosimetry of a^{238}Pu-based α-Particle Irradiator and Its Biological Application in a Study of the Bystander Effect. J. DAHLE, E. KALANXHI, N. TISNEK *(Oslo, Norway)* 2113

P-Glycoprotein Modulation by Valspodar and Cyclosporin Does Not Increase Tumor Uptake of Doxorubicin Administered *via* Isolated Lung Perfusion to Rats Bearing Sarcoma Lung Metastases. A. KUEMMERLE, H. YAN, T. KRUEGER, T. BUCLIN, O. BRAISSANT, H. HENRY, H.-B. RIS, L.A. DECOSTERD *(Lausanne, Switzerland)* 2121

Cyclosporine A Induces Apoptosis of Human Lung Adenocarcinoma Cells *via* Caspase-dependent Pathway. M. SATO, I. TSUJINO, M. FUKUNAGA, K. MIZUMURA, Y. GON, N. TAKAHASHI, S. HASHIMOTO *(Tokyo, Japan)* 2129

Quantitative Analysis of Thymidine Kinase 1 and 5'(3')-Deoxyribonucleotidase mRNA Expression: The Role of Fluorothymidine Uptake. S.J. LEE, H.J. LEE, D.H. MOON *(Seoul, South Korea)* 2135

Huachansu, Containing Cardiac Glycosides, Enhances Radiosensitivity of Human Lung Cancer Cells. L. WANG, U. RAJU, L. MILAS, D. MOLKENTINE, Z. ZHANG, P. YANG, L. COHEN, Z. MENG, Z. LIAO *(Houston, TX, USA; Shanghai, PR China)* 2141

Estimating Preclinical Efficacy Targets Utilizing Cetuximab Efficacy in *KRAS* Mutant and Wild-type Colorectal Cancer Models. M. PREWETT, R. BASSI, K. PAZ, M. AMATULLI, D. DEEVI, H. LI, S. WANG, L. WITTE, S. SAMAKOGLU, J.R. TONRA *(New York, NY, USA)* 2149

Development of Glioblastoma Cell Lines Expressing Red Fluorescence for Non-invasive Live Imaging of Intracranial Tumors. M. VERREAULT, D. STRUTT, D. MASIN, D. FINK, R. GILL, M.B. BALLY *(Vancouver, BC, Canada; Vienna, Austria)* 2161

Inhibition of Expression of HTLV-1 Structural Genes Mediated by Short Hairpin RNA *In Vitro*. R. HADDAD, S. KASHIMA, E.S. RODRIGUES, P.V.B. PALMA, M.A. ZAGO, D.T. COVAS *(Ribeirão Preto, São Paulo, Brazil)* 2173

3-Oxoolean-12-en-27-oic Acid Inhibits the Proliferation of Non-small Cell Lung Carcinoma Cells by Inducing Cell-cycle Arrest at G_0/G_1 Phase. N. TAE, J. SEO, B.-S. MIN, S. RYOO, J.-H. LEE *(Chuncheon; Gyeongsan, Republic of Korea)* 2179

Mucous Gland Metaplasia in the Esophagus and Gastric Mucosa in Baboons. C.A. RUBIO, M. OWSTON, A. ORREGO, R. NILSSON, H. LÖFDAHL, G. NESI, E.J. DICK Jr. *(San Antonio, TX, USA)* 2187

Correlation between COX-2 and APC Expression in Left *Versus* Right-sided Human Colon Cancer. A. NASIR, A. LOPEZ, D. BOULWARE, M. MALAFA, D. COPPOLA *(Tampa, FL, USA)* 2191

Circulating 20S Proteasome in Patients with Non-metastasized Breast Cancer. O. HOFFMANN, M. HEUBNER, T. ANLASIK, M. WINTERHALTER, B. DAHLMANN, S. KASIMIR-BAUER, R. KIMMIG, J. WOHLSCHLAEGER, S.U. SIXT *(Essen; Duesseldorf; Berlin, Germany)* 2197

Etomidate Induces Cytotoxic Effects and Gene Expression in a Murine Leukemia Macrophage Cell Line (RAW264.7). R.S.-C. WU, K.-C. WU, J.-S. YANG, S.-M. CHIOU, C.-S. YU, S.-J. CHANG, F.-S. CHUEH, J.-G. CHUNG *(Taichung; Kaohsiung, Taiwan, ROC)* 2203

18β-Glycyrrhetinic Acid and Glabridin Prevent Oxidative DNA Fragmentation in UVB-irradiated Human Keratinocyte Cultures. E. VERATTI, T. ROSSI, S. GIUDICE, L. BENASSI, G. BERTAZZONI, D. MORINI, P. AZZONI, E. BRUNI, A. GIANNETTI, C. MAGNONI *(Modena, Italy)* 2209

NK4 Gene Expression Enhances 5-Fluorouracil-induced Apoptosis of Murine Colon Cancer Cells. H. TAIYOH, T. KUBOTA, H. FUJIWARA, A. MATSUMURA, Y. MURAYAMA, K. OKAMOTO, D. ICHIKAWA, T. OCHIAI, T. NAKAMURA, K. MATSUMOTO, T. NAKAMURA, E. OTSUJI *(Kyoto; Kanazawa, Ishikawa; Osaka, Japan)* 2217

Paraoxonase-1 192/55 Polymorphisms and the Risk of Lung Cancer in a Turkish Population. P. AKSOY-SAGIRLI, B. CAKMAKOGLU, T. ISBIR, E. KAYTAN-SAGLAM, A. KIZIR, E. TOPUZ, H. BERKKAN *(Istanbul, Turkey)* 2225

Combined Valproic Acid and Celecoxib Treatment Induced Synergistic Cytotoxicity and Apoptosis in Neuroblastoma Cells. Y. CHEN, Y.-H. TSAI, S.-H. TSENG *(New Taipei; Taoyuan; Taipei, Taiwan, ROC)* 2231

Selective Inhibition of HTLV-1-infected Cell Proliferation by a Novel Tetramethylnaphthalene Derivative. T. HAMASAKI, M. TOYAMA, H. AOYAMA, Y. WHITE, M. OKAMOTO, N. ARIMA, Y. HASHIMOTO, M. BABA *(Kagoshima; Tokyo, Japan)* 2241

Down-regulation of *EGFL8*: A Novel Prognostic Biomarker for Patients with Colorectal Cancer. F. WU, A. SHIRAHATA, K. SAKURABA, Y. KITAMURA, T. GOTO, M. SAITO, K. ISHIBASHI, G. KIGAWA, H. NEMOTO, Y. SANADA, K. HIBI *(Guangzhou, PR China; Yokohama, Japan)* 2249

Phosphorylation of p53 Modifies Sensitivity to Ionizing Radiation. K. OKAICHI, K. NOSE, T. KOTAKE, N. IZUMI, T. KUDO *(Nagasaki, Japan)* 2255

Association of C-Reactive Protein (CRP) Gene Polymorphisms, Serum CRP Levels and Cervical Cancer Prognosis. S. POLTERAUER, C. GRIMM, R. ZEILLINGER, G. HEINZE, C. TEMPFER, A. REINTHALLER, L. HEFLER *(Vienna, Austria; Bochum, Germany)* 2259

Clinical Studies

Induction Treatment for Diffuse Intrinsic Pontine Glioma, Experience of M.D. Anderson Cancer Center. J.E. WOLFF, M. RYTTING, T. VATS, J. ATER, A. MAHAJAN, S. WOO, L. KETONEN, J. KUTTESCH, D. LIU, P. THALL, E.L. CHANG *(Houston, TX; Boston, MA; Nashivlle, TN, USA)* 2265

Phase II Trial of Weekly Alternating Sequential BIBF 1120 and Afatinib for Advanced Colorectal Cancer. O. BOUCHE, F. MAINDRAULT-GOEBEL, M. DUCREUX, G. LLEDO, T. ANDRE, P. STOPFER, N. AMELLAL, M. MERGER, A. DE GRAMONT *(Paris; Lyon, France; Biberach, Germany)* 2271

* Review: Endoglin (CD105): A Review of its Role in Angiogenesis and Tumor Diagnosis, Progression and Therapy. F. NASSIRI, M.D. CUSIMANO, B.W. SCHEITHAUER, F. ROTONDO, A. FAZIO, G.M. YOUSEF, L.V. SYRO, K. KOVACS, R.V. LLOYD *(Toronto, ON, Canada; Rochester, MN; Madison, WI, USA; Medellin, Colombia)* 2283

Percutaneous Radiofrequency Ablation of Hepatocellular Carcinoma Compared to Percutaneous Ethanol Injection in Treatment of Cirrhotic Patients: An Italian Randomized Controlled Trial. A. GIORGIO, A. DI SARNO, G. DE STEFANO, U. SCOGNAMIGLIO, N. FARELLA, A. MARINIELLO, V. ESPOSITO, C. COPPOLA, V. GIORGIO *(Naples, Italy)* 2291

Efficacy and Safety of Bortezomib plus Dexamethasone Therapy for Refractory or Relapsed Multiple Myeloma: Once-weekly Administration of Bortezomib May Reduce the Incidence of Gastrointestinal Adverse Events. T. FUKUSHIMA, T. NAKAMURA, H. IWAO, A. NAKAJIMA, M. MIKI, T. SATO, T. SAKAI, T. SAWAKI, Y. FUJITA, M. TANAKA, Y. MASAKI, H. NAKAJIMA, Y. MOTOO, H. UMEHARA *(Ishikawa, Japan)* 2297

Identification of Polymorphisms Associated with Hypertriglyceridemia and Prolonged Survival Induced by Bexarotene in Treating Non-small Cell Lung Cancer. W. LUO, N.J. SCHORK, K.B. MARSCHKE, S.-C. NG, T.W. HERMANN, J. ZHANG, J.M. SANDERS, P. TOOKER, N. MALO, M.A. ZAPALA, Z.E. DZIEWANOWSKA, A. NEGRO-VILAR, M.D. MEGLASSON *(San Diego; La Jolla, CA, USA)* 2303

Surgical Management of Bisphosphonate-related Osteonecrosis of the Jaw in Oncologic Patients: A Challenging Problem. A.M. ECKARDT, J. LEMOUND, D. LINDHORST, M. RANA, N.-C. GELLRICH *(Hannover, Germany)* 2313

Expression of iNOS - A Favourable Prognostic Marker for Early-stage Carcinoma of the Uterine Cervix. T. EGGEN, G. SAGER, M. ARNES, I. PETTERSEN, A. ØRBO *(Tromsø, Norway)* 2319

Mammographic Features Are Associated with Clinicopathological Characteristics in Invasive Breast Cancer. L. JIANG, T. MA, M.S. MORAN, X. KONG, X. LI, B.G. HAFFTY, Q. YANG *(Ji'nan, Shandong, PR China; New Haven, CT; Brunswick, NJ, USA)* 2327

Response of Recurrent Urachal Cancer to Gemcitabine and Cisplatin Therapy: A Case Report and Literature Review. Y. MIYATA, Y. SAGARA, T. MATSUO, K. OHBA, H. TAKAHASHI, H. SAKAI, H. KANETAKE *(Nagasaki, Japan)* 2335

Complete Response to Chemoradiotherapy in a Patient with Synchronous Double Gastric and Esophageal Cancer. N. YOSHIDA, M. KOCHI, M. FUJII, N. KANAMORI, T. KAIGA, Y. MIHARA, T. FUNADA, H. TAMEGAI, M. WATANABE, T. TAKAYAMA *(Tokyo, Japan)* 2339

Spreading of Acute Myeloid Leukemia Cells by Trafficking along the Peripheral Outflow Pathway of Cerebrospinal Fluid. M. SCHMITT, A. NEUBAUER, J. GREINER, X. XU, T.F.E. BARTH, K. BECHTER *(Rostock; Marburg; Ulm; Günzburg, Germany)* 2343

Variations in Demography and Prognosis by Colon Cancer Location. K. DERWINGER, B. GUSTAVSSON *(Gothenburg, Sweden)* 2347

Clinical Significance of HIF-1α Expression in Patients with Esophageal Cancer Treated with Concurrent Chemoradiotherapy. K. OGAWA, I. CHIBA, T. MORIOKA, H. SHIMOJI, W. TAMAKI, R. TAKAMATSU, T. NISHIMAKI, N. YOSHIMI, S. MURAYAMA *(Okinawa, Japan)* 2351

Comparison of Staging between the Old (6th Edition) and New (7th Edition) TNM Classifications in Advanced Gastric Cancer. S. KIKUCHI, N. FUTAWATARI, S. SAKURAMOTO, N. KATADA, K. YAMASHITA, T. SHIBATA, M. NEMOTO, M. WATANABE *(Kanagawa, Japan)* 2361

Case Report of a Poorly Differentiated Uterine Tumour with t(10;17) Translocation and Neuroectodermal Phenotype. F. AMANT, T. TOUSSEYN, L. COENEGRACHTS, J. DECLOEDT, P. MOERMAN, M. DEBIEC-RYCHTER *(Leuven; Dendermonde, Belgium)* 2367

Cutaneous Metastasis of Signet-ring Gastric Adenocarcinoma to the Breast with Unusual Clinicopathological Features. G. AVGERINOU, I. FLESSAS, E. HATZIOLOU, G. ZOGRAFOS, I. NITSIOS, F. ZAGOURI, A. KATSAMBAS, J. KANITAKIS *(Athens, Greece; Lyon, France)* 2373

Docetaxel, Cisplatin and 5-Fluorouracil plus Granulocyte Colony-stimulating Factor Prophylaxis in Patients with Metastatic Adenocarcinoma of the Stomach and Gastroesophageal Junction: Experience at the Medical University of Vienna. M. BOJIC, U. PLUSCHNIG, J. ZACHERL, C.M.R. THALLINGER, A. BASSALAMAH, J. MARESCH, P. DATLER, S.F. SCHOPPMANN, M. HEJNA *(Vienna, Austria)* 2379

Incidence of Venous Thromboembolism during Chemotherapy for Breast Cancer: Impact on Cancer Outcome. C.C. KIRWAN, G. MCDOWELL, C.N. MCCOLLUM, G.J. BYRNE *(Manchester, UK)* 2383

Expression of p53, Ki-67, E-Cadherin, N-Cadherin and TOP2A in Triple-negative Breast Cancer. M. NAKAGAWA, Y. BANDO, T. NAGAO, M. MORIMOTO, C. TAKAI, T. OHNISHI, J. HONDA, T. MORIYA, K. IZUMI, M. TAKAHASHI, M. SASA, A. TANGOKU *(Tokushima; Itano, Fukushima; Kakogawa, Hyogo; Kurashiki, Okayama, Japan)* 2389

Methylenetetrahydrofolate Reductase (*MTHFR*) Genotype, Smoking Habit, Metastasis and Oral Cancer in Taiwan. C.-W. TSAI, C.-F. HSU, M.-H. TSAI, Y.-A. TSOU, C.-H. HUA, W.-S. CHANG, C.-C. LIN, D.-T. BAU *(Taichung; Chang-Hua, Taiwan, ROC)* 2395

Book Reviews 2401

Announcements 2407

Reviews (pages 2053, 2283)

Number 7

Proceedings of the 14th Annual Meeting of the Society of Biotherapeutic Approaches December 11, 2010, Fukuoka, Japan. Special Issue Edited by M. Kuroki, S. Oshiro, G.-I. Soma

Preface 2409

* Review: KRAS-induced Actin-interacting Protein: A Potent Target for Obesity, Diabetes and Cancer. T. FUJIMOTO, S. SHIRASAWA *(Fukuoka, Japan)* 2413

Induction of Cytotoxic T Lymphocytes by CEA Peptide-pulsed γδ T-Cells Isolated from Patients with Advanced Cancer. A. YAMASAKI, H. ONISHI, T. MORISAKI, M. KATANO *(Fukuoka, Japan)* 2419

* Review: Sonodynamic Cancer Therapy: A Non-invasive and Repeatable Approach Using Low-intensity Ultrasound with a Sonosensitizer. H. SHIBAGUCHI, H. TSURU, MOTOMU KUROKI, MASAHIDE KUROKI *(Fukuoka, Japan)* 2425

* Short Review: Oral Administration of Lipopolysaccharides for the Prevention of Various Diseases: Benefit and Usefulness. H. INAGAWA, C. KOHCHI, G.-I. SOMA *(Kagawa-ken; Chiba-ken; Tokushima-ken, Japan)* 2431

* Short Review: Lipopolysaccharide IP-PA1 from *Pantoea agglomerans* Prevents Suppression of Macrophage Function in Stress-induced Diseases. K. NAKATA, H. INAGAWA, G.-I. SOMA *(Okayama; Kagawa; Tokushima, Japan)* .. 2437

WT1 Peptide Vaccine Stabilized Intractable Ovarian Cancer Patient for One Year: A Case Report. S. DOHI, S. OHNO, Y. OHNO, M. TAKAKURA, S. KYO, G.-I. SOMA, H. SUGIYAMA, M. INOUE *(Ishikawa; Tokyo; Tokushima; Chiba; Osaka, Japan)* 2441

Frequency of Myeloid Dendritic Cells Can Predict the Efficacy of Wilms' Tumor 1 Peptide Vaccination. S. OHNO, F. TAKANO, Y. OHTA, S. KYO, S. MYOJO, S. DOHI, H. SUGIYAMA, T. OHTA, M. INOUE *(Tokyo; Ishikawa; Osaka, Japan)* 2447

Oncogenic KRAS Regulates miR-200c and miR-221/222 in a 3D-Specific Manner in Colorectal Cancer Cells. T. TSUNODA, Y. TAKASHIMA, Y. YOSHIDA, K. DOI, Y. TANAKA, T. FUJIMOTO, T. MACHIDA, T. OTA, M. KOYANAGI, M. KUROKI, T. SASAZUKI, S. SHIRASAWA *(Fukuoka, Japan)* 2453

A Possible Clinical Adaptation of CRM197 in Combination with Conventional Chemotherapeutic Agents for Ovarian Cancer. H. TSUJIOKA, T. FUKAMI, F. YOTSUMOTO, T. UEDA, S. HIKITA, Y. TAKAHASHI, H. KONDO, M. KUROKI, S. MIYAMOTO *(Fukuoka, Japan)* 2461

Functional Characterization of Lipopolysaccharide derived from Symbiotic Bacteria in Rice as a Macrophage-activating Substance. T. KADOWAKI, H. INAGAWA, C. KOHCHI, M. HIRASHIMA, G.-I. SOMA *(Kagawa-ken, Yamaguchi-ken; Chiba-ken; Tokushima-ken, Japan)* 2467

Design, Synthesis and Destructive Dynamic Effects of BODIPY-containing and Curcuminoid Boron Tracedrugs for Neutron Dynamic Therapy. E. NAKATA, M. KOIZUMI, Y. YAMASHITA, K. ONAKA, Y. SAKURAI, N. KONDO, K. ONO, Y. UTO, H. HORI *(Tokushima; Osaka, Japan)* 2477

Antitumor Effects of CRM197, A Specific Inhibitor of HB-EGF, in T-Cell Acute Lymphoblastic Leukemia. N. KUNAMI, F. YOTSUMOTO, K. ISHITSUKA, T. FUKAMI, T. ODAWARA, S. MANABE, T. ISHIKAWA, K. TAMURA, M. KUROKI, S. MIYAMOTO *(Fukuoka; Osaka, Japan)* 2483

Effect of the Gc-derived Macrophage-activating Factor Precursor (preGcMAF) on Phagocytic Activation of Mouse Peritoneal Macrophages. Y. UTO, S. YAMAMOTO, R. TAKEUCHI, Y. NAKAGAWA, K. HIROTA, H. TERADA, S. ONIZUKA, E. NAKATA, H. HORI *(Tokushima; Tokyo; Chiba; Nagasaki; Kyoto, Japan)* 2489

Differential Expression of mRNA in Human Monocytes following Interaction with Human Colon Cancer Cells. T. HONDA, H. INAGAWA, I. YAMAMOTO *(Kanagawa; Kagawa, Japan)* 2493

Clinical Course of Colorectal Cancer in Patients with Ulcerative Colitis. D. HIGASHI, K. FUTAMI, Y. ISHIBASHI, Y. EGAWA, T. MAEKAWA, T. MATSUI, A. IWASHITA, M. KUROKI *(Chikushino-shi; Fukuoka, Japan)* 2499

Combinatorial Cytotoxicity of Gemcitabine and Cytokine-activated Killer Cells in Hepatocellular Carcinoma *via* the NKG2D-MICA/B System. T. MORISAKI, H. ONISHI, N. KOYA, A. KIYOTA, H. TANAKA, M. UMEBAYASHI, T. OGINO, I. NAGAMATSU, M. KATANO *(Fukuoka, Japan)* 2505

Novel Complementary Peptides to Target Molecules. H. OKADA, M. IMAI, F. ONO, A. OKADA, T. TADA, Y. MIZUE, K. TERAO, N. OKADA *(Nagoya; Tsukuba; Sapporo, Japan)* 2511

Decreased Expression of Claudin-1 in Rectal Cancer: A Factor for Recurrence and Poor Prognosis. T. YOSHIDA, T. KINUGASA, Y. AKAGI, A. KAWAHARA, K. ROMEO, I. SHIRATSUCHI, Y. RYU, Y. GOTANDA, K. SHIROUZU *(Fukuoka, Japan)* 2517

Sonodynamic Therapy with 5-Aminolevulinic Acid and Focused Ultrasound for Deep-seated Intracranial Glioma in Rat. T. OHMURA, T. FUKUSHIMA, H. SHIBAGUCHI, S. YOSHIZAWA, T. INOUE, M. KUROKI, K. SASAKI, S.-I. UMEMURA *(Fukuoka; Miyagi, Saitama, Japan)* 2527

KRAS-mediated Up-regulation of RRM2 Expression Is Essential for the Proliferation of Colorectal Cancer Cell Lines. Y. YOSHIDA, T. TSUNODA, K. DOI, Y. TANAKA, T. FUJIMOTO, T. MACHIDA, T. OTA, M. KOYANAGI, Y. TAKASHIMA, T. SASAZUKI, M. KUROKI, A. IWASAKI, S. SHIRASAWA *(Fukuoka, Japan)* 2535

Expression of IGF-1 and IGF-1R and Their Relation to Clinicopathological Factors in Colorectal Cancer. I. SHIRATSUCHI, Y. AKAGI, A. KAWAHARA, T. KINUGASA, K. ROMEO, T. YOSHIDA, Y. RYU, Y. GOTANDA, M. KAGE, K. SHIROUZU *(Fukuoka, Japan)* 2541

Relationship between Ulcerative Colitis Patients Treated with Leukocytapheresis and Ulcerative Colitis-associated Colorectal Cancer. T. KINUGASA, Y. AKAGI, K. MUROTANI, K. ROMEO, T. YOSHIDA, Y. RYU, I. SHIRATUCHI, K. SHIROUZU *(Fukuoka; Kobe, Japan)* 2547

Assessment of HB-EGF Levels in Peritoneal Fluid and Serum of Ovarian Cancer Patients using ELISA. S. HIKITA, F. YOTSUMOTO, T. FUMAKI, S. HORIUCHI, A. SANUI, K. MIYATA, S.O. NAM, H. TSUJIOKA, T. UEDA, K. SHIROTA, T. YOSHIZATO, K. MAEDA, T. ISHIKAWA, Y. OKUNO, M. KUROKI, E. MEKADA, S. MIYAMOTO *(Fukuoka; Osaka, Japan)* 2553

Efficiency of Antimicrobial Defense: Molecular Flexibility of Natural Defensin and Artificial *Bis*-quaternary Ammonium Compound. K. OHKURA, Y. SHINOHARA, H. HORI *(Suzuka, Mie; Tokushima, Japan)* 2561

* Reviews (pages 2413, 2425, 2431, 2437)

Number 8

Current Aspects and Future Direction in Gynaecological Oncology
Special Issue Edited by J. Sehouli, W. Lichtenegger

Preface 2565

First Evaluation of the Diagnostic Accuracy of an Automated 3D Ultrasound System in a Breast Screening Setting. F. STÖBLEN, S. LANDT, R. STELKENS-GEBHARDT, J. SEHOULI, M. REZAI, S. KÜMMEL *(Essen; Düsseldorf; Berlin, Germany)* 2569

High-frequency Breast Ultrasound for the Detection of Microcalcifications and Associated Masses in BI-RADS 4a Patients. F. STÖBLEN, S. LANDT, R. ISHAQ, R. STELKENS-GEBHARDT, M. REZAI, P. SKAANE, J.-U. BLOHMER, J. SEHOULI, S. KÜMMEL *(Essen; Düsseldorf; Berlin, Germany; Oslo, Norway)* 2575

Predictive Factors in Relapsed Ovarian Cancer for Complete Tumor Resection. B. GIL-IBÁÑEZ, G. OSKAY-ÖZCELIK, R. RICHTER, C. FOTOPOULOU, E.I. BRAICU, P. NEUHAUS, W. LICHTENEGGER, J. SEHOULI; On behalf of the Tumor Bank Ovarian Cancer Network (TOC) and European Competence Centre for Ovarian Cancer (EKZE Berlin) *(Berlin, Germany)* 2583

Prognostic Significance of Angiogenic Factors in Uterine Cervical Cancer. S. LANDT, M. WEHLING, H. HEIDECKE, S. JESCHKE, S. KORLACH, F. STÖBLEN, P. SCHMID, J.-U. BLOHMER, W. LICHTENEGGER, J. SEHOULI, S. KÜMMEL *(Düsseldorf; Essen; Luckenwalde; Berlin, Germany; Brighton, UK)* 2589

CT-Guided High-Dose-Rate Brachytherapy of Metachronous Ovarian Cancer Metastasis to the Liver: Initial Experience. F. COLLETTINI, A. POELLINGER, D. SCHNAPAUFF, T. DENECKE, P. WUST, I.E. BRAICU, J. SEHOULI, B. HAMM, B. GEBAUER *(Berlin, Germany)* 2597

First Surgical Experience of Intraperitoneal Treatment with the Trifunctional Antibody Catumaxomab (Anti-EpCam × Anti-CD3) for Epithelial Ovarian Cancer. G. PAPANIKOLAOU, C. FOTOPOULOU, I. BRAICU, R. CHEKEROV, S.C. SCHMIDT, K. PIETZNER, J. SEHOULI *(Berlin, Germany)* 2603

In Vitro Vascular Tube Formation Testing as a Tool for Treatment Individualisation in Patients with Cervical Cancer. S. LANDT, H. HEIDECKE, S. KORLACH, C. REUTER, I. SCHWIDDE, J. BARINOFF, M. THILL, J. SEHOULI, S. KÜMMEL *(Düsseldorf; Luckenwalde; Berlin; Essen; Lübeck, Germany)* 2609

Influence of a Dose-dense Adjuvant Chemotherapy on sVCAM-1/sICAM-1 Serum Levels in Breast Cancer Patients with 1-3 Positive Lymph Nodes. H. EGGEMAN, F. STÖBLEN, M. THILL, S. KORLACH, P. SCHMID, D. LÜFTNER, D. ELLING, F.-A. TARAN, S. KÜMMEL, S. LANDT *(Magdeburg; Essen; Lübeck; Berlin; Düsseldorf, Germany; Brighton, UK)* 2617

* Review: Cell-free DNA in the Circulation as a Potential Cancer Biomarker. C. KOHLER, Z. BAREKATI, R. RADPOUR, X.Y. ZHONG *(Basel, Switzerland)* 2623

Systemic Changes of Tryptophan Catabolites *via* the Indoleamine-2,3-dioxygenase Pathway in Primary Cervical Cancer. C. FOTOPOULOU, J. SEHOULI, R. PSCHOWSKI, S. VON HAEHLING, G. DOMANSKA, E.-I. BRAICU, G. FUSCH, P. REINKE, J.C. SCHEFOLD *(Berlin; Greifswald, Germany)* 2629

Effect of Melatonin on Intra-abdominal Fat in Correlation with Endometrial Proliferation in Ovariectomized Rats. R. CIORTEA, N. COSTIN, I. BRAICU, D. HARAGÂŞ, A. HUDACSKO, C. BONDOR, D. MIHU, C.M. MIHU *(Cluj-Napoca, Romania; Berlin, Germany)* 2637

The Utility of an *In Vitro* Angiogenesis Score for Prognosis Assessment in Patients with Cervical Cancer. S. LANDT, H. HEIDECKE, C. REUTER, S. KORLACH, J.-U. BLOHMER, W. LICHTENEGGER, T. HEUSNER, F. STÖBLEN, M. THILL, J. BARINOFF, J. SEHOULI, S. KÜMMEL *(Düsseldorf; Luckenwalde; Berlin; Essen; Lübeck, Germany)* 2645

Prognostic Significance of the Angiogenic Factors Angiogenin, Endoglin and Endostatin in Cervical Cancer. S. LANDT, K. MORDELT, I. SCHWIDDE, J. BARINOFF, S. KORLACH, F. STÖBLEN, W. LICHTENEGGER, J. SEHOULI, S. KÜMMEL *(Düsseldorf; Berlin; Essen, Germany)* 2651

First Evaluation of the Joint Clinical Registry Data of Patients with Primary Ovarian Cancer at the Coordinating Tumor Center of Berlin. R. CHEKEROV, S. BRAUN, A.D. EBERT, C. HERBSTREIT, A. JAGOTA, K.D. JOHANNSMEYER, C. KRONENBERGER, J. POTENBERG, J.P. SCHARF, R. RICHTER, U. ULRICH, J. SEHOULI *(Berlin, Germany)* 2657

* Review: The Mutational Profile of Sporadic Epithelial Ovarian Carcinoma. S. KALAMANATHAN, V. BATES, R. LORD, J.A. GREEN *(Liverpool; Wirral, Merseyside, UK)* 2661

Optimizing the Clinical Management of Gynecological and Breast Cancer *via* Online Tumor Conferences. J.K. SCHROEDER, S. KUEMMEL, K. PIETZNER, J. HECTOR, J. SEHOULI, R. CHEKEROV *(Essen; Berlin, Germany)* 2669

Long Term Combination Treatment with Bevacizumab, Pegylated Liposomal Doxorubicin and Regional Abdominal Hyperthermia in Platinum Refractory Ovarian Cancer: A Case Report and Review of the Literature. K. PIETZNER, R.B. SCHMUCK, C. FOTOPOULOU, J. GELLERMANN, F. ISMAEEL, C.H. CHO, M. KALDEN, J. SEHOULI *(Berlin; Jena; Dortmund, Germany)* 2675

Bevacizumab in Heavily Pre-treated and Platinum Resistant Ovarian Cancer: A Retrospective Study of the North-Eastern German Society of Gynaecologic Oncology (NOGGO) Ovarian Cancer Study Group. K. PIETZNER, R. RICHTER, R. CHEKEROV, E. EROL, G. OSKAY-ÖZCELIK, W. LICHTENEGGER, J. SEHOULI *(Berlin, Germany)* 2679

* Reviews (pages 2623, 2661)

Number 9

Experimental Studies

Gankyrin, A Biomarker for Epithelial Carcinogenesis, Is Overexpressed in Human Oral Cancer. J. LI, T.J. KNOBLOCH, L.A. KRESTY, Z. ZHANG, J.C. LANG, D.E. SCHULLER, C.M. WEGHORST *(Columbus, OH; Miami, FL, USA)* 2683

Expression of Selenium-containing Proteins in Human Colon Carcinoma Tissue. V. YAGUBLU, J.R. ARTHUR, S.N. BABAYEVA, F. NICOL, S. POST, M. KEESE *(Mannheim; Frankfurt Main, Germany; Aberdeen, UK; Baku, Azerbaijan)* 2693

Pomegranate Extract Induces Cell Cycle Arrest and Alters Cellular Phenotype of Human Pancreatic Cancer Cells. V. NAIR, Z. DAI, M. KHAN, H.P. CIOLINO *(Austin, TX; Rockville, MD, USA)* 2699

6-Thioguanine Inhibition of Parathyroid Hormone-related Protein Expression Is Mediated by GLI2. R.W. JOHNSON, A.R. MERKEL, S. DANILIN, M.P. NGUYEN, G.R. MUNDY, J.A. STERLING *(Nashville, TN, USA)* 2705

The mTOR Inhibitor RAD001 Sensitizes Tumor Cells to the Cytotoxic Effect of Carboplatin in Breast Cancer *In Vitro*. H. LIU, C. ZANG, J.-H. SCHEFE, S. SCHWARZLOSE-SCHWARCK, A.-C. REGIERER, E. ELSTNER, C.-O. SCHULZ, C. SCHOLZ, K. POSSINGER, J. EUCKER *(Berlin, Germany)* 2713

Histone Deacetylase Inhibitors Reverse CpG Methylation by Regulating DNMT1 through ERK Signaling. S. SARKAR, A.L. ABUJAMRA, J.E. LOEW, L.W. FORMAN, S.P. PERRINE, D.V. FALLER *(Boston, MA, USA)* 2723

Protein-bound Polysaccharide-K (PSK) Induces Apoptosis and Inhibits Proliferation of Promyelomonocytic Leukemia HL-60 Cells. N. HIRAHARA, M. FUJIOKA, T. EDAMATSU, A. FUJIEDA, F. SEKINE, T. WADA, T. TANAKA *(Izumo; Tokyo, Japan)* 2733

Clioquinol Suppresses Cyclin D1 Gene Expression through Transcriptional and Post-transcriptional Mechanisms. J. ZHENG, D.M. BENBROOK, H. YU, W.-Q. DING *(Oklahoma City, OK, USA; Wuhan, PR China)* 2739

Prognostic Relevance of Disseminated Tumor Cells in the Bone Marrow of Patients with Primary Breast Cancer – Results of a Standardized Follow-Up. C. SCHINDLBECK, G. PFAB, J. JUECKSTOCK, U. ANDERGASSEN, H. SOMMER, W. JANNI, K. FRIESE, B. RACK *(Traunstein; Munich; Duesseldorf, Germany)* 2749

Modulation of Cisplatin Cytotoxicity due to its Combination with Bortezomib and the Nature of its Administration. Z. AL-EISAWI, P. BEALE, C. CHAN, J.Q. YU, F. HUQ *(Sydney, NSW, Australia)* 2757

Prognostic Significance of Thymidylate Synthase Expression in the Adjuvant Chemotherapy after Resection for Pulmonary Metastases from Colorectal Cancer. K. KAIRA, T. OKUMURA, Y. OHDE, T. TAKAHASHI, H. MURAKAMI, H. KONDO, T. NAKAJIMA. N. YAMAMOTO *(Shizuoka, Japan)* 2763

In Vitro and *In Vivo* Anticancer Activity of (+)-Spongistatin 1. Q. XU, K.-C. HUANG, K. TENDYKE, J. MARSH, J. LIU, D. QIU, B.A. LITTLEFIELD, K. NOMOTO, O. ATASOYLU, C.A. RISATTI, J.B. SPERRY, A.B. SMITH III *(Andover, MA; Philadelphia, PA, USA)* 2773

Interaction of Dacarbazine and Imexon, *In Vitro* and *In Vivo,* in Human A375 Melanoma Cells. B.K. SAMULITIS, R.T. DORR, H.-H.S. CHOW *(Tucson, AZ, USA)* 2781

Acquired Drug Resistance to Vascular Endothelial Growth Factor Receptor 2 Tyrosine Kinase Inhibitor in Human Vascular Endothelial Cells. T. ARAO, K. MATSUMOTO, K. FURUTA, K. KUDO, H. KANEDA, T. NAGAI, K. SAKAI, Y. FUJITA, D. TAMURA, K. AOMATSU, F. KOIZUMI, K. NISHIO *(Osaka-Sayama; Tokyo, Japan)* 2787

SDF1β Expression in Renal Cell Carcinoma Correlates with Grading and Infiltration by $CD8^+$ T-Cells. T.C. WEHLER, C. GRAF, K. ALTHERR, T. ZIMMERMANN, W. BRENNER, J.W. THÜROFF, S. BIESTERFELD, I. GOCKEL, M. THEOBALD, P.R. GALLE, C.C. SCHIMANSKI *(Mainz; Duesseldorf, Germany)* 2797

Activation of the Wnt/Beta-catenin Signaling Pathway during Oral Carcinogenesis Process Is Not Influenced by the Absence of Galectin-3 in Mice. J.M. SANT'ANA, R. CHAMMAS, F.-T. LIU, S. NONOGAKI, S.V. CARDOSO, A.M. LOYOLA, P.R. DE FARIA *(Uberlândia; São Paulo, Brazil; Sacramento, CA, USA)* 2805

Anti-*MDR1* siRNA Restores Chemosensitivity in Chemoresistant Breast Carcinoma and Osteosarcoma Cell Lines. J. PEREZ, C. BARDIN, C. RIGAL, B. ANTHONY, R. ROUSSEAU, A. DUTOUR *(Lyon; Villeurbanne, France)* 2813

Gallic Acid Induces G_0/G_1 Phase Arrest and Apoptosis in Human Leukemia HL-60 Cells through Inhibiting Cyclin D and E, and Activating Mitochondria-dependent Pathway. R.-D. YEH, J.-C. CHEN, T.-Y. LAI, J.-S. YANG, C.-S. YU, J.-H. CHIANG, C.-C. LU, S.-T. YANG, C.-C. YU, S.-J. CHANG, H.-Y. LIN, J.-G. CHUNG *(Kaohsiung; Taichung, Taiwan, ROC)* 2821

Correlation between Expression of Metallothionein and Expression of Ki-67 and MCM-2 Proliferation Markers in Non-small Cell Lung Cancer. B. WERYNSKA, B. PULA, B. MUSZCZYNSKA-BERNHARD, A. PIOTROWSKA, A. JETHON, M. PODHORSKA-OKOLOW, P. DZIEGIEL, R. JANKOWSKA *(Wroclaw; Poznan, Poland)* 2833

Evaluation of Anticancer Activities of Benzo[*c*]phenanthridine Alkaloid Sanguinarine in Oral Squamous Cell Carcinoma Cell Line. H. TSUKAMOTO, S. KONDO, Y. MUKUDAI, T. NAGUMO, A. YASUDA, Y. KURIHARA, T. KAMATANI, S. SHINTANI *(Tokyo, Japan)* 2841

Interaction of Radiation and Pemetrexed on a Human Malignant Mesothelioma Cell Line *In Vitro*. D. YOSHIDA, T. EBARA, Y. SATO, T. KAMINUMA, T. TAKAHASHI, T. ASAO, T. NAKANO *(Maebashi, Gunma, Japan)* 2847

Antitumor Therapeutic Effects of Cytosine Deaminase and Interferon-β Against Endometrial Cancer Cells Using Genetically Engineered Stem Cells *In Vitro*. B.-R. YI, N.-H. KANG, K.-A. HWANG, S.U. KIM, E.-B. JEUNG, K.-C. CHOI *(Cheongju, Chungbuk, Republic of Korea; Vancouver, BC, Canada)* 2853

Determination of Clofarabine Triphosphate Concentrations in Leukemia Cells Using Sensitive, Isocratic High-performance Liquid Chromatography. T. YAMAUCHI, R. NISHI, T. UEDA *(Fukui, Japan)* 2863

H-ras Up-regulates Expression of BNIP3. W. KALAS, E. SWIDEREK, A. RAPAK, M. KOPIJ, J. RAK, L. STRZADALA *(Wroclaw, Poland; Montreal, QC, Canada)* 2869

K-ras Mutations in Lung Tumors from NNK-treated Mice with Lipopolysaccharide-elicited Lung Inflammation. P. KEOHAVONG, B. KAHKONEN, E. KINCHINGTON, J. YIN, J. JIN, X. LIU, J.M. SIEGFRIED, Y.P. DI *(Pittsburgh, PA, USA)* 2877

Prediction of Synergistic Antitumour Effect of Gefitinib and Radiation *In Vitro*. H.Q. LIN, H. MERIATY, A. KATSIFIS *(Lucas Heights, NSW, Australia)* 2883

Methylation of the Homeobox Gene, *HOPX*, Is Frequently Detected in Poorly Differentiated Colorectal Cancer. Y. HARADA, K. KIJIMA, K. SHINMURA, M. SAKATA, K. SAKURABA, K. YOKOMIZO, Y. KITAMURA, A. SHIRAHATA, T. GOTO, H. MIZUKAMI, M. SAITO, G. KIGAWA, H. NEMOTO, K. HIBI *(Yokohama, Japan)* 2889

Etodolac Improves 5-FU Sensitivity of Head and Neck Cancer Cells through Inhibition of Thymidylate Synthase. S. MURATA, M. ADACHI, M. KIOI, S. TORIGOE, K. IJICHI, Y. HASEGAWA, T. OGAWA, M.K. BHAYANI, S.Y. LAI, K. MITSUDO, I. TOHNAI *(Yokohama; Nagoya; Nagakute, Aichi, Japan; Houston, TX, USA)* 2893

Down-regulation of Expression of Interleukin-6 and its Receptor Results in Growth Inhibition of MCF-7 Breast Cancer Cells. X.-P. JIANG, D.C. YANG, R.L. ELLIOTT, J.F. HEAD *(Baton Rouge, LA, USA)* 2899

Comparison of μCT, MRI and Optical Reflectance Imaging for Assessing the Growth of GFP/RFP-expressing Tumors. L. ABOU-ELKACEM, F. GREMSE, S. BARTH, R.M. HOFFMAN, F. KIESSLING, W. LEDERLE *(Aachen, Germany; San Francisco; San Diego, CA, USA)* 2907

Panipenem Does Not Alter the Pharmacokinetics of the Active Metabolite of Irinotecan SN-38 and Inactive Metabolite SN-38 Glucuronide (SN-38G) in Rats. A. KATO, J. UEYAMA, F. ABE, K. HOTTA, I. TSUKIYAMA, T. OSHIMA, F. KONDO, H. SAITO, T. HASEGAWA *(Aichi-gun; Nagoya, Aichi; Kanazawa, Ishikawa, Japan)* 2915

Clinical Studies

* Review: CT and MR Imaging of the Adrenal Glands in Cortisol-secreting Tumors. F. LUMACHI, P. MARCHESI, D. MIOTTO, R. MOTTA *(Padova, Italy)* 2923

Cryotreatment against Metastatic Renal Cell Bone Tumour Reduced Multiple Lung Metastases. H. NISHIDA, T. SHIRAI, K. HAYASHI, A. TAKEUCHI, Y. TANZAWA, A. MIZOKAMI, M. NAMIKI, H. TSUCHIYA *(Kanazawa, Japan)* 2927

Nonhepatic Cancer in Liver Cirrhosis: A Retrospective Study of Prevalence, Complication Rate after Specific Oncological Treatment, Follow-up and Prognostic Predictors of Outcome in 354 Patients with Cirrhosis. F. GUNDLING, H. SEIDL, F. SCHMIDTLER, N. LÖFFLER, I. STRASSEN, P. WOLF, C. PEHL, T. SCHMIDT, W. SCHEPP *(Munich; Vilsbiburg, Germany)* 2931

Serum 25-Hydroxyvitamin D and Prevention of Breast Cancer: Pooled Analysis. S.B. MOHR, E.D. GORHAM, J.E. ALCARAZ, C.J. KANE, C.A. MACERA, J. KELLOGG PARSONS, D.L. WINGARD, C.F. GARLAND *(La Jolla; San Diego, CA, USA)* 2939

Basic Clinical Parameters Predict Gefitinib Efficacy in Non-small Cell Lung Cancer. A. PIRCHER, E. ULSPERGER, R. HACK, H. JAMNIG, G. PALL, B. ZELGER, W. STERLACCI, W. HILBE, M. FIEGL *(Innsbruck; Vienna; Tyrol; Feldkirch, Austria)* 2949

Palladin is a Marker of Liver Metastasis in Primary Pancreatic Endocrine Carcinomas. E.B. HENDERSON-JACKSON, J. HELM, J. STROSBERG, N.A. NASIR, T.J. YEATMAN, L.K. KVOLS, D. COPPOLA, A. NASIR *(Tampa, FL, USA)* 2957

Elevated YB-1 Expression is a New Unfavorable Prognostic Factor in Non-Hodgkin's Lymphomas. K. SZCZURASZEK, A. HALON, V. MATERNA, G. MAZUR, T. WROBEL, K. KULICZKOWSKI, P. DONIZY, P.S. HOLM, H. LAGE, P. SUROWIAK *(Wroclaw, Poland; Berlin; Munich, Germany)* 2963

The Efficacy of Gemcitabine as Salvage Treatment in Patients with Refractory Advanced Colorectal Cancer (CRC): A Single Institution Experience. M.W. SAIF, K. KALEY, R. PENNEY, S. HOTCHKISS, K.N. SYRIGOS, A.S. STRIMPAKOS *(New York, NY, USA)* 2971

RASSF1A Methylation is Predictive of Poor Prognosis in Female Breast Cancer in a Background of Overall Low Methylation Frequency. A. BUHMEIDA, A. MERDAD, J. EL-MAGHRABI, F. AL-THOBAITI, M. ATA, A. BUGIS, K. SYRJÄNEN, A. ABUZENADAH, A. CHAUDHARY, M. GARI, M. AL-QAHTANI, A. DALLOL *(Jeddah, Saudi Arabia; Turku, Finland)* 2975

Safety and Short-term Therapeutic Effects of Miriplatin–Lipiodol Suspension in Transarterial Chemoembolization (TACE) for Hepatocellular Carcinoma. K. OKABE, T. BEPPU, K. HARAOKA, Y. OH-UCHIDA, S. YAMAMURA, S. TOMIYASU, T. YAMANAKA, O. SANO, T. MASUDA, A. CHIKAMOTO, S. FUJIYAMA, H. BABA *(Kumamoto, Japan)* 2983

A Low-grade Myofibroblastic Sarcoma in the Abdominal Cavity. M. MIYAZAWA, Y. NARITAKA, A. MIYAKI, S. ASAKA, N. ISOHATA, K. YAMAGUCHI, M. MURAYAMA, T. SHIMAKAWA, T. KATSUBE, K. OGAWA, M. FUJIBAYASHI *(Tokyo, Japan)* 2989

Preoperative Neutrophil to Lymphocyte Ratio as a Prognostic Predictor after Curative Resection for Non-small Cell Lung Cancer. M. TOMITA, T. SHIMIZU, T. AYABE, A. YONEI, T. ONITSUKA *(Miyazaki, Japan)* 2995

Lapatinib Enhances Herceptin-mediated Antibody-dependent Cellular Cytotoxicity by Up-regulation of Cell Surface HER2 Expression. T. MARUYAMA, K. MIMURA, S. IZAWA, A. INOUE, S. SHIBA, M. WATANABE, Y. KAWAGUCHI, M. INOUE, H. NOGATA, S. INOUE, H. FUJII, K. KONO *(Chuo; Kofu, Yamanashi, Japan)* ... 2999

Paclitaxel and Bevacizumab as First Line Combined Treatment in Patients with Metastatic Breast Cancer: The Hellenic Cooperative Oncology Group Experience with Biological Marker Evaluation. G. FOUNTZILAS, H.P. KOUREA, M. BOBOS, D. TELEVANTOU, V. KOTOULA, C. PAPADIMITRIOU, K.T. PAPAZISIS, E. TIMOTHEADOU, I. EFSTRATIOU, A. KOUTRAS, G. PENTHEROUDAKIS, C. CHRISTODOULOU, G. ARAVANTINOS, D. MILIARAS, K. PETRAKI, C.N. PAPANDREOU, P. PAPAKOSTAS, D. BAFALOUKOS, D. REPANA, E. RAZIS, D. PECTASIDES, A.M. DIMOPOULOS *(Thessaloniki; Patras; Athens; Ioannina; Larissa, Greece)* 3007

Differential Activation of MAPK and PI3K/AKT/mTOR Pathways and IGF1R Expression in Gastrointestinal Stromal Tumors. M.J. RÍOS-MORENO, S. JARAMILLO, M. DÍAZ-DELGADO, M. SÁNCHEZ-LEÓN, I. TRIGO-SÁNCHEZ, J. POLO PADILLO, J. AMÉRIGO, R. GONZÁLEZ-CÁMPORA *(Seville; Badajoz; Almeria, Spain)* 3019

Correlation of Intensity of MT-I/II Expression with Ki-67 and MCM-2 Proteins in Invasive Ductal Breast Carcinoma. A. WOJNAR, B. PULA, A. PIOTROWSKA, A. JETHON, K. KUJAWA, C. KOBIERZYCKI, J. RYS, M. PODHORSKA-OKOLOW, P. DZIEGIEL *(Wroclaw; Poznan; Krakow, Poland)* 3027

Phase I Study of S-1 in Combination with Trastuzumab for HER2-positive Metastatic Breast Cancer. T. NAKAYAMA, S. MORITA, T. TAKASHIMA, S. KAMIGAKI, K. YOSHIDOME, T. ITO, T. TAGUCHI, J. SAKAMOTO, S. NOGUCHI *(Osaka; Kanagawa; Nagoya, Aichi, Japan)* 3035

Pathological Complete Response and Prognosis in Patients Receiving Neoadjuvant Paclitaxel and Trastuzumab with and without Anthracyclines for Stage II and III, HER2-positive Operable Breast Cancer: A Single-institute Experience. J. HORIGUCHI, T. OYAMA, D. TAKATA, N. ROKUTANDA, R. NAGAOKA, H. ODAWARA, H. TOKINIWA, K. TOZUKA, M. KIKUCHI, A. SATO, I. TAKEYOSHI *(Maebashi, Gunma, Japan)* 3041

Fertility-sparing Management of Grade 2 and 3 Endometrial Adenocarcinomas. M. KOSKAS, C. YAZBECK, F. WALKER, E. CLOUQUEUR, A. AGOSTINI, S. RUAT, J.P. LUCOT, E. LAMBAUDIE, D. LUTON, P. MADELENAT *(Paris; Lille; Marselle, France)* 3047

Effect of Glutathione-S-Transferase M1 and T1 Allelic Polymorphisms on HPV-induced Cervical Precancer Formation. J. CSEH, E. PÁZSIT, Z. ORSÓS, E. MAREK, A. HUSZÁR, S. BALOGH, I. EMBER, I. KISS *(Székesfehérvár; Miskolc; Pécs; Budapest, Hungary)* 3051

Gene Polymorphisms *MTHFR* C677T and A2756G as Predictive Factors in Adjuvant Chemotherapy for Stage III Colorectal Cancer. H. TAFLIN, Y. WETTERGREN, E. ODIN, G. CARLSSON, K. DERWINGER *(Gothenburg, Sweden)* 3057

Evaluation of Oral Etoposide in Combination with Cisplatin for Patients with Recurrent Cervical Cancer: Long-term Follow-up Results of a Japanese Multicenter Study. Y. WATANABE, H. HOSHIAI, T. NAKANISHI, N. KAWAMURA, N. TANAKA, K. ISAKA, S. KAMIURA, M. OHMICHI, M. HATAE, K. OCHIAI *(Osaka; Nagoya; Chiba; Tokyo; Kagoshima, Japan)* 3063

Pleomorphic Ductal Carcinoma of the Male Breast: Report of a Rare Case and Review of Literature. R. CARUSO, R. PALMERI, S. RACCHIUSA, A. BONANNO, R. LUCIANÒ, M. SCARDIGNO, G. BRANCA, F. FEDELE *(Messina, Italy)* 3069

Neoadjuvant Chemoradiotherapy for Clinical Stage II-III Esophageal Squamous Cell Carcinoma. H. SAEKI, M. MORITA, Y. NAKASHIMA, H. SONODA, K. HASHIMOTO, A. EGASHIRA, E. OKI, T. OHGA, Y. KAKEJI, Y. MAEHARA *(Fukuoka, Japan)* 3073

Phase I Study of Neoadjuvant Chemoradiotherapy Consisting of S-1 and Cisplatin for Patients with Resectable Advanced Gastric Cancer (KOGC-01). T. TAKAHASHI, Y. SAIKAWA, H. TAKAISHI, H. TAKEUCHI, N. WADA, T. OYAMA, K. FUKUDA, J. FUKADA, O. KAWAGUCHI, N. SHIGEMATSU, Y. KITAGAWA *(Tokyo, Japan)* 3079

Feasibility Study of Triplet Combination Chemotherapy of Paclitaxel, Cisplatin and S-1 for Advanced Gastric Cancer. K. FUJITANI, H. HASEGAWA, M. HIRAO, Y. KUROKAWA, T. TSUJINAKA *(Osaka, Japan)* 3085

Evaluation of Kallikrein-related Peptidase 5 Expression and its Significance for Breast Cancer Patients: Association with Kallikrein-related Peptidase 7 Expression. M. TALIERI, M. DEVETZI, A. SCORILAS, P. PREZAS, A. ARDAVANIS, A. APOSTOLAKI, A. KARAMERIS *(Athens, Greece)* 3093

Sifneos Alexithymia Questionnaire in Assessment of General Alexithymia in Patients with Breast Disease and Breast Cancer: A Prospective Case–Control Study in Finland. M. ESKELINEN, P. OLLONEN *(Kuopio, Finland)* 3101

The Role of MonoTotal in the Primary Diagnosis, Prognosis and Follow-up of Patients with Non-small Cell Lung Cancer (NSCLC). M. PRAZAKOVA, J. VRZALOVA, J.M. AUGE, J. SAFRANEK, O. TOPOLCAN, R. FUCHSOVA, M. SPISAKOVA, S. SVOBODOVA, L. HOLUBEC JR., M. PESTA *(Prague; Pilsen, Czech Republic; Barcelona, Spain)* 3107

Erratum 3113

* Review (page 2923)

Number 10

Experimental Studies

Autologous Stem Cell Transplantation: Leukapheresis Product has Anti-angiogenic Effects *In Vivo* Correlating with Neutrophil-derived VEGFR1. A. LUETHY, F. STENNER, C. LOHRI, C. MULLER, P. SAMARAS, R. STEINER, M. VAN DEN BROEK, A. MISCHO, C. RENNER, A. KNUTH, C. RUEGG, R.H. WENGER, M. ZWEIFEL *(Zurich; Fribourg, Switzerland)* 3115

A Rapid Imageable *In Vivo* Metastasis Assay for Circulating Tumor Cells. R.S. MENEN, E. PINNEY, K. KOLOSTOVA, V. BOBEK, A. SUETSUGU, N. ZHANG, M. BOUVET, R.M. HOFFMAN *(San Diego; Oakland, CA, USA; Prague, Czech Republic)* 3125

EBP1 Inhibits Translation of Androgen Receptor mRNA in Castration Resistant Prostate Cancer Cells. H. ZHOU, Y. ZHANG, A.W. HAMBURGER *(Baltimore, MD, USA)* 3129

FISH Scoring on Paraffin Sections *Versus* Single-cell Suspension for Chromophobe Renal Carcinoma and Renal Oncocytoma. M. BRUNELLI, D. SEGALA, B. DELAHUNT, C. PAROLINI, S. BERSANI, L. CHENG, J.N EBLE, M. CHILOSI, S. GOBBO, G. MARTIGNONI *(Verona, Italy; Wellington South, New Zealand; Indianapolis, IN, USA)* 3137

In Vitro Evaluation of Targeted Antisense ^{177}Lu Radiotherapy. E.R. BALKIN, F. JIA, W.H. MILLER, M.R. LEWIS *(Columbia, MO, USA)* 3143

Cyclin B1 Expression and p53 Status in Squamous Cell Carcinomas of the Head and Neck. T.K. HOFFMANN, S. TRELLAKIS, K. OKULICZ, P. SCHULER, J. GREVE, J. ARNOLDS, C. BERGMANN, M. BAS, S. LANG, G. LEHNERDT, S. BRANDAU, S. MATTHEIS, K. SCHECKENBACH, O.J. FINN, T.L. WHITESIDE, E. SONKOLY *(Essen; Duesseldorf; Munich, Germany; Pittsburgh, PA, USA; Stockholm, Sweden)* 3151

TGF-β Regulation of Focal Adhesion Proteins and Motility of Premalignant Oral Lesions *via* Protein Phosphatase 1. J.E. WALSH, M.R. YOUNG *(Charleston, SC, USA)* 3159

Anticancer Activity of Branched-chain Derivatives of Oleic Acid. O.D. DAILEY JR., X. WANG, F. CHEN, G. HUANG *(New Orleans, LA; Clemson, SC, USA)* 3165

Enhanced Efficacy of Gemcitabine by Indole-3-carbinol in Pancreatic Cell Lines: The Role of Human Equilibrative Nucleoside Transporter 1. H. WANG, B.R. WORD, B.D. LYN-COOK *(Jefferson, AR, USA)* 3171

Silencing of Selected Glutamate Receptor Subunits Modulates Cancer Growth. H. LUKSCH, O. UCKERMANN, A. STEPULAK, S. HENDRUSCHK, J. MARZAHN, S. BASTIAN, C. STAUFNER, A. TEMME, C. IKONOMIDOU *(Dresden; Heidelberg, Germany; Lublin, Poland; Madison, WI, USA)* 3181

Paclitaxel and TRAIL Synergize to Kill Paclitaxel-resistant Small Cell Lung Cancer Cells through a Caspase-independent Mechanism Mediated through AIF. T.B. HUNTER, N.J. MANIMALA, K.A. LUDDY, T. CATLIN, S.J. ANTONIA *(Tampa, FL, USA)* 3193

Metastasis Suppressor-1, MTSS1, Acts as a Putative Tumour Suppressor in Human Bladder Cancer. P. DU, L. YE, F. RUGE, Y. YANG, W.G. JIANG *(Cardiff, UK; Beijing, PR China)* 3205

Cytotoxicity of Chalcone Derivatives towards Glioblastoma. P. CHAMPELOVIER, M. MININNO, E. DUCHAMP, E. NICOLLE, V. CURRI, A. BOUMENDJEL, J. BOUTONNAT *(Grenoble, France)* 3213

Breast Cancer Cell-derived Cytokines, Macrophages and Cell Adhesion: Implications for Metastasis. C. EICHBAUM, A.-S. MEYER, N. WANG, E. BISCHOFS, A. STEINBORN, T. BRUCKNER, P. BRODT, C. SOHN, M.H.R. EICHBAUM *(Heidelberg, Germany; Montreal, QC, Canada)* 3219

Intracellular Metabolism, Subcellular Localization and Phototoxicity of HMME/HB in Ovarian Cancer Cells. K. SONG, J. LI, L. LI, P. ZHANG, F. GENG, R. DONG, Q. YANG, X. QU, B. KONG *(Ji'nan, Shandong, PR China)* 3229

The Role of the 3D Environment in Hypoxia-induced Drug and Apoptosis Resistance. J.W. KIM, W.J. HO, B.M. WU *(Los Angeles, CA, USA)* 3237

Anticancer SAR Models for MCF-7 and MDA-MB-231 Breast Cell Lines. S. QAMAR, C.A. CARRASQUER, S.L. CUNNINGHAM, A.R. CUNNINGHAM *(Louisville, KY, USA)* 3247

Down-regulation of EGFR Prolonged Cell Growth of Glioma but Did Not Increase the Sensitivity to Temozolomide. N. INABA, K. FUJIOKA, H. SAITO, M. KIMURA, K. IKEDA, Y. INOUE, S. ISHIZAWA, Y. MANOME *(Tokyo, Japan)* 3253

Fluvastatin Enhances Sorafenib Cytotoxicity in Melanoma Cells *via* Modulation of AKT and JNK Signaling Pathways. S. ZHANG, N.A. DOUDICAN, E. QUAY, S.J. ORLOW *(New York, NY, USA)* 3259

Epigenetic Modifiers Exert Renal Toxicity through Induction of p66shc. I. ARANY, J.S. CLARK, I. EMBER, L.A. JUNCOS *(Jackson, MS, USA; Pécs, Hungary)* 3267

Oncostatin M and IL-6 Induce u-PA and VEGF in Prostate Cancer Cells and Correlate *In Vivo*. T. W. WEISS, R. SIMAK, C. KAUN, G. REGA, H. PFLÜGER, G. MAURER, K. HUBER, J. WOJTA *(Vienna, Austria; Ulleval, Norway)* 3273

Prevention of Mouse Lung Tumors by Combinations of Chemopreventive Agents Using Concurrent and Sequential Administration. B.C. CASTO, M.A. PEREIRA *(Columbus, OH, USA)* 3279

Modulation of Multidrug Efflux Pump Activity by New Hydantoin Derivatives on Colon Adenocarcinoma Cells without Inducing Apoptosis. G. SPENGLER, J. HANDZLIK, I. OCSOVSZKI, M. VIVEIROS, K. KIEĆ-KONONOWICZ, J. MOLNAR, L. AMARAL *(Szeged, Hungary; Lisboa,, Portugal; Cracow, Poland; Brussels, Belgium)* 3285

Polo-like Kinase 1 Inhibition as a New Therapeutic Modality in Therapy of Cholangiocarcinoma. S. THRUM, J. LORENZ, J. MÖSSNER, M. WIEDMANN *(Leipzig; Berlin, Germany)* 3289

Phytoestrogens Induce Apoptosis *via* Extrinsic Pathway, Inhibiting Nuclear Factor-κB Signaling in HER2-overexpressing Breast Cancer Cells. H.S. SEO, HAN SEOK CHOI, HYEONG SIM CHOI, Y.K. CHOI, J.-Y. UM, I. CHOI, Y.C. SHIN, S.-G. KO *(Seoul, Republic of Korea)* 3301

Biodistribution of ^{131}I-labeled Anti-CK8 Monoclonal Antibody in HNSCC in Xenotransplanted SCID Mice. M. ANDRATSCHKE, C.W. LUEBBERS, V. JOHANNSON, B. SCHMITT, B. MACK, R. ZEIDLER, S. LANG, B. WOLLENBERG, F.J. GILDEHAUS *(Munich; Luebeck; Essen, Germany)* 3315

Combination of Resveratrol and Antiandrogen Flutamide Has Synergistic Effect on Androgen Receptor Inhibition in Prostate Cancer Cells. L. KAI, A.S. LEVENSON *(Jackson, MS, USA)* 3323

Up-regulation of 42 kDa Tubulin Alpha-6 Chain Fragment in Well-differentiated Hepatocellular Carcinoma Tissues from Patients Infected with Hepatitis C Virus. Y. KURAMITSU, M. TAKASHIMA, Y. YOKOYAMA, N. IIZUKA, T. TAMESA, J.K. AKADA, Y. WANG, T. TODA, I. SAKAIDA, K. OKITA, M. OKA, K. NAKAMURA *(Ube; Tokyo, Japan)* 3331

Effects of Non-motorized Voluntary Running on Experimental and Spontaneous Metastasis in Mice. L. YAN, L.C. DEMARS *(Grand Forks, ND, USA)* 3337

Differential Expression of Apoptosis, Cell Cycle Regulation and Intermediate Filament Genes in Oral Squamous Cell Carcinomas Associated with *Toombak* Use in Sudan. M.M. JALOULI, J. JALOULI, D. SAPKOTA, S.O. IBRAHIM, L. SAND, J.-M. HIRSCH *(Uppsala, Sweden; Bergen, Norway)* 3345

ERas Enhances Resistance to CPT-11 in Gastric Cancer. E. KUBOTA, H. KATAOKA, M. TANAKA, Y. OKAMOTO, M. EBI, Y. HIRATA, K. MURAKAMI, T. MIZOSHITA, T. SHIMURA, Y. MORI, S. TANIDA, T. KAMIYA, M. AOYAMA, K. ASAI, T. JOH *(Nagoya, Japan)* 3353

Antitumor Effect of New HER2 Peptide Vaccination Based on B Cell Epitope. H. MIYAKO, Y. KAMETANI, I. KATANO, R. ITO, B. TSUDA, A. FURUKAWA, Y. SAITO, D. ISHIKAWA, K. OGINO, S. SASAKI, K. IMAI, S. HABU, H. MAKUUCHI, Y. TOKUDA *(Kanagawa; Saitama; Tokushima; Hokkaido; Tokyo, Japan)* 3361

Effects of Acute and Chronic Hypoxia on the Radiosensitivity of Gastric and Esophageal Cancer Cells. Y. KATO, M. YASHIRO, Y. FUYUHIRO, S. KASHIWAGI, J. MATSUOKA,T. HIRAKAWA, S. NODA, N. AOMATSU, T. HASEGAWA, T. MATSUZAKI, T. SAWADA, M. OHIRA, K. HIRAKAWA *(Osaka, Japan)* 3369

Down-regulation of EGFL8: A Novel Biomarker for Advanced Gastric Cancer. F. WU, A. SHIRAHATA, K. SAKURABA, Y. KITAMURA, T. GOTO, M. SAITO, K. ISHIBASHI, G. KIGAWA, H. NEMOTO, Y. SANADA, K. HIBI *(Guangzhou, China; Yokohama, Japan)* 3377

Increased Soluble Leptin Receptor Levels Are Associated with Advanced Tumor Stage in Colorectal Cancer Patients. V. TUTINO, M. NOTARNICOLA, V. GUERRA, D. LORUSSO, M.G. CARUSO *(Castellana Grotte, Bari, Italy)* 3381

Low-Dose Combinations of LBH589 and TRAIL Can Overcome TRAIL-resistance in Colon Cancer Cell Lines. S.-C. LEE, H.-J. CHEONG, S.-J. KIM, J. YOON, HAN JO KIM, K.H. KIM, S.H. KIM, HYUN JUNG KIM, S.B. BAE, C.-K. KIM, N. LEE, K.T. LEE, S.K. PARK, D.S. HONG, H.S. PARK, J.-H. WON *(Seoul; Gyeonggi-Do; Chungchungnam-Do, Republic of Korea)* 3385

Thiamine Supplementation Attenuated Hepatocellular Carcinoma in the Atp7b Mouse Model of Wilson's Disease. C.T. SHELINE *(New Orleans, LA, USA)* 3395

Effects of Cytokinins, Cytokinin Ribosides and their Analogs on the Viability of Normal and Neoplastic Human Cells. S. CASATI, R. OTTRIA, E. BALDOLI, E. LOPEZ, J.A.M. MAIER, P. CIUFFREDA *(Milan, Italy)* 3401

Antiproliferative Effects of N-Heterocyclic Indolyl Glyoxylamide Derivatives on Human Lung Cancer Cells. T.-H. HUANG, S.-J. CHIU, P.-H. CHIANG, S.-H. CHIOU, W.-T. LI, C.-T. CHEN, C.A. CHANG, J.-C. CHEN, Y.-J. LEE *(Taipei; Hualien; Zhunan, Taiwan, ROC)* 3407

Tumor Endothelial Marker 8 Expression in Triple-negative Breast Cancer. L.G. GUTWEIN, S.Z. AL-QURAN, S. FERNANDO, B.S. FLETCHER, E.M. COPELAND, S.R. GROBMYER *(Gainesville, FL, USA)* 3417

Clinical Studies

Clinical Value of Combined Detection of Serum Matrix Metalloproteinase-9, Heparanase, and Cathepsin for Determining Ovarian Cancer Invasion and Metastasis. W. ZHANG, H.-C. YANG, Q. WANG, Z.-J. YANG, H. CHEN, S.-M. WANG, Z.-M. PAN, B.-J. TANG, Q.Q. LI, L. LI *(Guangxi, PR China; Bethesda, MD, USA)* ... 3423

Case Report of Pneumatosis Intestinalis Secondary to Sunitinib Treatment for Refractory Gastrointestinal Stromal Tumor. A. JARKOWSKI III, R. HARE, V. FRANCESCUTTI, N. WILKINSON, N. KHUSHALANI *(Buffalo, NY, USA)* 3429

Diagnostic Value of 16 Cellular Tumor Markers for Metastatic Thyroid Cancer: An Immunohistochemical Study. H. LIANG, Y. ZHONG, Z. LUO, Y. HUANG, H. LIN, S. ZHAN, K. XIE, Q.Q. LI *(Beihai; Nanning; Pingnal; Guangzhou, China; Bethesda, MD, USA)* 3433

Conventional Cytogenetics and Breakpoint Distribution by Fluorescent *In Situ* Hybridization in Patients with Malignant Hemopathies Associated with inv(3)(q21;q26) and t(3;3)(q21;q26). E. DE BRAEKELEER, N. DOUET-GUILBERT, A. BASINKO, C. BOVO, N. GUÉGANIC, M.-J. LE BRIS, F. MOREL, M. DE BRAEKELEER *(Brest, France)* 3441

Phase II Study of Topotecan with Cisplatin in Japanese Patients with Small Cell Lung Cancer. Y. HOSOMI, M. SHIBUYA, S. NIHO, Y. ICHINOSE, K. KIURA, H. SAKAI, K. TAKEDA, S. KUDO, K. EGUCHI, K. MATSUI, N. MASUDA, M. ANDO, K. WATANABE *(Tokyo; Chiba; Fukuoka; Okayama; Saitama; Osaka; Kanagawa; Fukushima, Japan)* 3449

Erlotinib in First-line Therapy for Non-small Cell Lung Cancer: A Prospective Phase II Study. D.R. CHOI, D.H. LEE, C.-M. CHOI, S.-W. KIM, C. SUH, J.-S. LEE *(Seoul, Republic of Korea)* 3457

Clinicopathological Study of Poorly Differentiated Colorectal Adenocarcinomas: Comparison between Solid-type and Non-solid-type Adenocarcinomas. K. KOMORI, Y. KANEMITSU, S. ISHIGURO, Y. SHIMIZU, T. SANO, S. ITO, T. ABE, Y. SENDA, K. MISAWA, Y. ITO, N. UEMURA, T. KATO *(Nagoya, Aichi, Japan)* 3463

Uterobrush Method in the Detection of Endometrial Pathology. C. IAVAZZO, G. VORGIAS, G. MASTORAKOS, G. STEFANATOU, A. PANOUSSI, A. ALEXIADOU, S. PLYTA, C. LEKKA, N. KALINOGLOU, V. DERTIMAS, T. AKRIVOS, S. FOTIOU *(Athens; Piraeus, Greece)* 3469

Expression Status of Ribonucleotide Reductase Small Subunits hRRM2/p53R2 as Prognostic Biomarkers in Stage I and II Non-small Cell Lung Cancer. N.-Y. HSU, J.-Y. WU, X. LIU, Y. YEN, C.-Y. CHEN, M.-C. CHOU, C.-H. LIN, H. LEE, Y.-W. CHENG *(Taichung; Hsinchu, Taiwan, ROC; Duarte, CA, USA)* 3475

Patterns of Failures in Endometrial Cancer: Clinicopathological Variables Predictive of the Risk of Local, Distant and Retroperitoneal Failure. A. GADDUCCI, S. COSIO, M.G. FABRINI, A. FANUCCHI, C. BARSOTTI, R. CRISTOFANI, C. GRECO, A.R. GENAZZANI *(Pisa, Italy)* 3483

* Review: No Detection of BK Virus, JC Virus, KI, WU and Merkel Cell Polyomaviruses in Cerebrospinal Fluid of Patients with Neurological Complications after Hematopoetic Stem Cell Transplantation. J. RUBIN, G. GIRAUD, P. PRIFTAKIS, K. WIDE, B. GUSTAFSSON, T. RAMQVIST, T. DALIANIS *(Stockholm; Eskilstuna, Sweden)* 3489

Oxaliplatin Scale and National Cancer Institute-Common Toxicity Criteria in the Assessment of Chemotherapy-induced Peripheral Neuropathy. A.-L. KAUTIO, M. HAANPÄÄ, H. KAUTIAINEN, A. LEMINEN, E. KALSO, T. SAARTO *(Helsinki; Jyväskylä; Tampere, Finland)* 3493

Bowel Complication during Robotic-assisted Laparoscopic Radical Prostatectomy. C.-F. HUNG, C.-K. YANG, C.-L. CHENG, Y.-C. OU *(Taichung, Taiwan, ROC)* 3497

* Review: The Prognostic Role of Lymphovascular Invasion in Urothelial-cell Carcinoma of Upper and Lower Urinary Tract. E. BRUNOCILLA, R. PERNETTI, G. MARTORANA *(Bologna, Italy)* 3503

Sunitinib Re-challenge in Metastatic Renal Cell Carcinoma Treated Sequentially with Tyrosine Kinase Inhibitors and Everolimus. B. PAULE, N. BRION *(Creteil; Guyancourt, France)* 3507

Significant Association of Caveolin-1 (*CAV1*) Genotypes with Breast Cancer in Taiwan. L.-C. LIU, C.-H. SU, H.-C. WANG, C.-W. TSAI, W.-S. CHANG, C.-Y. HO, C.-I WU, F.-J. LI, C.-H. LIN, H.-Y. LANE, D.-T. BAU *(Taichung, Taiwan, ROC)* 3511

Endoscopic Appearance and Clinicopathological Character of Breast Cancer. D. YAMAMOTO, Y. TSUBOTA, H. YOSHIDA, S. KANEMATSU, N. SUEOKA, Y. UEMURA, K. TANAKA, A-H. KWON *(Osaka, Japan)* 3517

Expression of Thymidylate Synthase and Dihydropyrimidine Dehydrogenase in Primary Oral Squamous Cell Carcinoma and Corresponding Metastases in Cervical Lymph Nodes: Association with the Metastasis Suppressor CD82. G. KAWASAKI, I. YOSHITOMI, S. YANAMOTO, S.-I. YAMADA, A. MIZUNO, M. UMEDA *(Nagasaki, Japan)* 3521

Severe Late Complications in Patients with Uterine Cancer Treated with Postoperative Radiotherapy. G. KASUYA, K. OGAWA, S. IRAHA, Y. NAGAI, M. SHIRAISHI, M. HIRAKAWA, H. SAMURA, T. TOITA, Y. KAKINOHANA, W. KUDAKA, M. INAMINE, T. ARIGA, T. NISHIMAKI, Y. AOKI, S. MURAYAMA *(Okinawa, Japan)* 3527

Docetaxel plus 5-Fluorouracil and Cisplatin (DCF) Induction Chemotherapy for Locally Advanced Borderline-resectable T4 Esophageal Cancer. T. YOKOTA, S. HATOOKA, T. URA, T. ABE, D. TAKAHARI, K. SHITARA, M. NOMURA, C. KONDO, A. MIZOTA, Y. YATABE, M. SHINODA, K. MURO *(Nagoya, Japan)* 3535

* Review: The Role of Chemotherapy in Metastatic Gastric Cancer. F. PASINI, A.P. FRACCON, G. DE MANZONI *(Rovigo; Verona, Italy)* 3543

Hypofractionated Radiotherapy with or without IGRT in Prostate Cancer: Preliminary Report of Acute Toxicity. M. VALERIANI, F. MONACO, M.F. OSTI, V. DE SANCTIS, G. MINNITI, R.M. ENRICI *(Rome, Italy)* 3555

Changes in Serial Magnetic Resonance Spectroscopy Predict Outcome in High-grade Glioma During and After Postoperative Radiotherapy. H. QUON, B. BRUNET, A. ALEXANDER, A. MURTHA, B. ABDULKARIM, D. FULTON, M. SMERDELY, M. JOHNSON, R. URTASUN, S. PATEL, S. GHOSH, W. ROA *(Edmonton, AB, Canada)* 3559

Efficacy of Meloxicam in Combination with Preoperative Chemotherapy for Breast Cancer - Japan Breast Cancer Research Network (JBCRN) 02-1 Trial. D. YAMAMOTO, S. IWASE, H. YOSHIDA, Y. KURODA, C. YAMAMOTO, K. KITAMURA, H. ODAGIRI, Y. NAGUMO *(Osaka; Tokyo; Fukuoka; Hirosaki, Japan)* 3567

Metabolic Activation of Irinotecan during Intra-arterial Chemotherapy of Metastatic Colorectal Cancer. M. CZEJKA, A. KISS, C. KOESSNER, R. TERKOLA, D. ETTLINGER, J. SCHUELLER *(Vienna, Austria)* 3573

Long-term Disease-free Survival Following Dendritic Cell Therapy and Resection of Small Bowel Melanoma Metastases – A Case Report. K. VANDERLINDEN, S. WILGENHOF, N. VAN DE WINKEL, C. GEERS, K. THIELEMANS, B. NEYNS, K. DE VOGELAERE, G. DELVAUX *(Brussels, Belgium)* 3579

Immunohistochemical Expression and Prognostic Significance of CCND3, MCM2 and MCM7 in Hodgkin's Lymhoma. A. MARNERIDES, T.P. VASSILAKOPOULOS, E. BOLTETSOU, G. LEVIDOU, M.K. ANGELOPOULOU, I. THYMARA, M.-C. KYRTSONIS, V. PAPPI, O. TSOPRA, P. PANAYIOTIDIS, G.A. PANGALIS, P. BERIS, E. PATSOURIS, P. KORKOLOPOULOU *(Athens, Greece; Stockholm, Sweden)* 3585

Expression of Zinc Finger 23 Gene in Human Hepatocellular Carcinoma. Y. SHI, L. ZHENG, G. LUO, J. WEI, J. ZHANG, Y. YU, Y. FENG, M. LI, N. XU *(Changzhou, PR China; Lund, Sweden)* 3595

Interaction of *CCND1* Genotype and Smoking Habit in Taiwan Lung Cancer Patients. T.-C. HSIA, C.-J. LIU, C.-H. LIN, W.-S. CHANG, C.-C. CHU, L.-W. HANG, H.-Z. LEE, W.-C. LO, D.-T. BAU *(Taichung, Taiwan, ROC)* 3601

Identification of The Distinctive Type *i/Xho*I+ Strain of Epstein-Barr Virus in Gastric Carcinoma in Peru. P. ORDONEZ, C. KORIYAMA, S. DING, E. YOSHIWARA, A.H. CORVALAN, J. TAKANO, J.L. CHIRINOS, J. WATANABE, J. MIYAGUI, H. HIDALGO, P. CHACON, V. LINARES, Y. EIZURU, S. AKIBA *(Kagoshima, Japan; Lima; Huanuco; Chiclayo, Peru; Santiago, Chile)* 3607

Lower Serum Total Testosterone is Associated with Lymph Node Metastases in a Radical Prostatectomy Cohort Study. C. KRATZIK, I. WOMASTEK, C. BIEGLMAYER, G. SCHATZL, J. LACKNER, C. FREIBAUER, G. LUNGLMAYR *(Wien; Mistelbach, Austria)* 3615

Vitamin D in Colorectal, Breast, Prostate and Lung Cancer: A Pilot Study. P. PAZDIORA, S. SVOBODOVA, R. FUCHSOVA, R. KUČERA, M. PRAZAKOVA, J. VRZALOVA, A. NARSANSKA, M. STRAKOVA, I. TRESKOVA, L. PECEN, V. TRESKA, L. HOLUBEC JR., M. PESEK, J. FINEK, O. TOPOLCAN *(Pilsen; Prague, Czech Republic)* 3619

Effect of Ibandronate on Disseminated Tumor Cells in the Bone Marrow of Patients with Primary Breast Cancer: A Pilot Study. O. HOFFMANN, B. AKTAS, C. GOLDNAU, M. HEUBNER, C. OBERHOFF, R. KIMMIG, S. KASIMIR-BAUER *(Essen, Germany)* 3623

Association of Caveolin-1 Genotypes with Nasopharyngeal Carcinoma Susceptibility in Taiwan. Y.-A. TSOU, C.-W. TSAI, M.-H. TSAI, W.-S. CHANG, F.-J. LI, Y.-F. LIU, C.-F. CHIU, C.-C. LIN, D.-T. BAU *(Taichung, Taiwan, ROC)* 3629

An Evaluation of Prognostic Value of Death-associated Protein Kinase 1 in Breast Cancer. S.-E. CHOU, C.-Y. HUANG, S.-M. SHEEN-CHEN, Y.-W. LIU, C.-H. TSAI, Y.-H. LIN, C.-C. HUANG, R.-P. TANG *(Kaohsiung; Linkou, Taiwan, ROC; Xiamen, PR China)* 3633

Errata 3637

Book Reviews 3639

Announcements 3643

* Reviews (pages 3489, 3503, 3543)

Number 11

Experimental Studies

* Review: Rho Kinase Proteins—Pleiotropic Modulators of Cell Survival and Apoptosis. C.A. STREET, B.A. BRYAN *(Worcester, MA; El Paso, TX, USA)* 3645

Selective Gelatinase Inhibitor Peptide Is Effective in Targeting Tongue Carcinoma Cell Tumors *In Vivo*. J. SUOJANEN, S.-T. VILEN, P. NYBERG, P. HEIKKILÄ, O. PENATE-MEDINA, P.E.J. SARIS, J. HAGSTRÖM, T.-M. RANTA, T. SALO, T. SORSA, J. REUNANEN *(Helsinki; Oulu, Finland; New York, NY, USA)* 3659

Comparison of Cancer-Cell Seeding, Viability and Deformation in the Lung, Muscle and Liver, Visualized by Subcellular Real-time Imaging in the Live Mouse. K. HAYASHI, H. KIMURA, K. YAMAUCHI, N. YAMAMOTO, H. TSUCHIYA, K. TOMITA, H. KISHIMOTO, A. HASEGAWA, M. BOUVET, R.M. HOFFMAN *(San Diego, CA, USA; Kanazawa, Ishikawa; Okayama, Japan)* 3665

Synthetic Oleanane Triterpenoid, CDDO-Me, Induces Apoptosis in Ovarian Cancer Cells by Inhibiting Prosurvival AKT/NF-κB/mTOR Signaling. X. GAO, Y. LIU, D. DEEB, A.S. ARBAB, A.M. GUO, S.A. DULCHAVSKY, S.C. GAUTAM *(Detroit, MI, USA)* 3673

Targeting Cyclin D1 in Non-small Cell Lung Cancer and Mesothelioma Cells by Antisense Oligonucleotides. S.S. SAINI, M.A. KLEIN *(Minneapolis, MN, USA)* 3683

Antitumour Activity of S-1 in Combination with Cetuximab on Human Gastric Cancer Cell Lines *In Vivo*. T. KOBUNAI, T. WATANABE, T. FUKUSATO *(Tokyo, Japan)* 3691

Melanocyte-specific Immune Response in a Patient with Multiple Regressing Nevi and a History of Melanoma. R. SPEECKAERT, N. VAN GEEL, R.M. LUITEN, M. VAN GELE, M. SPEECKAERT, J. LAMBERT, K. VERMAELEN, E.P.M. TJIN, L. BROCHEZ *(Ghent, Belgium; Amsterdam, Netherlands)* 3697

MSC^{TRAIL}-mediated HepG2 Cell Death in Direct and Indirect Co-cultures. X.-Y. SUN, J. NONG, K. QIN, H. LU, M.R. MONIRI, L.-J. DAI, G.L. WARNOCK *(Nanning, PR China; Vancouver, BC, Canada)* 3705

Cell to Cell Interactions Influence Sensitivity of Liver Cell Lines during Hyperthermia. U. MAYRHAUSER, P. STIEGLER, V. STADLBAUER, S. KOESTENBAUER, B. LEBER, K. KONRAD, F. IBERER, K. TSCHELIESSNIGG *(Graz, Austria)* 3713

Novel Curcumin Analogs, GO-Y030 and GO-Y078, Are Multitargeted Agents with Enhanced Abilities for Multiple Myeloma. C. KUDO, H. YAMAKOSHI, A. SATO, H. OHORI, C. ISHIOKA, Y. IWABUCHI, H. SHIBATA *(Akita; Sendai, Japan)* 3719

Cell Death Forms and HSP70 Expression in U87 Cells after Ionizing Radiation and/or Chemotherapy. A. PAOLINI, F. PASI, A. FACOETTI, G. MAZZINI, F. CORBELLA, R. DI LIBERTO, R. NANO *(Pavia, Italy)* 3727

Indole-3-carbinol Inhibits Telomerase Activity and Gene Expression in Prostate Cancer Cell Lines. S. ADLER, G. RASHID, A. KLEIN *(Kfar Saba; Tel Aviv, Israel)* 3733

Differential Cytotoxicity of Triphala and its Phenolic Constituent Gallic acid on Human Prostate Cancer LNCap and Normal Cells. L.H. RUSSELL JR., E. MAZZIO, R.B. BADISA, Z.-P. ZHU, M. AGHARAHIMI, D.J. MILLINGTON, C.B. GOODMAN *(Tallahassee; Gainesville, FL, USA)* 3739

Mechanisms Underlying Gemcitabine Resistance in Pancreatic Cancer and Sensitisation by the iMiD™ Lenalidomide. R.A. FRYER, B. BARLETT, C. GALUSTIAN, A.G. DALGLEISH *(London, UK; Summit, NJ, USA)* 3747

5-Azacytidine Reverses Drug Resistance in Bladder Cancer Cells. K. RAMACHANDRAN, E. GORDIAN, R. SINGAL *(Miami, FL, USA)* 3757

Silibinin Suppresses EGFR Ligand-induced CD44 Expression through Inhibition of EGFR Activity in Breast Cancer Cells. S. KIM, J. HAN, J.S. KIM, J.-H. KIM, J.-H. CHOE, J.-H. YANG, S.J. NAM, J.E. LEE *(Seoul, South Korea)* 3767

Relationship between LAT1 Expression and Response to Platinum-based Chemotherapy in Non-small Cell Lung Cancer Patients with Postoperative Recurrence. K. KAIRA, T. TAKAHASHI, H. MURAKAMI, T. SHUKUYA, H. KENMOTSU, T. NAITO, N. ORIUCHI, Y. KANAI, M. ENDO, H. KONDO, T. NAKAJIMA, N. YAMAMOTO *(Shizuoka; Gunma; Osaka, Japan)* 3775

Differential Akt Signalling in Non-seminomatous Testicular Germ Cell Tumors. J. HENNENLOTTER, B. AMEND, U. VOGEL, M. RENNINGER, C. SPRINGER, U. KUEHS, A. STENZL, J. BEDKE *(Tuebingen; Karlsruhe, Germany)* 3783

Synergism from Combinations of Cisplatin and Oxaliplatin with Quercetin and Thymoquinone in Human Ovarian Tumour Models. M.U. NESSA, P. BEALE, C. CHAN, J.Q. YU, F. HUQ *(Lidcombe; Concord, NSW, Australia)* 3789

Induction of Apoptosis by Cannabinoids in Prostate and Colon Cancer Cells Is Phosphatase Dependent. S. SREEVALSAN, S. JOSEPH, I. JUTOORU, G. CHADALAPAKA, S.H. SAFE *(College Station; Houston, TX, USA)* 3799

An Active Endocytosis Pathway Is Required for the Cytotoxic Effects of Glycosylated Antitumor Ether Lipids. P. SAMADDER, H.-S. BYUN, R. BITTMAN, G. ARTHUR *(Winnipeg, MB, Canada; Flushing, NY, USA)*... 3809

Phosphorylation of STAT3 in Head and Neck Cancer Requires p38 MAPKinase, whereas Phosphorylation of STAT1 Occurs via a Different Signaling Pathway. C. RIEBE, R. PRIES, K.N. SCHROEDER, B. WOLLENBERG *(Lübeck, Germany)*..... 3819

The Role of Circulating Dendritic Cells in Patients with Unresectable Pancreatic Cancer. S. HIROOKA, H. YANAGIMOTO, S. SATOI, T. YAMAMOTO, H. TOYOKAWA, S. YAMAKI, R. YUI, K. INOUE, T. MICHIURA, A-H. KWON *(Hirakata, Osaka, Japan)*..... 3827

Detection of *TFPI2* Methylation in the Serum of Gastric Cancer Patients. K. HIBI, T. GOTO, A. SHIRAHATA, M. SAITO, G. KIGAWA, H. NEMOTO, Y. SANADA *(Yokohama, Japan)* 3835

Inhibition of Tumor Growth by Antibody to ADAMTS1 in Mouse Xenografts of Breast Cancer. T. HIRANO, K. HIROSE, K. SAKURAI, M. MAKISHIMA, K. SASAKI, S. AMANO *(Tokyo, Japan)* 3839

Relationship between *TYMS* and *ERCC1* mRNA Expression and *In Vitro* Chemosensitivity in Colorectal Cancer. Y.B. CHO, H.J. CHUNG, W.Y. LEE, S.H. CHOI, H.C. KIM, S.H. YUN, H.-K. CHUN *(Seoul, South Korea)* 3843

Mode of Cell Death Associated with Adenovirus-mediated Suicide Gene Therapy in HNSCC Tumor Model. D. SRIVASTAVA, G. JOSHI, K. SOMASUNDARAM, R. MULHERKAR *(Mumbai; Bangalore, India)*..... 3851

Down-regulation of MiR-206 Promotes Proliferation and Invasion of Laryngeal Cancer by Regulating VEGF Expression. T. ZHANG, M. LIU, C. WANG, C. LIN, Y. SUN, D. JIN *(Harbin, PR China)* 3859

Clinical Studies

Lymph Node Assessment with ^{18}F-FDG-PET and MRI in Uterine Cervical Cancer. J. MONTEIL, A. MAUBON, S. LEOBON, S. ROUX, B. MARIN, J. RENAUDIE, D. GENET, V. FERMEAUX, Y. AUBARD, N. TUBIANA-MATHIEU *(Limoges, France)* 3865

Prolonged Administration of Temozolomide in Adult Patients with Anaplastic Glioma. C.F. FREYSCHLAG, D.R. SMOLCZYK, E. JANZEN, K. SCHMIEDER, C. THOMÉ, F. LOHR, F. WENZ, C. WEISS, J. TUETTENBERG, M. SEIZ *(Innsbruck, Austria; Mannheim; Idar-Oberstein, Germany)* 3873

Serum *N*-Telopeptide of Type I Collagen and Bone Alkaline Phosphatase and their Relationship in Patients with Non-small Cell Lung Carcinoma and Bone Metastases. Preliminary Results. F. LUMACHI, F. MARINO, G. FANTI, G.B. CHIARA, S.M.M. BASSO *(Padova; Pordenone, Italy)* 3879

Correlation of Gene Expression of ATP-binding Cassette Protein and Tyrosine Kinase Signaling Pathway in Patients with Hepatocellular Carcinoma. K. HOFFMANN, L. SHIBO, Z. XIAO, T. LONGERICH, M.W. BÜCHLER, P. SCHEMMER *(Heidelberg, Germany)*..... 3883

Cigarette Smoking and the Risk of Dying from Tobacco-related Malignancies by Race. J.N. CURRAN, E. GARRETT-MAYER, M.J. CARPENTER, M.E. FORD, G.A. SILVESTRI, D.T. LACKLAND, A.J. ALBERG *(Charleston, SC, USA)* 3891

Ethnic Differences in Neuroendocrine Expression in Prostate Cancer Tissue. T.B. DORFF, S.V. LIU, S. XIONG, J. CAI, D. HAWES, J. PINSKI *(Los Angeles, CA, USA)* 3897

Patients' Satisfaction with Different Modalities of Prostate Cancer Therapy – A Retrospective Survey among 634 Patients. W. WAGNER, T. BÖLLING, C. HAMBRUEGGE, J. HARTLAPP, M.G. KRUKEMEYER *(Osnabrück; Extertal, Germany)* 3903

Intra-arterial Chemoinfusion prior to Chemoradiotherapy with Full-dose Systemic Gemcitabine for Management of Locally Advanced Pancreatic Cancer. T. TANAKA, H. NISHIOFUKU, T. TAMAMOTO, M. SHO, H. ANAI, S. SUEYOSHI, H. SAKAGUCHI, M. HASEGAWA, Y. NAKAJIMA, K. KICHIKAWA *(Nara, Japan)* 3909

Investigative Clinical Study on Prostate Cancer Part VII: Prolactin and the Pituitary–Testis–Prostate Axis at the Time of Initial Diagnosis and Subsequent Cluster Selection of the Patient Population. A.B. PORCARO, C. GHIMENTON, A. PETROZZIELLO, F. MIGLIORINI, M. ROMANO, T. SAVA, B. CARUSO, C. COCCO, S.Z. ANTONIOLLI, V. LACOLA, E. RUBILOTTA, C. MONACO, L. COMUNALE *(Verona, Italy)* 3913

ADH-1 in the Treatment of Metastatic Adrenocortical Carcinoma - Case Report. N. YAROM, D. STEWART, L. AVRUCH, R. MALIK, J. WELLS, D.J. JONKER *(Ottawa, ON, Canada; Houston, TX, USA)* 3921

Hepatic Intra-arterial Cetuximab in Combination with 5-Fluorouracil and Cisplatin as Salvage Treatment for Sorafenib-refractory Hepatocellular Carcinoma. G. POGGI, B. MONTAGNA, F. MELCHIORRE, P. QUARETTI, A. DELMONTE, A. RICCARDI, B. TAGLIAFERRI, F. SOTTOTETTI, P. DI CESARE, M.G. STELLA, L. VILLANI, M. ZORZETTO, G. GRECO, G. CORNALBA, G. BERNARDO *(Pavia; Milan, Italy)*..... 3927

Repeated Localized Treatment for Extranodal Marginal Zone Lymphoma – Case Report and Review of Literature. C.E. SCHÖNKNECHT, C. NIEDER, M. MOLLS, S.T. ASTNER *(Munich, Germany; Bodø; Tromsø, Norway)* 3935

Association of *hOGG1* and *XPD* Polymorphisms with Urothelial Carcinoma in Taiwan. Y.-H. WANG, S.-D. YEH, K.-H. SHEN, C.-H. SHEN, M.-C. TUNG, C.-T. LIU, H.-Y. CHIOU *(Taipei; Tainan; Chiayi; Taichung, Taiwan, ROC)*..... 3939

Polymorphisms in DNA Repair Gene *XRCC1* and Skin Cancer Risk: A Meta-analysis. H. ZHANG, W. LI, M.J. FRANKLIN, A.Z. DUDEK *(New York, NY; Lexington, KY; Minneapolis, MN, USA)* 3945

Bevacizumab in Pediatric Patients: How Safe Is It? M.D. DE PASQUALE, A. CASTELLANO, L. DE SIO, C. DE LAURENTIS, A. MASTRONUZZI, A. SERRA, R. COZZA, A. JENKNER, M.A. DE IORIS *(Rome, Italy)*..... 3953

Prevalence of Level V Metastases in Node-positive Head and Neck Squamous Cell Carcinoma. S. WIEGAND, A.P. ZIMMERMANN, A.M. SESTERHENN, J.A. WERNER *(Marburg, Germany)* 3959

Tumor Response and Negative Distal Resection Margins of Rectal Cancer after Hyperthermochemoradiation Therapy. S. TSUTSUMI, Y. TABE, T. FUJII, S. YAMAGUCHI, T. SUTO, R. YAJIMA, H. MORITA, T. KATO, M. SHIOYA, J.-I. SAITO, T. ASAO, T. NAKANO, H. KUWANO *(Maebashi, Gunma, Japan)* 3963

Arterial Blood Pressure, Serum Calcium and PTH in Elderly Men with Parathyroid Tumors and Primary Hyperparathyroidism. F. LUMACHI, V. CAMOZZI, G. LUISETTO, S. ZANELLA, S.M.M. BASSO *(Padova; Pordenone, Italy)* 3969

Beckwith-Wiedemann Syndrome: Potassium Ascorbate with Ribose Therapy in a Syndrome with High Neoplastic Risk. C. ANICHINI, C. LO RIZZO, M. LONGINI, G. PAOLI, R.M. DI BARTOLO, F. PROIETTI, G. BUONOCORE *(Siena; Firenze, Italy)*..... 3973

Characterization of Dysplastic Nodules, Early Hepatocellular Carcinoma and Progressed Hepatocellular Carcinoma in Cirrhosis with Contrast-Enhanced Ultrasound. A. GIORGIO, G. CALISTI, A. DI SARNO, N. FARELLA, G. DE STEFANO, U. SCOGNAMIGLIO, V. GIORGIO *(Naples; Rome, Italy)* 3977

Clinical Experience with Chemoradiotherapy Comprising S-1 Plus Low-dose Cisplatin in a Patient with Stage IV Anal Cancer. N. NITORI, Y. KATO, A. KATO, T. DEGUCHI, A. OKADA, M. KOJIMA, J. KURODA, T. KADOMURA, K. KUBOTA, N. ORIGUCHI, M. FUJISAKI, M. KITAJIMA *(Tokyo; Tochigi, Japan)* 3983

Resection of Solitary Metachronous Lymph Node Metastasis from Hepatocellular Carcinoma Following Transarterial Chemotherapy with Cisplatin: A Case Report. T. KUROKAWA, S. YAMAZAKI, M. MORIGUCHI, M. AOKI, Y. WATANABE, T. HIGAKI, T. TAKAYAMA *(Tokyo, Japan)* 3991

Long-term Vaccine Therapy with Autologous Whole Tumor Cell-pulsed Dendritic Cells for a Patient with Recurrent Rectal Carcinoma. H. ONISHI, T. MORISAKI, E. BABA, M. NAKAMURA, S. INABA, H. KUROKI, K. MATSUMOTO, M. KATANO *(Fukuoka; Kumamoto; Kanagawa, Japan)* 3995

Impact of Baseline Hepatitis B Viral DNA Levels on Survival of Patients with Advanced Hepatocellular Carcinoma. Y.-Y. SHAO, P.-J. CHEN, Z.-Z. LIN, C.-C. HUANG, Y.-H. DING, Y.-H. LEE, C.-H. HSU, A.-L. CHENG *(Taipei; Yunlin, Taiwan, ROC)* 4007

Assessment of 'Cancer-prone Personality' Characteristics in Healthy Study Subjects and in Patients with Breast Disease and Breast Cancer Using the Commitment Questionnaire: A Prospective Case–Control Study in Finland. M. ESKELINEN, P. OLLONEN *(Kuopio, Finland)* 4013

Measurement of Pessimism: Hopelessness Scale in Healthy Study Subjects, and in Patients with Benign Breast Disease and Breast Cancer: A Prospective Case–Control Study in Finland. M. ESKELINEN, P. OLLONEN *(Kuopio, Finland)* 4019

Symptomatic Bone Marrow Involvement in Breast Cancer – Clinical Presentation, Treatment, and Prognosis: A Single Institution Review of 22 Cases. H.-G. KOPP, K. KRAUSS, T. FEHM, A. STAEBLER, J. ZAHM, W. VOGEL, L. KANZ, F. MAYER *(Tuebingen, Germany)* 4025

Prognostic Significance of TIMP-1 in Non-small Cell Lung Cancer. M. PESTA, V. KULDA, R. KUCERA, M. PESEK, J. VRZALOVA, V. LISKA, L. PECEN, V. TRESKA, J. SAFRANEK, M. PRAZAKOVA, O. VYCITAL, J. BRUHA, L. HOLUBEC, O. TOPOLCAN *(Prague; Pilsen, Czech Republic)* 4031

3D Breast Ultrasound: A Significant Predictor in Breast Cancer Reduction under Pre-operative Chemotherapy. M. WARM, V. DUDA, C. EICHLER, N. HARBECK, A. GOSSMANN, A. THOMAS, M. HOOPMANN, R. OHLINGER, M. BREIDENBACH, R.E. KATES *(Cologne; Marburg; Berlin; Greifswald; Otterfing, Germany)* 4039

Nomogram for Suboptimal Cytoreduction at Primary Surgery for Advanced Stage Ovarian Cancer. C.G. GERESTEIN, M.J. EIJKEMANS, J. BAKKER, O.E. ELGERSMA, M.E.L VAN DER BURG, G.S. KOOI, C.W. BURGER *(Rotterdam; Utrecht; Dordrecht, Netherlands)* 4043

Errata 4051

* Review (page 3645)

Number 12

Experimental Studies

Quantification of Angiogenesis in Breast Cancer by Automated Vessel Identification in CD34 Immunohistochemical Sections. L.T.G. MIKALSEN, H.P. DHAKAL, Ø.S. BRULAND, J.M. NESLAND, D.R. OLSEN *(Oslo; Bergen, Norway)* 4053

Establishing Efficient Xenograft Models with Intrinsic Vascularisation for Growing Primary Human Low-grade Sarcomas. D. TILKORN, A. DAIGELER, I. STRICKER, A. SCHAFFRAN, I. SCHMITZ, L. STEINSTRAESSER, J. HAUSER, A. RING, H.-U. STEINAU, S. AL-BENNA *(Ludwigshafen; Bochum, Germany)* 4061

Inhibition of Human Tumor Xenograft Growth in Nude Mice by a Novel Monoclonal Anti-HSPG Isolated from Human Liver. P. VONGCHAN, S. KOTHAN, Y. WUTTI-IN, R.J. LINHARDT *(Ciang Mai, Thailand; Troy, NY, USA)* 4067

L-Type Amino Acid Transporter 1 (LAT1) Expression in Malignant Pleural Mesothelioma. K. KAIRA, N. ORIUCHI, T. TAKAHASHI, K. NAKAGAWA, Y. OHDE, T. OKUMURA, H. MURAKAMI, T. SHUKUYA, H. KENMOTSU, T. NAITO, Y. KANAI, M. ENDO, H. KONDO, T. NAKAJIMA, N. YAMAMOTO *(Shizuoka; Maebashi, Gunma; Osaka, Japan)* 4075

* Review: Electrotransfer of RNAi-based Oligonucleotides for Oncology. S. CHABOT, S. PELOFY, A. PAGANIN-GIOANNI, J. TEISSIE, M. GOLZIO *(Toulouse, France)* 4083

The Novel Vitamin D Analog ZK191784 Inhibits Prostate Cancer Cell Invasion. M. STIO, M. MARTINESI, A. SIMONI, U. ZUEGEL, A. STEINMEYER, R. SANTI, C. TREVES, G. NESI *(Florence, Italy; Berlin, Germany)* 4091

Characterization of T-Cell Memory Phenotype after *In Vitro* Expansion of Tumor-infiltrating Lymphocytes from Melanoma Patients. J. ZHOU, P. NAGARKATTI, Y. ZHONG, M. NAGARKATTI *(Columbia, SC, USA)* 4099

Effects of Artemisinin Dimers on Rat Breast Cancer Cells *In Vitro* and *In Vivo*. N.P. SINGH, H.C. LAI, J.S. PARK, T.E. GERHARDT, B.J. KIM, S. WANG, T. SASAKI *(Seattle, WA, USA)* 4111

Histone-modifier Gene Expression Profiles Are Associated with Pathological and Clinical Outcomes in Human Breast Cancer. N. PATANI, W.G. JIANG, R.F. NEWBOLD, K. MOKBEL *(London; Cardiff, Wales, UK)* 4115

PINCH mRNA Overexpression in Colorectal Carcinomas Correlated with *VEGF* and *FAS mRNA* Expression. Z.Y. ZHANG, Y.F. TIAN, Y.Y. WANG, L.J. ZHANG, Z.R. ZHAO, X.F. SUN *(Tangshan; Shijiazhuang, PR China; Linköping, Sweden)* 4127

ERCC1 Expression and Outcomes in Head and Neck Cancer Treated with Concurrent Cisplatin and Radiation. M. HAYES, C. LAN, J. YAN, Y. XIE, T. GRAY, R.H. AMIRKHAN, J.E. DOWELL *(Miramar Beach, FL; Modesto, CA; Dallas, TX, USA)* 4135

Treatment of Bone Metastasis in Prostate Cancer: Efficacy of a Novel Poly*bis*phosphonate. F. DAUBINE, R. LE BOT, M. MÁRQUEZ, S. NILSSON, T. SCHRÖDER, A.R. HOLMBERG *(Nantes, France; Stockholm, Sweden)* 4141

REG4, NEIL2, and *BIRC5* Gene Expression Correlates with Gamma-radiation Sensitivity in Patients with Rectal Cancer Receiving Radiotherapy. T. KOBUNAI, T. WATANABE, T. FUKUSATO *(Tokyo, Japan)* 4147

Overexpressed HER2 in NSCLC Is a Possible Therapeutic Target of EGFR Inhibitors. N. ISE, K. OMI, D. NAMBARA, S. HIGASHIYAMA, K. GOISHI *(Tokyo; Ehime, Japan)* 4155

Acridine Orange Inhibits Pulmonary Metastasis of Mouse Osteosarcoma. H. SATONAKA, K. KUSUZAKI, K. AKEDA, M. TSUJII, T. IINO, T. UEMURA, T. MATSUBARA, T. NAKAMURA, K. ASANUMA, A. MATSUMINE, A. SUDO *(Tsu City, Mie; Kyoto City, Kyoto, Japan)* 4163

Effects of Inorganic and Organic Arsenic Compounds on Growth and Apoptosis of Human T-Lymphoblastoid Leukemia Cells. E. HIKITA, M. ARAI, S. TANAKA, K. ONDA, H. UTSUMI, B. YUAN, H. TOYODA, T. HIRANO *(Hachioji; Tokyo, Tokyo; Sagamihara, Kanagawa, Japan)* 4169

Mutational Screening of *RET, HRAS, KRAS, NRAS, BRAF, AKT1,* and *CTNNB1* in Medullary Thyroid Carcinoma. H.-J. SCHULTEN, J. AL-MAGHRABI, K. AL-GHAMDI, S. SALAMA, S. AL-MUHAYAWI, A. CHAUDHARY, O. HAMOUR, A. ABUZENADAH, M. GARI, M. AL-QAHTANI *(Jeddah, Saudi Arabia)* 4179

Inactivated Orf virus (*Parapoxvirus ovis*) Induces Antitumoral Activity in Transplantable Tumor Models. H.-H. FIEBIG, A. SIEGLING, H.-D. VOLK, A. FRIEBE, P. KNOLLE, A. LIMMER, O. WEBER *(Freiburg; Wuppertal; Bonn, Germany)* 4185

Expression of the Apoptosis-related Genes *Bcl-2* and *p53* in Clinical Samples from Endometrial Carcinoma Patients. I. GONZÁLEZ-RODILLA, V. VERNA, A.-B. MUÑOZ, J. ESTÉVEZ, M. BOIX, J. SCHNEIDER *(Santander, Spain)* 4191

Yeast-derived Beta-(1-3),(1-6)-D-glucan Induces Up-regulation of CD86 on Dectin-1-^{positive} Human B-Lymphoma Cell Lines. U. HARNACK, U. KELLERMANN, G. PECHER *(Berlin, Germany)* 4195

Thioridazine Induces Apoptosis of Multidrug-resistant Mouse Lymphoma Cells Transfected with the Human *ABCB1* and Inhibits the Expression of P-Glycoprotein. G. SPENGLER, J. MOLNAR, M. VIVEIROS, L. AMARAL *(Szeged, Hungary; Lisboa, Portugal; Brussels, Belgium)* 4201

Reliability of Direct Sequencing of EGFR: Comparison between Cytological and Histological Samples from the Same Patient. P. BRUNO, S. MARIOTTA, A. RICCI, E. DURANTI, D. SCOZZI, A. NOTO, R. MANCINI, E. GIARNIERI, M.R. GIOVAGNOLI *(Rome, Italy)* 4207

Prognostic Significance of N-Cadherin Expression in Oral Squamous Cell Carcinoma. M. DI DOMENICO, G.M. PIERANTONI, A. FEOLA, F. ESPOSITO, L. LAINO, A. DE ROSA, R. RULLO, M. MAZZOTTA, M. MARTANO, F. SANGUEDOLCE, L. PERILLO, L. D'ANGELO, S. PAPAGERAKIS, S. TORTORELLA, P. BUFO, L. LO MUZIO, G. PANNONE, A. SANTORO *(Naples; Foggia; Bari, Italy; Ann Arbor, MI, USA)* 4211

Circulating Tumor Cells and "Suspicious Objects" Evaluated Through CellSearch® in Metastatic Renal Cell Carcinoma. A. GRADILONE, R. IACOVELLI, E. CORTESI, C. RAIMONDI, W. GIANNI, C. NICOLAZZO, A. PETRACCA, A. PALAZZO, F. LONGO, L. FRATI, P. GAZZANIGA *(Rome, Italy)* 4219

Resveratrol Reduces TNF-α-induced U373MG Human Glioma Cell Invasion through Regulating NF-κB Activation and uPA/uPAR Expression. J. RYU, B.M. KU, Y.K. LEE, J.Y. JEONG, S. KANG, J. CHOI, Y. YANG, D.H. LEE, G.S. ROH, H.J. KIM, G.J. CHO, W.S. CHOI, N. KIM, S.S. KANG *(Jinju; Gimhae; Seoul, South Korea)* 4223

Quantitative Structure-Activity Relationship (QSAR) Analysis of Tumor-specificity of 1,2,3,4-Tetrahydroisoquinoline Derivatives. Y. UESAWA, K. MOHRI, M. KAWASE, M. ISHIHARA, H. SAKAGAMI *(Tokyo; Matsuyama; Saitama, Japan)* 4231

Cytoskeleton Network and Cellular Migration Modulated by Nuclear-localized Receptor Tyrosine Kinase ROR1. H.-C. TSENG, H.-W. KAO, M.-R. HO, Y.-R. CHEN, T.-W. LIN, P.-C. LYU, W.-C. LIN *(Hsinchu; Taipei, Taiwan, ROC)* 4239

Novel Cytotoxic Isolated from Jamaican Hyptis verticillata jacq Induces Apoptosis and Overcomes Multidrug Resistance. Y. WHITE, T. HAMADA, M. YOSHIMITSU, M. NAKASHIMA, M. HACHIMAN, T. KOZAKO, K. MATSUSHITA, K. UOZUMI, S. SUZUKI, H. KOFUNE, T. FURUKAWA, N. ARIMA *(Kagoshima; Fukuoka, Japan)* 4251

IGF1Ec Expression in MG-63 Human Osteoblast-like Osteosarcoma Cells. A. PHILIPPOU, A. ARMAKOLAS, Z. PANTELEAKOU, N. PISSIMISSIS, A. NEZOS, A. THEOS, M. KAPARELOU, N. ARMAKOLAS, S.G. PNEUMATICOS, M. KOUTSILIERIS *(Athens, Greece)* 4259

Mutations of Mitochondrial DNA as Potential Biomarkers in Breast Cancer. F.F. CAI, C. KOHLER, B. ZHANG, W.J. CHEN, Z. BAREKATI, H.S.P. GARRITSEN, P. LENNER, P. TONIOLO, J.J. ZHANG, X.Y. ZHONG *(Basel; Lausanne, Switzerland; Braunschweig, Germany; Umeä, Sweden; Hefei, Anhui, PR China)* 4267

Differential CD133 Expression Pattern during Mouse Colon Tumorigenesis. V. ARENA, E. CAREDDA, V. CUFINO, E. STIGLIANO, F. SCALDAFERRI, A. GASBARRINI, A. CITTADINI, A. SGAMBATO *(Rome, Italy)* 4273

The Expression of Ki-67, but Not Proliferating Cell Nuclear Antigen, Predicts Poor Disease Free Survival in Patients with Adenocarcinoma of the Lung. S. OKA, H. URAMOTO, H. SHIMOKAWA, T. IWANAMI, F. TANAKA *(Kitakyushu, Japan)* 4277

Synergism from the Combination of Oxaliplatin with Selected Phytochemicals in Human Ovarian Cancer Cell Lines. N.M. YUNOS, P. BEALE, J.Q. YU, F. HUQ *(Kepong, Malaysia; Sydney, NSW, Australia)* 4283

Investigation of Cell Death Induced by *N*-Methyl-*N*-Nitrosourea in Cell Lines of Human Origin and Implication of RNA Binding Protein Alterations. A. KORYLLOU, M. PATRINOU-GEORGOULA, A. DIMOZI, S.A. KYRTOPOULOS, V. PLETSA *(Athens, Greece)* 4291

Association of *p53* and *CDKN1A* Genotypes with Endometriosis. T.-H. YING, C.-J. TSENG, S.-J. TSAI, S.-C. HSIEH, H.-Z. LEE, Y.-H. HSIEH, D.-T. BAU *(Taichung, Taiwan, ROC)* 4301

Human Brain Endothelial Cell-derived COX-2 Facilitates Extravasation of Breast Cancer Cells Across the Blood-brain Barrier. K.Y. LEE, Y.-J. KIM, H. YOO, S.H. LEE, J.B. PARK, H.J. KIM *(Goyang; Daejeon, Republic of Korea)* 4307

Differential Cytotoxic Effects of Sodium Meta-arsenite on Human Cancer Cells, Dental Papilla Stem Cells and Somatic Cells Correlate with Telomeric Properties and Gene Expression. B.-G. JEON, B.M KUMAR, E-J. KANG, G.-H. MAENG, Y.-M. LEE, Y.-S. HAH, S.-A OCK, D.-O. KWACK, B.-W. PARK, G.-J. RHO *(Jinju, Republic of Korea)* 4315

Genome-wide Identification of Chemosensitive Single Nucleotide Polymorphism Markers in Gastric Cancer. Y.J. HA, S.N. YOON, Y.J. JEON, D.H. CHO, S.A. ROH, B.S. KIM, H.J. KIM, S.Y. KIM, Y.S. KIM, J.C. KIM *(Seoul; Daejeon; Gyeoggi-Do, Republic of Korea)* 4329

De-alcoholization of Paclitaxel Injection for Clinical Application. I. TSUKIYAMA, M. TAKEUCHI, F. ABE, T. KISI, H. SAITO, Y. OBAYASHI, K. WATANABE, A. WAKATSUKI, K.-I. MIYAMOTO, T. HASEGAWA *(Aichi-gun, Aichi; Kanazawa, Ishikawa, Japan)* 4339

Modulation of PGE2-induced EP4 Expression on *Snail* Signaling and the Impact on Epithelial-Mesenchymal Transition: Significance of EP4 Antagonism. H.N. KIM, N.K. NARAYANAN, S. LASANO, B. NARAYANAN *(Tuxedo, NY, USA)* 4347

Clinical Studies

* Review: Impact of Cyclooxygenase-2 in Breast Cancer. F. HOELLEN, K. KELLING, C. DITTMER, K. DIEDRICH, M. FRIEDRICH, M. THILL *(Luebeck; Krefeld, Germany)* 4359

* Review: Estrogen Pathway Polymorphisms and Mammographic Density. I. DUMAS, C. DIORIO *(Quebec City, QC, Canada)* 4369

* Review: Targeting AKT Protein Kinase in Gastric Cancer. K. ALMHANNA, J. STROSBERG, M. MALAFA *(Tampa, FL, USA)* 4387

Feasibility of Image-guided Radiotherapy Based on Tomotherapy for the Treatment of Locally Advanced Anal Carcinoma. N.P. NGUYEN, J. VOCK, T. SROKA, R. KHAN, S. JANG, A. CHI, M. BETZ, L. EWELL, D. COHEN, R.P. VO, M. MILLS, V. VINH-HUNG *(Galveston, TX, USA; Bern; Geneva, Switzerland)* 4393

Primary Peritoneal Carcinoma in Complete Remission: a Case Report. J. RAMOS, K.S. GUNTURU, S. KRISHNAMOORTHY, B. KENNEY, M.W. SAIF *(New Haven, CT; New York, NY, USA)* 4397

Loss of p27^{KIP1} Expression in Fully-staged Node-negative Breast Cancer: Association with Lack of Hormone Receptors in T1a/b, but not T1c Infiltrative Ductal Carcinoma. D. MIRCHANDANI, D.F. ROSES, G. INGHIRAMI, A. ZELENIUCH-JACQUOTTE, J. CANGIARELLA, A. GUTH, R.A. SAFYAN, S.C. FORMENTI, M. PAGANO, F. MUGGIA *(New York, NY, USA)* 4401

Triple Induction Chemotherapy and Chemoradiotherapy for Locally Advanced Esophageal Cancer. A Phase II Study. W. EISTERER, A. DE VRIES, D. KENDLER, B. SPECHTENHAUSER, A. KÖNIGSRAINER, H. NEHODA, I. VIRGOLINI, P. LUKAS, O. BECHTER, E. WÖLL, D. ÖFNER *(Innsbruck; Feldkirch; Kufstein; St. Johann; Zams; Salzburg, Austria; Tübingen, Germany)* 4407

Intraepidermal Nerve Fibre Density in Cancer Patients Receiving Adjuvant Chemotherapy. M.J. KOSKINEN, A.-L. KAUTIO, M.L. HAANPÄÄ, H.K. HAAPASALO, P.-L. KELLOKUMPU-LEHTINEN, T. SAARTO, A.J. HIETAHARJU *(Tampere; Helsinki, Finland)* 4413

First Study of Oral Artenimol-R in Advanced Cervical Cancer: Clinical Benefit, Tolerability and Tumor Markers. F. H. JANSEN, I. ADOUBI, K.C. COMOE, T. DE CNODDER, N. JANSEN, A. TSCHULAKOW, T. EFFERTH *(Abidjan, Côte d'Ivoire; Liège, Belgium; Mainz, Germany)* 4417

Impaired Bone Microenvironment: Correlation between Bone Density and Presence of Disseminated Tumor Cells. B. KRAEMER, R. ROTHMUND, M. BANYS, N. KRAWCZYK, E.-F. SOLOMAYER, C. MACK, D. WALLWIENER, T. FEHM *(Tuebingen; Hamburg; Homburg, Germany)* 4423

Immunohistochemical Study of VEGF Expression in Oral Squamous Cell Carcinomas: Correlation with the mTOR-HIF-1α Pathway. T. NARUSE, G. KAWASAKI, S. YANAMOTO, A. MIZUNO, M. UMEDA *(Nagasaki, Japan)* 4429

Oxaliplatin, Irinotecan and Cetuximab in Advanced Gastric Cancer. A Multicenter Phase II Trial (Gastric-2) of the Arbeitsgemeinschaft Medikamentose Tumortherapie (AGMT). E. WÖLL, R. GREIL, W. EISTERER, O. BECHTER, M.A. FRIDRIK, B. GRÜNBERGER, A. ZABERNIGG, B. MAYRBAURL, G. RUSS, M. DLASKA, P. OBRIST, J. THALER *(Zams; Salzburg; Innsbruck; Linz; Vienna; Kufstein; Wels, Austria)* 4439

PCA3 Score vs PSA Free/Total Accuracy in Prostate Cancer Diagnosis at Repeat Saturation Biopsy. P. PEPE, F. ARAGONA *(Catania, Italy)* 4445

The EMT Status in the Primary Tumor Does Not Predict Postoperative Recurrence or Disease-free Survival in Lung Adenocarcinoma. Y. CHIKAISHI, H. URAMOTO, F. TANAKA *(Kitakyushu, Japan)* 4451

Correlation between *IDH1* Gene Mutation Status and Survival of Patients Treated for Recurrent Glioma. S. LV, E. TEUGELS, J. SADONES, E. QUARTIER, M. HUYLEBROUCK, S. DU FOUR, M. LE MERCIER, O. DE WITTE, I. SALMON, A. MICHOTTE, J. DE GRÈVE, B. NEYNS *(Brussels, Belgium)* 4457

Effect of Maintenance Chemotherapy with Gemcitabine and Paclitaxel on Recurrent Squamous Cell Carcinoma of the Bladder: A Case Report. Y. MIYATA, S.-I. WATANABE, H. TAKAHASHI, Y. SAGARA, T. MATSUO, K. OHBA, H. SAKAI *(Nagasaki, Japan)* 4465

External Validation of a Laparoscopic-based Score to Evaluate Resectability for Patients with Advanced Ovarian Cancer Undergoing Interval Debulking Surgery. E. CHEREAU, V. LAVOUE, M. BALLESTER, C. COUTANT, F. SELLE, A. CORTEZ, E. DARAÏ, J. LEVEQUE, R. ROUZIER *(Paris; Rennes, France)* 4469

Anaplastic Oligodendroglial Tumors Harboring 1p/19q Deletion Can Be Successfully Treated without Radiotherapy. Y. IWADATE, T. MATSUTANI, N. SHINOZAKI, N. SAEKI *(Chiba City, Chiba, Japan)* 4475

Synchronous Double Tumor of Breast Cancer and Gastrointestinal Stromal Tumor in a Patient with Neurofibromatosis Type 1: Report of a Case. H. TAKEUCHI, S. HIROSHIGE, K. HASHIMOTO, T. KUSUMOTO, Y. YOSHIKAWA, Y. MUTO *(Beppu, Japan)* 4481

Clinical and Histopathological Profile of Primary or Secondary Osteosarcoma of the Jaws. F. ANGIERO, F. MOLTRASIO, G. CATTORETTI, M.G. VALENTE *(Genoa; Milan, Italy)* 4485

The Cancer Stem Cell Antigens CD133, BCRP1/ABCG2 and CD117/c-KIT Are Not Associated with Prognosis in Resected Early-stage Non-small Cell Lung Cancer. E. HERPEL, K. JENSEN, T. MULEY, A. WARTH, P.A. SCHNABEL, M. MEISTER, F.J.F. HERTH, H. DIENEMANN, M. THOMAS, S. GOTTSCHLING *(Heidelberg, Germany)* 4491

Evidence for Acute Vascular Toxicity of Cisplatin-based Chemotherapy in Patients with Germ Cell Tumour. K.-P. DIECKMANN, W.J. STRUSS, U. BUDDE *(Hamburg, Germany)* 4501

Circulating CD95-ligand as a Potential Prognostic Marker for Recurrence in Patients with Synchronous Colorectal Liver Metastases. F.J.H. HOOGWATER, N. SNOEREN, M.W. NIJKAMP, A.C. GUNNING, W.J. VAN HOUDT, M.T. DE BRUIJN, E.E. VOEST, R. VAN HILLEGERSBERG, O. KRANENBURG, I.H.M. BOREL RINKES *(Utrecht, Netherlands)* 4507

Dissection of Unsuspicious Para-aortic Lymph Nodes Does Not Improve Prognosis of Advanced Endometrial Carcinoma with Intra- or Extra-abdominal Metastasis. Y. UEDA, M. OKAZAWA, T. ENOMOTO, T. EGAWA-TAKATA, KIMURA TOSHIHIRO, K. YOSHINO, M. FUJITA, Y. OHTA, S. KAMIURA, KIMURA TADASHI *(Osaka, Japan)* 4513

Continuous Administration of EGFR-TKIs Following Radiotherapy after Disease Progression in Bone Lesions for Non-small Cell Lung Cancer. M. INOMATA, T. SHUKUYA, T. TAKAHASHI, A. ONO, Y. NAKAMURA, A. TSUYA, H. KENMOTSU, T. NAITO, H. MURAKAMI, H. HARADA, M. ENDO, N. YAMAMOTO *(Shizuoka; Toyama; Tokyo, Japan)* 4519

Hypersensitivity Reactions Associated with Platinum-containing Antineoplastic Agents for Thoracic Malignancies. M. TAMIYA, H. KUHARA, T. HIRASHIMA, Y. KONDO, M. SANTO, N. MORISHITA, H. SUZUKI, S. SASADA, N. OKAMOTO, M. KOBAYASHI, I. KAWASE *(Osaka; Tokyo, Japan)* 4525

Carbonic Anhydrase IX, Hypoxia-inducible Factor-1α, Ezrin and Glucose Transporter-1 as Predictors of Disease Outcome in Rectal Cancer: Multivariate Cox Survival Models following Data Reduction by Principal Component Analysis of the Clinicopathological Predictors. E.A. KORKEILA, J. SUNDSTRÖM, S. PYRHÖNEN, K. SYRJÄNEN *(Turku, Finland)* 4529

Retrospective Study of Patients with Brain Metastases from Melanoma Receiving Concurrent Whole-brain Radiation and Temozolomide. N. DEVITO, M. YU, R. CHEN, E. PAN *(Tampa, FL, USA)* 4537

Perioperative Non-tumorous Factors Associated with Survival in HCC Patients Who Underwent Hepatectomy. A. NANASHIMA, T. ABO, K. HAMASAKI, K. WAKATA, T. TOMINAGA, S. HIDAKA, H. TAKESHITA, T. NAGAYASU *(Nagasaki, Japan)* 4545

Initial Experience with Hepatic Intraarterial Fotemustine and Interferon Alpha 2b Combination for Treatment of Liver Tumors. F.V. VITALE, P. ROMEO, E.M. DI MAGGIO, A. PARISI, E. MALAPONTE, S. CALÌ, F. VASTA, V. PANEBIANCO, D. ARCORIA, F. FERRAÙ *(Taormina; Catania, Italy)* 4553

Prospective Study Evaluating the Plasma Concentrations of Twenty-six Cytokines and Response to Morphine Treatment in Cancer Patients. C. MAKIMURA, T. ARAO, H. MATSUOKA, M. TAKEDA, H. KIYOTA, J. TSURUTANI, Y. FUJITA, K. MATSUMOTO, H. KIMURA, M. OTSUKA, A. KOYAMA, C.K. IMAMURA, T. YAMANAKA, K. TANAKA, K. NISHIO, K. NAKAGAWA *(Osaka, Sakai; Habikino, Osaka; Tokyo; Fukuoka, Japan)* 4561

Impact of Chemotherapy for Colorectal Cancer on Regulatory T-Cells and Tumor Immunity. K. MAEDA, S. HAZAMA, K. TOKUNO, S. KAN, Y. MAEDA, Y. WATANABE, R. KAMEI, Y. SHINDO, N. MAEDA, K. YOSHIMURA, S. YOSHINO, M. OKA *(Yamaguchi, Japan)* 4569

Radiofrequency Ablation for Intrahepatic Cholangiocarcinoma: Retrospective Analysis of a Single Centre Experience. A. GIORGIO, G. CALISTI, G. DE STEFANO, N. FARELLA, A. DI SARNO, F. AMENDOLA, U. SCOGNAMIGLIO, V. GIORGIO *(Naples; Rome, Italy)* 4575

Trans-Arterial Chemoembolization of Metastatic Colorectal Carcinoma to the Liver Adopting DC Bead®, Drug-eluting Bead Loaded with Irinotecan: Results of a Phase II Clinical Study. C. ALIBERTI, G. FIORENTINI, P.C. MUZZIO, F. POMERRI, M. TILLI, S. DALLARA, G. BENEA *(Padova; Pesaro; Ferrrara, Italy)* 4581

Docetaxel, Nedaplatin, and S-1 (DGS) Chemotherapy for Advanced Esophageal Carcinoma: A Phase I Dose-escalation Study. Y. TANAKA, K. YOSHIDA, S. OSADA, K. YAMAGUCHI, T. TAKAHASHI *(Gifu City, Gifu, Japan)* 4589

Long-term Survival Following Resection of Brain Metastases from Pancreatic Cancer. J. LEMKE, T.F.E. BARTH, M. JUCHEMS, T. KAPAPA, D. HENNE-BRUNS, M. KORNMANN *(Ulm, Germany)* 4599

Comparison of Lymphangiogenesis between Primary Colorectal Cancer and Corresponding Liver Metastases. A. SCHOPPMANN, D. TAMANDL, B. HERBERGER, F. LANGLE, P. BIRNER, S. GELEFF, T. GRÜNBERGER, S.F. SCHOPPMANN *(Vienna, Austria)* 4605

Salvage Chemotherapy for Ovarian Carcinoma Recurring During or After Consolidation Chemotherapy with Paclitaxel. Y. MIYOSHI, Y. UEDA, A. MORIMOTO, T. YOKOYAMA, S. MATSUZAKI, E. KOBAYASHI, KIMURA TOSHIHIRO, K. YOSHINO, M. FUJITA, T. ENOMOTO, KIMURA TADASHI *(Suita, Osaka, Japan)* 4613

Clinical Significance of *BRAF* Gene Mutations in Patients with Non-small Cell Lung Cancer. M. KOBAYASHI, M. SONOBE, T. TAKAHASHI, A. YOSHIZAWA, M. ISHIKAWA, R. KIKUCHI, K. OKUBO, C.-L. HUANG, H. DATE *(Kyoto, Japan)* 4619

Weekly Paclitaxel in Combination with Doxifluridine for Peritoneally Disseminated Gastric Cancer with Malignant Ascites. I. TAKEYOSHI, F. MAKITA, S. IWAZAKI, H. ISHIKAWA, S. KAKINUMA, Y. SATO, T. OHYA, K. NAKAGAMI, N. TOMIZAWA, M. IZUMI, I. KOBAYASHI, Y. TANAHASHI, J. KOBAYASHI, N. KAMOSHITA, S. KAWATE, Y. SUNOSE, I. SAKAMOTO, D. YOSHINARI, T. YAMADA, T. OKABE *(Maebashi; Shibukawa; Tatebayashi; Takasaki; Gunma; Fujiyoshida, Yamanashi; Usui; Koriyama, Fukushima; Ojiya, Niigata; Ogawa, Saitama; Suto, Kumamoto, Japan)* 4625

The Prognostic Significance of HER2 Overexpression in Non-small Cell Lung Cancer. M. TAKENAKA, T. HANAGIRI, S. SHINOHARA, T. KUWATA, Y. CHIKAISHI, S. OKA, Y. SHIGEMATSU, Y. NAGATA, H. SHIMOKAWA, M. NAKAGAWA, H. URAMOTO, T. SO, F. TANAKA *(Kitakyushu, Japan)* 4631

Single-agent Paclitaxel in Advanced Anal Cancer after Failure of Cisplatin and 5-Fluorouracil Chemotherapy. A. ABBAS, E. NEHME, M. FAKIH *(Buffalo, NY; Ann Arbor, MI, USA)* 4637

Clinical Characteristics and Treatment Outcomes of Hepatocellular Carcinoma with Inferior Vena Cava/Heart Invasion. Y.H. CHUN, S.H. AHN, J.Y. PARK, D.Y. KIM, K.-H. HAN, C.Y. CHON, S.J. BYUN, S.U. KIM *(Seoul, South Korea)* 4641

Clinical Significance of Hypermethylation Status in NSCLC: Evaluation of a 30-Gene Panel in Patients with Advanced Disease. M. PESEK, M. KOPECKOVA, L. BENESOVA, A. MESZAROSOVA, P. MUKENSNABL, F. BRUHA, M. MINARIK *(Pilsen; Prague, Czech Republic)* 4647

Growth Factors and Breast Tumors, Comparison of Selected Growth Factors with Traditional Tumor Markers. R. KUCERA, M. CERNA, A. NARSANSKA, S. SVOBODOVA, M. STRAKOVA, J. VRZALOVA, R. FUCHSOVA, I. TRESKOVA, T. KYDLICEK, V. TRESKA, L. PECEN, O. TOPOLCAN, P. PAZDIORA *(Pilsen; Prague, Czech Republic)* 4653

Multi-center Phase II Study of FLOX for Advanced Colorectal Cancer Patients in Japan: SWIFT 3 Study. T. KATO, N. NAGATA, M. FUJII, H. TAKEMOTO, K. KONDO, Y. OKUYAMA, H. TOMINAGA, J. SAKAMOTO, H. MISHIMA *(Hyogo; Kitakyushu; Osaka; Sakai; Nagoya; Kyoto; Hiroshima, Japan)* 4657

Low Dihydropyrimidine Dehydrogenase Correlates with Prolonged Survival in Patients with Lung Adenocarcinoma Treated with 5-Fluorouracil. Y. SHINTANI, M. INOUE, Y. FUNAKOSHI, A. MATSUMURA, M. OHTA, H. MAEDA, M. OKUMURA *(Osaka, Japan)* 4665

* Reviews (pages 4083, 4359, 4369, 4387)

Subject Index

(Figures refer to page numbers)

A20 lymphoma, β-glucan, cyclophosphamide, regulatory T-cell, 1169
A46, *Pantoea agglomerans*, LPS, LPSp, LPSa46, macrophage, M-CSF, GM-CSF, 2467
AAV, CXCR4, gene therapy, bioluminescence, breast cancer, 1627
ABC proteins, hepatocellular carcinoma, liver resection, multidrug resistance, tyrosine kinase, 3883
ABCB1 transporter, hydantoin derivatives, Colo 205 and Colo 320 colon adenocarcinoma cells, multidrug resistance, efflux pump, apoptosis, 3285
ABCB1 transporter, multidrug-resistant cancer cells, MDR mouse T-lymphoma cells, P-glycoprotein, phenothiazines, thioridazine, apoptosis, 4201
Abdominal tumor, low-grade myofibroblastic sarcoma, 2989
Ablation of liver metastases, CT-guided high-dose-rate brachytherapy, CT-HDRBT, ovarian cancer, metachronous liver metastasis, 2597
Absorption, LPS, endotoxin, oral administration, toxicity, lipopolysaccharide, review, 2431
Acceleration, prostate cancer, radiotherapy, hypofractionation, amifostine, cytoprotection, 1745
Acetoxycoumarins, cell viability, cell cycle, lethal dose, 2017
ACI rat serum, zeranol, breast cancer, mitogenic activity, 481
Acidification, colon cancer, metformin, phenformin, 2-deoxyglucose, 421
ACNU, glioma, oligodendroglioma, 1p19q, 1p, PAV, procarbazine, vincristine, chemotherapy, 4475
Acridine orange, osteosarcoma, pulmonary metastasis, photodynamic therapy, flash-wave light, fluorovisualization, 4163
K-Actin, hepatocellular carcinoma, survival, postoperative prognosis, 2037
Actin cytoskeleton, cell migration, nuclear localization, Ror1, receptor tyrosine kinase, 4239
Activation loop, proteasome inhibitor, receptor tyrosine kinase, multiple myeloma, ER stress, FGFR3, Lys650Glu mutation, K650E, bortezomide, plasma cell malignancy, 113
Active metabolite of irinotecan, SN-38, glucuronidation, SN-38 glucuronide (SN-38G), panipenem, pharmacokinetics, 2915
Activin A, maspin, androgen receptor, upper urinary tract urothelial carcinoma, prognosis, 1713
Acute effect, hypofractionated radiotherapy, prostate cancer, intermediate risk, image guided radiation therapy, hormonotherapy, 3555
Acute lymphoblastic leukemia, minimal residual disease, flow cytometry, children, early response, 1453
Acute myelogenous leukemia, deferasirox, iron chelation therapy, iron overload, chemotherapy-resistant, complete remission, 1741
Acute myeloid leukemia, immunotherapy, interleukin-2, peptide vaccination, cerebrospinal fluid, CSF, flow of CSF, chloroma, 2343
ADAGIO study, imatinib, gastrointestinal stromal tumor, adherence, 1407
ADAM, MMP, TIMP, solid cancer nest, invasive front, colorectal cancer, 1567
ADAMTS1, breast cancer, amphiregulin, xenograft, immunotherapy, 3839
ADCC, lapatinib, HER2, breast cancer, herceptin, 2999
Adenocarcinoma, *BRAF* mutation, *KRAS*, *EGFR*, ERBB2 mutation, V600E, lung cancer, squamous cell carcinoma, SSCP, 4619
Adenocarcinoma, Ki-67, PCNA, recurrence, lung, 4277
Adenocarcinoma, *MACC1*, recurrence, lung cancer, 1141
Adenosine triphosphate, thymidylate synthase, ERCC1, drug screening assay, colorectal neoplasm, 3843
Adenovirus, prodrug activation, HNSCC, ganciclovir, thymidine kinase, apoptosis, 3851
ADH-1, adrenocortical carcinoma, dynamic contrast enhancing magnetic resonance imaging (DCE-MRI), phase-I, N-cadherin, 3921
ADH1B, alcohol-dehydrogenase, polymorphism, oral cancer, laryngeal cancer, 677
Adherence, imatinib, gastrointestinal stromal tumor, ADAGIO study, 1407
Adhesion molecules, colorectal cancer, biological activity, tumor markers, angiogenetic factors, metalloproteinases, 373
Adhesion molecules, prostate cancer, vitamin D analog, ZK191784, MMP-2, MMP-9, 4091
Adjuvant chemotherapy, cancer, neurotoxicity, docetaxel, intraepidermal nerve fibres, neuropathy, skin biopsies, oxaliplatin, 4413
Adjuvant chemotherapy, colorectal cancer, *MTHFR C677T*, *MTR* A2756G, toxicity, survival, 3057
Adjuvant chemotherapy, colorectal cancer, pulmonary metastases, TS, OPRT, ERCC1, BRCA1, MVD, 2763
Adjuvant chemotherapy, endometrial carcinoma, para-aortic lymph node dissection, prognosis, 4513
Adjuvant chemotherapy, sequential therapy, breast cancer, 1483
ADM, colorectal cancer, prognostic factor, hypoxia, 507
ADOC, thymic carcinoma, chemotherapy, refractory, S-1, 299
Adrenal imaging, adrenocortical tumors, Cushing's syndrome, cancer, CT, MR, review, 2923
Adrenocortical carcinoma, ADH-1, dynamic contrast enhancing magnetic resonance imaging (DCE-MRI), phase-I, N-cadherin, 3921

Adrenocortical tumors, Cushing's syndrome, adrenal imaging, cancer, CT, MR, review, 2923
Adriamycin, cardiotoxicity, fatigue, myotoxicity, 2023
Advanced esophageal cancer, combined chemotherapy, docetaxel, CDDP, 5-FU, 633
Advanced gastric cancer, AKT, PI3K, chemoresistance, review, 4387
Advanced gastric cancer, triplet combination chemotherapy, paclitaxel, cisplatin, S-1, feasibility study, 3085
Advanced hepatocellular carcinoma (HCC), cetuximab, hepatic intra-arterial chemotherapy (HAIC), 3927
Advanced imaging modes, breast cancer, screening mammography, microcalcification, high-frequency ultrasound, 2575
Advanced NSCLC, LAT1, CD98, recurrence, *EGFR* mutation, prognosis, chemotherapy. Ki-67, p-Akt, p-mTOR, 3775
Advanced prostate cancer, castrate-resistant prostate cancer, predictors of survival, time to castration resistance, chemotherapy, 1475
Adverse effects, assessment, chemotherapy, neurotoxicity, peripheral neuropathy, 3493
Adverse event, paclitaxel (PTX), alcohol intolerance, de-alcoholization, pharmacokinetics, 4339
Afatinib, BIBF 1120, colorectal cancer, phase II, pharmacokinetics, 2271
AFP-IgM immune complexes, hepatocellular carcinoma, biomarker, alpha-fetoprotein, 687
AG1478, HNSCC, *EGFR*, polymorphism, Erk-1/2, cetuximab, 59
Age, breast cancer, grade, immunohistochemistry, measles virus, *p53,* 913
Age, colon cancer, microsatellite instability, tumor location, early onset, 967
AKT, advanced gastric cancer, PI3K, chemoresistance, review, 4387
Akt, HGF, c-Met, *NK4*, CT26, 5-fluorouracil, Erk1/2, thymidylate synthase, 2217
Akt, medicinal herb, bioactivity, p53 pathway, apoptosis, *Ruta graveolens*, 233
AKT, melanoma, sorafenib, fluvastatin, JNK, 3259
Akt, non-seminomatous testicular cancer, PTEN, $p27^{Kip1}$, subcellular distribution, 3783
AKT, ovarian cancer, gene mutations, BRCA 1/2, *TP53*, PI3K, *BRAF*, *KRAS*, review, 2661
AKT, ovarian cancer, methyl-2-cyano-3, 12-dioxooleana-1, 9(11)-dien-28-oate (CDDO-Me), apoptosis, NF-κB, mTOR, 3673
AKT1, medullary thyroid carcinoma, gene mutations, *RET*, *HRAS*, *KRAS*, *NRAS*, *BRAF*, *CTNNB1*, mutational screening, 4179
Alcohol intolerance, paclitaxel (PTX), de-alcoholization, pharmacokinetics, adverse event, 4339
Alcohol-dehydrogenase, ADH1B, polymorphism, oral cancer, laryngeal cancer, 677
Allogeneic stem cell transplantation, hemorrhagic cystitis, BK virus, review, 939
Alpha subunits, medulloblastoma, atypical teratoid/rhabdoid tumours, Na^+/K^+-ATPase, immunohistochemistry, 953
Alpha-fetoprotein, hepatocellular carcinoma, biomarker, AFP-IgM immune complexes, 687
Alternative splicing, angiogenesis, autologous stem cell transplantation, chick chorioallantoic membrane assay, high-dose chemotherapy, placental growth factor, vascular endothelial growth factor, V*EGFR*1, 3115
Alternative splicing, insulin-like growth factor 1, MG-63 osteosarcoma cells, 4259
Amifostine, prostate cancer, radiotherapy, hypofractionation, acceleration, cytoprotection, 1745
2-amino-1-methyl-6-phenylimidazo[4, 5-b]pyridine, Apc, C57Bl/6J, min mice, FVB, intestinal carcinogenesis, 785
5-aminolevulinic acid, sonodynamic therapy, focused ultrasound, glioma, deep-seated, rat model, 2527
5-aminolevulinic acid, sonodynamic therapy, SAS cell, mitochondrion, apoptosis, 39
Amphiregulin, breast cancer, ADAMTS1, xenograft, immunotherapy, 3839
Anal cancer, 5-FU, cisplatin, paclitaxel, 4637
Anal cancer, chemoradiation, image-guided radiotherapy, tomotherapy, 4393
Anaphylatoxin, antisense pepitide, complementary peptide, inflammation, sepsis, cytokine storm, 2511
Anaplastic ependymoma, multifocal recurrence, temozolomide, 1023
Anaplastic gliomas, long-term administration, temozolomide, 3873
Anastrazole, total estrogen blockade, high-dose chemotherapy, leuprorelin, premenopausal breast cancer, *VEGF*, 671
Anastrozole, aromatase inhibitors, anti-estrogens, breast cancer, steroid sulfatase, tamoxifen, postmenopausal women, 1367
Anastrozole, breast cancer, radiotherapy, ipsilateral breast tumor recurrence, tamoxifen, 367
Androgen receptor, combination strategy, flutamide, prostate cancer, prostate-specific antigen, resveratrol, 3323
Androgen receptor, maspin, activin A, upper urinary tract urothelial carcinoma, prognosis, 1713
Androgen receptor, prostate cancer, EBP1, mRNA translation, 3129
Angiogenesis, alternative splicing, autologous stem cell transplantation, chick chorioallantoic membrane assay, high-dose chemotherapy, placental growth factor, vascular endothelial growth factor, V*EGFR*1, 3115

Angiogenesis, breast cancer, image analysis, CD34, MVD, vessel identification, 4053
Angiogenesis, cancer, CD105, endoglin, tumor, review, 2283
Angiogenesis, colon cancer, orthotopic model, GFP, fluorescent protein imaging (FPI), MRI, selenium, 387
Angiogenesis, colon cancer, thrombin, vascular endothelial growth factor, vascular endothelial growth factor receptor-2, coagulation factor, 843
Angiogenesis, dihydroartemisinin, pancreatic cancer, cell proliferation, apoptosis, optical imaging, 1549
Angiogenesis, *VEGF*, mTOR, HIF-1α, oral cancer, 4429
Angiogenesis, V*EGFR*2, tyrosine kinase inhibitor, drug resistance, endothelial cells, HUVEC, 2787
Angiogenetic factors, colorectal cancer, biological activity, tumor markers, metalloproteinases, adhesion molecules, 373
Angiogenic factor, vascular tube formation, cervical cancer, antiangiogenic therapy, 2609
Angiogenic factors, angiogenin, endoglin, endostatin, cervical cancer, 2651
Angiogenic factors, cervical cancer, *VEGF*, angiogenin, endoglin, 2589
Angiogenic factors, vascular endothelial growth factor, basic fibroblast growth factor, endostatin, cervical cancer, 2645
Angiogenin, angiogenic factors, cervical cancer, *VEGF*, endoglin, 2589
Angiogenin, angiogenic factors, endoglin, endostatin, cervical cancer, 2651
Angiography, hepatocellular carcinoma, ^{1}H MRI, apparent diffusion coefficient, extracellular space, benzamide riboside, therapy response, motion effect, 2045
Angiotensin II type 1 receptor antagonist, osteosarcoma, metastasis, CV11974, 123
Animal models, neural stem cells, suicide genes, prodrugs, invasive tumors, gene-directed enzyme prodrug therapy review, 1249
Annexin V-FITC/PI assay, hepatocellular carcinoma, human zinc finger 23, real-time RT-PCR, apoptosis, 3595
Anoikis, metastasis, invasion, migration, renieramycin M, lung cancer cells, 193
Antagonist, laryngeal cancer, glutamate receptor, proliferation, ERK1/2 kinase, 565
Antiangiogenic therapy, angiogenic factor, vascular tube formation, cervical cancer, 2609
Antiangiogenic therapy, hepatitis B virus, hepatocellular carcinoma, prognosis, 4007
Antiapoptosis, colorectal cancer, gamma radiation, microarray, RT-PCR, *REG4*, *NEIL2*, *BIRC5*, 4147
Antibacterial activity, conformation, hydrophobicity, bis-quarternary compound, 2561
Anticancer agents, sphingomylinase, *Cox-2*, caspase-3, apoptosis, *p53,* cell cycle, 1345
Anticancer drug, apoptosis, cell-to-cell interaction, adhesion molecules, characteristics of cancer cells, anticancer drug resistance, chemotherapy, drug sensitivity, drug resistance-relating factors, gene expression analysis, evaluation and prediction of pharmacological effects, screening systems, 3237
Anticancer drug resistance, cell-to-cell interaction, adhesion molecules, characteristics of cancer cells, chemotherapy, apoptosis, drug sensitivity, drug resistance-relating factors, gene expression analysis, evaluation and prediction of pharmacological effects, screening systems, 3237
Anticancer drugs, sphingomyelinase, *p53,* Bax, cell cycle, apoptosis, 871
Anticancer models, cat-SAR, DTP, breast cancer, computational toxicology, 3247
Anticancer therapeutic agents, benzo[*c*]phenanthridine alkaloids, sanguinarine, oral squamous cell carcinoma, 2841
Anticancer, (+)-spongistatin 1, natural product, mitosis, xenograft model, 2773
Anticancer, branched-chain fatty acids, antitumor, human breast cancer, human colon cancer, HT-29, MCF-7, 3165
Anticancer, heparan sulfate, chitosan, breast cancer, cell proliferation, FGF-2, 1321
Anti-estrogens, aromatase inhibitors, breast cancer, steroid sulfatase, tamoxifen, anastrozole, postmenopausal women, 1367
Antigen presentation, γδ T-Cells, cytotoxic T-cells, 2419
Antimetastasis, sunitinib, antitumor, *VEGF*, V*EGFR*, phosphorylation, mammary cancer, 1225
Antineoplastic, carboplatin, cisplatin, hypersensitivity, thoracic malignancy, immunoglobulin E, 4525
Antioxidant enzyme expression, selenoprotein, colon cancer, glutathione, thioredoxin, 2693
Antiproliferative activity, isopentenyladenosine, cytokinins, modified nucleosides, 3401
Antisense oligonucleotide, cyclin D, cyclin E, cyclin-dependent kinase, retinoblastoma protein, non-small lung cancer cells, pleural mesothelioma cells, apoptosis, kinases, phosphatases, 3683
Antisense pepitide, complementary peptide, anaphylatoxin, inflammation, sepsis, cytokine storm, 2511
Antisense, interleukin-6, interleukin-6 receptor, breast cancer, MCF-7, oligodeoxynucleotides, 2899
Antitumor activity, Bcr-Abl, CML, *Daedalea gibbosa*, kinase, medicinal mushrooms, oleic acid, autophosphorylation, 177
Antitumor effect, Her-2/neu, peptide, vaccine, B-cell epitope, 3361
Antitumor effect, ultrasound, mono-l-aspartyl chlorin e6, sonodynamic therapy, sarcoma 180, colon 26, 501
Antitumor immunity, colorectal cancer, regulatory T-cells, FOLFOX, FOLFIRI, 4569

Antitumor, branched-chain fatty acids, anticancer, human breast cancer, human colon cancer, HT-29, MCF-7, 3165
Antitumor, sunitinib, antimetastasis, *VEGF*, V*EGFR*, phosphorylation, mammary cancer, 1225
Anti-*VEGF* therapy, vascular endothelial growth factor, *VEGF*, gene expression, bevacizumab, epithelial ovarian cancer, 731
Anxiety, STAI test, form Y-2, cancer risk, breast cancer, 1801
A-Particle radiation, 238-plutonium, Monte Carlo simulations, bystander effect, micronucleus assay, 2113
Apc, min mice, 2-amino-1-methyl-6-phenylimidazo[4, 5-b]pyridine, C57Bl/6J, FVB, intestinal carcinogenesis, 785
APE1, Ref-1, macrophages, inflammatory response, 379
ApoD, breast cancer, DAX-1, ERα, prognosis, 443
Apoptosis, adenovirus, prodrug activation, HNSCC, ganciclovir, thymidine kinase, 3851
Apoptosis, anticancer agents, sphingomylinase, *Cox-2*, caspase-3, *p53,* cell cycle, 1345
Apoptosis, anticancer drugs, sphingomyelinase, *p53,* Bax, cell cycle, 871
Apoptosis, antisense oligonucleotide, cyclin D, cyclin E, cyclin-dependent kinase, retinoblastoma protein, non-small lung cancer cells, pleural mesothelioma cells, kinases, phosphatases, 3683
Apoptosis, arsenic trioxide, arsenic acid, organic arsenicals, T-lymphoblastoid leukemia, daunorubicin resistance, 4169
Apoptosis, belinostat, bortezomib, pancreas cancer, histone deacetylase inhibitor, proteasome inhibitor, hepatocellular cancer, metabolomics, 1093
Apoptosis, breast cancer, genistein, quercetin, NFκB, 3301
Apoptosis, cancer, endometrium, *Bcl-2*, *p53,* E-cadherin, estrogen receptor, progesterone receptor, 4191
Apoptosis, cannabinoids, prostate cancer cell lines, protein tyrosine phosphatases, dual-specificity phosphatases, 3799
Apoptosis, celecoxib, cytotoxicity, neuroblastoma, valproic acid, 2231
Apoptosis, cyclosporine A, human lung adenocarcinoma cell, lung transplantation, caspase, 2129
Apoptosis, dihydroartemisinin, pancreatic cancer, cell proliferation, angiogenesis, optical imaging, 1549
Apoptosis, etomidate, Bax, Bcl-xl, caspase-3, RAW264.7 cells, 2203
Apoptosis, gallic acid (GA), human leukemia HL-60 cells, death receptor-mediated pathways, mitochondria-mediated pathways, 2821
Apoptosis, gastric carcinoma, carcinomatosis, glycolysis, energetic metabolism, necrosis, citrate, 797
Apoptosis, hepatocellular carcinoma, human zinc finger 23, real-time RT-PCR, annexin V-FITC/PI assay, 3595
Apoptosis, hydantoin derivatives, Colo 205 and Colo 320 colon adenocarcinoma cells, multidrug resistance, efflux pump, ABCB1 transporter, 3285
Apoptosis, lactoferrin, IGBP1, PP2Ac, lung adeno-carcinoma, 529
Apoptosis, laryngal squamous cell carcinoma, microRNA, proliferation, 3859
Apoptosis, liver metastases, invasion front, *FAS*, TRAIL, colorectal cancer, 1215
Apoptosis, medicinal herb, bioactivity, p53 pathway, *Ruta graveolens*, Akt, 233
Apoptosis, medulloblastoma, vincristine, lomustine, chemotherapy, 1721
Apoptosis, multidrug-resistant cancer cells, MDR mouse T-lymphoma cells, ABCB1 transporter, P-glycoprotein, phenothiazines, thioridazine, 4201
Apoptosis, neuroblastoma, radiotherapy, neem leaf extract, transcriptional response, 161
Apoptosis, oral squamous cell carcinomas, toombak, genes, cell cycle regulation, intermediate filament proteins, Sudan, 3345
Apoptosis, ovarian cancer, methyl-2-cyano-3, 12-dioxooleana-1, 9(11)-dien-28-oate (CDDO-Me), AKT, NF-κB, mTOR, 3673
Apoptosis, PEDF, c-FLIP, HCC, p38, PPARγ, hepatocellular carcinoma, 1173
Apoptosis, phenethyl isothiocyanate, cell cycle arrest, mitochondria, caspases, prostate cancer DU 145 cells, 1691
Apoptosis, photodynamic therapy, PDT, glycoconjugated chlorin, gastric cancer, colon cancer, 763
Apoptosis, PSK, HL-60, cell proliferation, caspase-3 activation, 2733
Apoptosis, radiation, pemetrexed, human mesothelioma cell line, radiosensitivity, 2847
Apoptosis, S_N1 methylating agents, O6-methylguanine-DNA methyltransferase (MGMT), RNA-binding proteins, *N*-methyl-*N*-nitrosourea, 4291
Apoptosis, sonodynamic therapy, 5-aminolevulinic acid, SAS cell, mitochondrion, 39
Apoptosis, TNF-alpha, hepatoma, proteomics, 2-DE, LC-MS/MS, 2059
Apoptosis, TRAIL, histone deacetylase inhibitor, LBH589, colon cancer, 3385
Apoptosis, triptolide, medicinal compounds, proteasome inhibitors, cancer therapy, 1
Apoptosis, *Zanthoxylum ailanthoides Sieb* and *Zucc*., human colon adenocarcinoma cell, colo 205 cells, caspases, flavone, 1667
Apparent diffusion coefficient, hepatocellular carcinoma, ^{1}H MRI, extracellular space, benzamide riboside, angiography, therapy response, motion effect, 2045
Arf-induced senescence, leiomyoma, HMGA2, MDM2 antagonists, fibroid cells, 753

Arg194Trp, polymorphism, *XRCC1*, Arg399Gln, *GSTP1* Ile104Val, *GSTT1*, *GSTM1*, gastric cancer, survival, 705
Arg399Gln, polymorphism, *XRCC1*, Arg194Trp, *GSTP1* Ile104Val, *GSTT1*, *GSTM1*, gastric cancer, survival, 705
Aromatase inhibitors, anti-estrogens, breast cancer, steroid sulfatase, tamoxifen, anastrozole, postmenopausal women, 1367
Arsenic acid, arsenic trioxide, organic arsenicals, T-lymphoblastoid leukemia, daunorubicin resistance, apoptosis, 4169
Arsenic trioxide, arsenic acid, organic arsenicals, T-lymphoblastoid leukemia, daunorubicin resistance, apoptosis, 4169
Artemisinin dimers, dihydroartemisinin, rat, breast cancer cells, 4111
Artenimol, cervical cancer, artesunate, clinical symptoms, tumour markers, 4417
Arterial blood pressure, parathyroid tumors, hyperparathyroidism, serum calcium, PTH, arterial hypertension, elderly, 3969
Arterial hypertension, parathyroid tumors, hyperparathyroidism, arterial blood pressure, serum calcium, PTH, elderly, 3969
Artesunate, cervical cancer, artenimol, clinical symptoms, tumour markers, 4417
Artificial neural network, 1, 2, 3, 4-tetrahydroisoquinolins, QSAR, tumor-specificity index, semi-empirical molecular-orbital method, 4231
Ascites, paclitaxel, doxifluridine, gastric cancer, 4625
Assessment, chemotherapy, neurotoxicity, peripheral neuropathy, adverse effects, 3493
Astrocytes, radioprotection, radiosensitivity, central nervous system, lymphoma, 33
Astrocytomas, epigenetics, DNA methylation, histone deacetylases, decitabine, 1337
Athymic mice, low-grade liposarcoma, soft tissue sarcoma, xenograft, vascularisation, 4061
ATL, HTLV-1, leukemia, *Hyptis verticillata* jacq, multidrug resistance, 4251
ATL, HTLV-1, tetramethylnaphthalene, inhibitor, cell cycle, 2241
ATM, 3-indole, cell cycle arrest, ATR, SMAD3, xenograft model, lung cancer cells, 203
ATR, 3-indole, cell cycle arrest, ATM, SMAD3, xenograft model, lung cancer cells, 203
Atypical teratoid/rhabdoid tumours, medulloblastoma, Na^+/K^+-ATPase, alpha subunits, immunohistochemistry, 953
AURKA, MT477, tumor growth, NRF2, 1181
Autologous stem cell transplantation, alternative splicing, angiogenesis, chick chorioallantoic membrane assay, high-dose chemotherapy, placental growth factor, vascular endothelial growth factor, V*EGFR*1, 3115
Automated 3D imaging, breast cancer, screening, mammography, ultrasound, 2569
Autophosphorylation, antitumor activity, Bcr-Abl, CML, *Daedalea gibbosa,* kinase, medicinal mushrooms, oleic acid, 177
Axillary clearing, breast cancer, sentinel node, sentinel node biopsy, axillary node sampling, axillary lymphadenectomy, 693
Axillary lymphadenectomy, breast cancer, sentinel node, sentinel node biopsy, axillary node sampling, axillary clearing, 693
Axillary node sampling, breast cancer, sentinel node, sentinel node biopsy, axillary lymphadenectomy, axillary clearing, 693
Ayurvedic medicine, prostate cancer, cytotoxicity, triphala, gallic acid, 3739
AZD0530, HNSCC, phase II, Src, saracatinib, 249
5-azacytidine, epigenetics, bladder cancer, DNA methylation, chemotherapy, chemoresistance, 3757
Azomymethane, CD133, colon cancer, tumorigenesis, dextran sodium sulphate, 4273
Baboon, esophagus, gastric reflux, mucus metaplasia, 2187
*Bam*HI W1/I1, EBV polymorphism, *Xho*I restriction site, EBV-associated gastric cancer, Latin America, 3607
BAP, lung cancer, non-small cell lung cancer, bone metastases, bone remodeling markers, *N*-telopeptide of type I collegen, NTx, bone alkaline phosphatase, 3879
Base of tongue cancer, tonsillar cancer, oropharyngeal cancer, head and neck cancer, HPV, review, 1515
Basic fibroblast growth factor, angiogenic factors, vascular endothelial growth factor, endostatin, cervical cancer, 2645
Bax, anticancer drugs, sphingomyelinase, *p53,* cell cycle, apoptosis, 871
Bax, etomidate, apoptosis, Bcl-xl, caspase-3, RAW264.7 cells, 2203
BBN, bladder cancer, BCG-CWS, liposome, rat, 2065
BBN, gemcitabine, sirolimus, mice, urothelial lesion, 1637
B-cell epitope, Her-2/neu, peptide, vaccine, antitumor effect, 3361
B-cell lymphoma, *dectin-1*, beta-glucan, CD86, proliferation, cell death, 4195
B-Cell lymphoma, marginal zone lymphoma, radiation therapy, local tumor control, 3935
BCG-CWS, bladder cancer, liposome, BBN, rat, 2065
Bcl-2, cancer, endometrium, apoptosis, *p53,* E-cadherin, estrogen receptor, progesterone receptor, 4191
BCL-2, lung cancer, paclitaxel-based chemoradiotherapy, MDR1, radiosensitivity, 1431
BCL2, non-Hodgkin's lymphoma, lutetium-177, somatostatin receptor, 3143
Bcl-xl, etomidate, apoptosis, Bax, caspase-3, RAW264.7 cells, 2203

Bcr-Abl, antitumor activity, CML, *Daedalea gibbosa,* kinase, medicinal mushrooms, oleic acid, autophosphorylation, 177
BCRP1, non-small cell lung cancer, cancer stem cell antigens, biomarkers, prognosis, CD133, CD117, tissue microarrays, 4491
Beckwith-Wiedemann syndrome, oxidative stress, potassium ascorbate, 3973
Belinostat, bortezomib, pancreas cancer, histone deacetylase inhibitor, proteasome inhibitor, hepatocellular cancer, apoptosis, metabolomics, 1093
Benign liver lesions, breast cancer liver metastases, liver surgery, tumour markers, prognostic factors, differental diagnosis, 1447
Benign breast disease, personality, type C, hopelessness, cancer risk, 4019
Benzamide riboside, hepatocellular carcinoma, ^{1}H MRI, apparent diffusion coefficient, extracellular space, angiography, therapy response, motion effect, 2045
Benzo[*a*]quinolizin derivatives, multidrug resistance, P-glycoprotein, 921
Benzo[*c*]phenanthridine alkaloids, sanguinarine, anticancer therapeutic agents, oral squamous cell carcinoma, 2841
Beta-catenin, oral carcinogenesis, immunohistochemistry, tongue, mice, 2805
Beta-glucan, *dectin-1*, B-cell lymphoma, CD86, proliferation, cell death, 4195
Beta-glucan, β-glucan, dendritic cells, maturation, immunomodulator, 1647
Bevacizumab, capecitabine, oxaliplatin, cetuximab, phase II, metastatic colorectal cancer, 255
Bevacizumab, diffuse intrinsic pontine glioma, chemotherapy, temozolomide, rofecoxib, inflammatory processes, 2265
Bevacizumab, FOLFIRI, XELIRI, colorectal cancer, efficacy, safety, 1777
Bevacizumab, hyperthermia, doxorubicin, platinum-refractory, ovarian cancer, 2675
Bevacizumab, *IDH1* mutation, glioma, cetuximab, sunitinib, 4457
Bevacizumab, ovarian cancer, platinum-resistant, 2679
Bevacizumab, paclitaxel, breast cancer, vascular endothelial growth factor receptors, 3007
Bevacizumab, panitumumab, metastatic colorectal cancer, treatment, 1033
Bevacizumab, primary peritoneal carcinoma, erlotinib, 4397
Bevacizumab, safety, pediatrics, *VEGF*, 3953
Bevacizumab, vascular endothelial growth factor, *VEGF*, gene expression, anti-*VEGF* therapy, epithelial ovarian cancer, 731
Bexarotene, pharmacogenomics, SNPs, RXR, lung cancer, 2303
BEZ235, lung cancer, *EGFR*, P13K/mTOR inhibitor, 849
BI 2536, polo-like kinase 1, cholangiocarcinoma, 5-fluorouracil, gemcitabine, 3289
BIBF 1120, afatinib, colorectal cancer, phase II, pharmacokinetics, 2271
Bilateral erythematous breast hypertrophy, gastric cancer, low back pain, pregnancy, 681
Bioactivity, medicinal herb, p53 pathway, apoptosis, *Ruta graveolens,* Akt, 233
Biochemical relapse, docetaxel, prostate cancer, chemotherapy, 973
Biological activity, colorectal cancer, tumor markers, angiogenetic factors, metalloproteinases, adhesion molecules, 373
Bioluminescence, AAV, CXCR4, gene therapy, breast cancer, 1627
Biomarker, breast cancer, triple negative, 2389
Biomarker, cell-free DNA, circulation, non-invasive, review, 2623
Biomarker, colorectal cancer, surgery, liver metastases, CD95-ligand, 4507
Biomarker, cytokeratin 4, fascin, tissue microarray, squamous cell carcinoma, esophagus, 945
Biomarker, hepatocellular carcinoma, AFP-IgM immune complexes, alpha-fetoprotein, 687
Biomarker, rectal cancer, radiotherapy, chemotherapy, prognostic factor, carbonic anhydrase IX, hypoxia-inducible factor-1a, ezrin, glucose transporter-1, 4529
Biomarker, thyroid cancer, diagnosis, sensitivity, specificity, metastasis, immunohistochemistry, 3433
Biomarkers, cetuximab, colorectal cancer, irinotecan, oxaliplatin, 2149
Biomarkers, diagnosis, early detection, head and neck cancer, review, 1161
Biomarkers, non-small cell lung cancer, cancer stem cell antigens, prognosis, CD133, CD117, BCRP1, tissue microarrays, 4491
Biomarkers, ovarian cancer, diagnosis, enzyme-linked immunosorbent assay, cathepsin, matrix metalloproteinase-9, heparanase, 3423
Biopsy, ischemia, immunohistochemistry, xenografts, phospho-proteins, pre-analytical variables, 2073
BIRC5, antiapoptosis, colorectal cancer, gamma radiation, microarray, RT-PCR, *REG4*, *NEIL2*, 4147
Bisphosphonate, osteonecrosis, mandible, BRONJ, 2313
Bisphosphonates, circulating tumor cells, disseminated tumor cells, 3623
Bis-quarternary compound, conformation, antibacterial activity, hydrophobicity, 2561
BK virus, hemorrhagic cystitis, allogeneic stem cell transplantation, review, 939
BK virus, human polyomavirus, JC virus, hemotopoetic stem cell transplantation, cerebrospinal fluid, KI, WU, 3489

Bladder cancer, BCG-CWS, liposome, BBN, rat, 2065
Bladder cancer, circulating tumor cells, disseminated tumor cells, detection, prostate cancer, renal cell carcinoma, chemotherapy, review, 2053
Bladder cancer, epigenetics, DNA methylation, chemotherapy, chemoresistance, 5-azacytidine, 3757
Bladder cancer, extented lymphadenectomy, lymph node metastasis, radical cystectomy, lymph node density, cancer-specific survival, short review, 271
Bladder cancer, metastasis suppressor-1, MTSS1, cellular migration, invasion, metastasis, 3205
Bladder cancer, mitomycin C, intravesical chemotherapy, 929
Bladder cancer, recurrence, intravesical chemotherapy, continuous saline bladder irrigation, 1471
Bladder cancer, squamous cell carcinoma, recurrence, gemcitabine, paclitaxel, 4465
Bladder cancer, transitional carcinoma, lymphovascular invasion, upper tract transitional carcinoma, prognostic role, review, 3503
Bladder cancer, TURBT, radiochemotherapy, radiation therapy, 985
Bladder carcinoma, interleukin-2, $CD8^{high}CD57^{+}$ lymphocytes, recurrences, 699
Blood plasma, non-small cell lung cancer, TIMP1, mRNA, DFI, survival, 4031
Blood–brain barrier, intravenous curcumin, post-traumatic sequelae, hippocampus, striatum, brain stem, 907
Blood–brain barrier, metastasis, extravasation, brain endothelial cells, COX-2, 4307
BNCT, boron tracedrug, BODIPY, curcuminoid, neutron dynamic therapy, dynamic drug, thermal neutron irradiation, 2477
BNIP3, ras, CD47, cancer, programmed cell death, 4N1K, 2869
BODIPY, boron tracedrug, curcuminoid, neutron dynamic therapy, dynamic drug, thermal neutron irradiation, BNCT, 2477
Bone alkaline phosphatase, lung cancer, non-small cell lung cancer, bone metastases, bone remodeling markers, *N*-telopeptide of type I collegen, NTx, BAP, 3879
Bone marrow carcinomatosis, breast cancer, metastasis, 4025
Bone marrow, breast cancer, disseminated tumor cells, bone mineral density, quantitative ultrasonometry, 4423
Bone marrow, breast cancer, disseminated tumor cells, prognosis, follow-up, 2749
Bone metastases, lung cancer, non-small cell lung cancer, bone remodeling markers, *N*-telopeptide of type I collegen, NTx, bone alkaline phosphatase, BAP, 3879
Bone metastasis, MMP-13, type I collagen, integrin, MAPK, 1307
Bone metastasis, non-small cell lung cancer, gefitinib, erlotinib, resistance, radiotherapy, *EGFR*-TKIs, 4519
Bone metastasis, polybisphosphonate, prostate cancer, 4141
Bone mineral density, breast cancer, disseminated tumor cells, bone marrow, quantitative ultrasonometry, 4423
Bone remodeling markers, lung cancer, non-small cell lung cancer, bone metastases, *N*-telopeptide of type I collegen, NTx, bone alkaline phosphatase, BAP, 3879
Bone, high hydrostatic pressure, revitalization, tissue engineering, 1235
Borderline-resectable T4, DCF, induction chemotherapy, esophageal cancer, cisplatin, 5-fluorouracil, docetaxel, 3535
Boron tracedrug, BODIPY, curcuminoid, neutron dynamic therapy, dynamic drug, thermal neutron irradiation, BNCT, 2477
Bortezomib, belinostat, pancreas cancer, histone deacetylase inhibitor, proteasome inhibitor, hepatocellular cancer, apoptosis, metabolomics, 1093
Bortezomib, cisplatin, CTR1, drug combination, proteasomal degradation, synergism, drug uptake, drug resistance, 2757
Bortezomib, multiple myeloma, once-weekly administration, dexamethasone, gastrointestinal adverse events, 2297
Bortezomide, proteasome inhibitor, receptor tyrosine kinase, activation loop, multiple myeloma, ER stress, FGFR3, Lys650Glu mutation, K650E, plasma cell malignancy, 113
Bowel injury, laparoscopic radical prostatectomy, LRP, prostatic neoplasm, rectal injury, robotic-assisted laparoscopic prostatectomy, RALP, robotics, 3497
BPF, fistula, operation, lung cancer, risk factor, concurrent disease, perioperative complication, infection, 619
BRAF mutation, *KRAS*, *EGFR*, ERBB2 mutation, V600E, lung cancer, adenocarcinoma, squamous cell carcinoma, SSCP, 4619
BRAF, medullary thyroid carcinoma, gene mutations, *RET*, *HRAS*, *KRAS*, *NRAS*, *AKT1*, *CTNNB1*, mutational screening, 4179
BRAF, ovarian cancer, gene mutations, BRCA 1/2, *TP53*, PI3K, AKT, *KRAS*, review, 2661
Brain endothelial cells, metastasis, extravasation, blood–brain barrier, COX-2, 4307
Brain metastases, breast cancer, human mammaglobin, PCR, 1061
Brain metastases, metastastic melanoma, melanoma, temozolomide, whole-brain radiation, 4537
Brain metastasis, circulating tumor cells, CTCs, prostate cancer, immunomagnetic beads, GFP, chick embryo, metastatic assay, fluorescence imaging, 3125
Brain metastasis, pancreatic cancer, pancreatic neoplasms, long-term survivors, surgery, 4599
Brain neoplasms, magnetic resonance spectroscopy, radiotherapy, prognosis, prospective studies, 3559

Brain stem, intravenous curcumin, blood–brain barrier, post-traumatic sequelae, hippocampus, striatum, 907
Brain tumor, quality control, survival, pediatric neuro-oncology, 661
Brain tumors, cytomegalovirus, glioblastoma, etiology, 959
Branched-chain fatty acids, anticancer, antitumor, human breast cancer, human colon cancer, HT-29, MCF-7, 3165
BRCA 1/2, ovarian cancer, gene mutations, *TP53*, PI3K, AKT, *BRAF*, *KRAS*, review, 2661
BRCA, pancreatic cancer, iniparib, chemotherapy, 1417
BRCA1, colorectal cancer, pulmonary metastases, TS, OPRT, ERCC1, MVD, adjuvant chemotherapy, 2763
Breakpoint distribution, Inv(3)(q21q26), t(3;3)(q21;q26), chromosomal abnormalities, fluorescent *in situ* hybridization, 3441
Breast cancer cell lines, estrogen receptor, flow cytometry, RT-PCR, Western blotting, 521
Breast cancer cells, artemisinin dimers, dihydroartemisinin, rat, 4111
Breast cancer liver metastases, liver surgery, tumour markers, prognostic factors, differental diagnosis, benign liver lesions, 1447
Breast cancer metastasis, silibinin, CD44, *EGFR*, EGF, TGF-α, MMP-9, 3767
Breast cancer recurrence, insulin-like growth factor-1, IGF-1, tamoxifen-resistance, oestrogen resistance, oestrogen receptor-alpha, *EGFR*, 23
Breast cancer, AAV, CXCR4, gene therapy, bioluminescence, 1627
Breast cancer, ADAMTS1, amphiregulin, xenograft, immunotherapy, 3839
Breast cancer, age, grade, immunohistochemistry, measles virus, *p53,* 913
Breast cancer, anastrozole, radiotherapy, ipsilateral breast tumor recurrence, tamoxifen, 367
Breast cancer, angiogenesis, image analysis, CD34, MVD, vessel identification, 4053
Breast cancer, aromatase inhibitors, anti-estrogens, steroid sulfatase, tamoxifen, anastrozole, postmenopausal women, 1367
Breast cancer, bone marrow carcinomatosis, metastasis, 4025
Breast cancer, brain metastases, human mammaglobin, PCR, 1061
Breast cancer, breast disease, Sifneos score, 3101
Breast cancer, carboplatin, RAD001, everolimus, mTOR inhibitor, 2713
Breast cancer, cat-SAR, anticancer models, DTP, computational toxicology, 3247
Breast cancer, caveolin-1, polymorphic genotypes, 3511
Breast cancer, chemotherapy, dose-dense, sICAM-1, sVCAM-1, 2617
Breast cancer, cortactin, tissue microarray, 293
Breast cancer, cyclooxygenase, COX-2, tumor, prostaglandin, carcinogenesis, 4359
Breast cancer, DAPK, tissue microarray, 3633
Breast cancer, DAX-1, ApoD, ERα, prognosis, 443
Breast cancer, disseminated tumor cells, bone marrow, bone mineral density, quantitative ultrasonometry, 4423
Breast cancer, disseminated tumor cells, bone marrow, prognosis, follow-up, 2749
Breast cancer, epigenetic regulation, histone-modifier genes, histone acetyltransferases, histone methyltransferases, 4115
Breast cancer, erythropoietin, erythropoietin receptor, erythropoiesis stimulating agents, 1189
Breast cancer, E-selectin, liver metastasis, endothelium, pro-inflammatory micro*env* ironment, 3219
Breast cancer, fiberoptic ductoscopy, nipple discharge, 3517
Breast cancer, FKBP52, geldanamycin, heat-shock proteins, lumican, 2095
Breast cancer, gastrointestinal stromal tumor, neurofibromatosis type 1, 4481
Breast cancer, genistein, p90RSK, cell proliferation, T47D cells, 209
Breast cancer, genistein, quercetin, apoptosis, NFκB, 3301
Breast cancer, GLI2, PTHrP, osteolysis, 6-thioguanine, 2705
Breast cancer, growth factors, tumor markers, CA 15-3, CEA, IGF1, EGF, HGF, 4653
Breast cancer, gynecological cancer, online tumor conference, interdisciplinary therapy management, second opinion, continuous medical training, 2669
Breast cancer, heparan sulfate, chitosan, anticancer, cell proliferation, FGF-2, 1321
Breast cancer, HuR, histological status, prognosis, 303
Breast cancer, interleukin-6, interleukin-6 receptor, MCF-7, antisense, oligodeoxynucleotides, 2899
Breast cancer, kallikrein-related peptidase 5, *KLK5*, *KLK7*, 3093
Breast cancer, lapatinib, HER2, ADCC, Herceptin, 2999
Breast cancer, lapatinib, imatinib, *EGFR*, ErbB2, c-ABL, RTK, 789
Breast cancer, lymphatic microvessel density, molecular classification, *VEGF*-C, V*EGFR*-3, 1757
Breast cancer, mammography, calcification, prognostic factor, 2327
Breast cancer, meloxicam, paclitaxel, neuropathy, JBCRN, 3567
Breast cancer, metallothionein, MT-I/II, Ki-67, MCM-2, 3027
Breast cancer, methylation, RASSF1A, prognosis, 2975
Breast cancer, metronomic, cyclophosphamide, doxorubicin, cardiotoxicity, rats, 215
Breast cancer, mitotic counts, prognosis, 97

Breast cancer, MtDNA mutation, D-loop region, plasma, mitochondrial DNA, 4267
Breast cancer, neoadjuvant chemotherapy, trastuzumab, pCR, 3041
Breast cancer, p27, node dissection, stage I, estrogen receptor, progesterone receptor, 4401
Breast cancer, paclitaxel, bevacizumab, vascular endothelial growth factor receptors, 3007
Breast cancer, PPARγ, PPARG, T0070907, migration, invasion, 813
Breast cancer, primary culture, chemotherapeutics, therapy personalization, oncogramme, individualized tumour response testing, 139
Breast cancer, recurrence, operation, survival, polychemotherapy, 277
Breast cancer, RGM, prostate cancer, prognosis, 1703
Breast cancer, screening mammography, microcalcification, high-frequency ultrasound, advanced imaging modes, 2575
Breast cancer, screening, mammography, ultrasound, automated 3D imaging, 2569
Breast cancer, sentinel lymph node, OSNA, cytokeratin 19, intra-operative method, 585
Breast cancer, sentinel node, sentinel node biopsy, axillary node sampling, axillary lymphadenectomy, axillary clearing, 693
Breast cancer, sequential therapy, adjuvant chemotherapy, 1483
Breast cancer, single nucleotide polymorphisms, estrogen pathway, steroid hormones, mammographic breast density, review, 4369
Breast cancer, STAI test, form Y-2, cancer risk, anxiety, 1801
Breast cancer, stem cells, pre-metastatic niche, metastasis, CD133, prognosis, 1315
Breast cancer, thromoboembolism, chemotherapy, 2383
Breast cancer, triple negative breast cancer, TEM8, immunohistochemistry, lymph node metastasis, 3417
Breast cancer, triple negative, biomarker, 2389
Breast cancer, ubiquitin–proteasome system, extracellular proteasome, 2197
Breast cancer, vitamin D, colorectal cancer, prostate cancer, lung cancer, 3619
Breast cancer, zeranol, ACI rat serum, mitogenic activity, 481
Breast carcinoma cells, metastasis, HPA, E-selectin, P-selectin, SCID mouse, lectin, colon adenocarcinoma, 1589
Breast disease, breast cancer, Sifneos score, 3101
Breast disease, depression, risk of cancer, 1065
Breast disease, psychosocial factors, psychiatric drugs, 739
Breast metastasis, gastric adenocarcinoma, signet-ring adenocarcinoma, skin, immunohistochemistry, 2373
Breast neoplasms, vitamin D, 25-hydroxyvitamin D, case–control studies, epidemiology, meta-analysis, prevention, 2939
Breast ultrasound, pre-operative therapy, prediction of therapy response, sonography, sphericity, 4039
Breast, ductal carcinoma *in situ*, lumpectomy, mastectomy, menopause, hormone replacement therapy, 1783
BRONJ, bisphosphonate, osteonecrosis, mandible, 2313
Brushing cytology, cholangiocarcinoma, MSX2, 1011
Bystander effect, α-Particle radiation, 238-plutonium, Monte Carlo simulations, micronucleus assay, 2113
C57Bl/6J, min mice, 2-amino-1-methyl-6-phenylimidazo[4, 5-b]pyridine, Apc, FVB, intestinal carcinogenesis, 785
C7orf24, γ-glutamyl cyclotransferase, osteosarcoma, 1297
CA 15-3, growth factors, breast cancer, tumor markers, CEA, IGF1, EGF, HGF, 4653
C-ABL, breast cancer, lapatinib, imatinib, *EGFR*, ErbB2, RTK, 789
E-Cadherin, cancer, endometrium, apoptosis, *Bcl-2*, *p53,* estrogen receptor, progesterone receptor, 4191
E-Cadherin, EMT, gamma catenin, vimentin, fibronectin, lung adenocarcinoma, 4451
E-Cadherin, P53, cancer, endometrium, apoptosis, *Bcl-2*, estrogen receptor, progesterone receptor, 4191
N-Cadherin, adrenocortical carcinoma, ADH-1, dynamic contrast enhancing magnetic resonance imaging (DCE-MRI), phase-I, 3921
Cadherins, immunohistochemistry, prognosis, OSCC, oral squamous cell carcinoma, 4211
CAIRO2, *KRAS*, *p53,* colorectal, oxaliplatin, 5-fluorouracil, capecitabine, clinical, sequence analysis, 1379
Calcification, breast cancer, mammography, prognostic factor, 2327
Cancer cell seeding, green fluorescent protein, red fluorescent protein, real-time imaging, lung, liver, muscle, 3665
Cancer cells, sodium meta-arsenite, stem cells, telomere length, telomerase activity, 4315
Cancer diagnosis, PCA3, PSA free/total, prostate cancer, saturation prostate biopsy, repeat biopsy, 4445
Cancer epidemiology, ovarian cancer, clinical cancer registry, 2657
Cancer risk, bening breast disease, personality, type C, hopelessness, 4019
Cancer risk, cervical cancer, *GSTM1*, *GSTT1*, genetic polymorphism, human papillomavirus, 3051
Cancer risk, personality, type C, commitment, 4013
Cancer risk, STAI test, form Y-2, breast cancer, anxiety, 1801
Cancer stem cell antigens, non-small cell lung cancer, biomarkers, prognosis, CD133, CD117, BCRP1, tissue microarrays, 4491
Cancer stem cell, recurrence, CD marker, CD133, CD44, rectal cancer, 495

Cancer susceptibility, genetic polymorphisms, DNA-repair genes, metabolizing genes, *CYP1A1*, *CYP1E1*, *XRCC1*, 1359
Cancer therapy, notch, stem cells, pancreatic cancer, signal pathway, natural agents, drug resistance, review, 1105
Cancer therapy, triptolide, medicinal compounds, proteasome inhibitors, apoptosis, 1
Cancer vaccine, Wilms' tumor 1 (WT1), myeloid dendritic cell, immunotherapy, 2447
Cancer, adrenocortical tumors, Cushing's syndrome, adrenal imaging, CT, MR, review, 2923
Cancer, angiogenesis, CD105, endoglin, tumor, review, 2283
Cancer, drug delivery, liposome, vincristine, folate receptor, drug targeting, 1521
Cancer, endometrium, apoptosis, *Bcl-2*, *p53,* E-cadherin, estrogen receptor, progesterone receptor, 4191
Cancer, glutamate receptor, PCR, shRNA, NR1, GLUR4, KA2, NR2D, 3181
Cancer, immunotherapy, prediction, survival, CD8, CD57, review, 639
Cancer, KRAP, *KRAS*, target, obesity, diabetes, review, 2413
Cancer, melatonin, endometrial proliferation, rats, 2637
Cancer, neurotoxicity, adjuvant chemotherapy, docetaxel, intraepidermal nerve fibres, neuropathy, skin biopsies, oxaliplatin, 4413
Cancer, ras, BNIP3, CD47, programmed cell death, 4N1K, 2869
Cancer-specific survival, bladder cancer, extented lymphadenectomy, lymph node metastasis, radical cystectomy, lymph node density, short review, 271
Cannabinoids, apoptosis, prostate cancer cell lines, protein tyrosine phosphatases, dual-specificity phosphatases, 3799
Capecitabine, 5-FU, hyperammonemia, encephalopathy, metastatic rectal adenocarcinoid, 335
Capecitabine, chemotherapy, fluorouracil, gemcitabine, colon cancer, 2971
Capecitabine, *KRAS*, *p53,* colorectal, oxaliplatin, 5-fluorouracil, clinical, CAIRO2, sequence analysis, 1379
Capecitabine, metastatic breast cancer, triple-negative, HER2-negative, prognostic factors, 1079
Capecitabine, oxaliplatin, bevacizumab, cetuximab, phase II, metastatic colorectal cancer, 255
Carbonic anhydrase IX, rectal cancer, radiotherapy, chemotherapy, prognostic factor, biomarker, hypoxia-inducible factor-1a, ezrin, glucose transporter-1, 4529
Carboplatin, chemotherapy, paclitaxel, vinorelbine, non-small cell lung cancer, 317
Carboplatin, cisplatin, hypersensitivity, antineoplastic, thoracic malignancy, immunoglobulin E, 4525
Carboplatin, RAD001, everolimus, breast cancer, mTOR inhibitor, 2713
Carcinogenesis, Cav-1, polymorphism, nasopharyngeal carcinoma, 3629
Carcinogenesis, *Cox-2*, polymorphism, prostate cancer, 221
Carcinogenesis, cyclooxygenase, COX-2, breast cancer, tumor, prostaglandin, 4359
Carcinogenesis, lung cancer, lung inflammation, lung tumors, *K-ras* mutations, mouse, 2877
Carcinoid, PTEN, serotonin, 1153
Carcinoma cell lines, P-Glycoprotein, chemotherapy, inhibition of multidrug resistance, osteosarcoma cell lines, siRNA, 2813
Carcinomatosis, gastric carcinoma, glycolysis, energetic metabolism, apoptosis, necrosis, citrate, 797
Cardiotoxicity, adriamycin, fatigue, myotoxicity, 2023
Cardiotoxicity, metronomic, cyclophosphamide, doxorubicin, breast cancer, rats, 215
Case–control studies, vitamin D, 25-hydroxyvitamin D, breast neoplasms, epidemiology, meta-analysis, prevention, 2939
Caspase, cyclosporine A, human lung adenocarcinoma cell, apoptosis, lung transplantation, 2129
Caspase-3 activation, PSK, apoptosis, HL-60, cell proliferation, 2733
Caspase-3, anticancer agents, sphingomylinase, *Cox-2*, apoptosis, *p53,* cell cycle, 1345
Caspase-3, etomidate, apoptosis, Bax, Bcl-xl, RAW264.7 cells, 2203
Caspases, phenethyl isothiocyanate, cell cycle arrest, apoptosis, mitochondria, prostate cancer DU 145 cells, 1691
Caspases, *Zanthoxylum ailanthoides Sieb and Zucc*., human colon adenocarcinoma cell, colo 205 cells, apoptosis, flavone, 1667
Castrate-resistant prostate cancer, predictors of survival, time to castration resistance, chemotherapy, advanced prostate cancer, 1475
B-Catenin, KL-6 mucin, MUC1, gastric cancer, invasion front, 535
Beta-Catenin, oral carcinogenesis, immunohistochemistry, tongue, mice, 2805
β-Catenin, MUC1, KL-6 mucin, gastric cancer, invasion front, 535
Cathepsin, cytokines, proliferation, lung cancer cells, 47
Cathepsin, ovarian cancer, diagnosis, biomarkers, enzyme-linked immunosorbent assay, matrix metalloproteinase-9, heparanase, 3423
Cationised gelatin, *NK4*, gene therapy, cisplatin, squamous cell carcinoma, 105
Cat-SAR, anticancer models, DTP, breast cancer, computational toxicology, 3247

Catumaxomab, ovarian cancer, relapse, intraperitoneal, surgical tumor debulking, operative morbidity, operative mortality, 2603
Cav-1, polymorphism, nasopharyngeal carcinoma, carcinogenesis, 3629
Caveolin-1, breast cancer, polymorphic genotypes, 3511
Caveolin-1, prostate cancer, single nucleotide polymorphism, DNA repair, 745
CCN family, esophageal cancer, WISP-1, WISP-1v, 991
CCND1 1722, *cyclin D1*, polymorphism, upper tract urothelial cancer, 1043
CCND1, *cyclin D1*, polymorphism, lung cancer, smoking, Taiwanese, 3601
CCND3, minichromosome maintenance proteins, MCMs, cyclin D3, Hodgkin lymphoma, survival, 3585
CD marker, cancer stem cell, recurrence, CD133, CD44, rectal cancer, 495
CD105, angiogenesis, cancer, endoglin, tumor, review, 2283
CD117, gastrointestinal stromal tumors (GISTs), Ras-Raf-ERK/MAPK Pathway, PI3K-Akt/mTOR pathway, insulin-like growth factor 1 receptor (IGF1R), 3019
CD117, non-small cell lung cancer, cancer stem cell antigens, biomarkers, prognosis, CD133, BCRP1, tissue microarrays, 4491
CD133, breast cancer, stem cells, pre-metastatic niche, metastasis, prognosis, 1315
CD133, cancer stem cell, recurrence, CD marker, CD44, rectal cancer, 495
CD133, colon cancer, tumorigenesis, azomymethane, dextran sodium sulphate, 4273
CD133, non-small cell lung cancer, cancer stem cell antigens, biomarkers, prognosis, CD117, BCRP1, tissue microarrays, 4491
CD14, polymorphism, ulcerative colitis, DNA methylation, p22PHOX, MBL, 933
CD34, angiogenesis, breast cancer, image analysis, MVD, vessel identification, 4053
CD44, cancer stem cell, recurrence, CD marker, CD133, rectal cancer, 495
CD44, memory T- cell, tumor-infiltrating lymphocytes, melanoma, 4099
CD44, renal cell carcinoma, circulating tumor cells, CellSearch, cytokeratins, 4219
CD44, silibinin, *EGFR*, EGF, TGF-α, MMP-9, breast cancer metastasis, 3767
CD44-CD41, PC3 side fraction, normoxia, hypoxia, 487
CD47, ras, BNIP3, cancer, programmed cell death, 4N1K, 2869
CD57, cancer, immunotherapy, prediction, survival, CD8, review, 639
CD8, cancer, immunotherapy, prediction, survival, CD57, review, 639
CD86, *dectin-1*, beta-glucan, B-cell lymphoma, proliferation, cell death, 4195
CD86, myeloma, YT, interleukin-2, cytotoxicity, 475
$CD8^{high}CD57^{+}$ lymphocytes, bladder carcinoma, interleukin-2, recurrences, 699
CD95-ligand, colorectal cancer, surgery, liver metastases, biomarker, 4507
CD98, LAT1, mesothelioma, hypoxia, prognosis, mTOR, 4075
CD98, LAT1, recurrence, advanced NSCLC, *EGFR* mutation, prognosis, chemotherapy. Ki-67, p-Akt, p-mTOR, 3775
CDDO-Me, ovarian cancer, methyl-2-cyano-3, 12-dioxooleana-1, apoptosis, AKT, NF-κB, mTOR, 3673
CDDP, advanced esophageal cancer, combined chemotherapy, docetaxel, 5-FU, 633
CDHP, S-1, 5-fluorouracil, Phase I, FBAL, tegafur, FT, reversible dihydropyrimidine dehydrogenase, DPD, gimeracil, solid tumors, 625
CDK4, lipid nanoparticles, siRNA, down-regulation, 1619
CDKN1A/WAF/CIP1, *p53, p21,* polymorphism, endometriosis, genotype, 4301
CEA, growth factors, breast cancer, tumor markers, CA 15-3, IGF1, EGF, HGF, 4653
Celecoxib, apoptosis, cytotoxicity, neuroblastoma, valproic acid, 2231
Cell culture, circulating tumor cells, CTCs, microfiltration by size, real-time quantitative reverse transcriptase-polymerase chain reaction, qRT-PCR, molecular biology, cytomorphology, FISH, lung cancer, 427
Cell cycle arrest, 3-Indole, ATM, ATR, SMAD3, Xenograft model, lung cancer cells, 203
Cell cycle arrest, phenethyl isothiocyanate, apoptosis, mitochondria, caspases, prostate cancer DU 145 cells, 1691
Cell cycle arrest, pomegranate, pancreatic cancer cells, phytochemicals, 2699
Cell cycle arrest, tumor suppressors, DNA N-methyl transferase, ERK, 2723
Cell cycle regulation, oral squamous cell carcinomas, toombak, genes, apoptosis, intermediate filament proteins, Sudan, 3345
Cell cycle, acetoxycoumarins, cell viability, lethal dose, 2017
Cell cycle, anticancer agents, sphingomylinase, *Cox-2*, caspase-3, apoptosis, *p53,* 1345
Cell cycle, anticancer drugs, sphingomyelinase, *p53,* Bax, apoptosis, 871
Cell cycle, cyclin B1, *p53,* squamous cell carcinoma, head and neck cancer, 3151
Cell cycle, glioma, *EGFR*, temozolomide, 3253
Cell cycle, glioma, PTEN, temozolomide, ionizing radiation, radiosensitivity, 1653

Cell cycle, HTLV-1, ATL, tetramethylnaphthalene, inhibitor, 2241
Cell cycle, radiation sensitivity, esophageal cancer, gastric cancer, hypoxia, reoxygenation, 3369
Cell death, chalcone, glioblastoma, G_2/M blockage, 3213
Cell death, cigarette smoking, Swedish-type smokeless tobacco, Snus, ethanol, human normal cells, endothelial cells, fibroblasts, 1527
Cell death, *dectin-1*, beta-glucan, B-cell lymphoma, CD86, proliferation, 4195
Cell death, ionizing radiation, temozolomide, immunogenicity, Hsp70, 3727
Cell death, pancreatic neoplasm, prostate neoplasm, nuclear matrix proteins, natriuretic peptides, 395
Cell line, hepatitis C virus, liver tumour, sarcomatoid tumour, culture, spectral karyotyping, xenograft, 129
Cell migration, actin cytoskeleton, nuclear localization, Ror1, receptor tyrosine kinase, 4239
Cell proliferation, dihydroartemisinin, pancreatic cancer, apoptosis, angiogenesis, optical imaging, 1549
Cell proliferation, genistein, breast cancer, p90RSK, T47D cells, 209
Cell proliferation, heparan sulfate, chitosan, anticancer, breast cancer, FGF-2, 1321
Cell proliferation, PSK, apoptosis, HL-60, caspase-3 activation, 2733
Cell proliferation, zeranol, protein disulfide isomerase, mammary tumorigenesis, 1659
Cell viability, acetoxycoumarins, cell cycle, lethal dose, 2017
Cell viability, indole, telomerase, prostate cancer, diethylstilbestrol, 3733
Cell-cycle arrest, 3-oxoolean-12-en-27-oic acid, lung cancer cells, 2179
Cell-free DNA, circulation, non-invasive, biomarker, review, 2623
CellSearch, renal cell carcinoma, circulating tumor cells, cytokeratins, CD44, 4219
Cell-to-cell interaction, adhesion molecules, characteristics of cancer cells, anticancer drug resistance, chemotherapy, apoptosis, drug sensitivity, drug resistance-relating factors, gene expression analysis, evaluation and prediction of pharmacological effects, screening systems, 3237
Cellular migration, metastasis suppressor-1, MTSS1, invasion, bladder cancer, metastasis, 3205
Central nervous system, radioprotection, radiosensitivity, astrocytes, lymphoma, 33
C-erbB-3, lung cancer, NSCLC, erlotinib, *EGFR*, 281
Cerebrospinal fluid, acute myeloid leukemia, immunotherapy, interleukin-2, peptide vaccination, CSF, flow of CSF, chloroma, 2343
Cerebrospinal fluid, human polyomavirus, BK virus, JC virus, hematopoetic stem cell transplantation, KI, WU, 3489
Cervical cancer, angiogenic factor, vascular tube formation, antiangiogenic therapy, 2609
Cervical cancer, angiogenic factors, angiogenin, endoglin, endostatin, 2651
Cervical cancer, angiogenic factors, vascular endothelial growth factor, basic fibroblast growth factor, endostatin, 2645
Cervical cancer, angiogenic factors, *VEGF*, angiogenin, endoglin, 2589
Cervical cancer, artesunate, artenimol, clinical symptoms, tumour markers, 4417
Cervical cancer, C-reactive protein, CRP, *CRP1919* (rs1417938), *CRP2667* (rs1800947), *CRP3872* (rs1205), *CRP5237* (rs2808630), gene polymorphism, prognosis, single nucleotide polymorphism, 2259
Cervical cancer, *GSTM1*, *GSTT1*, genetic polymorphism, human papillomavirus, cancer risk, 3051
Cervical cancer, indoleamine-2, 3-dioxygenase, immunomodulation, quinolinic acid, kynurenic acid, 2629
Cervical cancer, parametrium, micrometastasis, immunohistochemistry, 243
Cervical cancer, squamous cell carcinoma, stage IB-IIB, concurrent chemoradiotherapy, locoregional recurrence, 1437
Cervical carcinoma, prognosis, iNOS, guanylyl cyclase, phosphodiesterase, 2319
Cetuximab, advanced hepatocellular carcinoma (HCC), hepatic intra-arterial chemotherapy (HAIC), 3927
Cetuximab, capecitabine, oxaliplatin, bevacizumab, phase II, metastatic colorectal cancer, 255
Cetuximab, colorectal cancer, irinotecan, oxaliplatin, biomarkers, 2149
Cetuximab, gastric cancer, irinotecan, oxaliplatin, *KRAS* phase II trial, 4439
Cetuximab, gastric cancer, S-1, thymidylate synthase, 3691
Cetuximab, HNSCC, *EGFR*, polymorphism, Erk-1/2, AG1478, 59
Cetuximab, *IDH1* mutation, glioma, sunitinib, bevacizumab, 4457
Cetuximab, pancreatic neoplasm, erlotinib, chemotherapy, chemoresistance, chemosensitivity, 1039
CEUS, HCC, dysplastic nodule, vascularity, characterization, cirrhosis, 3977
C-FLIP, PEDF, HCC, p38, PPARγ, hepatocellular carcinoma, apoptosis, 1173
Chalcone, glioblastoma, G_2/M blockage, cell death, 3213
Characteristics of cancer cells, cell-to-cell interaction, adhesion molecules, anticancer drug resistance, chemotherapy, apoptosis, drug sensitivity, drug resistance-relating factors, gene expression analysis, evaluation and prediction of pharmacological effects, screening systems, 3237

Cheek, hemangiopericytoma, solitary fibrous tumor, oral cavity, soft tissue, 719
Chemoimmunotherapy, hepatocellular carcinoma, hepatic intraarterial therapy, interferon, fotemustine, 4553
Chemokine, tumour, microvesicles, monocyte, 1329
Chemo-naive, *EGFR* mutation, erlotinib, non-small cell lung cancer, platinum doublet, 3457
Chemoprevention, lung cancer, combined treatment, mouse model, 3279
Chemoprevention, serum 25(OH)D, vitamin D, toxicity, 607
Chemoradiation, anal cancer, image-guided radiotherapy, tomotherapy, 4393
Chemoradiation, rectal cancer, neoadjuvant therapy, complete clinical response, non-operative management, review, 1795
Chemoradiotherapy, double gastric and esophageal cancer, complete response, 2339
Chemoradiotherapy, metastatic anal cancer, cisplatin, S-1, 3983
Chemoradiotherapy, pancreatic cancer, gemcitabine, intra-arterial therapy, 3909
Chemoresistance, advanced gastric cancer, AKT, PI3K, review, 4387
Chemoresistance, epigenetics, bladder cancer, DNA methylation, chemotherapy, 5-azacytidine, 3757
Chemoresistance, pancreatic neoplasm, erlotinib, cetuximab, chemotherapy, chemosensitivity, 1039
Chemoresistance, virotherapy, pancreatic cancer, gemcitabine, PDAC, GFP, 1279
Chemosensitivity, esophageal cancer, IL-6, cisplatin, 67
Chemosensitivity, lung adenocarcinoma, 5-fluorouracil, dihydropyrimidine dehydrogenase, thymidylate synthase, 4665
Chemosensitivity, pancreatic neoplasm, erlotinib, cetuximab, chemotherapy, chemoresistance, 1039
Chemosensitivity, single nucleotide polymorphisms (SNPs), gastric cancer (GC), docetaxel, *DNASE2B*, *HTRIE*, 4329
Chemotherapeutics, breast cancer, primary culture, therapy personalization, oncogramme, individualized tumour response testing, 139
Chemotherapy resistance, ovarian cancer, claudin-4, 1271
Chemotherapy, assessment, neurotoxicity, peripheral neuropathy, adverse effects, 3493
Chemotherapy, BRCA, pancreatic cancer, iniparib, 1417
Chemotherapy, breast cancer, dose-dense, sICAM-1, sVCAM-1, 2617
Chemotherapy, carboplatin, paclitaxel, vinorelbine, non-small cell lung cancer, 317
Chemotherapy, castrate-resistant prostate cancer, predictors of survival, time to castration resistance, advanced prostate cancer, 1475
Chemotherapy, cell-to-cell interaction, adhesion molecules, characteristics of cancer cells, anticancer drug resistance, apoptosis, drug sensitivity, drug resistance-relating factors, gene expression analysis, evaluation and prediction of pharmacological effects, screening systems, 3237
Chemotherapy, circulating tumor cells, disseminated tumor cells, detection, prostate cancer, bladder cancer, renal cell carcinoma, review, 2053
Chemotherapy, circulating tumor cells, metastatic breast cancer, therapy efficacy, 979
Chemotherapy, colorectal, neuroendocrine cancer, small cell cancer, cisplatin, etoposide, 975
Chemotherapy, diffuse intrinsic pontine glioma, temozolomide, rofecoxib, bevacizumab, inflammatory processes, 2265
Chemotherapy, docetaxel, nedaplatin, S1, esophageal carcinoma, phase I, 4589
Chemotherapy, docetaxel, prostate cancer, biochemical relapse, 973
Chemotherapy, endometrial cancer, prognosis, survival, radiotherapy, 3483
Chemotherapy, epigenetics, bladder cancer, DNA methylation, chemoresistance, 5-azacytidine, 3757
Chemotherapy, ERas, gastric cancer, CPT-11, rapamycin, 3353
Chemotherapy, FLOX regimen, metastatic colorectal cancer, phase II study, 5-FU, leucovorin, oxaliplatin, 4657
Chemotherapy, 5-fluorouracil, gemcitabine, colon cancer, capecitabine, 2971
Chemotherapy, glioma, oligodendroglioma, 1p19q, 1p, PAV, ACNU, procarbazine, vincristine, 4475
Chemotherapy, GLUT-1, rectal cancer, radiotherapy, tumour regression, prognosis, 311
Chemotherapy, HIF-1α, esophageal neoplasm, radiotherapy, 2351
Chemotherapy, histone deacetylase inhibitor, multidrug resistant, sarcoma, PCI-24781, 1115
Chemotherapy, medulloblastoma, vincristine, lomustine, apoptosis, 1721
Chemotherapy, metastatic gastric cancer, review, 3543
Chemotherapy, non-anticoagulant heparins, heparins, 411
Chemotherapy, paclitaxel, doxifluridine, gastric cancer, thymidine phosphorylase, 287
Chemotherapy, pancreatic neoplasm, erlotinib, cetuximab, chemoresistance, chemosensitivity, 1039
Chemotherapy, P-glycoprotein, inhibition of multidrug resistance, osteosarcoma cell lines, carcinoma cell lines, siRNA, 2813
Chemotherapy, rectal cancer, radiotherapy, prognostic factor, biomarker, carbonic anhydrase IX, hypoxia-inducible factor-1a, ezrin, glucose transporter-1, 4529

Chemotherapy, small cell lung cancer, TRAIL, paclitaxel, 3193
Chemotherapy, thromboembolism, breast cancer, 2383
Chemotherapy, thymic carcinoma, ADOC, refractory, S-1, 299
Chemotherapy, urachal cancer, recurrence, gemcitabine, cisplatin, 2335
Chemotherapy. Ki-67, LAT1, CD98, recurrence, advanced NSCLC, *EGFR* mutation, prognosis, p-Akt, p-mTOR, 3775
Chemotherapy-resistant, deferasirox, iron chelation therapy, iron overload, acute myelogenous leukemia, complete remission, 1741
Chick chorioallantoic membrane assay, alternative splicing, angiogenesis, autologous stem cell transplantation, high-dose chemotherapy, placental growth factor, vascular endothelial growth factor, V*EGFR*1, 3115
Chick embryo, circulating tumor cells, CTCs, prostate cancer, immunomagnetic beads, GFP, brain metastasis, metastatic assay, fluorescence imaging, 3125
Chief cells, polyp, gastric, fundic glend polyps, 1789
Child's classification, hepatocellular carcinoma, liver cirrhosis, MELD-score, nonhepatic cancer, survival probability, TNM classification, 2931
Children, minimal residual disease, acute lymphoblastic leukemia, flow cytometry, early response, 1453
Chitosan, heparan sulfate, anticancer, breast cancer, cell proliferation, FGF-2, 1321
Chloroma, acute myeloid leukemia, immunotherapy, interleukin-2, peptide vaccination, cerebrospinal fluid, CSF, flow of CSF, 2343
Cholangiocarcinoma, MSX2, brushing cytology, 1011
Cholangiocarcinoma, polo-like kinase 1, 5-fluorouracil, gemcitabine, BI 2536, 3289
Cholangiocellular carcinoma, Na^+, H^+ exchange, oxidative stress, liver cancer, 459
Choline-deficient L-amino acid-defined diet, *Stk11*, *Lkb1*, hepatocellular carcinoma, nitrosamine, rat, 543
Chromophobe renal cell carcinoma, renal cell carcinoma, renal oncocytoma, fluorescence *in situ* hybridization, tissue sections, isolated nuclei, 3137
Chromophobe renal cell carcinoma, temsirolimus, mTOR, sorafenib, interferon, 331
Chromosomal abnormalities, Inv(3)(q21q26), t(3;3)(q21;q26), breakpoint distribution, fluorescent *in situ* hybridization, 3441
Chronic esophagitis, mutations, polymorphisms, *TP53*, *FHIT*, esophageal carcinoma, 1685
Chronic psychological stress, macrophage, LPS, priming, IP-PA1, review, 2437
Cigarette smoking, Swedish-type smokeless tobacco, Snus, ethanol, human normal cells, cell death, endothelial cells, fibroblasts, 1527
Cigarette smoking, tobacco-caused cancer, race, 3891
Circulating cancer cells, GFP, prostate cancer, PC-3, orthotopic, immunomagnetic beads, isolation, fluorescence, imaging, culture, 1535
Circulating dendritic cells, myeloid DC, dentritic cells, pancreatic cancer, prognostic factor, survival analysis, 3827
Circulating tumor cells, bisphosphonates, disseminated tumor cells, 3623
Circulating tumor cells, colon cancer, immunological detection methods, metastasis, 613
Circulating tumor cells, CTCs, microfiltration by size, real-time quantitative reverse transcriptase-polymerase chain reaction, qRT-PCR, molecular biology, cytomorphology, FISH, cell culture, lung cancer, 427
Circulating tumor cells, CTCs, prostate cancer, immunomagnetic beads, GFP, chick embryo, brain metastasis, metastatic assay, fluorescence imaging, 3125
Circulating tumor cells, disseminated tumor cells, detection, prostate cancer, bladder cancer, renal cell carcinoma, chemotherapy, review, 2053
Circulating tumor cells, metastatic breast cancer, chemotherapy, therapy efficacy, 979
Circulating tumor cells, renal cell carcinoma, CellSearch, cytokeratins, CD44, 4219
Circulation, cell-free DNA, non-invasive, biomarker, review, 2623
Cirrhosis, CEUS, HCC, dysplastic nodule, vascularity, characterization, 3977
Cirrhosis, hepatocellular carcinoma, percutaneous ablation, percutaneous ethanol injection, radiofrequency ablation, randomized controlled trial, 2291
Cirrhosis, radiofrequency ablation, RFA, intrahepatic cholangio-carcinoma, ICC, 4575
Cisplatin, anal cancer, 5-FU, paclitaxel, 4637
Cisplatin, carboplatin, hypersensitivity, antineoplastic, thoracic malignancy, immunoglobulin E, 4525
Cisplatin, colorectal, neuroendocrine cancer, small cell cancer, chemotherapy, etoposide, 975
Cisplatin, CTR1, bortezomib, drug combination, proteasomal degradation, synergism, drug uptake, drug resistance, 2757
Cisplatin, DCF, induction chemotherapy, borderline-resectable T4, esophageal cancer, 5-fluorouracil, docetaxel, 3535
Cisplatin, drug resistance, drug combination, synergism, quercetin, thymoquinone, oxaliplatin, 3789
Cisplatin, esophageal cancer, IL-6, chemosensitivity, 67
Cisplatin, estrogen receptor beta, ovarian cancer, prognostic factor, immunohistochemistry, 711
Cisplatin, gastric cancer, gastroesophageal junction adenocarcinoma, DCF, docetaxel, 5-fluorouracil, G-CSF, 2379

Cisplatin, germ cell tumour, thrombosis, hypercoagulation, vascular toxicity, von Willebrand factor, 4501
Cisplatin, head and neck neoplasms, ERCC1 protein, DNA repair, radiation, 4135
Cisplatin, metastatic anal cancer, chemoradiotherapy, S-1, 3983
Cisplatin, neoadjuvant chemoradiotherapy, gastric cancer, S-1, 3079
Cisplatin, neoadjuvant therapy, radiochemotherapy, esophageal cancer, docetaxel, phase II trials, 4407
Cisplatin, *NK4*, gene therapy, cationised gelatin, squamous cell carcinoma, 105
Cisplatin, ovarian cancer, consolidation chemotherapy, recurrent, salvage chemotherapy, treatment-free interval, paclitaxel, irinotecan, 4613
Cisplatin, ovarian cancer, curcumin, EGCG, synergism, drug combination, 1131
Cisplatin, PAMAM dendrimers, encapsulation, intracellular delivery, resistance, SMVT, ovarian cancer cell lines, 897
Cisplatin, recurrent cervical cancer, oral etoposide, second-line chemotherapy, feasibility study, 3063
Cisplatin, small cell lung cancer, topotecan, 3449
Cisplatin, triplet combination chemotherapy, paclitaxel, S-1, advanced gastric cancer, feasibility study, 3085
Cisplatin, urachal cancer, recurrence, gemcitabine, chemotherapy, 2335
Citrate, gastric carcinoma, carcinomatosis, glycolysis, energetic metabolism, apoptosis, necrosis, 797
Class III β-tubulin, histoculture drug response assay, non-small cell lung cancer, predictive marker, vinorelbine, 999
Claudin-1, prognostic factor, recurrence, rectal cancer, 2517
Claudin-4, ovarian cancer, chemotherapy resistance, 1271
Cl-F-ara-A, clofarabine, clofarabine triphosphate, Cl-F-ara-ATP, isocratic HPLC, leukemia cells, 2863
Cl-F-ara-ATP, clofarabine, Cl-F-ara-A, clofarabine triphosphate, isocratic HPLC, leukemia cells, 2863
Clinical cancer registry, ovarian cancer, cancer epidemiology, 2657
Clinical symptoms, cervical cancer, artesunate, artenimol, tumour markers, 4417
Clinical trial, fenretinide, LXS oral powder, phase I, 961
Clinical, *KRAS*, *p53,* colorectal, oxaliplatin, 5-fluorouracil, capecitabine, CAIRO2, sequence analysis, 1379
Clioquinol, zinc, *cyclin D1*, miR-302C, MCF-7 cells, 2739
Clofarabine triphosphate, clofarabine, Cl-F-ara-A, Cl-F-ara-ATP, isocratic HPLC, leukemia cells, 2863
Clofarabine, Cl-F-ara-A, clofarabine triphosphate, Cl-F-ara-ATP, isocratic HPLC, leukemia cells, 2863
Clonogenic assay, human lung cancer cell lines, surviving fraction, doubling time, radiobiology model, 1125
Clonogenic cell survival, radiation sensitivity, huachansu, lung cancer cells, inhibition of DNA repair, 2141
C-Met, HGF, *NK4*, CT26, 5-fluorouracil, Akt, Erk1/2, thymidylate synthase, 2217
CML, antitumor activity, Bcr-Abl, *Daedalea gibbosa*, kinase, medicinal mushrooms, oleic acid, autophosphorylation, 177
coagulation factor, colon cancer, thrombin, vascular endothelial growth factor, vascular endothelial growth factor receptor-2, angiogenesis, 843
Co-culture, hyperthermia, thermal cancer therapy, hepatic stellate cells, fibrosis, HCC, transwell, 3713
Colo 205 and Colo 320 colon adenocarcinoma cells, hydantoin derivatives, multidrug resistance, efflux pump, ABCB1 transporter, apoptosis, 3285
Colo 205 cells, *Zanthoxylum ailanthoides Sieb and Zucc*., human colon adenocarcinoma cell, caspases, apoptosis, flavone, 1667
Colon 26, ultrasound, mono-l-aspartyl chlorin e6, antitumor effect, sonodynamic therapy, sarcoma 180, 501
Colon adenocarcinoma, metastasis, HPA, E-selectin, P-selectin, SCID mouse, lectin, breast carcinoma cells, 1589
Colon cancer metastasis, epithelial-mesenchymal transition (EMT), endothelin axis, endothelin A and B receptor (ETAR and ETBR), phosphatase and tensin homolog (PTEN), 861
Colon cancer, CD133, tumorigenesis, azomymethane, dextran sodium sulphate, 4273
Colon cancer, chemotherapy, fluorouracil, gemcitabine, capecitabine, 2971
Colon cancer, circulating tumor cells, immunological detection methods, metastasis, 613
Colon cancer, cyclooxygenase, COX-2, W-APC, right colon, left colon, 2191
Colon cancer, metformin, phenformin, 2-deoxyglucose, acidification, 421
Colon cancer, microsatellite instability, tumor location, age, early onset, 967
Colon cancer, monocyte differentiation, macrophage, MCP-1, 2493
Colon cancer, NFκB, IκBα, IKKβ, p38, peroxynitrite, nitration, 1607
Colon cancer, orthotopic model, GFP, fluorescent protein imaging (FPI), MRI, selenium, angiogenesis, 387
Colon cancer, photodynamic therapy, PDT, glycoconjugated chlorin, apoptosis, gastric cancer, 763
Colon cancer, prognosis, left colon, right colon, sigmoid, survival, gender, 2347
Colon cancer, RRM2, *KRAS*, 2535
Colon cancer, selenoprotein, glutathione, thioredoxin, antioxidant enzyme expression, 2693
Colon cancer, thrombin, vascular endothelial growth factor, vascular endothelial growth factor receptor-2, coagulation factor, angiogenesis, 843

Colon cancer, thymidine kinase1, 5'(3')-deoxyribonucleotidase, fluorothymidine, proliferation, lung cancer, 2135
Colon cancer, TRAIL, histone deacetylase inhibitor, LBH589, apoptosis, 3385
Colorectal cancer, ADAM, MMP, TIMP, solid cancer nest, invasive front, 1567
Colorectal cancer, adjuvant chemotherapy, *MTHFR C677T*, *MTR* A2756G, toxicity, survival, 3057
Colorectal cancer, ADM, prognostic factor, hypoxia, 507
Colorectal cancer, afatinib, BIBF 1120, phase II, pharmacokinetics, 2271
Colorectal cancer, antiapoptosis, gamma radiation, microarray, RT-PCR, *REG4*, *NEIL2*, *BIRC5*, 4147
Colorectal cancer, apoptosis, liver metastases, invasion front, *FAS*, TRAIL, 1215
Colorectal cancer, bevacizumab, FOLFIRI, XELIRI, efficacy, safety, 1777
Colorectal cancer, biological activity, tumor markers, angiogenetic factors, metalloproteinases, adhesion molecules, 373
Colorectal cancer, cetuximab, irinotecan, oxaliplatin, biomarkers, 2149
Colorectal cancer, Egfl8, quantitative polymerase chain reaction, 2249
Colorectal cancer, glycated apolipoprotein B, immuno-histochemistry, 555
Colorectal cancer, *HOPX*, gene methylation, 2889
Colorectal cancer, insulin-like growth factor, IGF-1, IGF-1R, 2541
Colorectal cancer, integrins, survival, polymorphisms, single nucleotide polymorphisms, 1373
Colorectal cancer, *KRAS*, microRNA, PTEN, miR-221/222, 3D culture, 2453
Colorectal cancer, liver metastases, lung metastases, synchronous, metachronous, 1049
Colorectal cancer, lymphangiogenesis, lymphovascular invasion, liver metastases, *VEGF*-C, 4605
Colorectal cancer, *OSMR*, quantitative methylation-specific PCR, 1293
Colorectal cancer, p16^{INK4a}, methylation, 1643
Colorectal cancer, polymorphism, MMP2, *VEGF*, HIF1A, SNP, 575
Colorectal cancer, prognostic factor, stanniocalcin 1, PCR, 325
Colorectal cancer, pulmonary metastases, TS, OPRT, ERCC1, BRCA1, MVD, adjuvant chemotherapy, 2763
Colorectal cancer, regulatory T-cells, antitumor immunity, FOLFOX, FOLFIRI, 4569
Colorectal cancer, soluble leptin receptor, tumor stage, 3381
Colorectal cancer, surgery, liver metastases, biomarker, CD95-ligand, 4507
Colorectal cancer, ulcerative colitis, surveillance, 2499
Colorectal cancer, vitamin D, breast cancer, prostate cancer, lung cancer, 3619
Colorectal cancer, wnt pathway, immunohistochemistry, LGR5, stem cell marker, 263
Colorectal carcinoma, cysteine-histidine-rich protein (*PINCH*), epithelial mesenchymal transition (EMT), vascular endothelial growth factor (*VEGF*), *FAS*, 4127
Colorectal neoplasm, thymidylate synthase, ERCC1, adenosine triphosphate, drug screening assay, 3843
Colorectal, *KRAS*, *p53,* oxaliplatin, 5-fluorouracil, capecitabine, clinical, CAIRO2, sequence analysis, 1379
Colorectal, neuroendocrine cancer, small cell cancer, chemotherapy, cisplatin, etoposide, 975
Combination strategy, androgen receptor, flutamide, prostate cancer, prostate-specific antigen, resveratrol, 3323
Combination therapy, gefitinib, radiation, *EGFR*, predictor, melanoma, 2883
Combined chemotherapy, advanced esophageal cancer, docetaxel, CDDP, 5-FU, 633
Combined treatment, lung cancer, chemoprevention, mouse model, 3279
Commitment, personality, type C, cancer risk, 4013
Complementary peptide, antisense pepitide, anaphylatoxin, inflammation, sepsis, cytokine storm, 2511
Complete clinical response, rectal cancer, chemoradiation, neoadjuvant therapy, non-operative management, review, 1795
Complete remission, deferasirox, iron chelation therapy, iron overload, acute myelogenous leukemia, chemotherapy-resistant, 1741
Complete response, double gastric and esophageal cancer, chemoradiotherapy, 2339
Complete response, early-stage esophageal cancer, S-1 plus CDDP, 1019
Complete tumor resection, ovarian cancer relapse, secondary cytoreductive surgery, predictive factor, tumor residual, 2583
Complication, esophageal squamous cell carcinoma, neoadjuvant chemoradiotherapy, pathological response, prognosis, 3073
Computational toxicology, cat-SAR, anticancer models, DTP, breast cancer, 3247
Concurrent chemoradiotherapy, cervical cancer, squamous cell carcinoma, stage IB-IIB, locoregional recurrence, 1437
Concurrent disease, BPF, fistula, operation, lung cancer, risk factor, perioperative complication, infection, 619
Conformation, antibacterial activity, hydrophobicity, bis-quarternary compound, 2561
Conservative management, grade 2, grade 3, endometrial cancer, fertility, 3047

Consolidation chemotherapy, ovarian cancer, recurrent, salvage chemotherapy, treatment-free interval, paclitaxel, cisplatin, irinotecan, 4613
Continuous medical training, gynecological cancer, breast cancer, online tumor conference, interdisciplinary therapy management, second opinion, 2669
Continuous saline bladder irrigation, bladder cancer, recurrence, intravesical chemotherapy, 1471
Contrast-enhanced ultrasonography, prostate cancer, transrectal ultrasonography, 1421
Copper overload, reactive oxygen species, pyruvate dehydrogenase, Long Evans Cinnamon, 3395
Cortactin, breast cancer, tissue microarray, 293
Cox-2, anticancer agents, sphingomylinase, caspase-3, apoptosis, *p53,* cell cycle, 1345
COX-2, cyclooxygenase, breast cancer, tumor, prostaglandin, carcinogenesis, 4359
COX-2, cyclooxygenase, W-APC, right colon, left colon, colon cancer, 2191
COX-2, metastasis, extravasation, blood–brain barrier, brain endothelial cells, 4307
Cox-2, polymorphism, carcinogenesis, prostate cancer, 221
CPT-11, ERas, gastric cancer, chemotherapy, rapamycin, 3353
C-reactive protein, cervical cancer, CRP, *CRP1919* (rs1417938), *CRP2667* (rs1800947), *CRP3872* (rs1205), *CRP5237* (rs2808630), gene polymorphism, prognosis, single nucleotide polymorphism, 2259
CRM197, HB-EGF, doxorubicin, T-ALL, 2483
CRM197, ovarian cancer, HB-EGF, targeted therapy, 2461
CRP, cervical cancer, C-reactive protein, *CRP1919* (rs1417938), *CRP2667* (rs1800947), *CRP3872* (rs1205), *CRP5237* (rs2808630), gene polymorphism, prognosis, single nucleotide polymorphism, 2259
CRP1919 (rs1417938), cervical cancer, C-reactive protein, CRP, *CRP2667* (rs1800947), *CRP3872* (rs1205), *CRP5237* (rs2808630), gene polymorphism, prognosis, single nucleotide polymorphism, 2259
CRP2667 (rs1800947), cervical cancer, C-reactive protein, CRP, *CRP1919* (rs1417938), *CRP3872* (rs1205), *CRP5237* (rs2808630), gene polymorphism, prognosis, single nucleotide polymorphism, 2259
CRP3872 (rs1205), cervical cancer, C-reactive protein, CRP, *CRP1919* (rs1417938), *CRP2667* (rs1800947), *CRP5237* (rs2808630), gene polymorphism, prognosis, single nucleotide polymorphism, 2259
CRP5237 (rs2808630), cervical cancer, C-reactive protein, CRP, *CRP1919* (rs1417938), *CRP2667* (rs1800947), *CRP3872* (rs1205), gene polymorphism, prognosis, single nucleotide polymorphism, 2259
Cryoimmunology, cryotreatment, renal cell carcinoma, immunotherapy, 2927
Cryotreatment, cryoimmunology, renal cell carcinoma, immunotherapy, 2927
CSF, acute myeloid leukemia, immunotherapy, interleukin-2, peptide vaccination, cerebrospinal fluid, flow of CSF, chloroma, 2343
CT, adrenocortical tumors, Cushing's syndrome, adrenal imaging, cancer, MR, review, 2923
CT26, HGF, c-Met, *NK4*, 5-fluorouracil, Akt, Erk1/2, thymidylate synthase, 2217
CTCs, circulating tumor cells, microfiltration by size, real-time quantitative reverse transcriptase-polymerase chain reaction, qRT-PCR, molecular biology, cytomorphology, FISH, cell culture, lung cancer, 427
CTCs, circulating tumor cells, prostate cancer, immunomagnetic beads, GFP, chick embryo, brain metastasis, metastatic assay, fluorescence imaging, 3125
CT-guided high-dose-rate brachytherapy, CT-HDRBT, ovarian cancer, metachronous liver metastasis, ablation of liver metastases, 2597
CT-HDRBT, CT-guided high-dose-rate brachytherapy, ovarian cancer, metachronous liver metastasis, ablation of liver metastases, 2597
CTNNB1, medullary thyroid carcinoma, gene mutations, *RET*, *HRAS*, *KRAS*, *NRAS*, *BRAF*, *AKT1*, mutational screening, 4179
CTR1, cisplatin, bortezomib, drug combination, proteasomal degradation, synergism, drug uptake, drug resistance, 2757
Culture, GFP, prostate cancer, PC-3, orthotopic, circulating cancer cells, immunomagnetic beads, isolation, fluorescence, imaging, 1535
Culture, hepatitis C virus, liver tumour, sarcomatoid tumour, cell line, spectral karyotyping, xenograft, 129
Curcumin analog, multiple myeloma, NF-κB, PI3K/AKT, JAK/STAT3, IRF4, 3719
Curcumin, ovarian cancer, cisplatin, EGCG, synergism, drug combination, 1131
Curcuminoid, boron tracedrug, BODIPY, neutron dynamic therapy, dynamic drug, thermal neutron irradiation, BNCT, 2477
Cushing's syndrome, adrenocortical tumors, adrenal imaging, cancer, CT, MR, review, 2923
CV11974, osteosarcoma, metastasis, angiotensin II type 1 receptor antagonist, 123
CXCR4, AAV, gene therapy, bioluminescence, breast cancer, 1627
Cyclin B1, cell cycle, *p53,* squamous cell carcinoma, head and neck cancer, 3151
Cyclin D, antisense oligonucleotide, cyclin E, cyclin-dependent kinase, retinoblastoma protein, non-small lung cancer cells, pleural mesothelioma cells, apoptosis, kinases, phosphatases, 3683
Cyclin D1, CCND1 1722, polymorphism, upper tract urothelial cancer, 1043

Cyclin D1, CCND1, polymorphism, lung cancer, smoking, Taiwanese, 3601
Cyclin D1, clioquinol, zinc, miR-302C, MCF-7 cells, 2739
Cyclin D1, polymorphism, oral cancer, smoking, 227
Cyclin D3, minichromosome maintenance proteins, MCMs, CCND3, Hodgkin lymphoma, survival, 3585
Cyclin E, antisense oligonucleotide, cyclin D, cyclin-dependent kinase, retinoblastoma protein, non-small lung cancer cells, pleural mesothelioma cells, apoptosis, kinases, phosphatases, 3683
Cyclin-dependent kinase, antisense oligonucleotide, cyclin D, cyclin E, retinoblastoma protein, non-small lung cancer cells, pleural mesothelioma cells, apoptosis, kinases, phosphatases, 3683
Cyclooxygenase, COX-2, breast cancer, tumor, prostaglandin, carcinogenesis, 4359
Cyclooxygenase, COX-2, W-APC, right colon, left colon, colon cancer, 2191
Cyclooxygenase-2, 5-FU resistance, thymidylate synthase, etodolac, 2893
Cyclophosphamide, metronomic, doxorubicin, breast cancer, cardiotoxicity, rats, 215
Cyclophosphamide, β-glucan, A20 lymphoma, regulatory T-cell, 1169
Cyclosporine, isolated lung perfusion, sarcoma lung metastases, p-gp modulation, doxorubicin, valspodar, 2121
Cyclosporine A, human lung adenocarcinoma cell, apoptosis, lung transplantation, caspase, 2129
CYP1A1, genetic polymorphisms, cancer susceptibility, DNA-repair genes, metabolizing genes, *CYP1E1*, *XRCC1*, 1359
CYP1E1, genetic polymorphisms, cancer susceptibility, DNA-repair genes, metabolizing genes, *CYP1A1*, *XRCC1*, 1359
Cysteine-histidine-rich protein (*PINCH*), colorectal carcinoma, epithelial mesenchymal transition (EMT), vascular endothelial growth factor (*VEGF*), *FAS*, 4127
Cytogenetics, hyperdiploid multiple myeloma, tumor progression, 1599
Cytokeratin 19, breast cancer, sentinel lymph node, OSNA, intra-operative method, 585
Cytokeratin 4, fascin, biomarker, tissue microarray, squamous cell carcinoma, esophagus, 945
Cytokeratin 8, radioimmunotherapy, HNSCC, SCID mice, xenografts, radio-labeled monoclonal antibody, 3315
Cytokeratins, monoTotal, lung cancer, tumour markers, 3107
Cytokeratins, renal cell carcinoma, circulating tumor cells, CellSearch, CD44, 4219
Cytokine storm, antisense pepitide, complementary peptide, anaphylatoxin, inflammation, sepsis, 2511
Cytokines, cathepsin, proliferation, lung cancer cells, 47
Cytokines, morphine, plasma, MIP-1α, IL-12, 4561
Cytokines, voluntary running, metastasis, mice, 3337
Cytokinins, isopentenyladenosine, modified nucleosides, antiproliferative activity, 3401
Cytology, DNA ploidy, image analysis, cytometry, hematoxylin staining, Feulgen staining, Papanicolaou staining, 53
Cytology, endometrial brush, endometrial cancer, endometrial pathology, screening test, uterobrush, 3469
Cytology, epidermal growth factor receptor (*EGFR*), lung cancer, fiberbronchoscopy, diagnosis, 4207
Cytomegalovirus, brain tumors, glioblastoma, etiology, 959
Cytometry, DNA ploidy, image analysis, cytology, hematoxylin staining, Feulgen staining, Papanicolaou staining, 53
Cytomorphology, circulating tumor cells, CTCs, microfiltration by size, real-time quantitative reverse transcriptase-polymerase chain reaction, qRT-PCR, molecular biology, FISH, cell culture, lung cancer, 427
Cytoprotection, prostate cancer, radiotherapy, hypofractionation, acceleration, amifostine, 1745
Cytoreductive surgery, ovarian cancer, residual disease, prediction models, 4043
Cytosine deaminase, endometrial cancer, engineered stem cells, interferon-β, 2853
Cytoskeleton, paxillin, phosphatase, PP-1, TGF-β, 3159
Cytotherapy, mesenchymal stem cells, gene therapy, hepatocellular carcinoma, 3705
Cytotoxic T-cells, γδ T-cells, antigen presentation, 2419
Cytotoxicity, apoptosis, celecoxib, neuroblastoma, valproic acid, 2231
Cytotoxicity, endocytosis, glycosylated antitumor ether lipid, mechanism of action, methyl-β-cyclodextrin, 3809
Cytotoxicity, ferrocene, ethynyl phosphine, gold, platinum, HeLa, 825
Cytotoxicity, hENT1, gemcitabine, I3C, pancreatic cancer, 3171
Cytotoxicity, myeloma, YT, CD86, interleukin-2, 475
Cytotoxicity, oxaliplatin, phytochemicals, ovarian cancer cell lines, synergism, 4283
Cytotoxicity, prostate cancer, triphala, gallic acid, Ayurvedic medicine, 3739
Cytotoxicity, trihaloacetylazulenes, QSAR, semiempirical molecular-orbital method, 515
Dacarbazine, imexon, melanoma, additivity, drug combinations, 2781
Daedalea gibbosa, antitumor activity, Bcr-Abl, CML, kinase, medicinal mushrooms, oleic acid, autophosphorylation, 177
DAPK, breast cancer, tissue microarray, 3633
Daunorubicin resistance, arsenic trioxide, arsenic acid, organic arsenicals, T-lymphoblastoid leukemia, apoptosis, 4169

DAX-1, breast cancer, ApoD, ERα, prognosis, 443
DC Bead, liver directed therapy, metastatic colon cancer, irinotecan, transarterial chemoembolization, DEBIRI, 4581
DC, vaccine, whole tumor cell, IFN-γ, ELISPOT, 3995
DCEMR, prostate cancer, PCA3 urinary test, MRSI, 1399
DCF, gastric cancer, gastroesophageal junction adenocarcinoma, docetaxel, cisplatin, 5-fluorouracil, G-CSF, 2379
DCF, induction chemotherapy, borderline-resectable T4, esophageal cancer, cisplatin, 5-fluorouracil, docetaxel, 3535
3D culture, *KRAS*, microRNA, colorectal cancer, PTEN, miR-221/222, 2453
2-DE, TNF-alpha, hepatoma, proteomics, LC-MS/MS, apoptosis, 2059
2-DE, tubulin alpha-6 chain, HCV-HCC, proteomics, MS, 3331
De-alcoholization, paclitaxel (PTX), alcohol intolerance, pharmacokinetics, adverse event, 4339
Death receptor-mediated pathways, gallic acid (GA), human leukemia HL-60 cells, apoptosis, mitochondria-mediated pathways, 2821
DEBIRI, liver directed therapy, metastatic colon cancer, irinotecan, transarterial chemoembolization, DC Bead, 4581
Decitabine, astrocytomas, epigenetics, DNA methylation, histone deacetylases, 1337
Dectin-1, beta-glucan, B-cell lymphoma, CD86, proliferation, cell death, 4195
Dectin-2 gene expression, microarray analysis, signaling pathway, macrophage, lignin-carbohydrate complex, LPS, LEM, 1241
Deep-seated, sonodynamic therapy, focused ultrasound, 5-aminolevulinic acid, glioma, rat model, 2527
Deferasirox, iron chelation therapy, iron overload, acute myelogenous leukemia, chemotherapy-resistant, complete remission, 1741
Del(20q), interphase FISH, MDS, normal karyotype, del(5q), 1007
Del(5q), interphase FISH, MDS, normal karyotype, del(20q), 1007
Demethylation, MAGE, non-small cell lung cancer NSCLC, expression, 171
Dendritic cell therapy, melanoma, small bowel, intussusception, disease-free survival, 3579
Dendritic cell, nucleotide, insoluble protein, T lymphocytes, immunotherapy, 881
Dendritic cells, β-glucan, beta-glucan, maturation, immunomodulator, 1647
Dentritic cells, myeloid DC, pancreatic cancer, prognostic factor, survival analysis, circulating dendritic cells, 3827
2-Deoxyglucose, colon cancer, metformin, phenformin, acidification, 421
5'(3')-Deoxyribonucleotidase, thymidine kinase1, fluorothymidine, proliferation, lung cancer, colon cancer, 2135
Depression, breast disease, risk of cancer, 1065
Detection, circulating tumor cells, disseminated tumor cells, prostate cancer, bladder cancer, renal cell carcinoma, chemotherapy, review, 2053
Dexamethasone, multiple myeloma, bortezomib, once-weekly administration, gastrointestinal adverse events, 2297
Dextran sodium sulphate, CD133, colon cancer, tumorigenesis, azomymethane, 4273
DFI, non-small cell lung cancer, TIMP1, mRNA, survival, blood plasma, 4031
Diabetes, KRAP, *KRAS*, target, cancer, obesity, review, 2413
Diagnosis, biomarkers, early detection, head and neck cancer, review, 1161
Diagnosis, epidermal growth factor receptor (*EGFR*), lung cancer, cytology, fiberbronchoscopy, 4207
Diagnosis, ovarian cancer, biomarkers, enzyme-linked immunosorbent assay, cathepsin, matrix metalloproteinase-9, heparanase, 3423
Diagnosis, thyroid cancer, biomarker, sensitivity, specificity, metastasis, immunohistochemistry, 3433
Diethylstilbestrol, indole, telomerase, prostate cancer, cell viability, 3733
Differental diagnosis, breast cancer liver metastases, liver surgery, tumour markers, prognostic factors, benign liver lesions, 1447
Diffuse intrinsic pontine glioma, chemotherapy, temozolomide, rofecoxib, bevacizumab, inflammatory processes, 2265
Dihydroartemisinin, artemisinin dimers, rat, breast cancer cells, 4111
Dihydroartemisinin, pancreatic cancer, cell proliferation, apoptosis, angiogenesis, optical imaging, 1549
Dihydropyrimidine dehydrogenase, lung adenocarcinoma, 5-fluorouracil, thymidylate synthase, chemosensitivity, 4665
Dihydropyrimidine dehydrogenase, oral squamous cell carcinoma, thymidylate synthase, lymph node metastasis, KAI1/CD82, 3521
12-Dioxooleana-1, ovarian cancer, methyl-2-cyano-3, 9(11)-dien-28-oate (CDDO-Me), apoptosis, AKT, NF-κB, mTOR, 3673
3-Dioxygenase, indoleamine-2, immunomodulation, cervical cancer, quinolinic acid, kynurenic acid, 2629
Disease-free survival, melanoma, small bowel, intussusception, dendritic cell therapy, 3579
Disseminated histiocytic sarcoma, quantitative PCR, immunohistochemistry, HMGB1, RAGE, 1541
Disseminated tumor cells, bisphosphonates, circulating tumor cells, 3623

Disseminated tumor cells, breast cancer, bone marrow, bone mineral density, quantitative ultrasonometry, 4423
Disseminated tumor cells, breast cancer, bone marrow, prognosis, follow-up, 2749
Disseminated tumor cells, circulating tumor cells, detection, prostate cancer, bladder cancer, renal cell carcinoma, chemotherapy, review, 2053
Distal margins, rectal cancer, hyperthermo-chemo-radiation therapy, HCRT, tumor response, 3963
D-loop region, MtDNA mutation, breast cancer, plasma, mitochondrial DNA, 4267
DNA interaction and fragmentation, quinazoliniminium salts, tumor cell proliferation, Ki-67 expression, macromolecule syntheses, multiple mitotic figures, nuclei, micronuclei, 2083
DNA methylation, astrocytomas, epigenetics, histone deacetylases, decitabine, 1337
DNA methylation, epigenetics, bladder cancer, chemotherapy, chemoresistance, 5-azacytidine, 3757
DNA methylation, polymorphism, ulcerative colitis, CD14, p22PHOX, MBL, 933
DNA N-methyl transferase, tumor suppressors, cell cycle arrest, ERK, 2723
DNA ploidy, image analysis, cytometry, cytology, hematoxylin staining, Feulgen staining, Papanicolaou staining, 53
DNA repair, caveolin-1, prostate cancer, single nucleotide polymorphism, 745
DNA repair, head and neck neoplasms, ERCC1 protein, cisplatin, radiation, 4135
DNA repair, X-ray repair cross-complementing group 1, *XRCC1*, polymorphism, skin cancer, meta-analysis, 3945
DNA-repair genes, genetic polymorphisms, cancer susceptibility, metabolizing genes, *CYP1A1*, *CYP1E1*, *XRCC1*, 1359
DNASE2B, single nucleotide polymorphisms (SNPs), gastric cancer (GC), chemosensitivity, docetaxel, *HTRIE*, 4329
Docetaxel, advanced esophageal cancer, combined chemotherapy, CDDP, 5-FU, 633
Docetaxel, cancer, neurotoxicity, adjuvant chemotherapy, intraepidermal nerve fibres, neuropathy, skin biopsies, oxaliplatin, 4413
Docetaxel, chemotherapy, nedaplatin, S1, esophageal carcinoma, phase I, 4589
Docetaxel, DCF, induction chemotherapy, borderline-resectable T4, esophageal cancer, cisplatin, 5-fluorouracil, 3535
Docetaxel, gastric cancer, gastroesophageal junction adenocarcinoma, DCF, cisplatin, 5-fluorouracil, G-CSF, 2379
Docetaxel, neoadjuvant therapy, radiochemotherapy, esophageal cancer, cisplatin, phase II trials, 4407
Docetaxel, prostate cancer, chemotherapy, biochemical relapse, 973
Docetaxel, single nucleotide polymorphisms (SNPs), gastric cancer (GC), chemosensitivity, *DNASE2B*, *HTRIE*, 4329
Docetaxel, stealth liposomes, PEG liposomes, locoregional chemotherapy, liver metastases, hepatic arterial infusion, 153
Dose-dense, breast cancer, chemotherapy, sICAM-1, sVCAM-1, 2617
Double gastric and esophageal cancer, chemoradiotherapy, complete response, 2339
Doubling time, human lung cancer cell lines, surviving fraction, radiobiology model, clonogenic assay, 1125
Down-regulation, lipid nanoparticles, *CDK4*, siRNA, 1619
Doxifluridine, paclitaxel, gastric cancer, ascites, 4625
Doxifluridine, paclitaxel, gastric cancer, thymidine phosphorylase, chemotherapy, 287
Doxorubicin, HB-EGF, CRM197, T-ALL, 2483
Doxorubicin, hyperthermia, bevacizumab, platinum-refractory, ovarian cancer, 2675
Doxorubicin, isolated lung perfusion, sarcoma lung metastases, p-gp modulation, cyclosporine, valspodar, 2121
Doxorubicin, metronomic, cyclophosphamide, breast cancer, cardiotoxicity, rats, 215
DPD, S-1, 5-fluorouracil, Phase I, FBAL, tegafur, FT, reversible dihydropyrimidine dehydrogenase, gimeracil, CDHP, solid tumors, 625
Drug combination, cisplatin, CTR1, bortezomib, proteasomal degradation, synergism, drug uptake, drug resistance, 2757
Drug combination, drug resistance, synergism, quercetin, thymoquinone, cisplatin, oxaliplatin, 3789
Drug combination, ovarian cancer, cisplatin, curcumin, EGCG, synergism, 1131
Drug combinations, imexon, dacarbazine, melanoma, additivity, 2781
Drug delivery, cancer, liposome, vincristine, folate receptor, drug targeting, 1521
Drug resistance, cisplatin, CTR1, bortezomib, drug combination, proteasomal degradation, synergism, drug uptake, 2757
Drug resistance, drug combination, synergism, quercetin, thymoquinone, cisplatin, oxaliplatin, 3789
Drug resistance, notch, stem cells, pancreatic cancer, signal pathway, natural agents, cancer therapy, review, 1105
Drug resistance, V*EGFR*2, tyrosine kinase inhibitor, angiogenesis, endothelial cells, HUVEC, 2787
Drug screening assay, thymidylate synthase, ERCC1, adenosine triphosphate, colorectal neoplasm, 3843

Drug sensitivity, drug resistance-relating factors, gene expression analysis, cell-to-cell interaction, adhesion molecules, characteristics of cancer cells, anticancer drug resistance, chemotherapy, apoptosis, evaluation and prediction of pharmacological effects, screening systems, 3237
Drug targeting, drug delivery, cancer, liposome, vincristine, folate receptor, 1521
Drug uptake, cisplatin, CTR1, bortezomib, drug combination, proteasomal degradation, synergism, drug resistance, 2757
DTP, cat-SAR, anticancer models, breast cancer, computational toxicology, 3247
Dual-specificity phosphatases, cannabinoids, apoptosis, prostate cancer cell lines, protein tyrosine phosphatases, 3799
Ductal carcinoma *in situ*, breast, lumpectomy, mastectomy, menopause, hormone replacement therapy, 1783
Ductal pleomorphic carcinoma, male breast, histopathology, immunohistochemistry, 3069
Dynamic contrast enhancing magnetic resonance imaging (DCE-MRI), adrenocortical carcinoma, ADH-1, phase-I, N-cadherin, 3921
Dynamic drug, boron tracedrug, BODIPY, curcuminoid, neutron dynamic therapy, thermal neutron irradiation, BNCT, 2477
Dysplastic nevi, immune response, melanocyte, melanoma, regression, 3697
Dysplastic nodule, CEUS, HCC, vascularity, characterization, cirrhosis, 3977
Eag1, epithelial to mesenchymal transition, lung cancer, potassium channels, TGF-β, 1265
EAP, gefitinib, non-small cell lung cancer, NSCLC, epidermal growth factor receptor, *EGFR*, skin toxicity, expanded access programme, 2949
Early detection, biomarkers, diagnosis, head and neck cancer, review, 1161
Early onset, colon cancer, microsatellite instability, tumor location, age, 967
Early response, minimal residual disease, acute lymphoblastic leukemia, flow cytometry, children, 1453
Early-stage esophageal cancer, S-1 plus CDDP, complete response, 1019
EBP1, prostate cancer, mRNA translation, androgen receptor, 3129
EBV polymorphism, *Bam*HI W1/I1, *Xho*I restriction site, EBV-associated gastric cancer, Latin America, 3607
EBV-associated gastric cancer, EBV polymorphism, *Bam*HI W1/I1, *Xho*I restriction site, Latin America, 3607
E-Cadherin, cancer, endometrium, apoptosis, *Bcl-2*, *p53,* estrogen receptor, progesterone receptor, 4191
E-Cadherin, EMT, gamma catenin, vimentin, fibronectin, lung adenocarcinoma, 4451
ECM, EMMPRIN, Fyn, integrin, oral SCC, 1205
Efficacy, bevacizumab, FOLFIRI, XELIRI, colorectal cancer, safety, 1777
Efflux pump, hydantoin derivatives, Colo 205 and Colo 320 colon adenocarcinoma cells, multidrug resistance, ABCB1 transporter, apoptosis, 3285
EGCG, ovarian cancer, cisplatin, curcumin, synergism, drug combination, 1131
EGF, growth factors, breast cancer, tumor markers, CA 15-3, CEA, IGF1, HGF, 4653
EGF, silibinin, CD44, *EGFR*, TGF-α, MMP-9, breast cancer metastasis, 3767
Egfl8, colorectal cancer, quantitative polymerase chain reaction, 2249
EGFL8, gastric cancer, quantitative polymerase chain reaction, 3377
EGFR mutation, chemo-naive, erlotinib, non-small cell lung cancer, platinum doublet, 3457
EGFR mutation, LAT1, CD98, recurrence, advanced NSCLC, prognosis, chemotherapy. Ki-67, p-Akt, p-mTOR, 3775
EGFR mutation, NSCLC, methylation, MLPA, targeted therapy, gene methylation, TKIs, smoking, 4647
EGFR tyrosine kinase inhibitor, *EGFR*, HER2, NSCLC, oncogene addiction, 4155
EGFR, BEZ235, lung cancer, P13K/mTOR inhibitor, 849
EGFR, *BRAF* mutation, *KRAS*, ERBB2 mutation, V600E, lung cancer, adenocarcinoma, squamous cell carcinoma, SSCP, 4619
EGFR, breast cancer, lapatinib, imatinib, ErbB2, c-ABL, RTK, 789
EGFR, gefitinib, non-small cell lung cancer, NSCLC, epidermal growth factor receptor, skin toxicity, expanded access programme, EAP, 2949
EGFR, gefitinib, radiation, combination therapy, predictor, melanoma, 2883
EGFR, glioma, cell cycle, temozolomide, 3253
EGFR, HER2, *EGFR* tyrosine kinase inhibitor, NSCLC, oncogene addiction, 4155
EGFR, HNSCC, polymorphism, Erk-1/2, AG1478, cetuximab, 59
EGFR, insulin-like growth factor-1, IGF-1, tamoxifen-resistance, oestrogen resistance, breast cancer recurrence, oestrogen receptor-alpha, 23
EGFR, Ki-67, translational research, squamous cell carcinoma, head and neck cancer, 665
EGFR, lung cancer, NSCLC, erlotinib, c-erbB-3, 281
EGFR, mutation, estrogen receptor, lung cancer, 855
EGFR, mutation, methylation, tobacco smoking, lung adenocarcinoma, *FHIT*, RASSF1A, RUNX3, 1211
EGFR, silibinin, CD44, EGF, TGF-α, MMP-9, breast cancer metastasis, 3767
EGFR-TKIs, non-small cell lung cancer, gefitinib, erlotinib, resistance, bone metastasis, radiotherapy, 4519

Elderly, parathyroid tumors, hyperparathyroidism, arterial blood pressure, serum calcium, PTH, arterial hypertension, 3969
Electroporation, oligonucleotides, siRNA, miRNA, review, 4083
ELISA, HB-EGF, ovarian cancer, 2553
ELISPOT, DC, vaccine, whole tumor cell, IFN-γ, 3995
EMMPRIN, Fyn, integrin, oral SCC, ECM, 1205
EMT, E-cadherin, gamma catenin, vimentin, fibronectin, lung adenocarcinoma, 4451
Encapsulation, PAMAM dendrimers, intracellular delivery, resistance, SMVT, cisplatin, ovarian cancer cell lines, 897
Encephalopathy, 5-FU, hyperammonemia, capecitabine, metastatic rectal adenocarcinoid, 335
Endocytosis, cytotoxicity, glycosylated antitumor ether lipid, mechanism of action, methyl-β-cyclodextrin, 3809
Endoglin, angiogenesis, cancer, CD105, tumor, review, 2283
Endoglin, angiogenic factors, angiogenin, endostatin, cervical cancer, 2651
Endoglin, angiogenic factors, cervical cancer, *VEGF*, angiogenin, 2589
Endometrial brush, cytology, endometrial cancer, endometrial pathology, screening test, uterobrush, 3469
Endometrial cancer, conservative management, grade 2, grade 3, fertility, 3047
Endometrial cancer, cytology, endometrial brush, endometrial pathology, screening test, uterobrush, 3469
Endometrial cancer, engineered stem cells, cytosine deaminase, interferon-β, 2853
Endometrial cancer, prognosis, survival, radiotherapy, chemotherapy, 3483
Endometrial carcinoma, para-aortic lymph node dissection, adjuvant chemotherapy, prognosis, 4513
Endometrial pathology, cytology, endometrial brush, endometrial cancer, screening test, uterobrush, 3469
Endometrial proliferation, melatonin, cancer, rats, 2637
Endometrial stromal sarcoma, t(10;17) translocation, neuroectodermal, 2367
Endometriosis, *p53, p21, CDKN1A/WAF/CIP1*, polymorphism, genotype, 4301
Endometrium, cancer, apoptosis, *Bcl-2*, *p53,* E-cadherin, estrogen receptor, progesterone receptor, 4191
Endostatin, angiogenic factors, angiogenin, endoglin, cervical cancer, 2651
Endostatin, angiogenic factors, vascular endothelial growth factor, basic fibroblast growth factor, cervical cancer, 2645
Endothelial cells, cigarette smoking, Swedish-type smokeless tobacco, Snus, ethanol, human normal cells, cell death, fibroblasts, 1527
Endothelial cells, HAVcR-1, tight junction, tight junction regulation, 467
Endothelial cells, V*EGFR*2, tyrosine kinase inhibitor, drug resistance, angiogenesis, HUVEC, 2787
Endothelin A and B receptor (ETAR and ETBR), colon cancer metastasis, epithelial-mesenchymal transition (EMT), endothelin axis, phosphatase and tensin homolog (PTEN), 861
Endothelin axis, colon cancer metastasis, epithelial-mesenchymal transition (EMT), endothelin A and B receptor (ETAR and ETBR), phosphatase and tensin homolog (PTEN), 861
Endothelium, breast cancer, E-selectin, liver metastasis, pro-inflammatory micro*env* ironment, 3219
Endotoxin, LPS, oral administration, toxicity, absorption, lipopolysaccharide, review, 2431
Energetic metabolism, gastric carcinoma, carcinomatosis, glycolysis, apoptosis, necrosis, citrate, 797
Engineered stem cells, endometrial cancer, cytosine deaminase, interferon-β, 2853
Enterocolitis, radiation therapy, risk factor, leg edema, postoperative radiotherapy, gynecological malignancies, 3527
Enzyme-linked immunosorbent assay, ovarian cancer, diagnosis, biomarkers, cathepsin, matrix metalloproteinase-9, heparanase, 3423
EP4, prostate cancer, PGE2, p-Akt, *Snail*, epithelial-mesenchymal transition, 4347
Epidemiology, vitamin D, 25-hydroxyvitamin D, breast neoplasms, case–control studies, meta-analysis, prevention, 2939
Epidermal growth factor receptor (*EGFR*), lung cancer, cytology, fiberbronchoscopy, diagnosis, 4207
Epidermal growth factor receptor, gefitinib, non-small cell lung cancer, NSCLC, *EGFR*, skin toxicity, expanded access programme, EAP, 2949
Epigenetic modifiers, kidney, toxicity, ROS, p66shc, mitochondria, 3267
Epigenetic regulation, breast cancer, histone-modifier genes, histone acetyltransferases, histone methyltransferases, 4115
Epigenetics, astrocytomas, DNA methylation, histone deacetylases, decitabine, 1337
Epigenetics, bladder cancer, DNA methylation, chemotherapy, chemoresistance, 5-azacytidine, 3757
Epithelial-mesenchymal transition (EMT), cysteine-histidine-rich protein (*PINCH*), colorectal carcinoma, vascular endothelial growth factor (*VEGF*), *FAS*, 4127
Epithelial-mesenchymal transition, lung cancer, potassium channels, Eag1, TGF-β, 1265
Epithelial-mesenchymal transition (EMT), colon cancer metastasis, endothelin axis, endothelin A and B receptor (ETAR and ETBR), phosphatase and tensin homolog (PTEN), 861

Epithelial-mesencymal transition, prostate cancer, PGE2, EP4, p-Akt, *Snail*, 4347
Epithelial ovarian cancer, vascular endothelial growth factor, *VEGF*, gene expression, anti-*VEGF* therapy, bevacizumab, 731
ER stress, proteasome inhibitor, receptor tyrosine kinase, activation loop, multiple myeloma, FGFR3, Lys650Glu mutation, K650E, bortezomide, plasma cell malignancy, 113
ERas, gastric cancer, chemotherapy, CPT-11, rapamycin, 3353
ERBB2 mutation, *BRAF* mutation, *KRAS*, *EGFR*, V600E, lung cancer, adenocarcinoma, squamous cell carcinoma, SSCP, 4619
ErbB2, breast cancer, lapatinib, imatinib, *EGFR*, c-ABL, RTK, 789
ERCC1 protein, head and neck neoplasms, cisplatin, DNA repair, radiation, 4135
ERCC1, colorectal cancer, pulmonary metastases, TS, OPRT, BRCA1, MVD, adjuvant chemotherapy, 2763
ERCC1, thymidylate synthase, adenosine triphosphate, drug screening assay, colorectal neoplasm, 3843
ERK, pancreatic cancer, gemcitabine, resistance, lenalidomide, 3747
ERK, tumor suppressors, cell cycle arrest, DNA N-methyl transferase, 2723
ERK1/2 kinase, laryngeal cancer, glutamate receptor, antagonist, proliferation, 565
Erk1/2, HGF, c-Met, *NK4*, CT26, 5-fluorouracil, Akt, thymidylate synthase, 2217
Erk-1/2, HNSCC, *EGFR*, polymorphism, AG1478, cetuximab, 59
Erlotinib, chemo-naive, *EGFR* mutation, non-small cell lung cancer, platinum doublet, 3457
Erlotinib, lung cancer, NSCLC, *EGFR*, c-erbB-3, 281
Erlotinib, non-small cell lung cancer, gefitinib, resistance, bone metastasis, radiotherapy, *EGFR*-TKIs, 4519
Erlotinib, non-small cell lung cancer, third-line treatment, gefitinib, review, 649
Erlotinib, pancreatic neoplasm, cetuximab, chemotherapy, chemoresistance, chemosensitivity, 1039
Erlotinib, primary peritoneal carcinoma, bevacizumab, 4397
Erythropoiesis stimulating agents, erythropoietin, breast cancer, erythropoietin receptor, 1189
Erythropoietin receptor, erythropoietin, breast cancer, erythropoiesis stimulating agents, 1189
Erythropoietin, breast cancer, erythropoietin receptor, erythropoiesis stimulating agents, 1189
ERα, breast cancer, DAX-1, ApoD, prognosis, 443
E-Selectin, breast cancer, liver metastasis, endothelium, pro-inflammatory micro*env* ironment, 3219
E-Selectin, metastasis, HPA, P-selectin, SCID mouse, lectin, breast carcinoma cells, colon adenocarcinoma, 1589
Esophageal cancer, CCN family, WISP-1, WISP-1v, 991
Esophageal cancer, DCF, induction chemotherapy, borderline-resectable T4, cisplatin, 5-fluorouracil, docetaxel, 3535
Esophageal cancer, IL-6, cisplatin, chemosensitivity, 67
Esophageal cancer, neoadjuvant therapy, radiochemotherapy, docetaxel, cisplatin, phase II trials, 4407
Esophageal cancer, radiation sensitivity, gastric cancer, hypoxia, cell cycle, reoxygenation, 3369
Esophageal carcinoma, chemotherapy, docetaxel, nedaplatin, S1, phase I, 4589
Esophageal carcinoma, mutations, polymorphisms, *TP53*, *FHIT*, chronic esophagitis, 1685
Esophageal neoplasm, HIF-1α, radiotherapy, chemotherapy, 2351
Esophageal squamous cell carcinoma, neoadjuvant chemoradiotherapy, pathological response, complication, prognosis, 3073
Esophagus, baboon, gastric reflux, mucus metaplasia, 2187
Esophagus, cytokeratin 4, fascin, biomarker, tissue microarray, squamous cell carcinoma, 945
Estrogen pathway, single nucleotide polymorphisms, steroid hormones, mammographic breast density, breast cancer, review, 4369
Estrogen receptor beta, ovarian cancer, prognostic factor, immunohistochemistry, cisplatin, 711
Estrogen receptor, breast cancer cell lines, flow cytometry, RT-PCR, Western blotting, 521
Estrogen receptor, cancer, endometrium, apoptosis, *Bcl-2*, *p53,* E-cadherin, progesterone receptor, 4191
Estrogen receptor, *EGFR*, mutation, lung cancer, 855
Estrogen receptor, p27, breast cancer, node dissection, stage I, progesterone receptor, 4401
Ethanol, cigarette smoking, Swedish-type smokeless tobacco, Snus, human normal cells, cell death, endothelial cells, fibroblasts, 1527
Ethnicity, prostate cancer, neuroendocrine differentiation, 3897
Ethynyl phosphine, ferrocene, gold, platinum, cytotoxicity, HeLa, 825
Etiology, brain tumors, cytomegalovirus, glioblastoma, 959
Etodolac, 5-FU resistance, thymidylate synthase, cyclooxygenase-2, 2893
Etomidate, apoptosis, Bax, Bcl-xl, caspase-3, RAW264.7 cells, 2203
Etoposide, colorectal, neuroendocrine cancer, small cell cancer, chemotherapy, cisplatin, 975
Evaluation and prediction of pharmacological effects, cell-to-cell interaction, adhesion molecules, characteristics of cancer cells, anticancer drug resistance, chemotherapy, apoptosis, drug sensitivity, drug resistance-relating factors, gene expression analysis, screening systems, 3237

Everolimus, carboplatin, RAD001, breast cancer, mTOR inhibitor, 2713
Expanded access programme, gefitinib, non-small cell lung cancer, NSCLC, epidermal growth factor receptor, *EGFR*, skin toxicity, EAP, 2949
Extented lymphadenectomy, bladder cancer, lymph node metastasis, radical cystectomy, lymph node density, cancer-specific survival, short review, 271
Extracellular proteasome, ubiquitin–proteasome system, breast cancer, 2197
Extracellular space, hepatocellular carcinoma, ^{1}H MRI, apparent diffusion coefficient, benzamide riboside, angiography, therapy response, motion effect, 2045
Extravasation, metastasis, blood–brain barrier, brain endothelial cells, COX-2, 4307
Ezrin, rectal cancer, radiotherapy, chemotherapy, prognostic factor, biomarker, carbonic anhydrase IX, hypoxia-inducible factor-1a, glucose transporter-1, 4529
FAS, apoptosis, liver metastases, invasion front, TRAIL, colorectal cancer, 1215
FAS, cysteine-histidine-rich protein (*PINCH*), colorectal carcinoma, epithelial mesenchymal transition (EMT), vascular endothelial growth factor (*VEGF*), 4127
Fascin, cytokeratin 4, biomarker, tissue microarray, squamous cell carcinoma, esophagus, 945
Fatigue, adriamycin, cardiotoxicity, myotoxicity, 2023
FBAL, S-1, 5-fluorouracil, Phase I, tegafur, FT, reversible dihydropyrimidine dehydrogenase, DPD, gimeracil, CDHP, solid tumors, 625
FDG-PET, uterine cervical cancer, lymph node, MRI, 3865
Feasibility study, recurrent cervical cancer, oral etoposide, cisplatin, second-line chemotherapy, 3063
Feasibility study, triplet combination chemotherapy, paclitaxel, cisplatin, S-1, advanced gastric cancer, 3085
Fenretinide, LXS oral powder, phase I, clinical trial, 961
Ferrocene, ethynyl phosphine, gold, platinum, cytotoxicity, HeLa, 825
Fertility, conservative management, grade 2, grade 3, endometrial cancer, 3047
Feulgen staining, DNA ploidy, image analysis, cytometry, cytology, hematoxylin staining, Papanicolaou staining, 53
FGF-2, heparan sulfate, chitosan, anticancer, breast cancer, cell proliferation, 1321
FGFR3, proteasome inhibitor, receptor tyrosine kinase, activation loop, multiple myeloma, ER stress, Lys650Glu mutation, K650E, bortezomide, plasma cell malignancy, 113
FHIT, *EGFR*, mutation, methylation, tobacco smoking, lung adenocarcinoma, RASSF1A, RUNX3, 1211
FHIT, mutations, polymorphisms, *TP53*, chronic esophagitis, esophageal carcinoma, 1685
Fiberbronchoscopy, epidermal growth factor receptor (*EGFR*), lung cancer, cytology, diagnosis, 4207
Fiberoptic ductoscopy, breast cancer, nipple discharge, 3517
Fibroblasts, cigarette smoking, Swedish-type smokeless tobacco, Snus, ethanol, human normal cells, cell death, endothelial cells, 1527
Fibroid cells, leiomyoma, Arf-induced senescence, HMGA2, MDM2 antagonists, 753
Fibronectin, EMT, E-cadherin, gamma catenin, vimentin, lung adenocarcinoma, 4451
Fibrosarcoma, progression, inflammation-associated carcinogenesis, non-nuclear protein, 1259
Fibrosis, hyperthermia, thermal cancer therapy, hepatic stellate cells, HCC, HepG2, 1583
Fibrosis, hyperthermia, thermal cancer therapy, hepatic stellate cells, HCC, transwell, co-culture, 3713
FISH, circulating tumor cells, CTCs, microfiltration by size, real-time quantitative reverse transcriptase-polymerase chain reaction, qRT-PCR, molecular biology, cytomorphology, cell culture, lung cancer, 427
Fistula, BPF, operation, lung cancer, risk factor, concurrent disease, perioperative complication, infection, 619
FKBP52, breast cancer, geldanamycin, heat-shock proteins, lumican, 2095
Flash-wave light, acridine orange, osteosarcoma, pulmonary metastasis, photodynamic therapy, fluorovisualization, 4163
Flavone, *Zanthoxylum ailanthoides Sieb* and *Zucc*., human colon adenocarcinoma cell, colo 205 cells, caspases, apoptosis, 1667
Flow cytometry, estrogen receptor, breast cancer cell lines, RT-PCR, Western blotting, 521
Flow cytometry, minimal residual disease, acute lymphoblastic leukemia, children, early response, 1453
Flow of CSF, acute myeloid leukemia, immunotherapy, interleukin-2, peptide vaccination, cerebrospinal fluid, CSF, chloroma, 2343
FLOX regimen, chemotherapy, metastatic colorectal cancer, phase II study, 5-FU, leucovorin, oxaliplatin, 4657
Fluorescence imaging, circulating tumor cells, CTCs, prostate cancer, immunomagnetic beads, GFP, chick embryo, brain metastasis, metastatic assay, 3125
Fluorescence *in situ* hybridization, renal cell carcinoma, chromophobe renal cell carcinoma, renal oncocytoma, tissue sections, isolated nuclei, 3137
Fluorescence, GFP, prostate cancer, PC-3, orthotopic, circulating cancer cells, immunomagnetic beads, isolation, imaging, culture, 1535
Fluorescent *in situ* hybridization, Inv(3)(q21q26), t(3;3)(q21;q26), breakpoint distribution, chromosomal abnormalities, 3441
Fluorescent protein imaging (FPI), colon cancer, orthotopic model, GFP, MRI, selenium, angiogenesis, 387
Fluorothymidine, thymidine kinase1, 5'(3')-deoxyribonucleotidase, proliferation, lung cancer, colon cancer, 2135

Fluorouracil, chemotherapy, gemcitabine, colon cancer, capecitabine, 2971
5-Fluorouracil, DCF, induction chemotherapy, borderline-resectable T4, esophageal cancer, cisplatin, docetaxel, 3535
5-Fluorouracil, gastric cancer, gastroesophageal junction adenocarcinoma, DCF, docetaxel, cisplatin, G-CSF, 2379
5-Fluorouracil, HGF, c-Met, *NK4*, CT26, Akt, Erk1/2, thymidylate synthase, 2217
5-Fluorouracil, *KRAS*, *p53,* colorectal, oxaliplatin, capecitabine, clinical, CAIRO2, sequence analysis, 1379
5-Fluorouracil, lung adenocarcinoma, dihydropyrimidine dehydrogenase, thymidylate synthase, chemosensitivity, 4665
5-Fluorouracil, polo-like kinase 1, cholangiocarcinoma, gemcitabine, BI 2536, 3289
5-Fluorouracil, S-1, Phase I, FBAL, tegafur, FT, reversible dihydropyrimidine dehydrogenase, DPD, gimeracil, CDHP, solid tumors, 625
Fluorovisualization, acridine orange, osteosarcoma, pulmonary metastasis, photodynamic therapy, flash-wave light, 4163
Flutamide, androgen receptor, combination strategy, prostate cancer, prostate-specific antigen, resveratrol, 3323
Fluvastatin, melanoma, sorafenib, JNK, AKT, 3259
Focused ultrasound, sonodynamic therapy, 5-aminolevulinic acid, glioma, deep-seated, rat model, 2527
Folate receptor, drug delivery, cancer, liposome, vincristine, drug targeting, 1521
FOLFIRI, bevacizumab, XELIRI, colorectal cancer, efficacy, safety, 1777
FOLFIRI, colorectal cancer, regulatory T-cells, antitumor immunity, FOLFOX, 4569
FOLFOX, colorectal cancer, regulatory T-cells, antitumor immunity, FOLFIRI, 4569
Follow-up, breast cancer, disseminated tumor cells, bone marrow, prognosis, 2749
Form Y-2, STAI test, cancer risk, breast cancer, anxiety, 1801
Fotemustine, hepatocellular carcinoma, hepatic intraarterial therapy, interferon, chemoimmunotherapy, 4553
FOXP3, lung cancer, NSCLC, immunohistochemistry, lymph node, metastasis, 1677
Free testosterone (FT), prolactin (PRL), luteinizing hormone (LH), total testosterone (TT), prostate-specific antigen (PSA), prostate cancer, 3913
Free testosterone, luteinizing hormone, LH, total testosterone, TT, FT, prostate-specific antigen, PSA, prostate cancer, 1071
FT, luteinizing hormone, LH, total testosterone, TT, free testosterone, prostate-specific antigen, PSA, prostate cancer, 1071
FT, S-1, 5-fluorouracil, Phase I, FBAL, tegafur, reversible dihydropyrimidine dehydrogenase, DPD, gimeracil, CDHP, solid tumors, 625
5-FU, advanced esophageal cancer, combined chemotherapy, docetaxel, CDDP, 633
5-FU, anal cancer, cisplatin, paclitaxel, 4637
5-FU, chemotherapy, FLOX regimen, metastatic colorectal cancer, phase II study, leucovorin, oxaliplatin, 4657
5-FU, hyperammonemia, encephalopathy, capecitabine, metastatic rectal adenocarcinoid, 335
5-FU, resistance, thymidylate synthase, cyclooxygenase-2, etodolac, 2893
5-FU, stealth liposomes, PEG liposomes, locoregional chemotherapy, liver metastases, 147
Fundic glend polyps, polyp, gastric, chief cells, 1789
FUS1, tumor suppressor gene, sarcoma, RT-PCR, immunohistochemistry, growth inhibition, 11
Fusion gene, prostate cancer, microRNA, *TMPRSS2:ERG*, 403
FVB, min mice, 2-amino-1-methyl-6-phenylimidazo[4, 5-b]pyridine, Apc, C57Bl/6J, intestinal carcinogenesis, 785
Fyn, EMMPRIN, integrin, oral SCC, ECM, 1205
G_2/M blockage, chalcone, glioblastoma, cell death, 3213
G_2/M phase arrest, N-heterocyclic indolyl glyoxylamides, p53-independent apoptosis, human lung cancer cells, radiosensitivity, 3407
Gag and *env* genes, HTLV-1, RNA interference, shRNA, 2173
Galectin-1, mucin-1, galectin-3, leiomyosarcoma, leiomyoma, myometrium, 451
Galectin-3, mucin-1, galectin-1, leiomyosarcoma, leiomyoma, myometrium, 451
Gallic acid (GA), human leukemia HL-60 cells, apoptosis, death receptor-mediated pathways, mitochondria-mediated pathways, 2821
Gallic acid, prostate cancer, cytotoxicity, triphala, Ayurvedic medicine, 3739
Gamma catenin, EMT, E-cadherin, vimentin, fibronectin, lung adenocarcinoma, 4451
Gamma radiation, antiapoptosis, colorectal cancer, microarray, RT-PCR, *REG4*, *NEIL2*, *BIRC5*, 4147
Gamma-delta T-cell, renal cell carcinoma, prognosis factor, 1027
Ganciclovir, adenovirus, prodrug activation, HNSCC, thymidine kinase, apoptosis, 3851
Gankyrin, overexpression, oral squamous cell carcinoma, 2683
Gastric adenocarcinoma, signet-ring adenocarcinoma, breast metastasis, skin, immunohistochemistry, 2373
Gastric atrophy, polymorphism, *Helicobacter pylori*, intestinal metaplasia, *XRCC1*, *GSTP1*, *GSTT1*, *GSTM1*, 1459

Gastric cancer (GC), single nucleotide polymorphisms (SNPs), chemosensitivity, docetaxel, *DNASE2B*, *HTRIE*, 4329
Gastric cancer, cetuximab, irinotecan, oxaliplatin, *KRAS* phase II trial, 4439
Gastric cancer, cetuximab, S-1, thymidylate synthase, 3691
Gastric cancer, *EGFL8*, quantitative polymerase chain reaction, 3377
Gastric cancer, ERas, chemotherapy, CPT-11, rapamycin, 3353
Gastric cancer, gastroesophageal junction adenocarcinoma, DCF, docetaxel, cisplatin, 5-fluorouracil, G-CSF, 2379
Gastric cancer, KL-6 mucin, MUC1, β-catenin, invasion front, 535
Gastric cancer, low back pain, pregnancy, bilateral erythematous breast hypertrophy, 681
Gastric cancer, lymph node dissection, prognosis, staging, 2361
Gastric cancer, neoadjuvant chemoradiotherapy, S-1, cisplatin, 3079
Gastric cancer, paclitaxel, doxifluridine, ascites, 4625
Gastric cancer, paclitaxel, doxifluridine, thymidine phosphorylase, chemotherapy, 287
Gastric cancer, photodynamic therapy, PDT, glycoconjugated chlorin, apoptosis, colon cancer, 763
Gastric cancer, polymorphism, *XRCC1*, Arg399Gln, Arg194Trp, *GSTP1* Ile104Val, *GSTT1*, *GSTM1*, survival, 705
Gastric cancer, radiation sensitivity, esophageal cancer, hypoxia, cell cycle, reoxygenation, 3369
Gastric cancer, *TFPI2*, methylation, 3835
Gastric cancer, TIP60, quantitative real-time PCR, 77
Gastric carcinoma, carcinomatosis, glycolysis, energetic metabolism, apoptosis, necrosis, citrate, 797
Gastric reflux, esophagus, baboon, mucus metaplasia, 2187
Gastric, polyp, chief cells, fundic glend polyps, 1789
Gastroesophageal junction adenocarcinoma, gastric cancer, DCF, docetaxel, cisplatin, 5-fluorouracil, G-CSF, 2379
Gastrointestinal adverse events, multiple myeloma, bortezomib, once-weekly administration, dexamethasone, 2297
Gastrointestinal stromal tumor, breast cancer, neurofibromatosis type 1, 4481
Gastrointestinal stromal tumor, imatinib, adherence, ADAGIO study, 1407
Gastrointestinal stromal tumor, sunitinib, pneumatosis intestinalis, 3429
Gastrointestinal stromal tumors (GISTs), Ras-Raf-ERK/MAPK Pathway, PI3K-Akt/mTOR pathway, insulin-like growth factor 1 receptor (IGF1R), CD117, 3019
Gc1f1f protein, Gc-derived macrophage-activating factor precursor, preGcMAF, 1f1f subtype of Gc protein, phagocytic activity, mouse peritoneal macrophages, 2489
Gc-derived macrophage-activating factor precursor, preGcMAF, 1f1f subtype of Gc protein, Gc1f1f protein, phagocytic activity, mouse peritoneal macrophages, 2489
G-CSF, gastric cancer, gastroesophageal junction adenocarcinoma, DCF, docetaxel, cisplatin, 5-fluorouracil, 2379
Gc protein, Gc-derived macrophage-activating factor precursor, preGcMAF, Gc1f1f protein, phagocytic activity, mouse peritoneal macrophages, 2489
Gefitinib, non-small cell lung cancer, erlotinib, resistance, bone metastasis, radiotherapy, *EGFR*-TKIs, 4519
Gefitinib, non-small cell lung cancer, NSCLC, epidermal growth factor receptor, *EGFR*, skin toxicity, expanded access programme, EAP, 2949
Gefitinib, non-small cell lung cancer, third-line treatment, erlotinib, review, 649
Gefitinib, radiation, combination therapy, *EGFR*, predictor, melanoma, 2883
Gelatinase, matrix metalloproteinases, tongue carcinoma, green fluorescent protein, xenograft, peptide, 3659
Geldanamycin, breast cancer, FKBP52, heat-shock proteins, lumican, 2095
Gemcitabine, BBN, sirolimus, mice, urothelial lesion, 1637
Gemcitabine, chemotherapy, fluorouracil, colon cancer, capecitabine, 2971
Gemcitabine, hENT1, cytotoxicity, I3C, pancreatic cancer, 3171
Gemcitabine, NKG2D, MICA, MICB, HCC, immunotherapy, 2505
Gemcitabine, pancreatic cancer, intra-arterial therapy, chemoradiotherapy, 3909
Gemcitabine, pancreatic cancer, resistance, ERK, lenalidomide, 3747
Gemcitabine, polo-like kinase 1, cholangiocarcinoma, 5-fluorouracil, BI 2536, 3289
Gemcitabine, squamous cell carcinoma, bladder cancer, recurrence, paclitaxel, 4465
Gemcitabine, urachal cancer, recurrence, cisplatin, chemotherapy, 2335
Gemcitabine, virotherapy, pancreatic cancer, chemoresistance, PDAC, GFP, 1279
Gender, prognosis, left colon, right colon, sigmoid, survival, colon cancer, 2347
Gene expression, vascular endothelial growth factor, *VEGF*, anti-*VEGF* therapy, bevacizumab, epithelial ovarian cancer, 731
Gene methylation, *HOPX*, colorectal cancer, 2889
Gene methylation, NSCLC, methylation, MLPA, targeted therapy, TKIs, smoking, *EGFR* mutation, 4647
Gene mutations, medullary thyroid carcinoma, *RET*, *HRAS*, *KRAS*, *NRAS*, *BRAF*, *AKT1*, *CTNNB1*, mutational screening, 4179

Gene mutations, ovarian cancer, BRCA 1/2, *TP53*, PI3K, AKT, *BRAF*, *KRAS*, review, 2661
Gene polymorphism, cervical cancer, C-reactive protein, CRP, *CRP1919* (rs1417938), *CRP2667* (rs1800947), *CRP3872* (rs1205), *CRP5237* (rs2808630), prognosis, single nucleotide polymorphism, 2259
Gene therapy, AAV, CXCR4, bioluminescence, breast cancer, 1627
Gene therapy, mesenchymal stem cells, cytotherapy, hepatocellular carcinoma, 3705
Gene therapy, *NK4*, cationised gelatin, cisplatin, squamous cell carcinoma, 105
Gene-directed enzyme prodrug therapy review, neural stem cells, suicide genes, prodrugs, invasive tumors, animal models, 1249
Genes, oral squamous cell carcinomas, toombak, apoptosis, cell cycle regulation, intermediate filament proteins, Sudan, 3345
Genetic polymorphism, cervical cancer, *GSTM1*, *GSTT1*, human papillomavirus, cancer risk, 3051
Genetic polymorphisms, cancer susceptibility, DNA-repair genes, metabolizing genes, *CYP1A1*, *CYP1E1*, *XRCC1*, 1359
Genistein, breast cancer, p90RSK, cell proliferation, T47D cells, 209
Genistein, breast cancer, quercetin, apoptosis, NFκB, 3301
Genotype, *p53, p21, CDKN1A/WAF/CIP1*, polymorphism, endometriosis, 4301
Germ cell tumour, cisplatin, thrombosis, hypercoagulation, vascular toxicity, von Willebrand factor, 4501
GFP, circulating tumor cells, CTCs, prostate cancer, immunomagnetic beads, chick embryo, brain metastasis, metastatic assay, fluorescence imaging, 3125
GFP, colon cancer, orthotopic model, fluorescent protein imaging (FPI), MRI, selenium, angiogenesis, 387
GFP, magnetic resonance imaging, micro-computed tomography, optical reflectance imaging, tumor volume, molecular imaging, RFP, 2907
GFP, prostate cancer, PC-3, orthotopic, circulating cancer cells, immunomagnetic beads, isolation, fluorescence, imaging, culture, 1535
GFP, virotherapy, pancreatic cancer, chemoresistance, gemcitabine, PDAC, 1279
Gimeracil, S-1, 5-fluorouracil, Phase I, FBAL, tegafur, FT, reversible dihydropyrimidine dehydrogenase, DPD, CDHP, solid tumors, 625
Glabridin, UVB, normal human keratinocytes, 18β-glycyrrhetinic acid, ROS, 2209
GLI2, PTHrP, osteolysis, breast cancer, 6-thioguanine, 2705
Glioblastoma model, mKate2, mCherry, intracranial, live imaging, temozolomide, 2161
Glioblastoma, brain tumors, cytomegalovirus, etiology, 959
Glioblastoma, chalcone, G_2/M blockage, cell death, 3213
Glioma, *EGFR*, cell cycle, temozolomide, 3253
Glioma, *IDH1* mutation, cetuximab, sunitinib, bevacizumab, 4457
1p, Glioma, oligodendroglioma, 1p19q, PAV, ACNU, procarbazine, vincristine, chemotherapy, 4475
Glioma, 1p19q, oligodendroglioma, 1p, PAV, ACNU, procarbazine, vincristine, chemotherapy, 4475
Glioma, oligodendroglioma, 1p19q, 1p, PAV, ACNU, procarbazine, vincristine, chemotherapy, 4475
Glioma, PTEN, cell cycle, temozolomide, ionizing radiation, radiosensitivity, 1653
Glioma, resveratrol, invasion, TNF-α, urokinase plasminogen activator, 4223
Glioma, sonodynamic therapy, focused ultrasound, 5-aminolevulinic acid, deep-seated, rat model, 2527
Beta-glucan, *dectin-1*, B-cell lymphoma, CD86, proliferation, cell death, 4195
Beta-glucan, β-glucan, dendritic cells, maturation, immunomodulator, 1647
Glucose transporter-1, hypoxia, hypoxia-inducible factor 1α, preoperative chemoradiotherapy, rectal cancer, 1559
Glucose transporter-1, rectal cancer, radiotherapy, chemotherapy, prognostic factor, biomarker, carbonic anhydrase IX, hypoxia-inducible factor-1a, ezrin, 4529
Glucuronidation, active metabolite of irinotecan, SN-38, SN-38 glucuronide (SN-38G), panipenem, pharmacokinetics, 2915
GLUR4, glutamate receptor, cancer, PCR, shRNA, NR1, KA2, NR2D, 3181
GLUT-1, rectal cancer, chemotherapy, radiotherapy, tumour regression, prognosis, 311
B-Glucan, beta-glucan, dendritic cells, maturation, immunomodulator, 1647
B-Glucan, cyclophosphamide, A20 lymphoma, regulatory T-cell, 1169
Glutamate receptor, cancer, PCR, shRNA, NR1, GLUR4, KA2, NR2D, 3181
Glutamate receptor, laryngeal cancer, antagonist, proliferation, ERK1/2 kinase, 565
γ-Glutamyl cyclotransferase, C7orf24, osteosarcoma, 1297
Glutathione, selenoprotein, colon cancer, thioredoxin, antioxidant enzyme expression, 2693
Glycated apolipoprotein B, colorectal cancer, immuno-histochemistry, 555
Glycoconjugated chlorin, photodynamic therapy, PDT, apoptosis, gastric cancer, colon cancer, 763
Glycolysis, gastric carcinoma, carcinomatosis, energetic metabolism, apoptosis, necrosis, citrate, 797
P-Glycoprotein, chemotherapy, inhibition of multidrug resistance, osteosarcoma cell lines, carcinoma cell lines, siRNA, 2813

P-Glycoprotein, multidrug resistance, benzo[*a*]quinolizin derivatives, 921
P-Glycoprotein, multidrug-resistant cancer cells, MDR mouse T-lymphoma cells, ABCB1 transporter, phenothiazines, thioridazine, apoptosis, 4201
Glycosylated antitumor ether lipid, cytotoxicity, endocytosis, mechanism of action, methyl-β-cyclodextrin, 3809
18β-Glycyrrhetinic acid, UVB, normal human keratinocytes, glabridin, ROS, 2209
GM-CSF, *Pantoea agglomerans*, A46, LPS, LPSp, LPSa46, macrophage, M-CSF, 2467
Gold, ferrocene, ethynyl phosphine, platinum, cytotoxicity, HeLa, 825
Grade 2, conservative management, grade 3, endometrial cancer, fertility, 3047
Grade 3, conservative management, grade 2, endometrial cancer, fertility, 3047
Grade, age, breast cancer, immunohistochemistry, measles virus, *p53,* 913
Grade, SDF1β, RCC, T-cell infiltration, 2797
Green fluorescent protein, matrix metalloproteinases, gelatinase, tongue carcinoma, xenograft, peptide, 3659
Green fluorescent protein, red fluorescent protein, cancer cell seeding, real-time imaging, lung, liver, muscle, 3665
Growth factors, breast cancer, tumor markers, CA 15-3, CEA, IGF1, EGF, HGF, 4653
Growth inhibition, tumor suppressor gene, *FUS1*, sarcoma, RT-PCR, immunohistochemistry, 11
GSTM1, cervical cancer, *GSTT1*, genetic polymorphism, human papillomavirus, cancer risk, 3051
GSTM1, polymorphism, *Helicobacter pylori*, gastric atrophy, intestinal metaplasia, *XRCC1*, *GSTP1*, *GSTT1*, 1459
GSTM1, polymorphism, *XRCC1*, Arg399Gln, Arg194Trp, *GSTP1* Ile104Val, *GSTT1*, gastric cancer, survival, 705
GSTP1 Ile104Val, polymorphism, *XRCC1*, Arg399Gln, Arg194Trp, *GSTT1*, *GSTM1*, gastric cancer, survival, 705
GSTP1, polymorphism, *Helicobacter pylori*, gastric atrophy, intestinal metaplasia, *XRCC1*, *GSTT1*, *GSTM1*, 1459
GSTT1, cervical cancer, *GSTM1*, genetic polymorphism, human papillomavirus, cancer risk, 3051
GSTT1, polymorphism, *Helicobacter pylori*, gastric atrophy, intestinal metaplasia, *XRCC1*, *GSTP1*, *GSTM1*, 1459
GSTT1, polymorphism, *XRCC1*, Arg399Gln, Arg194Trp, *GSTP1* Ile104Val, *GSTM1*, gastric cancer, survival, 705
Guanylyl cyclase, cervical carcinoma, prognosis, iNOS, phosphodiesterase, 2319
Gynecological cancer, breast cancer, online tumor conference, interdisciplinary therapy management, second opinion, continuous medical training, 2669
Gynecological malignancies, radiation therapy, risk factor, enterocolitis, leg edema, postoperative radiotherapy, 3527
H+ exchange, Na^+, oxidative stress, cholangiocellular carcinoma, liver cancer, 459
γ-H2AX, radiation therapy, spinal cord, radiation myelopathy, 561
HAVcR-1, tight junction, endothelial cells, tight junction regulation, 467
HB-EGF, CRM197, doxorubicin, T-ALL, 2483
HB-EGF, ovarian cancer, ELISA, 2553
HB-EGF, ovarian cancer, targeted therapy, CRM197, 2461
HCC, CEUS, dysplastic nodule, vascularity, cirrhosis, 3977
HCC, gemcitabine, NKG2D, MICA, MICB, immunotherapy, 2505
HCC, hyperthermia, thermal cancer therapy, hepatic stellate cells, fibrosis, HepG2, 1583
HCC, hyperthermia, thermal cancer therapy, hepatic stellate cells, fibrosis, transwell, co-culture, 3713
HCC, PEDF, c-FLIP, p38, PPARγ, hepatocellular carcinoma, apoptosis, 1173
HCRT, rectal cancer, hyperthermo-chemo-radiation therapy, distal margins, tumor response, 3963
HCV-HCC, tubulin alpha-6 chain, proteomics, 2-DE, MS, 3331
Head and neck cancer, biomarkers, diagnosis, early detection, review, 1161
Head and neck cancer, cyclin B1, cell cycle, *p53,* squamous cell carcinoma, 3151
Head and neck cancer, *EGFR*, Ki-67, translational research, squamous cell carcinoma, 665
Head and neck cancer, p38 MAPK, STAT1, STAT3, phosphorylation, 3819
Head and neck cancer, tonsillar cancer, base of tongue cancer, oropharyngeal cancer, HPV, revie, 1515
Head and neck neoplasms, ERCC1 protein, cisplatin, DNA repair, radiation, 4135
Head and neck squamous cell carcinoma HNSCC, *levisticum officinale* lovage, oral cavity squamous cell carcinoma OCSCC, natural product, pharmacogenomics, 185
Head and neck squamous cell carcinoma HNSCC, *Thymus vulgaris* L. (thyme), oral cavity squamous cell carcinoma OCSCC, natural product, pharmacogenomics, 81
Heart, hepatocellular carcinoma, inferior vena cava, prognosis, 4641
Heat-shock proteins, breast cancer, FKBP52, geldanamycin, lumican, 2095
Hedgehog, leukemia, notch, wnt, γ-secretase inhibitor, 893
Hedgehog, leukemia, self-renewal, 781
HeLa, ferrocene, ethynyl phosphine, gold, platinum, cytotoxicity, 825
Helicobacter pylori, polymorphism, gastric atrophy, intestinal metaplasia, *XRCC1*, *GSTP1*, *GSTT1*, *GSTM1*, 1459

Hemangiopericytoma, solitary fibrous tumor, oral cavity, cheek, soft tissue, 719
Hematoporphyrin monomethyl ether, ovarian cancer, hyprocrellin B, intracellular metabolism, subcellular localization, phototoxicity, 3229
Hematoxylin staining, DNA ploidy, image analysis, cytometry, cytology, Feulgen staining, Papanicolaou staining, 53
Hemorrhagic cystitis, allogeneic stem cell transplantation, BK virus, review, 939
Hemotopoetic stem cell transplantation, human polyomavirus, BK virus, JC virus, cerebrospinal fluid, KI, WU, 3489
HENT1, gemcitabine, cytotoxicity, I3C, pancreatic cancer, 3171
Heparan sulfate, chitosan, anticancer, breast cancer, cell proliferation, FGF-2, 1321
Heparan sulfate, proteoglycans, xenograft, HepG2 cells, immunotherapy, liver cancer, 4067
Heparanase, ovarian cancer, diagnosis, biomarkers, enzyme-linked immunosorbent assay, cathepsin, matrix metalloproteinase-9, 3423
Heparins, non-anticoagulant heparins, chemotherapy, 411
Hepatectomy, hepatocellular carcinoma, perioperative factors, uncontrolled ascites, prognosis, 4545
Hepatic arterial infusion, stealth liposomes, PEG liposomes, docetaxel, locoregional chemotherapy, liver metastases, 153
Hepatic intra-arterial chemotherapy (HAIC), advanced hepatocellular carcinoma (HCC), cetuximab, 3927
Hepatic intra-arterial infusion, irinotecan, metabolites, plasma disposition, pharmacokinetics, 3573
Hepatic intraarterial therapy, hepatocellular carcinoma, interferon, fotemustine, chemoimmunotherapy, 4553
Hepatic stellate cells, hyperthermia, thermal cancer therapy, fibrosis, HCC, HepG2, 1583
Hepatic stellate cells, hyperthermia, thermal cancer therapy, fibrosis, HCC, transwell, co-culture, 3713
Hepatitis B virus, antiangiogenic therapy, hepatocellular carcinoma, prognosis, 4007
Hepatitis C virus, liver tumour, sarcomatoid tumour, cell line, culture, spectral karyotyping, xenograft, 129
Hepatocellular cancer, belinostat, bortezomib, pancreas cancer, histone deacetylase inhibitor, proteasome inhibitor, apoptosis, metabolomics, 1093
Hepatocellular carcinoma, ^{1}H MRI, apparent diffusion coefficient, extracellular space, benzamide riboside, angiography, therapy response, motion effect, 2045
Hepatocellular carcinoma, antiangiogenic therapy, hepatitis B virus, prognosis, 4007
Hepatocellular carcinoma, biomarker, AFP-IgM immune complexes, alpha-fetoprotein, 687
Hepatocellular carcinoma, child's classification, liver cirrhosis, MELD-score, nonhepatic cancer, survival probability, TNM classification, 2931
Hepatocellular carcinoma, cirrhosis, percutaneous ablation, percutaneous ethanol injection, radiofrequency ablation, randomized controlled trial, 2291
Hepatocellular carcinoma, heart, inferior vena cava, prognosis, 4641
Hepatocellular carcinoma, hepatic intraarterial therapy, interferon, fotemustine, chemoimmunotherapy, 4553
Hepatocellular carcinoma, human zinc finger 23, real-time RT-PCR, annexin V-FITC/PI assay, apoptosis, 3595
Hepatocellular carcinoma, liver resection, multidrug resistance, ABC proteins, tyrosine kinase, 3883
Hepatocellular carcinoma, lymph node metastasis, transarterial chemoembolization, resection, 3991
Hepatocellular carcinoma, MACC 1, quantitative real-time PCR, 777
Hepatocellular carcinoma, mesenchymal stem cells, gene therapy, cytotherapy, 3705
Hepatocellular carcinoma, miriplatin, transarterial chemoembolization, 2983
Hepatocellular carcinoma, non-cirrhotic livers, viral hepatitis, 1055
Hepatocellular carcinoma, PEDF, c-FLIP, HCC, p38, PPARγ, apoptosis, 1173
Hepatocellular carcinoma, perioperative factors, uncontrolled ascites, hepatectomy, prognosis, 4545
Hepatocellular carcinoma, *Stk11*, *Lkb1*, nitrosamine, choline-deficient L-amino acid-defined diet, rat, 543
Hepatocellular carcinoma, vimentin, quantitative methylation-specific PCR, 1289
Hepatocellular carcinoma, κ-actin, survival, postoperative prognosis, 2037
Hepatoma, TNF-alpha, proteomics, 2-DE, LC-MS/MS, apoptosis, 2059
HepG2 cells, heparan sulfate, proteoglycans, xenograft, immunotherapy, liver cancer, 4067
HepG2, hyperthermia, thermal cancer therapy, hepatic stellate cells, fibrosis, HCC, 1583
HER2, *EGFR*, *EGFR* tyrosine kinase inhibitor, NSCLC, oncogene addiction, 4155
HER2, lapatinib, ADCC, breast cancer, Herceptin, 2999
HER2, non-small cell lung cancer, surgical resection, immunohistochemical staining, prognosis, 4631
Her-2/neu, peptide, vaccine, B-cell epitope, antitumor effect, 3361
HER2-negative, metastatic breast cancer, capecitabine, triple-negative, prognostic factors, 1079
HER2-positive, S-1, trastuzumab, metastatic breast cancer, 3035
Herceptin, lapatinib, HER2, ADCC, breast cancer, 2999

N-Heterocyclic indolyl glyoxylamides, p53-independent apoptosis, G_2/M phase arrest, human lung cancer cells, radiosensitivity, 3407
HGF, c-Met, *NK4*, CT26, 5-fluorouracil, Akt, Erk1/2, thymidylate synthase, 2217
HGF, growth factors, breast cancer, tumor markers, CA 15-3, CEA, IGF1, EGF, 4653
HIF, NSCLC, prognostic factors, NOTCH, lung cancer, 1603
HIF1A, polymorphism, colorectal cancer, MMP2, *VEGF*, SNP, 575
HIF-1α, esophageal neoplasm, radiotherapy, chemotherapy, 2351
HIF-1α, *VEGF*, mTOR, angiogenesis, oral cancer, 4429
High hydrostatic pressure, bone, revitalization, tissue engineering, 1235
High-dose chemotherapy, alternative splicing, angiogenesis, autologous stem cell transplantation, chick chorioallantoic membrane assay, placental growth factor, vascular endothelial growth factor, V*EGFR*1, 3115
High-dose chemotherapy, total estrogen blockade, leuprorelin, anastrazole, premenopausal breast cancer, *VEGF*, 671
High-frequency ultrasound, breast cancer, screening mammography, microcalcification, advanced imaging modes, 2575
Hippocampus, intravenous curcumin, blood–brain barrier, post-traumatic sequelae, striatum, brain stem, 907
Histoculture drug response assay, non-small cell lung cancer, class III β-tubulin, predictive marker, vinorelbine, 999
Histological status, HuR, breast cancer, prognosis, 303
Histone acetyltransferases, breast cancer, epigenetic regulation, histone-modifier genes, histone methyltransferases, 4115
Histone deacetylase inhibitor, belinostat, bortezomib, pancreas cancer, proteasome inhibitor, hepatocellular cancer, apoptosis, metabolomics, 1093
Histone deacetylase inhibitor, chemotherapy, multidrug resistant, sarcoma, PCI-24781, 1115
Histone deacetylase inhibitor, TRAIL, LBH589, colon cancer, apoptosis, 3385
Histone deacetylases, astrocytomas, epigenetics, DNA methylation, decitabine, 1337
Histone methyltransferases, breast cancer, epigenetic regulation, histone-modifier genes, histone acetyltransferases, 4115
Histone-modifier genes, breast cancer, epigenetic regulation, histone acetyltransferases, histone methyltransferases, 4115
Histopathology, male breast, ductal pleomorphic carcinoma, immunohistochemistry, 3069
HL-60, PSK, apoptosis, cell proliferation, caspase-3 activation, 2733
HMGA2, leiomyoma, Arf-induced senescence, MDM2 antagonists, fibroid cells, 753
HMGB1, quantitative PCR, immunohistochemistry, RAGE, disseminated histiocytic sarcoma, 1541
HNSCC, adenovirus, prodrug activation, ganciclovir, thymidine kinase, apoptosis, 3851
HNSCC, *EGFR*, polymorphism, Erk-1/2, AG1478, cetuximab, 59
HNSCC, phase II, Src, AZD0530, saracatinib, 249
HNSCC, radioimmunotherapy, SCID mice, xenografts, radio-labeled monoclonal antibody, cytokeratin 8, 3315
Hodgkin lymphoma, minichromosome maintenance proteins, MCMs, cyclin D3, CCND3, survival, 3585
HOGG1, *XPD*, polymorphism, urothelial carcinoma, 3939
Hopelessness, bening breast disease, personality, type C, cancer risk, 4019
HOPX, colorectal cancer, gene methylation, 2889
Hormonal therapy, prostate cancer, patients' satisfaction, radiation, surgery, 3903
Hormone replacement therapy, ductal carcinoma *in situ*, breast, lumpectomy, mastectomy, menopause, 1783
Hormonotherapy, hypofractionated radiotherapy, prostate cancer, intermediate risk, acute effect, image guided radiation therapy, 3555
HPA, metastasis, E-selectin, P-selectin, SCID mouse, lectin, breast carcinoma cells, colon adenocarcinoma, 1589
HPV, tonsillar cancer, base of tongue cancer, oropharyngeal cancer, head and neck cancer, review, 1515
HRAS, medullary thyroid carcinoma, gene mutations, *RET*, *KRAS*, *NRAS*, *BRAF*, *AKT1*, *CTNNB1*, mutational screening, 4179
HRRM2, non-small cell lung cancer, ribonucleotide reductase, p53R2, 3475
Hsp70, ionizing radiation, temozolomide, immunogenicity, cell death, 3727
Hsp90 inhibitor, NVP-AUY922, oral squamous cell carcinoma, 1197
HT-29, branched-chain fatty acids, anticancer, antitumor, human breast cancer, human colon cancer, MCF-7, 3165
HTLV-1, ATL, leukemia, *Hyptis verticillata* jacq, multidrug resistance, 4251
HTLV-1, ATL, tetramethylnaphthalene, inhibitor, cell cycle, 2241
HTLV-1, *gag* and *env* genes, RNA interference, shRNA, 2173
HTRIE, single nucleotide polymorphisms (SNPs), gastric cancer (GC), chemosensitivity, docetaxel, *DNASE2B*, 4329
Huachansu, radiation sensitivity, clonogenic cell survival, lung cancer cells, inhibition of DNA repair, 2141
Human breast cancer, branched-chain fatty acids, anticancer, antitumor, human colon cancer, HT-29, MCF-7, 3165

Human colon adenocarcinoma cell, *Zanthoxylum ailanthoides Sieb* and *Zucc*., colo 205 cells, caspases, apoptosis, flavone, 1667
Human colon cancer, branched-chain fatty acids, anticancer, antitumor, human breast cancer, HT-29, MCF-7, 3165
Human leukemia HL-60 cells, gallic acid (GA), apoptosis, death receptor-mediated pathways, mitochondria-mediated pathways, 2821
Human lung adenocarcinoma cell, cyclosporine A, apoptosis, lung transplantation, caspase, 2129
Human lung cancer cell lines, surviving fraction, doubling time, radiobiology model, clonogenic assay, 1125
Human lung cancer cells, N-heterocyclic indolyl glyoxylamides, p53-independent apoptosis, G_2/M phase arrest, radiosensitivity, 3407
Human mammaglobin, breast cancer, brain metastases, PCR, 1061
Human mesothelioma cell line, radiation, pemetrexed, radiosensitivity, apoptosis, 2847
Human normal cells, cigarette smoking, Swedish-type smokeless tobacco, Snus, ethanol, cell death, endothelial cells, fibroblasts, 1527
Human papillomavirus, cervical cancer, *GSTM1*, *GSTT1*, genetic polymorphism, cancer risk, 3051
Human polyomavirus, BK virus, JC virus, hematopoietic stem cell transplantation, cerebrospinal fluid, KI, WU, 3489
Human zinc finger 23, hepatocellular carcinoma, real-time RT-PCR, annexin V-FITC/PI assay, apoptosis, 3595
HuR, breast cancer, histological status, prognosis, 303
HUVEC, V*EGFR*2, tyrosine kinase inhibitor, drug resistance, angiogenesis, endothelial cells, 2787
Hybrid steroidal alkylators, uridine phosphorylase, *in silico* molecular docking, *in vitro* assay, mitrogen mustards, pancreatic cancer cells, 831
Hydantoin derivatives, Colo 205 and Colo 320 colon adenocarcinoma cells, multidrug resistance, efflux pump, ABCB1 transporter, apoptosis, 3285
Hydrophobicity, conformation, antibacterial activity, bis-quarternary compound, 2561
8-Hydroxydeoxyguanosine, oxidative stress, ovarian cancer, reactive oxygen species, 1411
25-Hydroxyvitamin D, vitamin D, breast neoplasms, case–control studies, epidemiology, meta-analysis, prevention, 2939
Hyperammonemia, 5-FU, encephalopathy, capecitabine, metastatic rectal adenocarcinoid, 335
Hypercoagulation, germ cell tumour, cisplatin, thrombosis, vascular toxicity, von Willebrand factor, 4501
Hyperdiploid multiple myeloma, cytogenetics, tumor progression, 1599
Hyperosteoidosis, meningioma en plaque, somatostatin, hyperostosis, 591
Hyperostosis, meningioma en plaque, somatostatin, hyperosteoidosis, 591
Hyperparathyroidism, parathyroid tumors, arterial blood pressure, serum calcium, PTH, arterial hypertension, elderly, 3969
Hyperpigmentation, pemetrexed, skin toxicity, 1753
Hypersensitivity, carboplatin, cisplatin, antineoplastic, thoracic malignancy, immunoglobulin E, 4525
Hyperthermia, bevacizumab, doxorubicin, platinum-refractory, ovarian cancer, 2675
Hyperthermia, thermal cancer therapy, hepatic stellate cells, fibrosis, HCC, HepG2, 1583
Hyperthermia, thermal cancer therapy, hepatic stellate cells, fibrosis, HCC, transwell, co-culture, 3713
Hyperthermo-chemo-radiation therapy, rectal cancer, HCRT, distal margins, tumor response, 3963
Hypofractionated radiotherapy, prostate cancer, intermediate risk, acute effect, image guided radiation therapy, hormonotherapy, 3555
Hypofractionation, prostate cancer, radiotherapy, acceleration, amifostine, cytoprotection, 1745
Hypoxia, ADM, colorectal cancer, prognostic factor, 507
Hypoxia, CD44-CD41, PC3 side fraction, normoxia, 487
Hypoxia, glucose transporter-1, hypoxia-inducible factor 1α, preoperative chemoradiotherapy, rectal cancer, 1559
Hypoxia, LAT1, CD98, mesothelioma, prognosis, mTOR, 4075
Hypoxia, radiation sensitivity, esophageal cancer, gastric cancer, cell cycle, reoxygenation, 3369
Hypoxia-inducible factor 1α, glucose transporter-1, hypoxia, preoperative chemoradiotherapy, rectal cancer, 1559
Hypoxia-inducible factor-1a, rectal cancer, radiotherapy, chemotherapy, prognostic factor, biomarker, carbonic anhydrase IX, ezrin, glucose transporter-1, 4529
Hyprocrellin B, ovarian cancer, hematoporphyrin monomethyl ether, intracellular metabolism, subcellular localization, phototoxicity, 3229
Hyptis verticillata jacq, HTLV-1, ATL, leukemia, multidrug resistance, 4251
I3C, hENT1, gemcitabine, cytotoxicity, pancreatic cancer, 3171
ICC, radiofrequency ablation, RFA, intrahepatic cholangio-carcinoma, cirrhosis, 4575
IDH1 mutation, glioma, cetuximab, sunitinib, bevacizumab, 4457
IFN-γ, DC, vaccine, whole tumor cell, ELISPOT, 3995
IGBP1, lactoferrin, PP2Ac, apoptosis, lung adeno-carcinoma, 529
IGF-1, colorectal cancer, insulin-like growth factor, IGF-1R, 2541
IGF1, growth factors, breast cancer, tumor markers, CA 15-3, CEA, EGF, HGF, 4653

IGF-1, insulin-like growth factor-1, tamoxifen-resistance, oestrogen resistance, breast cancer recurrence, oestrogen receptor-alpha, *EGFR*, 23
IGF-1R, colorectal cancer, insulin-like growth factor, IGF-1, 2541
IGF-1R, phosphorylated MEK, Ras/Raf/MEK/ERK pathway, orthotopic mouse model of osteosarcoma, lung metastasis, 1147
IKKβ, NFκB, IκBα, p38, peroxynitrite, nitration, colon cancer, 1607
IL-12, cytokines, morphine, plasma, MIP-1α, 4561
IL-6, esophageal cancer, cisplatin, chemosensitivity, 67
Image analysis, angiogenesis, breast cancer, CD34, MVD, vessel identification, 4053
Image analysis, DNA ploidy, cytometry, cytology, hematoxylin staining, Feulgen staining, Papanicolaou staining, 53
Image guided radiation therapy, hypofractionated radiotherapy, prostate cancer, intermediate risk, acute effect, hormonotherapy, 3555
Image-guided radiotherapy, anal cancer, chemoradiation, tomotherapy, 4393
Imaging, GFP, prostate cancer, PC-3, orthotopic, circulating cancer cells, immunomagnetic beads, isolation, fluorescence, culture, 1535
Imatinib, breast cancer, lapatinib, *EGFR*, ErbB2, c-ABL, RTK, 789
Imatinib, gastrointestinal stromal tumor, adherence, ADAGIO study, 1407
Imexon, dacarbazine, melanoma, additivity, drug combinations, 2781
Immune response, dysplastic nevi, melanocyte, melanoma, regression, 3697
Immunogenicity, ionizing radiation, temozolomide, cell death, Hsp70, 3727
Immunoglobulin E, carboplatin, cisplatin, hypersensitivity, antineoplastic, thoracic malignancy, 4525
Immunohistochemical staining, HER2, non-small cell lung cancer, surgical resection, prognosis, 4631
Immunohistochemistry, age, breast cancer, grade, measles virus, *p53,* 913
Immunohistochemistry, cadherins, prognosis, OSCC, oral squamous cell carcinoma, 4211
Immunohistochemistry, cervical cancer, parametrium, micrometastasis, 243
Immunohistochemistry, estrogen receptor beta, ovarian cancer, prognostic factor, cisplatin, 711
Immunohistochemistry, FOXP3, lung cancer, NSCLC, lymph node, metastasis, 1677
Immunohistochemistry, gastric adenocarcinoma, signet-ring adenocarcinoma, breast metastasis, skin, 2373
Immuno-histochemistry, glycated apolipoprotein B, colorectal cancer, 555
Immunohistochemistry, ischemia, xenografts, phospho-proteins, pre-analytical variables, biopsy, 2073
Immunohistochemistry, male breast, ductal pleomorphic carcinoma, histopathology, 3069
Immunohistochemistry, medulloblastoma, atypical teratoid/rhabdoid tumours, Na^+/K^+-ATPase, alpha subunits, 953
Immuno-histochemistry, non-Hodgkin's lymphoma, YB-1, prognosis, 2963
Immunohistochemistry, oral carcinogenesis, beta-catenin, tongue, mice, 2805
Immunohistochemistry, prostaglandin E2 receptor, renal cell carcinoma, pathological features, survival, 597
Immunohistochemistry, quantitative PCR, HMGB1, RAGE, disseminated histiocytic sarcoma, 1541
Immunohistochemistry, thyroid cancer, biomarker, diagnosis, sensitivity, specificity, metastasis, 3433
Immunohistochemistry, triple negative breast cancer, TEM8, breast cancer, lymph node metastasis, 3417
Immunohistochemistry, tumor suppressor gene, *FUS1*, sarcoma, RT-PCR, growth inhibition, 11
Immunohistochemistry, wnt pathway, colorectal cancer, LGR5, stem cell marker, 263
Immunological detection methods, circulating tumor cells, colon cancer, metastasis, 613
Immunomagnetic beads, circulating tumor cells, CTCs, prostate cancer, GFP, chick embryo, brain metastasis, metastatic assay, fluorescence imaging, 3125
Immunomagnetic beads, GFP, prostate cancer, PC-3, orthotopic, circulating cancer cells, isolation, fluorescence, imaging, culture, 1535
Immunomodulation, immunotherapy, tumor models, natural killer cells, *Parapoxvirus ovis*, Orf virus, 4185
Immunomodulation, indoleamine-2, 3-dioxygenase, cervical cancer, quinolinic acid, kynurenic acid, 2629
Immunomodulator, β-glucan, beta-glucan, dendritic cells, maturation, 1647
Immunotherapy, acute myeloid leukemia, interleukin-2, peptide vaccination, cerebrospinal fluid, CSF, flow of CSF, chloroma, 2343
Immunotherapy, breast cancer, ADAMTS1, amphiregulin, xenograft, 3839
Immunotherapy, cancer, prediction, survival, CD8, CD57, review, 639
Immunotherapy, cryoimmunology, cryotreatment, renal cell carcinoma, 2927
Immunotherapy, gemcitabine, NKG2D, MICA, MICB, HCC, 2505
Immunotherapy, heparan sulfate, proteoglycans, xenograft, HepG2 cells, liver cancer, 4067
Immunotherapy, immunomodulation, tumor models, natural killer cells, *Parapoxvirus ovis*, Orf virus, 4185

Immunotherapy, nucleotide, insoluble protein, dendritic cell, T lymphocytes, 881
Immunotherapy, Wilms' tumor 1 (WT1), myeloid dendritic cell, cancer vaccine, 2447
Immunotherapy, WT1 peptide vaccine, ovarian cancer, 2441
In silico molecular docking, uridine phosphorylase, hybrid steroidal alkylators, *in vitro* assay, mitrogen mustards, pancreatic cancer cells, 831
In vitro assay, uridine phosphorylase, hybrid steroidal alkylators, *in silico* molecular docking, mitrogen mustards, pancreatic cancer cells, 831
Individualized tumour response testing, breast cancer, primary culture, chemotherapeutics, therapy personalization, oncogramme, 139
3-Indole, cell cycle arrest, ATM, ATR, SMAD3, Xenograft model, lung cancer cells, 203
Indole, telomerase, prostate cancer, diethylstilbestrol, cell viability, 3733
Indoleamine-2, 3-dioxygenase, immunomodulation, cervical cancer, quinolinic acid, kynurenic acid, 2629
Induction chemotherapy, DCF, borderline-resectable T4, esophageal cancer, cisplatin, 5-fluorouracil, docetaxel, 3535
Infection, BPF, fistula, operation, lung cancer, risk factor, concurrent disease, perioperative complication, 619
Inferior vena cava, heart, hepatocellular carcinoma, prognosis, 4641
Inflammation, antisense pepitide, complementary peptide, anaphylatoxin, sepsis, cytokine storm, 2511
Inflammation-associated carcinogenesis, progression, fibrosarcoma, non-nuclear protein, 1259
Inflammatory processes, diffuse intrinsic pontine glioma, chemotherapy, temozolomide, rofecoxib, bevacizumab, 2265
Inflammatory response, APE1, Ref-1, macrophages, 379
Inhibition of DNA repair, radiation sensitivity, clonogenic cell survival, huachansu, lung cancer cells, 2141
Inhibition of multidrug resistance, P-glycoprotein, chemotherapy, osteosarcoma cell lines, carcinoma cell lines, siRNA, 2813
Inhibitor, HTLV-1, ATL, tetramethylnaphthalene, cell cycle, 2241
Iniparib, BRCA, pancreatic cancer, chemotherapy, 1417
INOS, cervical carcinoma, prognosis, guanylyl cyclase, phosphodiesterase, 2319
Insoluble protein, nucleotide, dendritic cell, T lymphocytes, immunotherapy, 881
Insulin-like growth factor 1 receptor (IGF1R), gastrointestinal stromal tumors (GISTs), Ras-Raf-ERK/MAPK pathway, PI3K-Akt/mTOR pathway, CD117, 3019
Insulin-like growth factor 1, MG-63 osteosarcoma cells, alternative splicing, 4259
Insulin-like growth factor, colorectal cancer, IGF-1, IGF-1R, 2541
Insulin-like growth factor-1, IGF-1, tamoxifen-resistance, oestrogen resistance, breast cancer recurrence, oestrogen receptor-alpha, *EGFR*, 23
Integrin, EMMPRIN, Fyn, oral SCC, ECM, 1205
Integrin, MMP-13, bone metastasis, type I collagen, MAPK, 1307
Integrins, colorectal cancer, survival, polymorphisms, single nucleotide polymorphisms, 1373
Interdisciplinary therapy management, gynecological cancer, breast cancer, online tumor conference, second opinion, continuous medical training, 2669
Interferon, chromophobe renal cell carcinoma, temsirolimus, mTOR, sorafenib, 331
Interferon, hepatocellular carcinoma, hepatic intraarterial therapy, fotemustine, chemoimmunotherapy, 4553
Interferon-β, endometrial cancer, engineered stem cells, cytosine deaminase, 2853
Interleukin-2, acute myeloid leukemia, immunotherapy, peptide vaccination, cerebrospinal fluid, CSF, flow of CSF, chloroma, 2343
Interleukin-2, bladder carcinoma, $CD8^{high}CD57^{+}$ lymphocytes, recurrences, 699
Interleukin-2, myeloma, YT, CD86, cytotoxicity, 475
Interleukin-6 receptor, interleukin-6, breast cancer, MCF-7, antisense, oligodeoxynucleotides, 2899
Interleukin-6, interleukin-6 receptor, breast cancer, MCF-7, antisense, oligodeoxynucleotides, 2899
Interleukin-6, oncostatin M, *VEGF*, u-PA, prostate cancer, 3273
Interleukin-6, signal transducer and activator of transcription 3, pancreatic cancer, 2029
Intermediate filament proteins, oral squamous cell carcinomas, toombak, genes, apoptosis, cell cycle regulation, Sudan, 3345
Intermediate risk, hypofractionated radiotherapy, prostate cancer, acute effect, image guided radiation therapy, hormonotherapy, 3555
Interphase FISH, MDS, normal karyotype, del(5q), del(20q), 1007
Interval debulking surgery, ovarian cancer, staging laparoscopy, optimal logistic regression, 4469
Intestinal carcinogenesis, min mice, 2-amino-1-methyl-6-phenylimidazo[4, 5-b]pyridine, Apc, C57Bl/6J, FVB, 785
Intestinal metaplasia, polymorphism, *Helicobacter pylori*, gastric atrophy, *XRCC1*, *GSTP1*, *GSTT1*, *GSTM1*, 1459
Intra-arterial therapy, pancreatic cancer, gemcitabine, chemoradiotherapy, 3909
Intracellular delivery, PAMAM dendrimers, encapsulation, resistance, SMVT, cisplatin, ovarian cancer cell lines, 897
Intracellular metabolism, ovarian cancer, hyprocrellin B, hematoporphyrin monomethyl ether, subcellular localization, phototoxicity, 3229

Intracranial, mKate2, mCherry, glioblastoma model, live imaging, temozolomide, 2161
Intraepidermal nerve fibres, cancer, neurotoxicity, adjuvant chemotherapy, docetaxel, neuropathy, skin biopsies, oxaliplatin, 4413
Intrahepatic cholangio-carcinoma, radiofrequency ablation, RFA, ICC, cirrhosis, 4575
Intra-operative method, breast cancer, sentinel lymph node, OSNA, cytokeratin 19, 585
Intraperitoneal, ovarian cancer, relapse, catumaxomab, surgical tumor debulking, operative morbidity, operative mortality, 2603
Intravenous curcumin, blood–brain barrier, post-traumatic sequelae, hippocampus, striatum, brain stem, 907
Intravesical chemotherapy, bladder cancer, recurrence, continuous saline bladder irrigation, 1471
Intravesical chemotherapy, mitomycin C, bladder cancer, 929
Intussusception, melanoma, small bowel, disease-free survival, dendritic cell therapy, 3579
Inv(3)(q21q26), t(3;3)(q21;q26), breakpoint distribution, chromosomal abnormalities, fluorescent *in situ* hybridization, 3441
Invasion front, apoptosis, liver metastases, *FAS*, TRAIL, colorectal cancer, 1215
Invasion front, KL-6 mucin, MUC1, gastric cancer, β-catenin, 535
Invasion, metastasis suppressor-1, MTSS1, cellular migration, bladder cancer, metastasis, 3205
Invasion, metastasis, anoikis, migration, renieramycin M, lung cancer cells, 193
Invasion, PPARγ, breast cancer, PPARG, T0070907, migration, 813
Invasion, resveratrol, glioma, TNF-α, urokinase plasminogen activator, 4223
Invasive front, ADAM, MMP, TIMP, solid cancer nest, colorectal cancer, 1567
Invasive tumors, neural stem cells, suicide genes, prodrugs, animal models, gene-directed enzyme prodrug therapy review, 1249
Iodine radioisotopes, thyroid neoplasms, thyroglobulin, TENIS syndrome, 2109
Ionizing radiation, glioma, PTEN, cell cycle, temozolomide, radiosensitivity, 1653
Ionizing radiation, phosphorylation of *p53,* radiation-sensitivity, 2255
Ionizing radiation, temozolomide, immunogenicity, cell death, Hsp70, 3727
IP-PA1, macrophage, LPS, priming, chronic psychological stress, review, 2437
Ipsilateral breast tumor recurrence, breast cancer, anastrozole, radiotherapy, tamoxifen, 367
IRF4, multiple myeloma, curcumin analog, NF-κB, PI3K/AKT, JAK/STAT3, 3719
Irinotecan, cetuximab, colorectal cancer, oxaliplatin, biomarkers, 2149
Irinotecan, gastric cancer, cetuximab, oxaliplatin, *KRAS* phase II trial, 4439
Irinotecan, liver directed therapy, metastatic colon cancer, transarterial chemoembolization, DEBIRI, DC Bead, 4581
Irinotecan, metabolites, hepatic intra-arterial infusion, plasma disposition, pharmacokinetics, 3573
Irinotecan, metastatic colorectal cancer, pharmacogenetics, 359
Irinotecan, ovarian cancer, consolidation chemotherapy, recurrent, salvage chemotherapy, treatment-free interval, paclitaxel, cisplatin, 4613
Iron chelation therapy, deferasirox, iron overload, acute myelogenous leukemia, chemotherapy-resistant, complete remission, 1741
Iron overload, deferasirox, iron chelation therapy, acute myelogenous leukemia, chemotherapy-resistant, complete remission, 1741
Ischemia, immunohistochemistry, xenografts, phospho-proteins, pre-analytical variables, biopsy, 2073
Isocratic HPLC, clofarabine, Cl-F-ara-A, clofarabine triphosphate, Cl-F-ara-ATP, leukemia cells, 2863
Isolated lung perfusion, sarcoma lung metastases, p-gp modulation, doxorubicin, cyclosporine, valspodar, 2121
Isolated nuclei, renal cell carcinoma, chromophobe renal cell carcinoma, renal oncocytoma, fluorescence *in situ* hybridization, tissue sections, 3137
Isolation, GFP, prostate cancer, PC-3, orthotopic, circulating cancer cells, immunomagnetic beads, fluorescence, imaging, culture, 1535
Isopentenyladenosine, cytokinins, modified nucleosides, antiproliferative activity, 3401
IκBα, NFκB, IKKβ, p38, peroxynitrite, nitration, colon cancer, 1607
JAK/STAT3, multiple myeloma, curcumin analog, NF-κB, PI3K/AKT, IRF4, 3719
Jaw bones, osteosarcoma, maxilla, mandible, 4485
JBCRN, meloxicam, paclitaxel, neuropathy, breast cancer, 3567
JC virus, human polyomavirus, BK virus, hemotopoetic stem cell transplantation, cerebrospinal fluid, KI, WU, 3489
JNK, melanoma, sorafenib, fluvastatin, AKT, 3259
K650E, proteasome inhibitor, receptor tyrosine kinase, activation loop, multiple myeloma, ER stress, FGFR3, Lys650Glu mutation, bortezomide, plasma cell malignancy, 113
KA2, glutamate receptor, cancer, PCR, shRNA, NR1, GLUR4, NR2D, 3181
KAI1/CD82, oral squamous cell carcinoma, thymidylate synthase, dihydropyrimidine dehydrogenase, lymph node metastasis, 3521

Kallikrein-related peptidase 5, breast cancer, *KLK5*, *KLK7*, 3093
KI, human polyomavirus, BK virus, JC virus, hematopoietic stem cell transplantation, cerebrospinal fluid, WU, 3489
Ki-67 expression, quinazoliniminium salts, tumor cell proliferation, macromolecule syntheses, DNA interaction and fragmentation, multiple mitotic figures, nuclei, micronuclei, 2083
Ki-67, breast cancer, metallothionein, MT-I/II, MCM-2, 3027
Ki-67, *EGFR*, translational research, squamous cell carcinoma, head and neck cancer, 665
Ki-67, non-small lung cancer, metallothionein, MT, MCM-2, 2833
Ki-67, PCNA, recurrence, lung, adenocarcinoma, 4277
Kidney, epigenetic modifiers, toxicity, ROS, p66shc, mitochondria, 3267
Kinase, antitumor activity, Bcr-Abl, CML, *Daedalea gibbosa*, medicinal mushrooms, oleic acid, autophosphorylation, 177
Kinases, antisense oligonucleotide, cyclin D, cyclin E, cyclin-dependent kinase, retinoblastoma protein, non-small lung cancer cells, pleural mesothelioma cells, apoptosis, phosphatases, 3683
KIT, Merkel cell carcinoma, sequence variation, mutation, 807
KL-6 mucin, MUC1, gastric cancer, β-catenin, invasion front, 535
KLK5, breast cancer, kallikrein-related peptidase 5, *KLK7*, 3093
KLK7, breast cancer, kallikrein-related peptidase 5, *KLK5*, 3093
KRAP, *KRAS*, target, cancer, obesity, diabetes, review, 2413
K-ras mutations, lung cancer, lung inflammation, lung tumors, mouse, carcinogenesis, 2877
KRAS phase II trial, gastric cancer, cetuximab, irinotecan, oxaliplatin, 4439
KRAS, *BRAF* mutation, *EGFR*, ERBB2 mutation, V600E, lung cancer, adenocarcinoma, squamous cell carcinoma, SSCP, 4619
KRAS, KRAP, target, cancer, obesity, diabetes, review, 2413
KRAS, medullary thyroid carcinoma, gene mutations, *RET*, *HRAS*, *NRAS*, *BRAF*, *AKT1*, *CTNNB1*, mutational screening, 4179
KRAS, microRNA, colorectal cancer, PTEN, miR-221/222, 3D culture, 2453
KRAS, ovarian cancer, gene mutations, BRCA 1/2, *TP53*, PI3K, AKT, *BRAF*, review, 2661
KRAS, *p53,* colorectal, oxaliplatin, 5-fluorouracil, capecitabine, clinical, CAIRO2, sequence analysis, 1379
KRAS, RRM2, colon cancer, 2535
Kynurenic acid, indoleamine-2, 3-dioxygenase, immunomodulation, cervical cancer, quinolinic acid, 2629
Lactoferrin, IGBP1, PP2Ac, apoptosis, lung adenocarcinoma, 529
Laparoscopic radical prostatectomy, bowel injury, LRP, prostatic neoplasm, rectal injury, robotic-assisted laparoscopic prostatectomy, RALP, robotics, 3497
Lapatinib, breast cancer, imatinib, *EGFR*, ErbB2, c-ABL, RTK, 789
Lapatinib, HER2, ADCC, breast cancer, Herceptin, 2999
Laryngal squamous cell carcinoma, microRNA, proliferation, apoptosis, 3859
Laryngeal cancer, ADH1B, alcohol-dehydrogenase, polymorphism, oral cancer, 677
Laryngeal cancer, glutamate receptor, antagonist, proliferation, ERK1/2 kinase, 565
LAT1, CD98, mesothelioma, hypoxia, prognosis, mTOR, 4075
LAT1, CD98, recurrence, advanced NSCLC, *EGFR* mutation, prognosis, chemotherapy. Ki-67, p-Akt, p-mTOR, 3775
Latin America, EBV polymorphism, *Bam*HI W1/I1, *Xho*I restriction site, EBV-associated gastric cancer, 3607
LBH589, TRAIL, histone deacetylase inhibitor, colon cancer, apoptosis, 3385
LC-MS/MS, TNF-alpha, hepatoma, proteomics, 2-DE, apoptosis, 2059
LC-MS/MS, two-dimensional gel electrophoresis, pancreatic cancer, TS-1, proteomics, 2103
Lectin, metastasis, HPA, E-selectin, P-selectin, SCID mouse, breast carcinoma cells, colon adenocarcinoma, 1589
Left colon, cyclooxygenase, COX-2, W-APC, right colon, colon cancer, 2191
Left colon, prognosis, right colon, sigmoid, survival, colon cancer, gender, 2347
Leg edema, radiation therapy, risk factor, enterocolitis, postoperative radiotherapy, gynecological malignancies, 3527
Leiomyoma, Arf-induced senescence, HMGA2, MDM2 antagonists, fibroid cells, 753
Leiomyoma, mucin-1, galectin-1, galectin-3, leiomyosarcoma, myometrium, 451
Leiomyosarcoma, mucin-1, galectin-1, galectin-3, leiomyoma, myometrium, 451
LEM, microarray analysis, dectin-2 gene expression, signaling pathway, macrophage, lignin-carbohydrate complex, LPS, 1241
Lenalidomide, pancreatic cancer, gemcitabine, resistance, ERK, 3747
Lethal dose, acetoxycoumarins, cell viability, cell cycle, 2017

Leucovorin, chemotherapy, FLOX regimen, metastatic colorectal cancer, phase II study, 5-FU, oxaliplatin, 4657
Leukemia cells, clofarabine, Cl-F-ara-A, clofarabine triphosphate, Cl-F-ara-ATP, isocratic HPLC, 2863
Leukemia, hedgehog, self-renewal, 781
Leukemia, HTLV-1, ATL, *Hyptis verticillata* jacq, multidrug resistance, 4251
Leukemia, notch, wnt, hedgehog, γ-secretase inhibitor, 893
Leukocytapheresis, ulcerative colitis, UC-associated colorectal cancer, 2547
Leuprorelin, total estrogen blockade, high-dose chemotherapy, anastrazole, premenopausal breast cancer, *VEGF*, 671
Level V, posterior triangle, neck dissection, 3959
Levisticum officinale lovage, oral cavity squamous cell carcinoma OCSCC, head and neck squamous cell carcinoma HNSCC, natural product, pharmacogenomics, 185
LGR5, wnt pathway, colorectal cancer, immunohistochemistry, stem cell marker, 263
LH, luteinizing hormone, total testosterone, TT, free testosterone, FT, prostate-specific antigen, PSA, prostate cancer, 1071
Lignin-carbohydrate complex, microarray analysis, dectin-2 gene expression, signaling pathway, macrophage, LPS, LEM, 1241
Lipid nanoparticles, *CDK4*, siRNA, down-regulation, 1619
Lipid nanoparticles, microfluidics, oligonucleotide, 771
Lipopolysaccharide, LPS, endotoxin, oral administration, toxicity, absorption, review, 2431
Liposome, bladder cancer, BCG-CWS, BBN, rat, 2065
Liposome, drug delivery, cancer, vincristine, folate receptor, drug targeting, 1521
Live imaging, mKate2, mCherry, glioblastoma model, intracranial, temozolomide, 2161
Liver cancer, heparan sulfate, proteoglycans, xenograft, HepG2 cells, immunotherapy, 4067
Liver cancer, Na^+, H^+ exchange, oxidative stress, cholangiocellular carcinoma, 459
Liver cirrhosis, child's classification, hepatocellular carcinoma, MELD-score, nonhepatic cancer, survival probability, TNM classification, 2931
Liver directed therapy, metastatic colon cancer, irinotecan, transarterial chemoembolization, DEBIRI, DC Bead, 4581
Liver function tests, uveal melanoma, metastasis, tumor markers, OPN, S-100β, MIA, TPS, 351
Liver hypertrophy, portal vein embolisation, tumor progression, serum markers, 339
Liver metastases, apoptosis, invasion front, *FAS*, TRAIL, colorectal cancer, 1215
Liver metastases, colorectal cancer, lung metastases, synchronous, metachronous, 1049
Liver metastases, colorectal cancer, surgery, biomarker, CD95-ligand, 4507
Liver metastases, lymphangiogenesis, lymphovascular invasion, colorectal cancer, *VEGF*-C, 4605
Liver metastases, stealth liposomes, PEG liposomes, 5-FU, locoregional chemotherapy, 147
Liver metastases, stealth liposomes, PEG liposomes, docetaxel, locoregional chemotherapy, hepatic arterial infusion, 153
Liver metastasis, breast cancer, E-selectin, endothelium, pro-inflammatory micro*env* ironment, 3219
Liver resection, hepatocellular carcinoma, multidrug resistance, ABC proteins, tyrosine kinase, 3883
Liver surgery, breast cancer liver metastases, tumour markers, prognostic factors, differental diagnosis, benign liver lesions, 1447
Liver tumour, hepatitis C virus, sarcomatoid tumour, cell line, culture, spectral karyotyping, xenograft, 129
Liver, green fluorescent protein, red fluorescent protein, cancer cell seeding, real-time imaging, lung, muscle, 3665
Lkb1, *Stk11*, hepatocellular carcinoma, nitrosamine, choline-deficient L-amino acid-defined diet, rat, 543
Local tumor control, B-Cell lymphoma, marginal zone lymphoma, radiation therapy, 3935
Locoregional chemotherapy, stealth liposomes, PEG liposomes, 5-FU, liver metastases, 147
Locoregional chemotherapy, stealth liposomes, PEG liposomes, docetaxel, liver metastases, hepatic arterial infusion, 153
Locoregional recurrence, cervical cancer, squamous cell carcinoma, stage IB-IIB, concurrent chemoradiotherapy, 1437
Lomustine, medulloblastoma, vincristine, apoptosis, chemotherapy, 1721
Long Evans Cinnamon, reactive oxygen species, pyruvate dehydrogenase, copper overload, 3395
Long-term administration, anaplastic gliomas, temozolomide, 3873
Long-term survivors, pancreatic cancer, pancreatic neoplasms, surgery, brain metastasis, 4599
Low back pain, gastric cancer, pregnancy, bilateral erythematous breast hypertrophy, 681
Low-grade liposarcoma, athymic mice, soft tissue sarcoma, xenograft, vascularisation, 4061
Low-grade myofibroblastic sarcoma, abdominal tumor, 2989
Low-intensity ultrasound, sonodynamic therapy, sonosensitizers, review, 2425
LPS, endotoxin, oral administration, toxicity, absorption, lipopolysaccharide, review, 2431
LPS, macrophage, priming, IP-PA1, chronic psychological stress, review, 2437

LPS, microarray analysis, dectin-2 gene expression, signaling pathway, macrophage, lignin-carbohydrate complex, LEM, 1241
LPS, *Pantoea agglomerans*, A46, LPSp, LPSa46, macrophage, M-CSF, GM-CSF, 2467
LPSa46, *Pantoea agglomerans*, A46, LPS, LPSp, macrophage, M-CSF, GM-CSF, 2467
LPSp, *Pantoea agglomerans*, A46, LPS, LPSa46, macrophage, M-CSF, GM-CSF, 2467
LRP, bowel injury, laparoscopic radical prostatectomy, prostatic neoplasm, rectal injury, robotic-assisted laparoscopic prostatectomy, RALP, robotics, 3497
Lumican, breast cancer, FKBP52, geldanamycin, heat-shock proteins, 2095
Lumpectomy, ductal carcinoma *in situ*, breast, mastectomy, menopause, hormone replacement therapy, 1783
Lung adenocarcinoma, 5-fluorouracil, dihydropyrimidine dehydrogenase, thymidylate synthase, chemosensitivity, 4665
Lung adenocarcinoma, *EGFR*, mutation, methylation, tobacco smoking, *FHIT*, RASSF1A, RUNX3, 1211
Lung adenocarcinoma, EMT, E-cadherin, gamma catenin, vimentin, fibronectin, 4451
Lung adeno-carcinoma, lactoferrin, IGBP1, PP2Ac, apoptosis, 529
Lung cancer cells, 3-Indole, cell cycle arrest, ATM, ATR, SMAD3, xenograft model, 203
Lung cancer cells, 3-oxoolean-12-en-27-oic acid, cell-cycle arrest, 2179
Lung cancer cells, cathepsin, cytokines, proliferation, 47
Lung cancer cells, metastasis, anoikis, invasion, migration, renieramycin M, 193
Lung cancer cells, radiation sensitivity, clonogenic cell survival, huachansu, inhibition of DNA repair, 2141
Lung cancer risk, paraoxonase 1, *PON1*, polymorphism, SNP, 2225
Lung cancer, BEZ235, *EGFR*, P13K/mTOR inhibitor, 849
Lung cancer, BPF, fistula, operation, risk factor, concurrent disease, perioperative complication, infection, 619
Lung cancer, *BRAF* mutation, *KRAS*, *EGFR*, ERBB2 mutation, V600E, adenocarcinoma, squamous cell carcinoma, SSCP, 4619
Lung cancer, chemoprevention, combined treatment, mouse model, 3279
Lung cancer, circulating tumor cells, CTCs, microfiltration by size, real-time quantitative reverse transcriptase-polymerase chain reaction, qRT-PCR, molecular biology, cytomorphology, FISH, cell culture, 427
Lung cancer, *cyclin D1*, CCND1, polymorphism, smoking, Taiwanese, 3601
Lung cancer, *EGFR*, mutation, estrogen receptor, 855
Lung cancer, epidermal growth factor receptor (*EGFR*), cytology, fiberbronchoscopy, diagnosis, 4207
Lung cancer, epithelial to mesenchymal transition, potassium channels, Eag1, TGF-β, 1265
Lung cancer, FOXP3, NSCLC, immunohistochemistry, lymph node, metastasis, 1677
Lung cancer, lung inflammation, lung tumors, *K-ras* mutations, mouse, carcinogenesis, 2877
Lung cancer, *MACC1*, recurrence, adenocarcinoma, 1141
Lung cancer, monoTotal, cytokeratins, tumour markers, 3107
Lung cancer, non-small cell lung cancer, bone metastases, bone remodeling markers, *N*-telopeptide of type I collegen, NTx, bone alkaline phosphatase, BAP, 3879
Lung cancer, NSCLC, erlotinib, *EGFR*, c-erbB-3, 281
Lung cancer, NSCLC, prognostic factors, HIF, NOTCH, 1603
Lung cancer, paclitaxel-based chemoradiotherapy, BCL-2, MDR1, radiosensitivity, 1431
Lung cancer, pharmacogenomics, SNPs, bexarotene, RXR, 2303
Lung cancer, thymidine kinase1, 5'(3')-deoxyribonucleotidase, fluorothymidine, proliferation, colon cancer, 2135
Lung cancer, vitamin D, colorectal cancer, breast cancer, prostate cancer, 3619
Lung inflammation, lung cancer, lung tumors, *K-ras* mutations, mouse, carcinogenesis, 2877
Lung metastases, colorectal cancer, liver metastases, synchronous, metachronous, 1049
Lung metastasis, IGF-1R, phosphorylated MEK, Ras/Raf/MEK/ERK pathway, orthotopic mouse model of osteosarcoma, 1147
Lung transplantation, cyclosporine A, human lung adenocarcinoma cell, apoptosis, caspase, 2129
Lung tumors, lung cancer, lung inflammation, *K-ras* mutations, mouse, carcinogenesis, 2877
Lung, green fluorescent protein, red fluorescent protein, cancer cell seeding, real-time imaging, liver, muscle, 3665
Lung, Ki-67, PCNA, recurrence, adenocarcinoma, 4277
Luteinizing hormone (LH), prolactin (PRL), total testosterone (TT), free testosterone (FT), prostate-specific antigen (PSA), prostate cancer, 3913
Luteinizing hormone, LH, total testosterone, TT, free testosterone, FT, prostate-specific antigen, PSA, prostate cancer, 1071
Lutetium-177, non-Hodgkin's lymphoma, BCL2, somatostatin receptor, 3143
LXS oral powder, fenretinide, phase I, clinical trial, 961
Lymph node density, bladder cancer, extented lymphadenectomy, lymph node metastasis, radical cystectomy, cancer-specific survival, short review, 271
Lymph node dissection, gastric cancer, prognosis, staging, 2361

Lymph node metastasis, bladder cancer, extented lymphadenectomy, radical cystectomy, lymph node density, cancer-specific survival, short review, 271
Lymph node metastasis, hepatocellular carcinoma, transarterial chemoembolization, resection, 3991
Lymph node metastasis, oral squamous cell carcinoma, thymidylate synthase, dihydropyrimidine dehydrogenase, KAI1/CD82, 3521
Lymph node metastasis, sialic fibronectin, thyroid malignant neoplasma, MoAb Jt-95, 1395
Lymph node metastasis, triple negative breast cancer, TEM8, breast cancer, immunohistochemistry, 3417
Lymph node, FOXP3, lung cancer, NSCLC, immunohistochemistry, metastasis, 1677
Lymph node, skin cancer, non-melanoma, metastasis, literature review, sentinel lymph node biopsy, 1443
Lymph node, uterine cervical cancer, FDG-PET, MRI, 3865
Lymphangiogenesis, lymphovascular invasion, liver metastases, colorectal cancer, *VEGF*-C, 4605
Lymphatic microvessel density, breast cancer, molecular classification, *VEGF*-C, V*EGFR*-3, 1757
Lymphoma, radioprotection, radiosensitivity, astrocytes, central nervous system, 33
Lymphovascular invasion, bladder cancer, transitional carcinoma, upper tract transitional carcinoma, prognostic role, review, 3503
Lymphovascular invasion, lymphangiogenesis, liver metastases, colorectal cancer, *VEGF*-C, 4605
Lys650Glu mutation, proteasome inhibitor, receptor tyrosine kinase, activation loop, multiple myeloma, ER stress, FGFR3, K650E, bortezomide, plasma cell malignancy, 113
MACC 1, quantitative real-time PCR, hepatocellular carcinoma, 777
MACC1, recurrence, lung cancer, adenocarcinoma, 1141
Macromolecule syntheses, quinazoliniminium salts, tumor cell proliferation, Ki-67 expression, DNA interaction and fragmentation, multiple mitotic figures, nuclei, micronuclei, 2083
Macrophage, LPS, priming, IP-PA1, chronic psychological stress, review, 2437
Macrophage, microarray analysis, dectin-2 gene expression, signaling pathway, lignin-carbohydrate complex, LPS, LEM, 1241
Macrophage, monocyte differentiation, colon cancer, MCP-1, 2493
Macrophage, *Pantoea agglomerans*, A46, LPS, LPSp, LPSa46, M-CSF, GM-CSF, 2467
Macrophages, APE1, Ref-1, inflammatory response, 379
MAGE, non-small cell lung cancer NSCLC, expression, demethylation, 171
Magnetic resonance imaging, micro-computed tomography, optical reflectance imaging, tumor volume, molecular imaging, GFP, RFP, 2907
Magnetic resonance spectroscopy, brain neoplasms, radiotherapy, prognosis, prospective studies, 3559
Male breast, ductal pleomorphic carcinoma, histopathology, immunohistochemistry, 3069
Malignant fibrous histiocytoma, osteosarcoma, MAPK signaling pathway, 549
Mammary cancer, sunitinib, antitumor, antimetastasis, *VEGF*, V*EGFR*, phosphorylation, 1225
Mammary tumorigenesis, zeranol, cell proliferation, protein disulfide isomerase, 1659
Mammographic breast density, single nucleotide polymorphisms, estrogen pathway, steroid hormones, breast cancer, review, 4369
Mammography, breast cancer, calcification, prognostic factor, 2327
Mammography, breast cancer, screening, ultrasound, automated 3D imaging, 2569
Mandible, bisphosphonate, osteonecrosis, BRONJ, 2313
Mandible, osteosarcoma, jaw bones, maxilla, 4485
MAPK signaling pathway, osteosarcoma, malignant fibrous histiocytoma, 549
MAPK, MMP-13, bone metastasis, type I collagen, integrin, 1307
MAPK, thyroid hormones, proliferation, PI3K, 89
Marginal zone lymphoma, B-Cell lymphoma, radiation therapy, local tumor control, 3935
Maspin, activin A, androgen receptor, upper urinary tract urothelial carcinoma, prognosis, 1713
Mastectomy, ductal carcinoma *in situ*, breast, lumpectomy, menopause, hormone replacement therapy, 1783
Matrix metalloproteinase-9, ovarian cancer, diagnosis, biomarkers, enzyme-linked immunosorbent assay, cathepsin, heparanase, 3423
Matrix metalloproteinases, gelatinase, tongue carcinoma, green fluorescent protein, xenograft, peptide, 3659
Maturation, β-glucan, beta-glucan, dendritic cells, immunomodulator, 1647
Maxilla, osteosarcoma, jaw bones, mandible, 4485
MBL, polymorphism, ulcerative colitis, DNA methylation, CD14, p22PHOX, 933
MCF-7 cells, clioquinol, zinc, *cyclin D1*, miR-302C, 2739
MCF-7, branched-chain fatty acids, anticancer, antitumor, human breast cancer, human colon cancer, HT-29, 3165
MCF-7, interleukin-6, interleukin-6 receptor, breast cancer, antisense, oligodeoxynucleotides, 2899
MCherry, mKate2, glioblastoma model, intracranial, live imaging, temozolomide, 2161
MCM-2, breast cancer, metallothionein, MT-I/II, Ki-67, 3027
MCM-2, non-small lung cancer, metallothionein, MT, Ki-67, 2833

MCMs, minichromosome maintenance proteins, cyclin D3, CCND3, Hodgkin lymphoma, survival, 3585
MCP-1, monocyte differentiation, macrophage, colon cancer, 2493
M-CSF, *Pantoea agglomerans*, A46, LPS, LPSp, LPSa46, macrophage, GM-CSF, 2467
MDM2 antagonists, leiomyoma, Arf-induced senescence, HMGA2, fibroid cells, 753
MDR mouse T-lymphoma cells, multidrug-resistant cancer cells, ABCB1 transporter, P-glycoprotein, phenothiazines, thioridazine, apoptosis, 4201
MDR1, lung cancer, paclitaxel-based chemoradiotherapy, BCL-2, radiosensitivity, 1431
MDS, interphase FISH, normal karyotype, del(5q), del(20q), 1007
Measles virus, age, breast cancer, grade, immunohistochemistry, *p53,* 913
Mechanism of action, cytotoxicity, endocytosis, glycosylated antitumor ether lipid, methyl-β-cyclodextrin, 3809
Medicinal compounds, triptolide, proteasome inhibitors, apoptosis, cancer therapy, 1
Medicinal herb, bioactivity, p53 pathway, apoptosis, *Ruta graveolens*, Akt, 233
Medicinal mushrooms, antitumor activity, Bcr-Abl, CML, *Daedalea gibbosa*, kinase, oleic acid, autophosphorylation, 177
Medullary thyroid carcinoma, gene mutations, *RET*, *HRAS*, *KRAS*, *NRAS*, *BRAF*, *AKT1*, *CTNNB1*, mutational screening, 4179
Medulloblastoma, atypical teratoid/rhabdoid tumours, Na^+/K^+-ATPase, alpha subunits, immunohistochemistry, 953
Medulloblastoma, vincristine, lomustine, apoptosis, chemotherapy, 1721
Melanocyte, dysplastic nevi, immune response, melanoma, regression, 3697
Melanoma, dysplastic nevi, immune response, melanocyte, regression, 3697
Melanoma, gefitinib, radiation, combination therapy, *EGFR*, predictor, 2883
Melanoma, imexon, dacarbazine, additivity, drug combinations, 2781
Melanoma, memory T- cell, CD44, tumor-infiltrating lymphocytes, 4099
Melanoma, metastastic melanoma, brain metastases, temozolomide, whole-brain radiation, 4537
Melanoma, small bowel, intussusception, disease-free survival, dendritic cell therapy, 3579
Melanoma, sorafenib, fluvastatin, JNK, AKT, 3259
Melatonin, cancer, endometrial proliferation, rats, 2637
MELD-score, child's classification, hepatocellular carcinoma, liver cirrhosis, nonhepatic cancer, survival probability, TNM classification, 2931
Meloxicam, paclitaxel, neuropathy, breast cancer, JBCRN, 3567
Memory T- cell, CD44, tumor-infiltrating lymphocytes, melanoma, 4099
Meningioma en plaque, somatostatin, hyperostosis, hyperosteoidosis, 591
Menopause, ductal carcinoma *in situ*, breast, lumpectomy, mastectomy, hormone replacement therapy, 1783
Merkel cell carcinoma, KIT, sequence variation, mutation, 807
Mesenchymal stem cells, gene therapy, cytotherapy, hepatocellular carcinoma, 3705
Mesothelioma, LAT1, CD98, hypoxia, prognosis, mTOR, 4075
Mesothelioma, renal failure, tumor markers, N-ERC/mesothelin, osteopontin, 1427
Meta-analysis, vitamin D, 25-hydroxyvitamin D, breast neoplasms, case–control studies, epidemiology, prevention, 2939
Meta-analysis, X-ray repair cross-complementing group 1, *XRCC1*, polymorphism, DNA repair, skin cancer, 3945
Metabolites, irinotecan, hepatic intra-arterial infusion, plasma disposition, pharmacokinetics, 3573
Metabolizing genes, genetic polymorphisms, cancer susceptibility, DNA-repair genes, *CYP1A1*, *CYP1E1*, *XRCC1*, 1359
Metabolomics, belinostat, bortezomib, pancreas cancer, histone deacetylase inhibitor, proteasome inhibitor, hepatocellular cancer, apoptosis, 1093
Metachronous liver metastasis, CT-guided high-dose-rate brachytherapy, CT-HDRBT, ovarian cancer, ablation of liver metastases, 2597
Metachronous, colorectal cancer, liver metastases, lung metastases, synchronous, 1049
Metalloproteinases, colorectal cancer, biological activity, tumor markers, angiogenetic factors, adhesion molecules, 373
Metallothionein, breast cancer, MT-I/II, Ki-67, MCM-2, 3027
Metallothionein, non-small lung cancer, MT, Ki-67, MCM-2, 2833
Metastasis suppressor-1, MTSS1, cellular migration, invasion, bladder cancer, metastasis, 3205
Metastasis, anoikis, invasion, migration, renieramycin M, lung cancer cells, 193
Metastasis, breast cancer, bone marrow carcinomatosis, 4025
Metastasis, breast cancer, stem cells, pre-metastatic niche, CD133, prognosis, 1315
Metastasis, circulating tumor cells, colon cancer, immunological detection methods, 613
Metastasis, extravasation, blood–brain barrier, brain endothelial cells, COX-2, 4307

Metastasis, FOXP3, lung cancer, NSCLC, immunohistochemistry, lymph node, 1677
Metastasis, HPA, E-selectin, P-selectin, SCID mouse, lectin, breast carcinoma cells, colon adenocarcinoma, 1589
Metastasis, metastasis suppressor-1, MTSS1, cellular migration, invasion, bladder cancer, 3205
Metastasis, methylenetetrahydrofolate reductase *MTHFR*, smoking, recurrence, oral cancer, 2395
Metastasis, osteosarcoma, angiotensin II type 1 receptor antagonist, CV11974, 123
Metastasis, palladin, neuroendocrine carcinomas, 2957
Metastasis, skin cancer, non-melanoma, lymph node, literature review, sentinel lymph node biopsy, 1443
Metastasis, thyroid cancer, biomarker, diagnosis, sensitivity, specificity, immunohistochemistry, 3433
Metastasis, uveal melanoma, liver function tests, tumor markers, OPN, S-100β, MIA, TPS, 351
Metastasis, uveal melanoma, tumor markers, OPN, S-100β, MIA, TPS, 345
Metastasis, voluntary running, cytokines, mice, 3337
Metastastic melanoma, melanoma, brain metastases, temozolomide, whole-brain radiation, 4537
Metastatic anal cancer, chemoradiotherapy, cisplatin, S-1, 3983
Metastatic assay, circulating tumor cells, CTCs, prostate cancer, immunomagnetic beads, GFP, chick embryo, brain metastasis, fluorescence imaging, 3125
Metastatic breast cancer, capecitabine, triple-negative, HER2-negative, prognostic factors, 1079
Metastatic breast cancer, circulating tumor cells, chemotherapy, therapy efficacy, 979
Metastatic breast cancer, HER2-positive, S-1, trastuzumab, 3035
Metastatic breast cancer, oxaliplatin, off-label use, 1765
Metastatic colon cancer, liver directed therapy, irinotecan, transarterial chemoembolization, DEBIRI, DC Bead, 4581
Metastatic colorectal cancer, capecitabine, oxaliplatin, bevacizumab, cetuximab, phase II, 255
Metastatic colorectal cancer, chemotherapy, FLOX regimen, phase II study, 5-FU, leucovorin, oxaliplatin, 4657
Metastatic colorectal cancer, irinotecan, pharmacogenetics, 359
Metastatic colorectal cancer, panitumumab, bevacizumab, treatment, 1033
Metastatic gastric cancer, chemotherapy, review, 3543
Metastatic rectal adenocarcinoid, 5-FU, hyperammonemia, encephalopathy, capecitabine, 335
Metastatic renal cell carcinoma, sunitinib, sequential treatment regimen, tyrosine kinase inhibitor, mTOR inhibitor, 3507
Metformin, colon cancer, phenformin, 2-deoxyglucose, acidification, 421
Methyl-2-cyano-3, ovarian cancer, 12-dioxooleana-1, 9(11)-dien-28-oate (CDDO-Me), apoptosis, AKT, NF-κB, mTOR, 3673
Methylation, breast cancer, RASSF1A, prognosis, 2975
Methylation, *EGFR*, mutation, tobacco smoking, lung adenocarcinoma, *FHIT*, RASSF1A, RUNX3, 1211
Methylation, NSCLC, MLPA, targeted therapy, gene methylation, TKIs, smoking, *EGFR* mutation, 4647
Methylation, p16I*NK4*a, colorectal cancer, 1643
Methylation, *TFPI2*, gastric cancer, 3835
Methylenetetrahydrofolate reductase *MTHFR*, smoking, metastasis, recurrence, oral cancer, 2395
O6-Methylguanine-DNA methyltransferase (MGMT), S_N1 methylating agents, apoptosis, RNA-binding proteins, *N*-methyl-*N*-nitrosourea, 4291
Methyl-β-cyclodextrin, cytotoxicity, endocytosis, glycosylated antitumor ether lipid, mechanism of action, 3809
N-methyl-*N*-nitrosourea, S_N1 methylating agents, apoptosis, O6-methylguanine-DNA methyltransferase (MGMT), RNA-binding proteins, 4291
Metronomic, cyclophosphamide, doxorubicin, breast cancer, cardiotoxicity, rats, 215
MG-63 osteosarcoma cells, insulin-like growth factor 1, alternative splicing, 4259
MIA, uveal melanoma, metastasis, liver function tests, tumor markers, OPN, S-100β, TPS, 351
MIA, uveal melanoma, metastasis, tumor markers, OPN, S-100β, TPS, 345
MICA, gemcitabine, NKG2D, MICB, HCC, immunotherapy, 2505
MICB, gemcitabine, NKG2D, MICA, HCC, immunotherapy, 2505
Mice, BBN, gemcitabine, sirolimus, urothelial lesion, 1637
Mice, oral carcinogenesis, immunohistochemistry, beta-catenin, tongue, 2805
Mice, voluntary running, metastasis, cytokines, 3337
Microarray analysis, dectin-2 gene expression, signaling pathway, macrophage, lignin-carbohydrate complex, LPS, LEM, 1241
Microarray, antiapoptosis, colorectal cancer, gamma radiation, RT-PCR, *REG4*, *NEIL2*, *BIRC5*, 4147
Microcalcification, breast cancer, screening mammography, high-frequency ultrasound, advanced imaging modes, 2575
Micro-computed tomography, magnetic resonance imaging, optical reflectance imaging, tumor volume, molecular imaging, GFP, RFP, 2907
Microfiltration by size, circulating tumor cells, CTCs, real-time quantitative reverse transcriptase-polymerase chain reaction, qRT-PCR, molecular biology, cytomorphology, FISH, cell culture, lung cancer, 427

Microfluidics, oligonucleotide, lipid nanoparticles, 771
Micrometastasis, cervical cancer, parametrium, immunohistochemistry, 243
Micronuclei, quinazoliniminium salts, tumor cell proliferation, Ki-67 expression, macromolecule syntheses, DNA interaction and fragmentation, multiple mitotic figures, nuclei, 2083
Micronucleus assay, α-particle radiation, 238-plutonium, Monte Carlo simulations, bystander effect, 2113
MicroRNA, *KRAS*, colorectal cancer, PTEN, miR-221/222, 3D culture, 2453
MicroRNA, laryngal squamous cell carcinoma, proliferation, apoptosis, 3859
MicroRNA, prostate cancer, Fusion gene, *TMPRSS2:ERG*, 403
Microsatellite instability, colon cancer, tumor location, age, early onset, 967
Microvesicles, tumour, chemokine, monocyte, 1329
Migration, metastasis, anoikis, invasion, renieramycin M, lung cancer cells, 193
Migration, PPARγ, breast cancer, PPARG, T0070907, invasion, 813
Min mice, 2-amino-1-methyl-6-phenylimidazo[4, 5-b]pyridine, Apc, C57Bl/6J, FVB, intestinal carcinogenesis, 785
Minichromosome maintenance proteins, MCMs, cyclin D3, CCND3, Hodgkin lymphoma, survival, 3585
Minimal residual disease, acute lymphoblastic leukemia, flow cytometry, children, early response, 1453
MIP-1α, cytokines, morphine, plasma, IL-12, 4561
MiR-221/222, *KRAS*, microRNA, colorectal cancer, PTEN, 3D culture, 2453
MiR-302C, clioquinol, zinc, *cyclin D1*, MCF-7 cells, 2739
Miriplatin, hepatocellular carcinoma, transarterial chemoembolization, 2983
MiRNA, electroporation, oligonucleotides, siRNA, review, 4083
Mitochondria, epigenetic modifiers, kidney, toxicity, ROS, p66shc, 3267
Mitochondria, phenethyl isothiocyanate, cell cycle arrest, apoptosis, caspases, prostate cancer DU 145 cells, 1691
Mitochondrial DNA, MtDNA mutation, D-loop region, breast cancer, plasma, 4267
Mitochondria-mediated pathways, gallic acid (GA), human leukemia HL-60 cells, apoptosis, death receptor-mediated pathways, 2821
Mitochondrion, sonodynamic therapy, 5-aminolevulinic acid, SAS cell, apoptosis, 39
Mitogenic activity, zeranol, ACI rat serum, breast cancer, 481
Mitomycin C, intravesical chemotherapy, bladder cancer, 929
Mitosis, (+)-Spongistatin 1, anticancer, natural product, xenograft model, 2773
Mitotic counts, breast cancer, prognosis, 97
Mitrogen mustards, uridine phosphorylase, hybrid steroidal alkylators, *in silico* molecular docking, *in vitro* assay, pancreatic cancer cells, 831
MKate2, mCherry, glioblastoma model, intracranial, live imaging, temozolomide, 2161
MLPA, NSCLC, methylation, targeted therapy, gene methylation, TKIs, smoking, *EGFR* mutation, 4647
MMP, ADAM, TIMP, solid cancer nest, invasive front, colorectal cancer, 1567
MMP-13, bone metastasis, type I collagen, integrin, MAPK, 1307
MMP2, polymorphism, colorectal cancer, *VEGF*, HIF1A, SNP, 575
MMP-2, prostate cancer, vitamin D analog, ZK191784, MMP-9, adhesion molecules, 4091
MMP-9, prostate cancer, vitamin D analog, ZK191784, MMP-2, adhesion molecules, 4091
MMP-9, silibinin, CD44, *EGFR*, EGF, TGF-α, breast cancer metastasis, 3767
MoAb Jt-95, sialic fibronectin, thyroid malignant neoplasma, lymph node metastasis, 1395
Modified nucleosides, isopentenyladenosine, cytokinins, antiproliferative activity, 3401
Molecular biology, circulating tumor cells, CTCs, microfiltration by size, real-time quantitative reverse transcriptase-polymerase chain reaction, qRT-PCR, cytomorphology, FISH, cell culture, lung cancer, 427
Molecular classification, breast cancer, lymphatic microvessel density, *VEGF*-C, V*EGFR*-3, 1757
Molecular imaging, magnetic resonance imaging, micro-computed tomography, optical reflectance imaging, tumor volume, GFP, RFP, 2907
Monocyte differentiation, macrophage, colon cancer, MCP-1, 2493
Monocyte, tumour, microvesicles, chemokine, 1329
Mono-l-aspartyl chlorin e6, ultrasound, antitumor effect, sonodynamic therapy, sarcoma 180, colon 26, 501
MonoTotal, lung cancer, cytokeratins, tumour markers, 3107
Monte Carlo simulations, α-particle radiation, 238-plutonium, bystander effect, micronucleus assay, 2113
Morphine, cytokines, plasma, MIP-1α, IL-12, 4561
Motion effect, hepatocellular carcinoma, ^{1}H MRI, apparent diffusion coefficient, extracellular space, benzamide riboside, angiography, therapy response, 2045
Mouse model, lung cancer, chemoprevention, combined treatment, 3279
Mouse peritoneal macrophages, Gc-derived macrophage-activating factor precursor, preGcMAF, 1f1f subtype of Gc protein, Gc1f1f protein, phagocytic activity, 2489
Mouse, lung cancer, lung inflammation, lung tumors, *K-ras* mutations, carcinogenesis, 2877

MR, adrenocortical tumors, Cushing's syndrome, adrenal imaging, cancer, CT, review, 2923
MRI, colon cancer, orthotopic model, GFP, fluorescent protein imaging (FPI), selenium, angiogenesis, 387
^{1}H MRI, hepatocellular carcinoma, apparent diffusion coefficient, extracellular space, benzamide riboside, angiography, therapy response, motion effect, 2045
MRI, uterine cervical cancer, FDG-PET, lymph node, 3865
MRNA translation, prostate cancer, EBP1, androgen receptor, 3129
MRNA, non-small cell lung cancer, TIMP1, DFI, survival, blood plasma, 4031
MRSI, prostate cancer, PCA3 urinary test, DCEMR, 1399
MS, tubulin alpha-6 chain, HCV-HCC, proteomics, 2-DE, 3331
MSX2, cholangiocarcinoma, brushing cytology, 1011
MT, non-small lung cancer, metallothionein, Ki-67, MCM-2, 2833
MT477, tumor growth, NRF2, AURKA, 1181
MtDNA mutation, D-loop region, breast cancer, plasma, mitochondrial DNA, 4267
MTHFR C677T, colorectal cancer, adjuvant chemotherapy, *MTR* A2756G, toxicity, survival, 3057
MT-I/II, breast cancer, metallothionein, Ki-67, MCM-2, 3027
MTOR inhibitor, carboplatin, RAD001, everolimus, breast cancer, 2713
MTOR inhibitor, sunitinib, metastatic renal cell carcinoma, sequential treatment regimen, tyrosine kinase inhibitor, 3507
MTOR, chromophobe renal cell carcinoma, temsirolimus, sorafenib, interferon, 331
MTOR, LAT1, CD98, mesothelioma, hypoxia, prognosis, 4075
MTOR, ovarian cancer, methyl-2-cyano-3, 12-dioxooleana-1, 9(11)-dien-28-oate (CDDO-Me), apoptosis, AKT, NF-κB, 3673
MTOR, *VEGF*, HIF-1α, angiogenesis, oral cancer, 4429
MTR A2756G, colorectal cancer, adjuvant chemotherapy, *MTHFR C677T*, toxicity, survival, 3057
MTSS1, metastasis suppressor-1, cellular migration, invasion, bladder cancer, metastasis, 3205
MUC1, KL-6 mucin, gastric cancer, β-catenin, invasion front, 535
Mucin-1, galectin-1, galectin-3, leiomyosarcoma, leiomyoma, myometrium, 451
Mucus metaplasia, esophagus, baboon, gastric reflux, 2187
Multidrug resistance, hepatocellular carcinoma, liver resection, ABC proteins, tyrosine kinase, 3883
Multidrug resistance, hydantoin derivatives, Colo 205 and Colo 320 colon adenocarcinoma cells, efflux pump, ABCB1 transporter, apoptosis, 3285
Multidrug resistance, P-glycoprotein, benzo[*a*]quinolizin derivatives, 921
Multidrug resistant, histone deacetylase inhibitor, chemotherapy, sarcoma, PCI-24781, 1115
Multidrug-resistant cancer cells, MDR mouse T-lymphoma cells, ABCB1 transporter, P-glycoprotein, phenothiazines, thioridazine, apoptosis, 4201
Multidrug resistance, HTLV-1, ATL, leukemia, *Hyptis verticillata* jacq, 4251
Multifocal recurrence, anaplastic ependymoma, temozolomide, 1023
Multiple mitotic figures, quinazoliniminium salts, tumor cell proliferation, Ki-67 expression, macromolecule syntheses, DNA interaction and fragmentation, nuclei, micronuclei, 2083
Multiple myeloma, bortezomib, once-weekly administration, dexamethasone, gastrointestinal adverse events, 2297
Multiple myeloma, curcumin analog, NF-κB, PI3K/AKT, JAK/STAT3, IRF4, 3719
Multiple myeloma, proteasome inhibitor, receptor tyrosine kinase, activation loop, ER stress, FGFR3, Lys650Glu mutation, K650E, bortezomide, plasma cell malignancy, 113
Multiple myeloma, signal transduction, Wnt pathway, myeloma, myeloma therapy, review, 725
Muscle, green fluorescent protein, red fluorescent protein, cancer cell seeding, real-time imaging, lung, liver, 3665
Mutation, *EGFR*, estrogen receptor, lung cancer, 855
Mutation, *EGFR*, methylation, tobacco smoking, lung adenocarcinoma, *FHIT*, RASSF1A, RUNX3, 1211
Mutation, Merkel cell carcinoma, KIT, sequence variation, 807
Mutational screening, medullary thyroid carcinoma, gene mutations, *RET*, *HRAS*, *KRAS*, *NRAS*, *BRAF*, *AKT1*, *CTNNB1*, 4179
Mutations, polymorphisms, *TP53*, *FHIT*, chronic esophagitis, esophageal carcinoma, 1685
MVD, angiogenesis, breast cancer, image analysis, CD34, vessel identification, 4053
MVD, colorectal cancer, pulmonary metastases, TS, OPRT, ERCC1, BRCA1, adjuvant chemotherapy, 2763
Myeloid DC, dentritic cells, pancreatic cancer, prognostic factor, survival analysis, circulating dendritic cells, 3827
Myeloid dendritic cell, Wilms' tumor 1 (WT1), cancer vaccine, immunotherapy, 2447
Myeloma therapy, multiple myeloma, signal transduction, Wnt pathway, myeloma, review, 725
Myeloma, multiple myeloma, signal transduction, Wnt pathway, myeloma therapy, review, 725
Myeloma, YT, CD86, interleukin-2, cytotoxicity, 475
Myeloproliferative neoplasm, non-Hodgkin's lymphoma, portal vein thrombosis, 1467
Myometrium, mucin-1, galectin-1, galectin-3, leiomyosarcoma, leiomyoma, 451

Myotoxicity, adriamycin, cardiotoxicity, fatigue, 2023
Na^+, H^+ exchange, oxidative stress, cholangiocellular carcinoma, liver cancer, 459
Na^+/K^+-ATPase, medulloblastoma, atypical teratoid/rhabdoid tumours, alpha subunits, immunohistochemistry, 953
Nasopharyngeal carcinoma, Cav-1, polymorphism, carcinogenesis, 3629
Natriuretic peptides, cell death, pancreatic neoplasm, prostate neoplasm, nuclear matrix proteins, 395
Natural agents, notch, stem cells, pancreatic cancer, signal pathway, cancer therapy, drug resistance, review, 1105
Natural killer cells, immunotherapy, immunomodulation, tumor models, *Parapoxvirus ovis*, Orf virus, 4185
Natural product, (+)-Spongistatin 1, anticancer, mitosis, xenograft model, 2773
Natural product, *Levisticum officinale* lovage, oral cavity squamous cell carcinoma OCSCC, head and neck squamous cell carcinoma HNSCC, pharmacogenomics, 185
Natural product, *Thymus vulgaris* L. (thyme), oral cavity squamous cell carcinoma OCSCC, head and neck squamous cell carcinoma HNSCC, pharmacogenomics, 81
N-cadherin, adrenocortical carcinoma, ADH-1, dynamic contrast enhancing magnetic resonance imaging (DCE-MRI), phase-I, 3921
Neck dissection, posterior triangle, level V, 3959
Necrosis, gastric carcinoma, carcinomatosis, glycolysis, energetic metabolism, apoptosis, citrate, 797
Nedaplatin, chemotherapy, docetaxel, S1, esophageal carcinoma, phase I, 4589
Neem leaf extract, neuroblastoma, radiotherapy, apoptosis, transcriptional response, 161
NEIL2, antiapoptosis, colorectal cancer, gamma radiation, microarray, RT-PCR, *REG4*, *BIRC5*, 4147
Neoadjuvant chemoradiotherapy, esophageal squamous cell carcinoma, pathological response, complication, prognosis, 3073
Neoadjuvant chemoradiotherapy, gastric cancer, S-1, cisplatin, 3079
Neoadjuvant chemotherapy, breast cancer, trastuzumab, pCR, 3041
Neoadjuvant therapy, radiochemotherapy, esophageal cancer, docetaxel, cisplatin, phase II trials, 4407
Neoadjuvant therapy, rectal cancer, chemoradiation, complete clinical response, non-operative management, review, 1795
Neoadjuvant therapy, response prediction, squamous-cell esophageal cancer, tumor-associated proteins, 1769
N-ERC/mesothelin, renal failure, mesothelioma, tumor markers, osteopontin, 1427
Neural stem cells, suicide genes, prodrugs, invasive tumors, animal models, gene-directed enzyme prodrug therapy review, 1249
Neuroblastoma, apoptosis, celecoxib, cytotoxicity, valproic acid, 2231
Neuroblastoma, radiotherapy, neem leaf extract, apoptosis, transcriptional response, 161
Neuroectodermal, endometrial stromal sarcoma, t(10;17) translocation, 2367
Neuroendocrine cancer, colorectal, small cell cancer, chemotherapy, cisplatin, etoposide, 975
Neuroendocrine carcinomas, palladin, metastasis, 2957
Neuroendocrine differentiation, prostate cancer, ethnicity, 3897
Neurofibromatosis type 1, breast cancer, gastrointestinal stromal tumor, 4481
Neuropathy, cancer, neurotoxicity, adjuvant chemotherapy, docetaxel, intraepidermal nerve fibres, skin biopsies, oxaliplatin, 4413
Neuropathy, meloxicam, paclitaxel, breast cancer, JBCRN, 3567
Neurotoxicity, assessment, chemotherapy, peripheral neuropathy, adverse effects, 3493
Neurotoxicity, cancer, adjuvant chemotherapy, docetaxel, intraepidermal nerve fibres, neuropathy, skin biopsies, oxaliplatin, 4413
Neutron dynamic therapy, boron tracedrug, BODIPY, curcuminoid, dynamic drug, thermal neutron irradiation, BNCT, 2477
Neutrophil-lymphocyte ratio, non-small cell lung cancer, survival, 2995
NFκB, breast cancer, genistein, quercetin, apoptosis, 3301
NFκB, IκBα, IKKβ, p38, peroxynitrite, nitration, colon cancer, 1607
NF-κB, multiple myeloma, curcumin analog, PI3K/AKT, JAK/STAT3, IRF4, 3719
NF-κB, ovarian cancer, methyl-2-cyano-3, 12-dioxooleana-1, 9(11)-dien-28-oate (CDDO-Me), apoptosis, AKT, mTOR, 3673
N-Heterocyclic indolyl glyoxylamides, p53-independent apoptosis, G_2/M phase arrest, human lung cancer cells, radiosensitivity, 3407
Nipple discharge, fiberoptic ductoscopy, breast cancer, 3517
Nitration, NFκB, IκBα, IKKβ, p38, peroxynitrite, colon cancer, 1607
Nitrosamine, *Stk11*, *Lkb1*, hepatocellular carcinoma, choline-deficient L-amino acid-defined diet, rat, 543
4N1K, ras, BNIP3, CD47, cancer, programmed cell death, 2869
NK4, gene therapy, cationised gelatin, cisplatin, squamous cell carcinoma, 105
NK4, HGF, c-Met, CT26, 5-fluorouracil, Akt, Erk1/2, thymidylate synthase, 2217
NKG2D, gemcitabine, MICA, MICB, HCC, immunotherapy, 2505

N-Methyl-*N*-nitrosourea, S_N1 methylating agents, apoptosis, O6-methylguanine-DNA methyltransferase (MGMT), RNA-binding proteins, 4291
Node dissection, p27, breast cancer, stage I, estrogen receptor, progesterone receptor, 4401
Non-anticoagulant heparins, chemotherapy, heparins, 411
Non-cirrhotic livers, hepatocellular carcinoma, viral hepatitis, 1055
Nonhepatic cancer, child's classification, hepatocellular carcinoma, liver cirrhosis, MELD-score, survival probability, TNM classification, 2931
Non-Hodgkin's lymphoma, BCL2, lutetium-177, somatostatin receptor, 3143
Non-Hodgkin's lymphoma, myeloproliferative neoplasm, portal vein thrombosis, 1467
Non-Hodgkin's lymphoma, YB-1, prognosis, immunohistochemistry, 2963
Non-invasive, cell-free DNA, circulation, biomarker, review, 2623
Non-melanoma, skin cancer, lymph node, metastasis, literature review, sentinel lymph node biopsy, 1443
Non-nuclear protein, progression, inflammation-associated carcinogenesis, fibrosarcoma, 1259
Non-operative management, rectal cancer, chemoradiation, neoadjuvant therapy, complete clinical response, review, 1795
Non-seminomatous testicular cancer, PTEN, Akt, $p27^{Kip1}$, subcellular distribution, 3783
Non-small cell lung cancer NSCLC, MAGE, expression, demethylation, 171
Non-small cell lung cancer, cancer stem cell antigens, biomarkers, prognosis, CD133, CD117, BCRP1, tissue microarrays, 4491
Non-small cell lung cancer, chemo-naive, *EGFR* mutation, erlotinib, platinum doublet, 3457
Non-small cell lung cancer, chemotherapy, carboplatin, paclitaxel, vinorelbine, 317
Non-small cell lung cancer, gefitinib, erlotinib, resistance, bone metastasis, radiotherapy, *EGFR*-TKIs, 4519
Non-small cell lung cancer, gefitinib, NSCLC, epidermal growth factor receptor, *EGFR*, skin toxicity, expanded access programme, EAP, 2949
Non-small cell lung cancer, HER2, surgical resection, immunohistochemical staining, prognosis, 4631
Non-small cell lung cancer, histoculture drug response assay, class III β-tubulin, predictive marker, vinorelbine, 999
Non-small cell lung cancer, lung cancer, bone metastases, bone remodeling markers, *N*-telopeptide of type I collegen, NTx, bone alkaline phosphatase, BAP, 3879
Non-small cell lung cancer, neutrophil-lymphocyte ratio, survival, 2995
Non-small cell lung cancer, ribonucleotide reductase, p53R2, hRRM2, 3475
Non-small cell lung cancer, third-line treatment, erlotinib, gefitinib, review, 649
Non-small cell lung cancer, TIMP1, mRNA, DFI, survival, blood plasma, 4031
Non-small cell lung cancer, TXNDC5, thioredoxin, protein disulphide isomerase, 1577
Non-small lung cancer cells, antisense oligonucleotide, cyclin D, cyclin E, cyclin-dependent kinase, retinoblastoma protein, pleural mesothelioma cells, apoptosis, kinases, phosphatases, 3683
Non-small lung cancer, metallothionein, MT, Ki-67, MCM-2, 2833
Non-solid type (Por2), poorly differentiated colorectal adenocarcinomas, solid type (Por1), 3463
Normal human keratinocytes, UVB, 18β-glycyrrhetinic acid, glabridin, ROS, 2209
Normal karyotype, interphase FISH, MDS, del(5q), del(20q), 1007
Normoxia, CD44-CD41, PC3 side fraction, hypoxia, 487
Notch, leukemia, wnt, hedgehog, γ-secretase inhibitor, 893
NOTCH, NSCLC, prognostic factors, HIF, lung cancer, 1603
Notch, stem cells, pancreatic cancer, signal pathway, natural agents, cancer therapy, drug resistance, review, 1105
NR1, glutamate receptor, cancer, PCR, shRNA, GLUR4, KA2, NR2D, 3181
NR2D, glutamate receptor, cancer, PCR, shRNA, NR1, GLUR4, KA2, 3181
NRAS, medullary thyroid carcinoma, gene mutations, *RET*, *HRAS*, *KRAS*, *BRAF*, *AKT1*, *CTNNB1*, mutational screening, 4179
NRF2, MT477, tumor growth, AURKA, 1181
NSAID, prostate cancer, PSA, statins, thiazide diuretic, 1735
NSCLC, *EGFR*, HER2, *EGFR* tyrosine kinase inhibitor, oncogene addiction, 4155
NSCLC, FOXP3, lung cancer, immunohistochemistry, lymph node, metastasis, 1677
NSCLC, gefitinib, non-small cell lung cancer, epidermal growth factor receptor, *EGFR*, skin toxicity, expanded access programme, EAP, 2949
NSCLC, lung cancer, erlotinib, *EGFR*, c-erbB-3, 281
NSCLC, methylation, MLPA, targeted therapy, gene methylation, TKIs, smoking, *EGFR* mutation, 4647
NSCLC, prognostic factors, HIF, NOTCH, lung cancer, 1603
N-telopeptide of type I collegen, lung cancer, non-small cell lung cancer, bone metastases, bone remodeling markers, NTx, bone alkaline phosphatase, BAP, 3879
NTx, lung cancer, non-small cell lung cancer, bone metastases, bone remodeling markers, *N*-telopeptide of type I collegen, bone alkaline phosphatase, BAP, 3879

Nuclear localization, actin cytoskeleton, cell migration, Ror1, receptor tyrosine kinase, 4239
Nuclear matrix proteins, cell death, pancreatic neoplasm, prostate neoplasm, natriuretic peptides, 395
Nuclei, quinazoliniminium salts, tumor cell proliferation, Ki-67 expression, macromolecule syntheses, DNA interaction and fragmentation, multiple mitotic figures, micronuclei, 2083
Nucleotide, insoluble protein, dendritic cell, T lymphocytes, immunotherapy, 881
NVP-AUY922, Hsp90 inhibitor, oral squamous cell carcinoma, 1197
O6-Methylguanine-DNA methyltransferase (MGMT), S_N1 methylating agents, apoptosis, RNA-binding proteins, *N*-methyl-*N*-nitrosourea, 4291
Obesity, KRAP, *KRAS*, target, cancer, diabetes, review, 2413
Oestrogen receptor-alpha, insulin-like growth factor-1, IGF-1, tamoxifen-resistance, oestrogen resistance, breast cancer recurrence, *EGFR*, 23
Oestrogen resistance, insulin-like growth factor-1, IGF-1, tamoxifen-resistance, breast cancer recurrence, oestrogen receptor-alpha, *EGFR*, 23
Off-label use, oxaliplatin, metastatic breast cancer, 1765
Oleic acid, antitumor activity, Bcr-Abl, CML, *Daedalea gibbosa*, kinase, medicinal mushrooms, autophosphorylation, 177
Oligodendroglioma, glioma, 1p19q, 1p, PAV, ACNU, procarbazine, vincristine, chemotherapy, 4475
Oligodeoxynucleotides, interleukin-6, interleukin-6 receptor, breast cancer, MCF-7, antisense, 2899
Oligonucleotide, microfluidics, lipid nanoparticles, 771
Oligonucleotides, electroporation, siRNA, miRNA, review, 4083
Once-weekly administration, multiple myeloma, bortezomib, dexamethasone, gastrointestinal adverse events, 2297
Oncogene addiction, *EGFR*, HER2, *EGFR* tyrosine kinase inhibitor, NSCLC, 4155
Oncogramme, breast cancer, primary culture, chemotherapeutics, therapy personalization, individualized tumour response testing, 139
Oncostatin M, interleukin-6, *VEGF*, u-PA, prostate cancer, 3273
Online tumor conference, gynecological cancer, breast cancer, interdisciplinary therapy management, second opinion, continuous medical training, 2669
Operation, BPF, fistula, lung cancer, risk factor, concurrent disease, perioperative complication, infection, 619
Operation, breast cancer, recurrence, survival, polychemotherapy, 277
Operative morbidity, ovarian cancer, relapse, intraperitoneal, catumaxomab, surgical tumor debulking, operative mortality, 2603
Operative mortality, ovarian cancer, relapse, intraperitoneal, catumaxomab, surgical tumor debulking, operative morbidity, 2603
OPN, uveal melanoma, metastasis, liver function tests, tumor markers, S-100β, MIA, TPS, 351
OPN, uveal melanoma, metastasis, tumor markers, S-100β, MIA, TPS, 345
OPRT, colorectal cancer, pulmonary metastases, TS, ERCC1, BRCA1, MVD, adjuvant chemotherapy, 2763
Optical imaging, dihydroartemisinin, pancreatic cancer, cell proliferation, apoptosis, angiogenesis, 1549
Optical reflectance imaging, magnetic resonance imaging, micro-computed tomography, tumor volume, molecular imaging, GFP, RFP, 2907
Optimal logistic regression, ovarian cancer, interval debulking surgery, staging laparoscopy, 4469
Oral administration, LPS, endotoxin, toxicity, absorption, lipopolysaccharide, review, 2431
Oral cancer, ADH1B, alcohol-dehydrogenase, polymorphism, laryngeal cancer, 677
Oral cancer, *cyclin D1*, polymorphism, smoking, 227
Oral cancer, methylenetetrahydrofolate reductase *MTHFR*, smoking, metastasis, recurrence, 2395
Oral cancer, *VEGF*, mTOR, HIF-1α, angiogenesis, 4429
Oral carcinogenesis, immunohistochemistry, beta-catenin, tongue, mice, 2805
Oral cavity squamous cell carcinoma OCSCC, *Levisticum officinale* lovage, head and neck squamous cell carcinoma HNSCC, natural product, pharmacogenomics, 185
Oral cavity squamous cell carcinoma OCSCC, *Thymus vulgaris* L. (thyme), head and neck squamous cell carcinoma HNSCC, natural product, pharmacogenomics, 81
Oral cavity, hemangiopericytoma, solitary fibrous tumor, cheek, soft tissue, 719
Oral etoposide, recurrent cervical cancer, cisplatin, second-line chemotherapy, feasibility study, 3063
Oral SCC, EMMPRIN, Fyn, integrin, ECM, 1205
Oral squamous cell carcinoma, benzo[*c*]phenanthridine alkaloids, sanguinarine, anticancer therapeutic agents, 2841
Oral squamous cell carcinoma, cadherins, immunohistochemistry, prognosis, OSCC, 4211
Oral squamous cell carcinoma, gankyrin, overexpression, 2683
Oral squamous cell carcinoma, Hsp90 inhibitor, NVP-AUY922, 1197
Oral squamous cell carcinoma, thymidylate synthase, dihydropyrimidine dehydrogenase, lymph node metastasis, KAI1/CD82, 3521
Oral squamous cell carcinomas, toombak, genes, apoptosis, cell cycle regulation, intermediate filament proteins, Sudan, 3345

Orf virus, immunotherapy, immunomodulation, tumor models, natural killer cells, *Parapoxvirus ovis*, 4185
Organic arsenicals, arsenic trioxide, arsenic acid, T-lymphoblastoid leukemia, daunorubicin resistance, apoptosis, 4169
Oropharyngeal cancer, tonsillar cancer, base of tongue cancer, head and neck cancer, HPV, revie, 1515
Orthotopic model, colon cancer, GFP, fluorescent protein imaging (FPI), MRI, selenium, angiogenesis, 387
Orthotopic mouse model of osteosarcoma, IGF-1R, phosphorylated MEK, Ras/Raf/MEK/ERK pathway, lung metastasis, 1147
Orthotopic, GFP, prostate cancer, PC-3, circulating cancer cells, immunomagnetic beads, isolation, fluorescence, imaging, culture, 1535
OSCC, cadherins, immunohistochemistry, prognosis, oral squamous cell carcinoma, 4211
OSMR, quantitative methylation-specific PCR, colorectal cancer, 1293
OSNA, breast cancer, sentinel lymph node, cytokeratin 19, intra-operative method, 585
Osteolysis, GLI2, PTHrP, breast cancer, 6-thioguanine, 2705
Osteonecrosis, bisphosphonate, mandible, BRONJ, 2313
Osteopontin, renal failure, mesothelioma, tumor markers, N-ERC/mesothelin, 1427
Osteosarcoma cell lines, P-Glycoprotein, chemotherapy, inhibition of multidrug resistance, carcinoma cell lines, siRNA, 2813
Osteosarcoma, acridine orange, pulmonary metastasis, photodynamic therapy, flash-wave light, fluorovisualization, 4163
Osteosarcoma, C7orf24, γ-glutamyl cyclotransferase, 1297
Osteosarcoma, jaw bones, maxilla, mandible, 4485
Osteosarcoma, malignant fibrous histiocytoma, MAPK signaling pathway, 549
Osteosarcoma, metastasis, angiotensin II type 1 receptor antagonist, CV11974, 123
Outcome, thromoboembolism, breast cancer, chemotherapy, 2383
Ovarian cancer cell lines, oxaliplatin, phytochemicals, synergism, cytotoxicity, 4283
Ovarian cancer cell lines, PAMAM dendrimers, encapsulation, intracellular delivery, resistance, SMVT, cisplatin, 897
Ovarian cancer relapse, secondary cytoreductive surgery, predictive factor, tumor residual, complete tumor resection, 2583
Ovarian cancer, 8-hydroxydeoxyguanosine, oxidative stress, reactive oxygen species, 1411
Ovarian cancer, bevacizumab, platinum-resistant, 2679
Ovarian cancer, cisplatin, curcumin, EGCG, synergism, drug combination, 1131
Ovarian cancer, claudin-4, chemotherapy resistance, 1271
Ovarian cancer, clinical cancer registry, cancer epidemiology, 2657
Ovarian cancer, consolidation chemotherapy, recurrent, salvage chemotherapy, treatment-free interval, paclitaxel, cisplatin, irinotecan, 4613
Ovarian cancer, CT-guided high-dose-rate brachytherapy, CT-HDRBT, metachronous liver metastasis, ablation of liver metastases, 2597
Ovarian cancer, cytoreductive surgery, residual disease, prediction models, 4043
Ovarian cancer, diagnosis, biomarkers, enzyme-linked immunosorbent assay, cathepsin, matrix metalloproteinase-9, heparanase, 3423
Ovarian cancer, estrogen receptor beta, prognostic factor, immunohistochemistry, cisplatin, 711
Ovarian cancer, gene mutations, BRCA 1/2, *TP53*, PI3K, AKT, *BRAF*, *KRAS*, review, 2661
Ovarian cancer, HB-EGF, ELISA, 2553
Ovarian cancer, HB-EGF, targeted therapy, CRM197, 2461
Ovarian cancer, hyperthermia, bevacizumab, doxorubicin, platinum-refractory, 2675
Ovarian cancer, hyprocrellin B, hematoporphyrin monomethyl ether, intracellular metabolism, subcellular localization, phototoxicity, 3229
Ovarian cancer, interval debulking surgery, staging laparoscopy, optimal logistic regression, 4469
Ovarian cancer, methyl-2-cyano-3, 12-dioxooleana-1, 9(11)-dien-28-oate (CDDO-Me), apoptosis, AKT, NF-κB, mTOR, 3673
Ovarian cancer, relapse, intraperitoneal, catumaxomab, surgical tumor debulking, operative morbidity, operative mortality, 2603
Ovarian cancer, WT1 peptide vaccine, immunotherapy, 2441
Overexpression, gankyrin, oral squamous cell carcinoma, 2683
Oxaliplatin, cancer, neurotoxicity, adjuvant chemotherapy, docetaxel, intraepidermal nerve fibres, neuropathy, skin biopsies, 4413
Oxaliplatin, capecitabine, bevacizumab, cetuximab, phase II, metastatic colorectal cancer, 255
Oxaliplatin, cetuximab, colorectal cancer, irinotecan, biomarkers, 2149
Oxaliplatin, chemotherapy, FLOX regimen, metastatic colorectal cancer, phase II study, 5-FU, leucovorin, 4657
Oxaliplatin, drug resistance, drug combination, synergism, quercetin, thymoquinone, cisplatin, 3789
Oxaliplatin, gastric cancer, cetuximab, irinotecan, *KRAS* phase II trial, 4439
Oxaliplatin, *KRAS*, *p53,* colorectal, 5-fluorouracil, capecitabine, clinical, CAIRO2, sequence analysis, 1379
Oxaliplatin, off-label use, metastatic breast cancer, 1765

Oxaliplatin, phytochemicals, ovarian cancer cell lines, synergism, cytotoxicity, 4283
Oxidative stress, 8-hydroxydeoxyguanosine, ovarian cancer, reactive oxygen species, 1411
Oxidative stress, Beckwith-Wiedemann syndrome, potassium ascorbate, 3973
Oxidative stress, Na^+, H^+ exchange, cholangiocellular carcinoma, liver cancer, 459
3-Oxoolean-12-en-27-oic acid, cell-cycle arrest, lung cancer cells, 2179
P13K/mTOR inhibitor, BEZ235, lung cancer, *EGFR*, 849
P16I*NK4*a, methylation, colorectal cancer, 1643
P21, *p53, CDKN1A/WAF/CIP1*, polymorphism, endometriosis, genotype, 4301
P22PHOX, polymorphism, ulcerative colitis, DNA methylation, CD14, MBL, 933
P27, breast cancer, node dissection, stage I, estrogen receptor, progesterone receptor, 4401
$p27^{Kip1}$, non-seminomatous testicular cancer, PTEN, Akt, subcellular distribution, 3783
P38 MAPK, head and neck cancer, STAT1, STAT3, phosphorylation, 3819
P38, NFκB, IκBα, IKKβ, peroxynitrite, nitration, colon cancer, 1607
P38, PEDF, c-FLIP, HCC, PPARγ, hepatocellular carcinoma, apoptosis, 1173
P53 pathway, medicinal herb, bioactivity, apoptosis, *Ruta graveolens*, Akt, 233
P53, age, breast cancer, grade, immunohistochemistry, measles virus, 913
P53, anticancer agents, sphingomylinase, *Cox-2*, caspase-3, apoptosis, cell cycle, 1345
P53, anticancer drugs, sphingomyelinase, Bax, cell cycle, apoptosis, 871
P53, cancer, endometrium, apoptosis, *Bcl-2*, E-cadherin, estrogen receptor, progesterone receptor, 4191
P53, cyclin B1, cell cycle, squamous cell carcinoma, head and neck cancer, 3151
P53, *KRAS*, colorectal, oxaliplatin, 5-fluorouracil, capecitabine, clinical, CAIRO2, sequence analysis, 1379
P53, *p21, CDKN1A/WAF/CIP1*, polymorphism, endometriosis, genotype, 4301
P53-independent apoptosis, N-heterocyclic indolyl glyoxylamides, G_2/M phase arrest, human lung cancer cells, radiosensitivity, 3407
P53R2, non-small cell lung cancer, ribonucleotide reductase, hRRM2, 3475
P66shc, epigenetic modifiers, kidney, toxicity, ROS, mitochondria, 3267
P90RSK, genistein, breast cancer, cell proliferation, T47D cells, 209
Paclitaxel (PTX), alcohol intolerance, de-alcoholization, pharmacokinetics, adverse event, 4339
Paclitaxel, anal cancer, 5-FU, cisplatin, 4637
Paclitaxel, bevacizumab, breast cancer, vascular endothelial growth factor receptors, 3007
Paclitaxel, chemotherapy, carboplatin, vinorelbine, non-small cell lung cancer, 317
Paclitaxel, doxifluridine, gastric cancer, ascites, 4625
Paclitaxel, doxifluridine, gastric cancer, thymidine phosphorylase, chemotherapy, 287
Paclitaxel, meloxicam, neuropathy, breast cancer, JBCRN, 3567
Paclitaxel, ovarian cancer, consolidation chemotherapy, recurrent, salvage chemotherapy, treatment-free interval, cisplatin, irinotecan, 4613
Paclitaxel, small cell lung cancer, TRAIL, chemotherapy, 3193
Paclitaxel, squamous cell carcinoma, bladder cancer, recurrence, gemcitabine, 4465
Paclitaxel, triplet combination chemotherapy, cisplatin, S-1, advanced gastric cancer, feasibility study, 3085
Paclitaxel-based chemoradiotherapy, lung cancer, BCL-2, MDR1, radiosensitivity, 1431
P-Akt, LAT1, CD98, recurrence, advanced NSCLC, *EGFR* mutation, prognosis, chemotherapy. Ki-67, p-mTOR, 3775
P-Akt, prostate cancer, PGE2, EP4, *Snail*, epithelial-mesencymal transition, 4347
Palladin, neuroendocrine carcinomas, metastasis, 2957
PAMAM dendrimers, encapsulation, intracellular delivery, resistance, SMVT, cisplatin, ovarian cancer cell lines, 897
Pancreas cancer, belinostat, bortezomib, histone deacetylase inhibitor, proteasome inhibitor, hepatocellular cancer, apoptosis, metabolomics, 1093
Pancreatic cancer cells, pomegranate, phytochemicals, cell cycle arrest, 2699
Pancreatic cancer cells, uridine phosphorylase, hybrid steroidal alkylators, *in silico* molecular docking, *in vitro* assay, mitrogen mustards, 831
Pancreatic cancer, BRCA, iniparib, chemotherapy, 1417
Pancreatic cancer, dihydroartemisinin, cell proliferation, apoptosis, angiogenesis, optical imaging, 1549
Pancreatic cancer, gemcitabine, intra-arterial therapy, chemoradiotherapy, 3909
Pancreatic cancer, gemcitabine, resistance, ERK, lenalidomide, 3747
Pancreatic cancer, hENT1, gemcitabine, cytotoxicity, I3C, 3171
Pancreatic cancer, interleukin-6, signal transducer and activator of transcription 3, 2029
Pancreatic cancer, myeloid DC, dentritic cells, prognostic factor, survival analysis, circulating dendritic cells, 3827
Pancreatic cancer, notch, stem cells, signal pathway, natural agents, cancer therapy, drug resistance, review, 1105

Pancreatic cancer, pancreatic neoplasms, long-term survivors, surgery, brain metastasis, 4599
Pancreatic cancer, two-dimensional gel electrophoresis, LC-MS/MS, TS-1, proteomics, 2103
Pancreatic cancer, virotherapy, chemoresistance, gemcitabine, PDAC, GFP, 1279
Pancreatic neoplasm, cell death, prostate neoplasm, nuclear matrix proteins, natriuretic peptides, 395
Pancreatic neoplasm, erlotinib, cetuximab, chemotherapy, chemoresistance, chemosensitivity, 1039
Pancreatic neoplasms, pancreatic cancer, long-term survivors, surgery, brain metastasis, 4599
Panipenem, active metabolite of irinotecan, SN-38, glucuronidation, SN-38 glucuronide (SN-38G), pharmacokinetics, 2915
Panitumumab, metastatic colorectal cancer, bevacizumab, treatment, 1033
Pantoea agglomerans, A46, LPS, LPSp, LPSa46, macrophage, M-CSF, GM-CSF, 2467
Papanicolaou staining, DNA ploidy, image analysis, cytometry, cytology, hematoxylin staining, Feulgen staining, 53
Para-aortic lymph node dissection, endometrial carcinoma, adjuvant chemotherapy, prognosis, 4513
Parametrium, cervical cancer, micrometastasis, immunohistochemistry, 243
Paraoxonase 1, *PON1*, polymorphism, lung cancer risk, SNP, 2225
Parapoxvirus ovis, immunotherapy, immunomodulation, tumor models, natural killer cells, Orf virus, 4185
Parathyroid tumors, hyperparathyroidism, arterial blood pressure, serum calcium, PTH, arterial hypertension, elderly, 3969
Pathological features, prostaglandin E2 receptor, renal cell carcinoma, survival, immunohistochemistry, 597
Pathological response, esophageal squamous cell carcinoma, neoadjuvant chemoradiotherapy, complication, prognosis, 3073
Patients' satisfaction, prostate cancer, radiation, surgery, hormonal therapy, 3903
PAV, glioma, oligodendroglioma, 1p19q, 1p, ACNU, procarbazine, vincristine, chemotherapy, 4475
Paxillin, cytoskeleton, phosphatase, PP-1, TGF-β, 3159
PC3 side fraction, CD44-CD41, normoxia, hypoxia, 487
PC-3, GFP, prostate cancer, orthotopic, circulating cancer cells, immunomagnetic beads, isolation, fluorescence, imaging, culture, 1535
PCA3 urinary test, prostate cancer, MRSI, DCEMR, 1399
PCA3, PSA free/total, prostate cancer, saturation prostate biopsy, repeat biopsy, cancer diagnosis, 4445
PCI-24781, histone deacetylase inhibitor, chemotherapy, multidrug resistant, sarcoma, 1115
PCNA, Ki-67, recurrence, lung, adenocarcinoma, 4277
PCR, breast cancer, brain metastases, human mammaglobin, 1061
PCR, breast cancer, neoadjuvant chemotherapy, trastuzumab, 3041
PCR, glutamate receptor, cancer, shRNA, NR1, GLUR4, KA2, NR2D, 3181
PCR, prognostic factor, stanniocalcin 1, colorectal cancer, 325
PDAC, virotherapy, pancreatic cancer, chemoresistance, gemcitabine, GFP, 1279
PDT, photodynamic therapy, glycoconjugated chlorin, apoptosis, gastric cancer, colon cancer, 763
PEDF, c-FLIP, HCC, p38, PPARγ, hepatocellular carcinoma, apoptosis, 1173
Pediatric neuro-oncology, quality control, brain tumor, survival, 661
Pediatrics, bevacizumab, safety, *VEGF*, 3953
PEG liposomes, stealth liposomes, 5-FU, locoregional chemotherapy, liver metastases, 147
PEG liposomes, stealth liposomes, docetaxel, locoregional chemotherapy, liver metastases, hepatic arterial infusion, 153
Pelvic nodal involvement, prostate cancer, serum total testosterone, 3615
Pemetrexed, radiation, human mesothelioma cell line, radiosensitivity, apoptosis, 2847
Pemetrexed, skin toxicity, hyperpigmentation, 1753
Peptide vaccination, acute myeloid leukemia, immunotherapy, interleukin-2, cerebrospinal fluid, CSF, flow of CSF, chloroma, 2343
Peptide, Her-2/neu, vaccine, B-cell epitope, antitumor effect, 3361
Peptide, matrix metalloproteinases, gelatinase, tongue carcinoma, green fluorescent protein, xenograft, 3659
Percutaneous ablation, hepatocellular carcinoma, cirrhosis, percutaneous ethanol injection, radiofrequency ablation, randomized controlled trial, 2291
Percutaneous ethanol injection, hepatocellular carcinoma, cirrhosis, percutaneous ablation, radiofrequency ablation, randomized controlled trial, 2291
Perioperative complication, BPF, fistula, operation, lung cancer, risk factor, concurrent disease, infection, 619
Perioperative factors, hepatocellular carcinoma, uncontrolled ascites, hepatectomy, prognosis, 4545
Peripheral neuropathy, assessment, chemotherapy, neurotoxicity, adverse effects, 3493
Peroxynitrite, NFκB, IκBα, IKKβ, p38, nitration, colon cancer, 1607
Personality, bening breast disease, type C, hopelessness, cancer risk, 4019
Personality, type C, commitment, cancer risk, 4013
PGE2, prostate cancer, EP4, p-Akt, *Snail*, epithelial-mesencymal transition, 4347

P-Glycoprotein, chemotherapy, inhibition of multidrug resistance, osteosarcoma cell lines, carcinoma cell lines, siRNA, 2813
P-Glycoprotein, multidrug resistance, benzo[*a*]quinolizin derivatives, 921
P-Glycoprotein, multidrug-resistant cancer cells, MDR mouse T-lymphoma cells, ABCB1 transporter, phenothiazines, thioridazine, apoptosis, 4201
P-gp modulation, isolated lung perfusion, sarcoma lung metastases, doxorubicin, cyclosporine, valspodar, 2121
Phagocytic activity, Gc-derived macrophage-activating factor precursor, preGcMAF, 1f1f subtype of Gc protein, Gc1f1f protein, mouse peritoneal macrophages, 2489
Pharmacogenetics, irinotecan, metastatic colorectal cancer, 359
Pharmacogenomics, *Levisticum officinale* lovage, oral cavity squamous cell carcinoma OCSCC, head and neck squamous cell carcinoma HNSCC, natural product, 185
Pharmacogenomics, SNPs, bexarotene, RXR, lung cancer, 2303
Pharmacogenomics, *Thymus vulgaris* L. (thyme), oral cavity squamous cell carcinoma OCSCC, head and neck squamous cell carcinoma HNSCC, natural product, 81
Pharmacokinetics, active metabolite of irinotecan, SN-38, glucuronidation, SN-38 glucuronide (SN-38G), panipenem, 2915
Pharmacokinetics, afatinib, BIBF 1120, colorectal cancer, phase II, 2271
Pharmacokinetics, irinotecan, metabolites, hepatic intra-arterial infusion, plasma disposition, 3573
Pharmacokinetics, paclitaxel (PTX), alcohol intolerance, de-alcoholization, adverse event, 4339
Phase I, chemotherapy, docetaxel, nedaplatin, S1, esophageal carcinoma, 4589
Phase I, fenretinide, LXS oral powder, clinical trial, 961
Phase I, S-1, 5-fluorouracil, FBAL, tegafur, FT, reversible dihydropyrimidine dehydrogenase, DPD, gimeracil, CDHP, solid tumors, 625
Phase II study, chemotherapy, FLOX regimen, metastatic colorectal cancer, 5-FU, leucovorin, oxaliplatin, 4657
Phase II trials, neoadjuvant therapy, radiochemotherapy, esophageal cancer, docetaxel, cisplatin, 4407
Phase II, afatinib, BIBF 1120, colorectal cancer, pharmacokinetics, 2271
Phase II, capecitabine, oxaliplatin, bevacizumab, cetuximab, metastatic colorectal cancer, 255
Phase II, HNSCC, Src, AZD0530, saracatinib, 249
Phase-I, adrenocortical carcinoma, ADH-1, dynamic contrast enhancing magnetic resonance imaging (DCE-MRI), N-cadherin, 3921
Phenethyl isothiocyanate, cell cycle arrest, apoptosis, mitochondria, caspases, prostate cancer DU 145 cells, 1691
Phenformin, colon cancer, metformin, 2-deoxyglucose, acidification, 421
Phenothiazines, multidrug-resistant cancer cells, MDR mouse T-lymphoma cells, ABCB1 transporter, P-glycoprotein, thioridazine, apoptosis, 4201
Phosphatase and tensin homolog (PTEN), colon cancer metastasis, epithelial-mesenchymal transition (EMT), endothelin axis, endothelin A and B receptor (ETAR and ETBR), 861
Phosphatase, cytoskeleton, paxillin, PP-1, TGF-β, 3159
Phosphatases, antisense oligonucleotide, cyclin D, cyclin E, cyclin-dependent kinase, retinoblastoma protein, non-small lung cancer cells, pleural mesothelioma cells, apoptosis, kinases, 3683
Phosphodiesterase, cervical carcinoma, prognosis, iNOS, guanylyl cyclase, 2319
Phospho-proteins, ischemia, immunohistochemistry, xenografts, pre-analytical variables, biopsy, 2073
Phosphorylated MEK, IGF-1R, Ras/Raf/MEK/ERK pathway, orthotopic mouse model of osteosarcoma, lung metastasis, 1147
Phosphorylation of *p53,* ionizing radiation, radiation-sensitivity, 2255
Phosphorylation, head and neck cancer, p38 MAPK, STAT1, STAT3, 3819
Phosphorylation, sunitinib, antitumor, antimetastasis, *VEGF*, V*EGFR*, mammary cancer, 1225
Photodynamic therapy, acridine orange, osteosarcoma, pulmonary metastasis, flash-wave light, fluorovisualization, 4163
Photodynamic therapy, PDT, glycoconjugated chlorin, apoptosis, gastric cancer, colon cancer, 763
Phototoxicity, ovarian cancer, hyprocrellin B, hematoporphyrin monomethyl ether, intracellular metabolism, subcellular localization, 3229
Phytochemicals, oxaliplatin, ovarian cancer cell lines, synergism, cytotoxicity, 4283
Phytochemicals, pomegranate, pancreatic cancer cells, cell cycle arrest, 2699
PI3K, advanced gastric cancer, AKT, chemoresistance, review, 4387
PI3K, ovarian cancer, gene mutations, BRCA 1/2, *TP53*, AKT, *BRAF*, *KRAS*, review, 2661
PI3K, thyroid hormones, proliferation, MAPK, 89
PI3K/AKT, multiple myeloma, curcumin analog, NF-κB, JAK/STAT3, IRF4, 3719
PI3K-Akt/mTOR pathway, gastrointestinal stromal tumors (GISTs), Ras-Raf-ERK/MAPK Pathway, insulin-like growth factor 1 receptor (IGF1R), CD117, 3019
Placental growth factor, alternative splicing, angiogenesis, autologous stem cell transplantation, chick chorioallantoic membrane assay, high-dose chemotherapy, vascular endothelial growth factor, V*EGFR*1, 3115

Plasma cell malignancy, proteasome inhibitor, receptor tyrosine kinase, activation loop, multiple myeloma, ER stress, FGFR3, Lys650Glu mutation, K650E, bortezomide, 113
Plasma disposition, irinotecan, metabolites, hepatic intra-arterial infusion, pharmacokinetics, 3573
Plasma, cytokines, morphine, MIP-1α, IL-12, 4561
Plasma, MtDNA mutation, D-loop region, breast cancer, mitochondrial DNA, 4267
Platinum doublet, chemo-naive, *EGFR* mutation, erlotinib, non-small cell lung cancer, 3457
Platinum, ferrocene, ethynyl phosphine, gold, cytotoxicity, HeLa, 825
Platinum-refractory, hyperthermia, bevacizumab, doxorubicin, ovarian cancer, 2675
Platinum-resistant, bevacizumab, ovarian cancer, 2679
Pleural mesothelioma cells, antisense oligonucleotide, cyclin D, cyclin E, cyclin-dependent kinase, retinoblastoma protein, non-small lung cancer cells, apoptosis, kinases, phosphatases, 3683
238-Plutonium, α-Particle radiation, Monte Carlo simulations, bystander effect, micronucleus assay, 2113
P-mTOR, LAT1, CD98, recurrence, advanced NSCLC, *EGFR* mutation, prognosis, chemotherapy. Ki-67, p-Akt, 3775
Pneumatosis intestinalis, sunitinib, gastrointestinal stromal tumor, 3429
Polo-like kinase 1, cholangiocarcinoma, 5-fluorouracil, gemcitabine, BI 2536, 3289
Polybisphosphonate, bone metastasis, prostate cancer, 4141
Polychemotherapy, breast cancer, recurrence, operation, survival, 277
Polymorphic genotypes, caveolin-1, breast cancer, 3511
Polymorphism, ADH1B, alcohol-dehydrogenase, oral cancer, laryngeal cancer, 677
Polymorphism, Cav-1, nasopharyngeal carcinoma, carcinogenesis, 3629
Polymorphism, CCND1 1722, *cyclin D1*, upper tract urothelial cancer, 1043
Polymorphism, colorectal cancer, MMP2, *VEGF*, HIF1A, SNP, 575
Polymorphism, *Cox-2*, carcinogenesis, prostate cancer, 221
Polymorphism, *cyclin D1*, CCND1, lung cancer, smoking, Taiwanese, 3601
Polymorphism, *cyclin D1*, oral cancer, smoking, 227
Polymorphism, *Helicobacter pylori*, gastric atrophy, intestinal metaplasia, *XRCC1*, *GSTP1*, *GSTT1*, *GSTM1*, 1459
Polymorphism, HNSCC, *EGFR*, Erk-1/2, AG1478, cetuximab, 59
Polymorphism, *hOGG1*, *XPD*, urothelial carcinoma, 3939
Polymorphism, *p53, p21, CDKN1A/WAF/CIP1*, endometriosis, genotype, 4301
Polymorphism, paraoxonase 1, *PON1*, lung cancer risk, SNP, 2225
Polymorphism, ulcerative colitis, DNA methylation, CD14, p22PHOX, MBL, 933
Polymorphism, X-ray repair cross-complementing group 1, *XRCC1*, DNA repair, skin cancer, meta-analysis, 3945
Polymorphism, *XRCC1*, Arg399Gln, Arg194Trp, *GSTP1* Ile104Val, *GSTT1*, *GSTM1*, gastric cancer, survival, 705
Polymorphisms, integrins, colorectal cancer, survival, single nucleotide polymorphisms, 1373
Polymorphisms, mutations, *TP53*, *FHIT*, chronic esophagitis, esophageal carcinoma, 1685
Polyp, gastric, chief cells, fundic glend polyps, 1789
Pomegranate, pancreatic cancer cells, phytochemicals, cell cycle arrest, 2699
PON1, paraoxonase 1, polymorphism, lung cancer risk, SNP, 2225
Poorly differentiated colorectal adenocarcinomas, solid type (Por1), non-solid type (Por2), 3463
Portal vein embolisation, liver hypertrophy, tumor progression, serum markers, 339
Portal vein thrombosis, myeloproliferative neoplasm, non-Hodgkin's lymphoma, 1467
Posterior triangle, level V, neck dissection, 3959
Postmenopausal women, aromatase inhibitors, anti-estrogens, breast cancer, steroid sulfatase, tamoxifen, anastrozole, 1367
Postoperative prognosis, κ-actin, hepatocellular carcinoma, survival, 2037
Postoperative radiotherapy, radiation therapy, risk factor, enterocolitis, leg edema, gynecological malignancies, 3527
Post-traumatic sequelae, intravenous curcumin, blood–brain barrier, hippocampus, striatum, brain stem, 907
Potassium ascorbate, oxidative stress, Beckwith-Wiedemann syndrome, 3973
Potassium channels, epithelial to mesenchymal transition, lung cancer, Eag1, TGF-β, 1265
PP-1, cytoskeleton, paxillin, phosphatase, TGF-β, 3159
PP2Ac, lactoferrin, IGBP1, apoptosis, lung adeno-carcinoma, 529
PPARG, PPARγ, breast cancer, T0070907, migration, invasion, 813
PPARγ, breast cancer, PPARG, T0070907, migration, invasion, 813
PPARγ, PEDF, c-FLIP, HCC, p38, hepatocellular carcinoma, apoptosis, 1173
Pre-analytical variables, ischemia, immunohistochemistry, xenografts, phospho-proteins, biopsy, 2073
Prediction models, ovarian cancer, cytoreductive surgery, residual disease, 4043
Prediction of therapy response, breast ultrasound, pre-operative therapy, sonography, sphericity, 4039

Prediction, cancer, immunotherapy, survival, CD8, CD57, review, 639
Predictive factor, ovarian cancer relapse, secondary cytoreductive surgery, tumor residual, complete tumor resection, 2583
Predictive marker, histoculture drug response assay, non-small cell lung cancer, class III β-tubulin, vinorelbine, 999
Predictor, gefitinib, radiation, combination therapy, *EGFR*, melanoma, 2883
Predictors of survival, castrate-resistant prostate cancer, time to castration resistance, chemotherapy, advanced prostate cancer, 1475
PreGcMAF, Gc-derived macrophage-activating factor precursor, 1f1f subtype of Gc protein, Gc1f1f protein, phagocytic activity, mouse peritoneal macrophages, 2489
Pregnancy, gastric cancer, low back pain, bilateral erythematous breast hypertrophy, 681
Premenopausal breast cancer, total estrogen blockade, high-dose chemotherapy, leuprorelin, anastrazole, *VEGF*, 671
Pre-metastatic niche, breast cancer, stem cells, metastasis, CD133, prognosis, 1315
Preoperative chemoradiotherapy, glucose transporter-1, hypoxia, hypoxia-inducible factor 1α, rectal cancer, 1559
Pre-operative therapy, breast ultrasound, prediction of therapy response, sonography, sphericity, 4039
Prevention, vitamin D, 25-hydroxyvitamin D, breast neoplasms, case–control studies, epidemiology, meta-analysis, 2939
Primary culture, breast cancer, chemotherapeutics, therapy personalization, oncogramme, individualized tumour response testing, 139
Primary peritoneal carcinoma, bevacizumab, erlotinib, 4397
Primary serous-papillary peritoneal carcinoma, retroperitoneal lymph nodes, spread pattern, review, 1387
Priming, macrophage, LPS, IP-PA1, chronic psychological stress, review, 2437
Procarbazine, glioma, oligodendroglioma, 1p19q, 1p, PAV, ACNU, vincristine, chemotherapy, 4475
Prodrug activation, adenovirus, HNSCC, ganciclovir, thymidine kinase, apoptosis, 3851
Prodrugs, neural stem cells, suicide genes, invasive tumors, animal models, gene-directed enzyme prodrug therapy review, 1249
Progesterone receptor, cancer, endometrium, apoptosis, *Bcl-2*, *p53,* E-cadherin, estrogen receptor, 4191
Progesterone receptor, p27, breast cancer, node dissection, stage I, estrogen receptor, 4401
Prognosis factor, renal cell carcinoma, gamma-delta T-cell, 1027
Prognosis, antiangiogenic therapy, hepatitis B virus, hepatocellular carcinoma, 4007
Prognosis, breast cancer, DAX-1, ApoD, ERα, 443
Prognosis, breast cancer, disseminated tumor cells, bone marrow, follow-up, 2749
Prognosis, breast cancer, methylation, RASSF1A, 2975
Prognosis, breast cancer, stem cells, pre-metastatic niche, metastasis, CD133, 1315
Prognosis, cadherins, immunohistochemistry, OSCC, oral squamous cell carcinoma, 4211
Prognosis, cervical cancer, C-reactive protein, CRP, *CRP1919* (rs1417938), *CRP2667* (rs1800947), *CRP3872* (rs1205), *CRP5237* (rs2808630), gene polymorphism, single nucleotide polymorphism, 2259
Prognosis, cervical carcinoma, iNOS, guanylyl cyclase, phosphodiesterase, 2319
Prognosis, endometrial cancer, survival, radiotherapy, chemotherapy, 3483
Prognosis, endometrial carcinoma, para-aortic lymph node dissection, adjuvant chemotherapy, 4513
Prognosis, esophageal squamous cell carcinoma, neoadjuvant chemoradiotherapy, pathological response, complication, 3073
Prognosis, gastric cancer, lymph node dissection, staging, 2361
Prognosis, GLUT-1, rectal cancer, chemotherapy, radiotherapy, tumour regression, 311
Prognosis, heart, hepatocellular carcinoma, inferior vena cava, 4641
Prognosis, hepatocellular carcinoma, perioperative factors, uncontrolled ascites, hepatectomy, 4545
Prognosis, HER2, non-small cell lung cancer, surgical resection, immunohistochemical staining, 4631
Prognosis, HuR, breast cancer, histological status, 303
Prognosis, LAT1, CD98, mesothelioma, hypoxia, mTOR, 4075
Prognosis, LAT1, CD98, recurrence, advanced NSCLC, *EGFR* mutation, chemotherapy. Ki-67, p-Akt, p-mTOR, 3775
Prognosis, left colon, right colon, sigmoid, survival, colon cancer, gender, 2347
Prognosis, magnetic resonance spectroscopy, brain neoplasms, radiotherapy, prospective studies, 3559
Prognosis, maspin, activin A, androgen receptor, upper urinary tract urothelial carcinoma, 1713
Prognosis, mitotic counts, breast cancer, 97
Prognosis, non-Hodgkin's lymphoma, YB-1, immuno-histochemistry, 2963
Prognosis, non-small cell lung cancer, cancer stem cell antigens, biomarkers, CD133, CD117, BCRP1, tissue microarrays, 4491
Prognosis, RGM, breast cancer, prostate cancer, 1703
Prognostic factor, ADM, colorectal cancer, hypoxia, 507
Prognostic factor, breast cancer, mammography, calcification, 2327
Prognostic factor, claudin-1, recurrence, rectal cancer, 2517

Prognostic factor, estrogen receptor beta, ovarian cancer, immunohistochemistry, cisplatin, 711
Prognostic factor, myeloid DC, dentritic cells, pancreatic cancer, survival analysis, circulating dendritic cells, 3827
Prognostic factor, rectal cancer, radiotherapy, chemotherapy, biomarker, carbonic anhydrase IX, hypoxia-inducible factor-1a, ezrin, glucose transporter-1, 4529
Prognostic factor, stanniocalcin 1, PCR, colorectal cancer, 325
Prognostic factors, breast cancer liver metastases, liver surgery, tumour markers, differental diagnosis, benign liver lesions, 1447
Prognostic factors, metastatic breast cancer, capecitabine, triple-negative, HER2-negative, 1079
Prognostic factors, NSCLC, HIF, NOTCH, lung cancer, 1603
Prognostic role, bladder cancer, transitional carcinoma, lymphovascular invasion, upper tract transitional carcinoma, review, 3503
Programmed cell death, ras, BNIP3, CD47, cancer, 4N1K, 2869
Progression, inflammation-associated carcinogenesis, fibrosarcoma, non-nuclear protein, 1259
Pro-inflammatory micro*env* ironment, breast cancer, E-selectin, liver metastasis, endothelium, 3219
Prolactin (PRL), luteinizing hormone (LH), total testosterone (TT), free testosterone (FT), prostate-specific antigen (PSA), prostate cancer, 3913
Proliferation, cathepsin, cytokines, lung cancer cells, 47
Proliferation, *dectin-1*, beta-glucan, B-cell lymphoma, CD86, cell death, 4195
Proliferation, laryngal squamous cell carcinoma, microRNA, apoptosis, 3859
Proliferation, laryngeal cancer, glutamate receptor, antagonist, ERK1/2 kinase, 565
Proliferation, thymidine kinase1, 5'(3')-deoxyribonucleotidase, fluorothymidine, lung cancer, colon cancer, 2135
Proliferation, thyroid hormones, PI3K, MAPK, 89
Prospective studies, magnetic resonance spectroscopy, brain neoplasms, radiotherapy, prognosis, 3559
Prostaglandin E2 receptor, renal cell carcinoma, pathological features, survival, immunohistochemistry, 597
Prostaglandin, cyclooxygenase, COX-2, breast cancer, tumor, carcinogenesis, 4359
Prostate cancer cell lines, cannabinoids, apoptosis, protein tyrosine phosphatases, dual-specificity phosphatases, 3799
Prostate cancer DU 145 cells, phenethyl isothiocyanate, cell cycle arrest, apoptosis, mitochondria, caspases, 1691
Prostate cancer, androgen receptor, combination strategy, flutamide, prostate-specific antigen, resveratrol, 3323
Prostate cancer, caveolin-1, single nucleotide polymorphism, DNA repair, 745
Prostate cancer, circulating tumor cells, CTCs, immunomagnetic beads, GFP, chick embryo, brain metastasis, metastatic assay, fluorescence imaging, 3125
Prostate cancer, circulating tumor cells, disseminated tumor cells, detection, bladder cancer, renal cell carcinoma, chemotherapy, review, 2053
Prostate cancer, *Cox-2*, polymorphism, carcinogenesis, 221
Prostate cancer, cytotoxicity, triphala, gallic acid, Ayurvedic medicine, 3739
Prostate cancer, docetaxel, chemotherapy, biochemical relapse, 973
Prostate cancer, EBP1, mRNA translation, androgen receptor, 3129
Prostate cancer, GFP, PC-3, orthotopic, circulating cancer cells, immunomagnetic beads, isolation, fluorescence, imaging, culture, 1535
Prostate cancer, hypofractionated radiotherapy, intermediate risk, acute effect, image guided radiation therapy, hormonotherapy, 3555
Prostate cancer, indole, telomerase, diethylstilbestrol, cell viability, 3733
Prostate cancer, luteinizing hormone, LH, total testosterone, TT, free testosterone, FT, prostate-specific antigen, PSA, 1071
Prostate cancer, microRNA, Fusion gene, *TMPRSS2:ERG*, 403
Prostate cancer, neuroendocrine differentiation, ethnicity, 3897
Prostate cancer, oncostatin M, interleukin-6, *VEGF*, u-PA, 3273
Prostate cancer, patients' satisfaction, radiation, surgery, hormonal therapy, 3903
Prostate cancer, PCA3 urinary test, MRSI, DCEMR, 1399
Prostate cancer, PCA3, PSA free/total, saturation prostate biopsy, repeat biopsy, cancer diagnosis, 4445
Prostate cancer, PGE2, EP4, p-Akt, *Snail*, epithelial-mesencymal transition, 4347
Prostate cancer, polybisphosphonate, bone metastasis, 4141
Prostate cancer, prolactin (PRL), luteinizing hormone (LH), total testosterone (TT), free testosterone (FT), prostate-specific antigen (PSA), 3913
Prostate cancer, PSA, statins, NSAID, thiazide diuretic, 1735
Prostate cancer, radiotherapy, hypofractionation, acceleration, amifostine, cytoprotection, 1745
Prostate cancer, RGM, breast cancer, prognosis, 1703
Prostate cancer, serum total testosterone, pelvic nodal involvement, 3615
Prostate cancer, transrectal ultrasonography, contrast-enhanced ultrasonography, 1421
Prostate cancer, vitamin D analog, ZK191784, MMP-2, MMP-9, adhesion molecules, 4091

Prostate cancer, vitamin D, colorectal cancer, breast cancer, lung cancer, 3619
Prostate neoplasm, cell death, pancreatic neoplasm, nuclear matrix proteins, natriuretic peptides, 395
Prostate-specific antigen (PSA), prolactin (PRL), luteinizing hormone (LH), total testosterone (TT), free testosterone (FT), prostate cancer, 3913
Prostate-specific antigen, androgen receptor, combination strategy, flutamide, prostate cancer, resveratrol, 3323
Prostate-specific antigen, luteinizing hormone, LH, total testosterone, TT, free testosterone, FT, PSA, prostate cancer, 1071
Prostatic neoplasm, bowel injury, laparoscopic radical prostatectomy, LRP, rectal injury, robotic-assisted laparoscopic prostatectomy, RALP, robotics, 3497
Proteasomal degradation, cisplatin, CTR1, bortezomib, drug combination, synergism, drug uptake, drug resistance, 2757
Proteasome inhibitor, belinostat, bortezomib, pancreas cancer, histone deacetylase inhibitor, hepatocellular cancer, apoptosis, metabolomics, 1093
Proteasome inhibitor, receptor tyrosine kinase, activation loop, multiple myeloma, ER stress, FGFR3, Lys650Glu mutation, K650E, bortezomide, plasma cell malignancy, 113
Proteasome inhibitors, triptolide, medicinal compounds, apoptosis, cancer therapy, 1
Protein disulfide isomerase, zeranol, cell proliferation, mammary tumorigenesis, 1659
Protein disulphide isomerase, non-small cell lung cancer, TXNDC5, thioredoxin, 1577
Protein tyrosine phosphatases, cannabinoids, apoptosis, prostate cancer cell lines, dual-specificity phosphatases, 3799
Proteoglycans, heparan sulfate, xenograft, HepG2 cells, immunotherapy, liver cancer, 4067
Proteomics, TNF-alpha, hepatoma, 2-DE, LC-MS/MS, apoptosis, 2059
Proteomics, tubulin alpha-6 chain, HCV-HCC, 2-DE, MS, 3331
Proteomics, two-dimensional gel electrophoresis, LC-MS/MS, pancreatic cancer, TS-1, 2103
PSA free/total, PCA3, prostate cancer, saturation prostate biopsy, repeat biopsy, cancer diagnosis, 4445
PSA, luteinizing hormone, LH, total testosterone, TT, free testosterone, FT, prostate-specific antigen, prostate cancer, 1071
PSA, prostate cancer, statins, NSAID, thiazide diuretic, 1735
P-Selectin, metastasis, HPA, E-selectin, SCID mouse, lectin, breast carcinoma cells, colon adenocarcinoma, 1589
PSK, apoptosis, HL-60, cell proliferation, caspase-3 activation, 2733
Psychiatric drugs, breast disease, psychosocial factors, 739
Psychosocial factors, breast disease, psychiatric drugs, 739
PTEN, carcinoid, serotonin, 1153
PTEN, glioma, cell cycle, temozolomide, ionizing radiation, radiosensitivity, 1653
PTEN, *KRAS*, microRNA, colorectal cancer, miR-221/222, 3D culture, 2453
PTEN, non-seminomatous testicular cancer, Akt, $p27^{Kip1}$, subcellular distribution, 3783
PTH, parathyroid tumors, hyperparathyroidism, arterial blood pressure, serum calcium, arterial hypertension, elderly, 3969
PTHrP, GLI2, osteolysis, breast cancer, 6-thioguanine, 2705
Pulmonary metastases, colorectal cancer, TS, OPRT, ERCC1, BRCA1, MVD, adjuvant chemotherapy, 2763
Pulmonary metastasis, acridine orange, osteosarcoma, photodynamic therapy, flash-wave light, fluorovisualization, 4163
Pyruvate dehydrogenase, reactive oxygen species, Long Evans Cinnamon, copper overload, 3395
QRT-PCR, circulating tumor cells, CTCs, microfiltration by size, real-time quantitative reverse transcriptase-polymerase chain reaction, molecular biology, cytomorphology, FISH, cell culture, lung cancer, 427
QSAR, 1, 2, 3, 4-tetrahydroisoquinolins, tumor-specificity index, semi-empirical molecular-orbital method, artificial neural network, 4231
QSAR, trihaloacetylazulenes, cytotoxicity, semiempirical molecular-orbital method, 515
Quality control, brain tumor, survival, pediatric neuro-oncology, 661
Quantitative methylation-specific PCR, *OSMR*, colorectal cancer, 1293
Quantitative methylation-specific PCR, vimentin, hepatocellular carcinoma, 1289
Quantitative PCR, immunohistochemistry, HMGB1, RAGE, disseminated histiocytic sarcoma, 1541
Quantitative polymerase chain reaction, Egfl8, colorectal cancer, 2249
Quantitative polymerase chain reaction, *EGFL8*, gastric cancer, 3377
Quantitative real-time PCR, MACC 1, hepatocellular carcinoma, 777
Quantitative real-time PCR, TIP60, gastric cancer, 77
Quantitative ultrasonometry, breast cancer, disseminated tumor cells, bone marrow, bone mineral density, 4423
Quercetin, breast cancer, genistein, apoptosis, NFκB, 3301
Quercetin, drug resistance, drug combination, synergism, thymoquinone, cisplatin, oxaliplatin, 3789
Quinazoliniminium salts, tumor cell proliferation, Ki-67 expression, macromolecule syntheses, DNA interaction and fragmentation, multiple mitotic figures, nuclei, micronuclei, 2083

Quinolinic acid, indoleamine-2, 3-dioxygenase, immunomodulation, cervical cancer, kynurenic acid, 2629
Race, cigarette smoking, tobacco-caused cancer, 3891
RAD001, carboplatin, everolimus, breast cancer, mTOR inhibitor, 2713
Radiation myelopathy, radiation therapy, spinal cord, γ-H2AX, 561
Radiation sensitivity, clonogenic cell survival, huachansu, lung cancer cells, inhibition of DNA repair, 2141
Radiation sensitivity, esophageal cancer, gastric cancer, hypoxia, cell cycle, reoxygenation, 3369
Radiation therapy, B-Cell lymphoma, marginal zone lymphoma, local tumor control, 3935
Radiation therapy, bladder cancer, TURBT, radiochemotherapy, 985
Radiation therapy, risk factor, enterocolitis, leg edema, postoperative radiotherapy, gynecological malignancies, 3527
Radiation therapy, spinal cord, radiation myelopathy, γ-H2AX, 561
Radiation, gefitinib, combination therapy, *EGFR*, predictor, melanoma, 2883
Radiation, head and neck neoplasms, ERCC1 protein, cisplatin, DNA repair, 4135
Radiation, pemetrexed, human mesothelioma cell line, radiosensitivity, apoptosis, 2847
Radiation, prostate cancer, patients' satisfaction, surgery, hormonal therapy, 3903
Radiation-sensitivity, ionizing radiation, phosphorylation of *p53,* 2255
Radical cystectomy, bladder cancer, extented lymphadenectomy, lymph node metastasis, lymph node density, cancer-specific survival, short review, 271
Radiobiology model, human lung cancer cell lines, surviving fraction, doubling time, clonogenic assay, 1125
Radiochemotherapy, bladder cancer, TURBT, radiation therapy, 985
Radiochemotherapy, neoadjuvant therapy, esophageal cancer, docetaxel, cisplatin, phase II trials, 4407
Radiofrequency ablation, hepatocellular carcinoma, cirrhosis, percutaneous ablation, percutaneous ethanol injection, randomized controlled trial, 2291
Radiofrequency ablation, RFA, intrahepatic cholangio-carcinoma, ICC, cirrhosis, 4575
Radioimmunotherapy, HNSCC, SCID mice, xenografts, radio-labeled monoclonal antibody, cytokeratin 8, 3315
Radio-labeled monoclonal antibody, radioimmunotherapy, HNSCC, SCID mice, xenografts, cytokeratin 8, 3315
Radioprotection, radiosensitivity, astrocytes, central nervous system, lymphoma, 33
Radiosensitivity, glioma, PTEN, cell cycle, temozolomide, ionizing radiation, 1653
Radiosensitivity, lung cancer, paclitaxel-based chemoradiotherapy, BCL-2, MDR1, 1431
Radiosensitivity, N-heterocyclic indolyl glyoxylamides, p53-independent apoptosis, G_2/M phase arrest, human lung cancer cells, 3407
Radiosensitivity, radiation, pemetrexed, human mesothelioma cell line, apoptosis, 2847
Radiosensitivity, radioprotection, astrocytes, central nervous system, lymphoma, 33
Radiotherapy, breast cancer, anastrozole, ipsilateral breast tumor recurrence, tamoxifen, 367
Radiotherapy, endometrial cancer, prognosis, survival, chemotherapy, 3483
Radiotherapy, GLUT-1, rectal cancer, chemotherapy, tumour regression, prognosis, 311
Radiotherapy, HIF-1α, esophageal neoplasm, chemotherapy, 2351
Radiotherapy, magnetic resonance spectroscopy, brain neoplasms, prognosis, prospective studies, 3559
Radiotherapy, neuroblastoma, neem leaf extract, apoptosis, transcriptional response, 161
Radiotherapy, non-small cell lung cancer, gefitinib, erlotinib, resistance, bone metastasis, *EGFR*-TKIs, 4519
Radiotherapy, prostate cancer, hypofractionation, acceleration, amifostine, cytoprotection, 1745
Radiotherapy, rectal cancer, chemotherapy, prognostic factor, biomarker, carbonic anhydrase IX, hypoxia-inducible factor-1a, ezrin, glucose transporter-1, 4529
RAGE, quantitative PCR, immunohistochemistry, HMGB1, disseminated histiocytic sarcoma, 1541
RALP, bowel injury, laparoscopic radical prostatectomy, LRP, prostatic neoplasm, rectal injury, robotic-assisted laparoscopic prostatectomy, robotics, 3497
Randomized controlled trial, hepatocellular carcinoma, cirrhosis, percutaneous ablation, percutaneous ethanol injection, radiofrequency ablation, 2291
Rapamycin, ERas, gastric cancer, chemotherapy, CPT-11, 3353
Ras, BNIP3, CD47, cancer, programmed cell death, 4N1K, 2869
Ras/Raf/MEK/ERK pathway, IGF-1R, phosphorylated MEK, orthotopic mouse model of osteosarcoma, lung metastasis, 1147
Ras-Raf-ERK/MAPK pathway, gastrointestinal stromal tumors (GISTs), PI3K-Akt/mTOR pathway, insulin-like growth factor 1 receptor (IGF1R), CD117, 3019
RASSF1A, breast cancer, methylation, prognosis, 2975
RASSF1A, *EGFR*, mutation, methylation, tobacco smoking, lung adenocarcinoma, *FHIT*, RUNX3, 1211
Rat model, sonodynamic therapy, focused ultrasound, 5-aminolevulinic acid, glioma, deep-seated, 2527
Rat, artemisinin dimers, dihydroartemisinin, breast cancer cells, 4111

Rat, bladder cancer, BCG-CWS, liposome, BBN, 2065
Rat, *Stk11*, *Lkb1*, hepatocellular carcinoma, nitrosamine, choline-deficient L-amino acid-defined diet, 543
Rats, melatonin, cancer, endometrial proliferation, 2637
Rats, metronomic, cyclophosphamide, doxorubicin, breast cancer, cardiotoxicity, 215
RAW264.7 cells, etomidate, apoptosis, Bax, Bcl-xl, caspase-3, 2203
RCC, SDF1β, T-cell infiltration, grade, 2797
Reactive oxygen species, 8-hydroxydeoxyguanosine, oxidative stress, ovarian cancer, 1411
Reactive oxygen species, pyruvate dehydrogenase, Long Evans Cinnamon, copper overload, 3395
Real-time imaging, green fluorescent protein, red fluorescent protein, cancer cell seeding, lung, liver, muscle, 3665
Real-time quantitative reverse transcriptase-polymerase chain reaction, circulating tumor cells, CTCs, microfiltration by size, qRT-PCR, molecular biology, cytomorphology, FISH, cell culture, lung cancer, 427
Real-time RT-PCR, hepatocellular carcinoma, human zinc finger 23, annexin V-FITC/PI assay, apoptosis, 3595
Receptor tyrosine kinase, actin cytoskeleton, cell migration, nuclear localization, Ror1, 4239
Receptor tyrosine kinase, proteasome inhibitor, activation loop, multiple myeloma, ER stress, FGFR3, Lys650Glu mutation, K650E, bortezomide, plasma cell malignancy, 113
Rectal cancer, cancer stem cell, recurrence, CD marker, CD133, CD44, 495
Rectal cancer, chemoradiation, neoadjuvant therapy, complete clinical response, non-operative management, review, 1795
Rectal cancer, claudin-1, prognostic factor, recurrence, 2517
Rectal cancer, glucose transporter-1, hypoxia, hypoxia-inducible factor 1α, preoperative chemoradiotherapy, 1559
Rectal cancer, GLUT-1, chemotherapy, radiotherapy, tumour regression, prognosis, 311
Rectal cancer, hyperthermo-chemo-radiation therapy, HCRT, distal margins, tumor response, 3963
Rectal cancer, radiotherapy, chemotherapy, prognostic factor, biomarker, carbonic anhydrase IX, hypoxia-inducible factor-1a, ezrin, glucose transporter-1, 4529
Rectal injury, bowel injury, laparoscopic radical prostatectomy, LRP, prostatic neoplasm, robotic-assisted laparoscopic prostatectomy, RALP, robotics, 3497
Recurrence, bladder cancer, intravesical chemotherapy, continuous saline bladder irrigation, 1471
Recurrence, breast cancer, operation, survival, polychemotherapy, 277
Recurrence, cancer stem cell, CD marker, CD133, CD44, rectal cancer, 495
Recurrence, claudin-1, prognostic factor, rectal cancer, 2517
Recurrence, Ki-67, PCNA, lung, adenocarcinoma, 4277
Recurrence, LAT1, CD98, advanced NSCLC, *EGFR* mutation, prognosis, chemotherapy. Ki-67, p-Akt, p-mTOR, 3775
Recurrence, *MACC1*, lung cancer, adenocarcinoma, 1141
Recurrence, methylenetetrahydrofolate reductase *MTHFR*, smoking, metastasis, oral cancer, 2395
Recurrence, squamous cell carcinoma, bladder cancer, gemcitabine, paclitaxel, 4465
Recurrence, urachal cancer, gemcitabine, cisplatin, chemotherapy, 2335
Recurrences, bladder carcinoma, interleukin-2, $CD8^{high}CD57^{+}$ lymphocytes, 699
Recurrent cervical cancer, oral etoposide, cisplatin, second-line chemotherapy, feasibility study, 3063
Recurrent, ovarian cancer, consolidation chemotherapy, salvage chemotherapy, treatment-free interval, paclitaxel, cisplatin, irinotecan, 4613
Red fluorescent protein, green fluorescent protein, cancer cell seeding, real-time imaging, lung, liver, muscle, 3665
Ref-1, APE1, macrophages, inflammatory response, 379
Refractory, thymic carcinoma, chemotherapy, ADOC, S-1, 299
REG4, antiapoptosis, colorectal cancer, gamma radiation, microarray, RT-PCR, *NEIL2*, *BIRC5*, 4147
Regression, dysplastic nevi, immune response, melanocyte, melanoma, 3697
Regulatory T-cell, β-Glucan, cyclophosphamide, A20 lymphoma, 1169
Regulatory T-cells, colorectal cancer, antitumor immunity, FOLFOX, FOLFIRI, 4569
Relapse, ovarian cancer, intraperitoneal, catumaxomab, surgical tumor debulking, operative morbidity, operative mortality, 2603
Renal cell carcinoma, chromophobe renal cell carcinoma, renal oncocytoma, fluorescence *in situ* hybridization, tissue sections, isolated nuclei, 3137
Renal cell carcinoma, circulating tumor cells, CellSearch, cytokeratins, CD44, 4219
Renal cell carcinoma, circulating tumor cells, disseminated tumor cells, detection, prostate cancer, bladder cancer, chemotherapy, review, 2053
Renal cell carcinoma, cryoimmunology, cryotreatment, immunotherapy, 2927
Renal cell carcinoma, gamma-delta T-cell, prognosis factor, 1027
Renal cell carcinoma, prostaglandin E2 receptor, pathological features, survival, immunohistochemistry, 597
Renal failure, mesothelioma, tumor markers, N-ERC/mesothelin, osteopontin, 1427

Renal oncocytoma, renal cell carcinoma, chromophobe renal cell carcinoma, fluorescence *in situ* hybridization, tissue sections, isolated nuclei, 3137
Renieramycin M, metastasis, anoikis, invasion, migration, lung cancer cells, 193
Reoxygenation, radiation sensitivity, esophageal cancer, gastric cancer, hypoxia, cell cycle, 3369
Repeat biopsy, PCA3, PSA free/total, prostate cancer, saturation prostate biopsy, cancer diagnosis, 4445
Resection, lymph node metastasis, hepatocellular carcinoma, transarterial chemoembolization, 3991
Residual disease, ovarian cancer, cytoreductive surgery, prediction models, 4043
Resistance, non-small cell lung cancer, gefitinib, erlotinib, bone metastasis, radiotherapy, *EGFR*-TKIs, 4519
Resistance, PAMAM dendrimers, encapsulation, intracellular delivery, SMVT, cisplatin, ovarian cancer cell lines, 897
Resistance, pancreatic cancer, gemcitabine, ERK, lenalidomide, 3747
Response prediction, neoadjuvant therapy, squamous-cell esophageal cancer, tumor-associated proteins, 1769
Resveratrol, androgen receptor, combination strategy, flutamide, prostate cancer, prostate-specific antigen, 3323
Resveratrol, glioma, invasion, TNF-α, urokinase plasminogen activator, 4223
RET, medullary thyroid carcinoma, gene mutations, *HRAS*, *KRAS*, *NRAS*, *BRAF*, *AKT1*, *CTNNB1*, mutational screening, 4179
Retinoblastoma protein, antisense oligonucleotide, cyclin D, cyclin E, cyclin-dependent kinase, non-small lung cancer cells, pleural mesothelioma cells, apoptosis, kinases, phosphatases, 3683
Retroperitoneal lymph nodes, primary serous-papillary peritoneal carcinoma, spread pattern, review, 1387
Reversible dihydropyrimidine dehydrogenase, S-1, 5-fluorouracil, Phase I, FBAL, tegafur, FT, DPD, gimeracil, CDHP, solid tumors, 625
Review, adrenocortical tumors, Cushing's syndrome, adrenal imaging, cancer, CT, MR, 2923
Review, advanced gastric cancer, AKT, PI3K, chemoresistance, 4387
Review, angiogenesis, cancer, CD105, endoglin, tumor, 2283
Review, biomarkers, diagnosis, early detection, head and neck cancer, 1161
Review, bladder cancer, transitional carcinoma, lymphovascular invasion, upper tract transitional carcinoma, prognostic role, 3503
Review, cancer, immunotherapy, prediction, survival, CD8, CD57, 639
Review, cell-free DNA, circulation, non-invasive, biomarker, 2623
Review, chemotherapy, metastatic gastric cancer, 3543
Review, circulating tumor cells, disseminated tumor cells, detection, prostate cancer, bladder cancer, renal cell carcinoma, chemotherapy, 2053
Review, electroporation, oligonucleotides, siRNA, miRNA, 4083
Review, hemorrhagic cystitis, allogeneic stem cell transplantation, BK virus, 939
Review, KRAP, *KRAS*, target, cancer, obesity, diabetes, 2413
Review, low-intensity ultrasound, sonodynamic therapy, sonosensitizers, 2425
Review, LPS, endotoxin, oral administration, toxicity, absorption, lipopolysaccharide, 2431
Review, macrophage, LPS, priming, IP-PA1, chronic psychological stress, 2437
Review, multiple myeloma, signal transduction, Wnt pathway, myeloma, myeloma therapy, 725
Review, non-small cell lung cancer, third-line treatment, erlotinib, gefitinib, 649
Review, notch, stem cells, pancreatic cancer, signal pathway, natural agents, cancer therapy, drug resistance, 1105
Review, ovarian cancer, gene mutations, BRCA 1/2, *TP53*, PI3K, AKT, *BRAF*, *KRAS*, 2661
Review, primary serous-papillary peritoneal carcinoma, retroperitoneal lymph nodes, spread pattern, 1387
Review, rectal cancer, chemoradiation, neoadjuvant therapy, complete clinical response, non-operative management, 1795
Review, ROCK, Rho kinase, ROCK signaling, ROCK pathways, 3645
Review, single nucleotide polymorphisms, estrogen pathway, steroid hormones, mammographic breast density, breast cancer, 4369
Review, tonsillar cancer, base of tongue cancer, oropharyngeal cancer, head and neck cancer, HPV, 1515
Revitalization, high hydrostatic pressure, bone, tissue engineering, 1235
RFA, radiofrequency ablation, intrahepatic cholangio-carcinoma, ICC, cirrhosis, 4575
RFP, magnetic resonance imaging, micro-computed tomography, optical reflectance imaging, tumor volume, molecular imaging, GFP, 2907
RGM, breast cancer, prostate cancer, prognosis, 1703
Rho kinase, ROCK, ROCK signaling, ROCK pathways, review, 3645
Ribonucleotide reductase, non-small cell lung cancer, p53R2, hRRM2, 3475
Right colon, cyclooxygenase, COX-2, W-APC, left colon, colon cancer, 2191
Right colon, prognosis, left colon, sigmoid, survival, colon cancer, gender, 2347

Risk factor, BPF, fistula, operation, lung cancer, concurrent disease, perioperative complication, infection, 619
Risk factor, radiation therapy, enterocolitis, leg edema, postoperative radiotherapy, gynecological malignancies, 3527
Risk of cancer, breast disease, depression, 1065
RNA interference, HTLV-1, *gag* and *env* genes, shRNA, 2173
RNA-binding proteins, S_N1 methylating agents, apoptosis, O6-methylguanine-DNA methyltransferase (MGMT), *N*-methyl-*N*-nitrosourea, 4291
Robotic-assisted laparoscopic prostatectomy, bowel injury, laparoscopic radical prostatectomy, LRP, prostatic neoplasm, rectal injury, RALP, robotics, 3497
Robotics, bowel injury, laparoscopic radical prostatectomy, LRP, prostatic neoplasm, rectal injury, robotic-assisted laparoscopic prostatectomy, RALP, 3497
ROCK pathways, ROCK, Rho kinase, ROCK signaling, review, 3645
ROCK signaling, ROCK, Rho kinase, ROCK pathways, review, 3645
ROCK, Rho kinase, ROCK signaling, ROCK pathways, review, 3645
Rofecoxib, diffuse intrinsic pontine glioma, chemotherapy, temozolomide, bevacizumab, inflammatory processes, 2265
Ror1, actin cytoskeleton, cell migration, nuclear localization, receptor tyrosine kinase, 4239
ROS, epigenetic modifiers, kidney, toxicity, p66shc, mitochondria, 3267
ROS, UVB, normal human keratinocytes, 18β-glycyrrhetinic acid, glabridin, 2209
RRM2, *KRAS*, colon cancer, 2535
RTK, breast cancer, lapatinib, imatinib, *EGFR*, ErbB2, c-ABL, 789
RT-PCR, antiapoptosis, colorectal cancer, gamma radiation, microarray, *REG4*, *NEIL2*, *BIRC5*, 4147
RT-PCR, estrogen receptor, breast cancer cell lines, flow cytometry, Western blotting, 521
RT-PCR, tumor suppressor gene, *FUS1*, sarcoma, immunohistochemistry, growth inhibition, 11
RUNX3, *EGFR*, mutation, methylation, tobacco smoking, lung adenocarcinoma, *FHIT*, RASSF1A, 1211
Ruta graveolens, medicinal herb, bioactivity, p53 pathway, apoptosis, Akt, 233
RXR, pharmacogenomics, SNPs, bexarotene, lung cancer, 2303
S-1 plus CDDP, early-stage esophageal cancer, complete response, 1019
S-1, 5-fluorouracil, Phase I, FBAL, tegafur, FT, reversible dihydropyrimidine dehydrogenase, DPD, gimeracil, CDHP, solid tumors, 625
S1, chemotherapy, docetaxel, nedaplatin, esophageal carcinoma, phase I, 4589
S-1, gastric cancer, cetuximab, thymidylate synthase, 3691
S-1, HER2-positive, trastuzumab, metastatic breast cancer, 3035
S-1, metastatic anal cancer, chemoradiotherapy, cisplatin, 3983
S-1, neoadjuvant chemoradiotherapy, gastric cancer, cisplatin, 3079
S-1, thymic carcinoma, chemotherapy, ADOC, refractory, 299
S-1, triplet combination chemotherapy, paclitaxel, cisplatin, advanced gastric cancer, feasibility study, 3085
S-100β, uveal melanoma, metastasis, liver function tests, tumor markers, OPN, MIA, TPS, 351
S-100β, uveal melanoma, metastasis, tumor markers, OPN, MIA, TPS, 345
Safety, bevacizumab, FOLFIRI, XELIRI, colorectal cancer, efficacy, 1777
Safety, bevacizumab, pediatrics, *VEGF*, 3953
Salvage chemotherapy, ovarian cancer, consolidation chemotherapy, recurrent, treatment-free interval, paclitaxel, cisplatin, irinotecan, 4613
Sanguinarine, benzo[*c*]phenanthridine alkaloids, anticancer therapeutic agents, oral squamous cell carcinoma, 2841
Saracatinib, HNSCC, phase II, Src, AZD0530, 249
Sarcoma 180, ultrasound, mono-l-aspartyl chlorin e6, antitumor effect, sonodynamic therapy, colon 26, 501
Sarcoma lung metastases, isolated lung perfusion, p-gp modulation, doxorubicin, cyclosporin, valspodar, 2121
Sarcoma, histone deacetylase inhibitor, chemotherapy, multidrug resistant, PCI-24781, 1115
Sarcoma, tumor suppressor gene, *FUS1*, RT-PCR, immunohistochemistry, growth inhibition, 11
Sarcomatoid tumour, hepatitis C virus, liver tumour, cell line, culture, spectral karyotyping, xenograft, 129
SAS cell, sonodynamic therapy, 5-aminolevulinic acid, mitochondrion, apoptosis, 39
Saturation prostate biopsy, PCA3, PSA free/total, prostate cancer, repeat biopsy, cancer diagnosis, 4445
SCID mice, radioimmunotherapy, HNSCC, xenografts, radio-labeled monoclonal antibody, cytokeratin 8, 3315
SCID mouse, metastasis, HPA, E-selectin, P-selectin, lectin, breast carcinoma cells, colon adenocarcinoma, 1589
Screening mammography, breast cancer, microcalcification, high-frequency ultrasound, advanced imaging modes, 2575
Screening systems, cell-to-cell interaction, adhesion molecules, characteristics of cancer cells, anticancer drug resistance, chemotherapy, apoptosis, drug sensitivity, drug resistance-relating factors, gene expression analysis, evaluation and prediction of pharmacological effects, 3237
Screening test, cytology, endometrial brush, endometrial cancer, endometrial pathology, uterobrush, 3469

Screening, breast cancer, mammography, ultrasound, automated 3D imaging, 2569
SDF1β, RCC, T-cell infiltration, grade, 2797
Second opinion, gynecological cancer, breast cancer, online tumor conference, interdisciplinary therapy management, continuous medical training, 2669
Secondary cytoreductive surgery, ovarian cancer relapse, predictive factor, tumor residual, complete tumor resection, 2583
Second-line chemotherapy, recurrent cervical cancer, oral etoposide, cisplatin, feasibility study, 3063
γ-Secretase inhibitor, leukemia, notch, wnt, hedgehog, 893
E-Selectin, breast cancer, liver metastasis, endothelium, pro-inflammatory micro*env* ironment, 3219
E-Selectin, metastasis, HPA, P-selectin, SCID mouse, lectin, breast carcinoma cells, colon adenocarcinoma, 1589
Selenium, colon cancer, orthotopic model, GFP, fluorescent protein imaging (FPI), MRI, angiogenesis, 387
Selenoprotein, colon cancer, glutathione, thioredoxin, antioxidant enzyme expression, 2693
Self-renewal, hedgehog, leukemia, 781
Semi-empirical molecular-orbital method, 1, 2, 3, 4-tetrahydroisoquinolins, QSAR, tumor-specificity index, artificial neural network, 4231
Semiempirical molecular-orbital method, trihaloacetylazulenes, QSAR, cytotoxicity, 515
Sentinel lymph node biopsy, skin cancer, non-melanoma, lymph node, metastasis, literature review, 1443
Sentinel lymph node, breast cancer, OSNA, cytokeratin 19, intra-operative method, 585
Sentinel node biopsy, breast cancer, sentinel node, axillary node sampling, axillary lymphadenectomy, axillary clearing, 693
Sentinel node, breast cancer, sentinel node biopsy, axillary node sampling, axillary lymphadenectomy, axillary clearing, 693
Sepsis, antisense pepitide, complementary peptide, anaphylatoxin, inflammation, cytokine storm, 2511
Sequence analysis, *KRAS*, *p53,* colorectal, oxaliplatin, 5-fluorouracil, capecitabine, clinical, CAIRO2, 1379
Sequence variation, Merkel cell carcinoma, KIT, mutation, 807
Sequential therapy, adjuvant chemotherapy, breast cancer, 1483
Sequential treatment regimen, sunitinib, metastatic renal cell carcinoma, tyrosine kinase inhibitor, mTOR inhibitor, 3507
Serotonin, carcinoid, PTEN, 1153
Serum 25(OH)D, vitamin D, toxicity, chemoprevention, 607
Serum calcium, parathyroid tumors, hyperparathyroidism, arterial blood pressure, PTH, arterial hypertension, elderly, 3969
Serum markers, portal vein embolisation, liver hypertrophy, tumor progression, 339
Serum total testosterone, prostate cancer, pelvic nodal involvement, 3615
Short review, bladder cancer, extented lymphadenectomy, lymph node metastasis, radical cystectomy, lymph node density, cancer-specific survival, 271
ShRNA, glutamate receptor, cancer, PCR, NR1, GLUR4, KA2, NR2D, 3181
ShRNA, HTLV-1, *gag* and *env* genes, RNA interference, 2173
Sialic fibronectin, thyroid malignant neoplasma, lymph node metastasis, MoAb Jt-95, 1395
SICAM-1, breast cancer, chemotherapy, dose-dense, sVCAM-1, 2617
Sifneos score, breast disease, breast cancer, 3101
Sigmoid, prognosis, left colon, right colon, survival, colon cancer, gender, 2347
Signal pathway, notch, stem cells, pancreatic cancer, natural agents, cancer therapy, drug resistance, review, 1105
Signal transducer and activator of transcription 3, interleukin-6, pancreatic cancer, 2029
Signal transduction, multiple myeloma, Wnt pathway, myeloma, myeloma therapy, review, 725
Signaling pathway, microarray analysis, dectin-2 gene expression, macrophage, lignin-carbohydrate complex, LPS, LEM, 1241
Signet-ring adenocarcinoma, gastric adenocarcinoma, breast metastasis, skin, immunohistochemistry, 2373
Silibinin, CD44, *EGFR*, EGF, TGF-α, MMP-9, breast cancer metastasis, 3767
Single nucleotide polymorphism, caveolin-1, prostate cancer, DNA repair, 745
Single nucleotide polymorphism, cervical cancer, C-reactive protein, CRP, *CRP1919* (rs1417938), *CRP2667* (rs1800947), *CRP3872* (rs1205), *CRP5237* (rs2808630), gene polymorphism, prognosis, 2259
Single nucleotide polymorphisms (SNPs), gastric cancer (GC), chemosensitivity, docetaxel, *DNASE2B*, *HTRIE*, 4329
Single nucleotide polymorphisms, estrogen pathway, steroid hormones, mammographic breast density, breast cancer, review, 4369
Single nucleotide polymorphisms, integrins, colorectal cancer, survival, polymorphisms, 1373
SiRNA, electroporation, oligonucleotides, miRNA, review, 4083
SiRNA, lipid nanoparticles, *CDK4*, down-regulation, 1619
SiRNA, P-glycoprotein, chemotherapy, inhibition of multidrug resistance, osteosarcoma cell lines, carcinoma cell lines, 2813
Sirolimus, BBN, gemcitabine, mice, urothelial lesion, 1637

Skin biopsies, cancer, neurotoxicity, adjuvant chemotherapy, docetaxel, intraepidermal nerve fibres, neuropathy, oxaliplatin, 4413
Skin cancer, non-melanoma, lymph node, metastasis, literature review, sentinel lymph node biopsy, 1443
Skin cancer, X-ray repair cross-complementing group 1, *XRCC1*, polymorphism, DNA repair, meta-analysis, 3945
Skin toxicity, gefitinib, non-small cell lung cancer, NSCLC, epidermal growth factor receptor, *EGFR*, expanded access programme, EAP, 2949
Skin toxicity, pemetrexed, hyperpigmentation, 1753
Skin, gastric adenocarcinoma, signet-ring adenocarcinoma, breast metastasis, immunohistochemistry, 2373
SMAD3, 3-Indole, cell cycle arrest, ATM, ATR, xenograft model, lung cancer cells, 203
Small bowel, melanoma, intussusception, disease-free survival, dendritic cell therapy, 3579
Small-cell cancer, colorectal, neuroendocrine cancer, chemotherapy, cisplatin, etoposide, 975
Small-cell lung cancer, cisplatin, topotecan, 3449
Small-cell lung cancer, TRAIL, paclitaxel, chemotherapy, 3193
Smoking, *cyclin D1*, CCND1, polymorphism, lung cancer, Taiwanese, 3601
Smoking, *cyclin D1*, polymorphism, oral cancer, 227
Smoking, methylenetetrahydrofolate reductase *MTHFR*, metastasis, recurrence, oral cancer, 2395
Smoking, NSCLC, methylation, MLPA, targeted therapy, gene methylation, TKIs, *EGFR* mutation, 4647
SMVT, PAMAM dendrimers, encapsulation, intracellular delivery, resistance, cisplatin, ovarian cancer cell lines, 897
S_N1 methylating agents, apoptosis, O6-methylguanine-DNA methyltransferase (MGMT), RNA-binding proteins, *N*-methyl-*N*-nitrosourea, 4291
SN-38 glucuronide (SN-38G), active metabolite of irinotecan, SN-38, glucuronidation, panipenem, pharmacokinetics, 2915
SN-38, active metabolite of irinotecan, glucuronidation, SN-38 glucuronide (SN-38G), panipenem, pharmacokinetics, 2915
Snail, prostate cancer, PGE2, EP4, p-Akt, epithelial-mesencymal transition, 4347
SNP, paraoxonase 1, *PON1*, polymorphism, lung cancer risk, 2225
SNP, polymorphism, colorectal cancer, MMP2, *VEGF*, HIF1A, 575
SNPs, pharmacogenomics, bexarotene, RXR, lung cancer, 2303
Snus, cigarette smoking, Swedish-type smokeless tobacco, ethanol, human normal cells, cell death, endothelial cells, fibroblasts, 1527
Sodium meta-arsenite, cancer cells, stem cells, telomere length, telomerase activity, 4315
Soft tissue sarcoma, athymic mice, low-grade liposarcoma, xenograft, vascularisation, 4061
Soft tissue, hemangiopericytoma, solitary fibrous tumor, oral cavity, cheek, 719
Solid cancer nest, ADAM, MMP, TIMP, invasive front, colorectal cancer, 1567
Solid tumors, S-1, 5-fluorouracil, phase I, FBAL, tegafur, FT, reversible dihydropyrimidine dehydrogenase, DPD, gimeracil, CDHP, 625
Solid type (Por1), poorly differentiated colorectal adenocarcinomas, non-solid type (Por2), 3463
Solitary fibrous tumor, hemangiopericytoma, oral cavity, cheek, soft tissue, 719
Soluble leptin receptor, tumor stage, colorectal cancer, 3381
Somatostatin receptor, non-Hodgkin's lymphoma, BCL2, lutetium-177, 3143
Somatostatin, meningioma en plaque, hyperostosis, hyperosteoidosis, 591
Sonodynamic therapy, 5-aminolevulinic acid, SAS cell, mitochondrion, apoptosis, 39
Sonodynamic therapy, focused ultrasound, 5-aminolevulinic acid, glioma, deep-seated, rat model, 2527
Sonodynamic therapy, low-intensity ultrasound, sonosensitizers, review, 2425
Sonodynamic therapy, ultrasound, mono-l-aspartyl chlorin e6, antitumor effect, sarcoma 180, colon 26, 501
Sonography, breast ultrasound, pre-operative therapy, prediction of therapy response, sphericity, 4039
Sonosensitizers, low-intensity ultrasound, sonodynamic therapy, review, 2425
Sorafenib, chromophobe renal cell carcinoma, temsirolimus, mTOR, interferon, 331
Sorafenib, melanoma, fluvastatin, JNK, AKT, 3259
Spectral karyotyping, hepatitis C virus, liver tumour, sarcomatoid tumour, cell line, culture, xenograft, 129
Sphericity, breast ultrasound, pre-operative therapy, prediction of therapy response, sonography, 4039
Sphingomyelinase, anticancer drugs, *p53,* Bax, cell cycle, apoptosis, 871
Sphingomyelinase, anticancer agents, *Cox-2*, caspase-3, apoptosis, *p53,* cell cycle, 1345
Spinal cord, radiation therapy, radiation myelopathy, γ-H2AX, 561
(+)-Spongistatin 1, anticancer, natural product, mitosis, xenograft model, 2773
Spread pattern, primary serous-papillary peritoneal carcinoma, retroperitoneal lymph nodes, review, 1387
Squamous cell carcinoma, bladder cancer, recurrence, gemcitabine, paclitaxel, 4465
Squamous cell carcinoma, *BRAF* mutation, *KRAS*, *EGFR*, ERBB2 mutation, V600E, lung cancer, adenocarcinoma, SSCP, 4619

Squamous cell carcinoma, cervical cancer, stage IB-IIB, concurrent chemoradiotherapy, locoregional recurrence, 1437
Squamous cell carcinoma, cyclin B1, cell cycle, *p53,* head and neck cancer, 3151
Squamous cell carcinoma, cytokeratin 4, fascin, biomarker, tissue microarray, esophagus, 945
Squamous cell carcinoma, *EGFR*, Ki-67, translational research, head and neck cancer, 665
Squamous cell carcinoma, *NK4*, gene therapy, cationised gelatin, cisplatin, 105
Squamous-cell esophageal cancer, neoadjuvant therapy, response prediction, tumor-associated proteins, 1769
Src, HNSCC, phase II, AZD0530, saracatinib, 249
SSCP, *BRAF* mutation, *KRAS*, *EGFR*, ERBB2 mutation, V600E, lung cancer, adenocarcinoma, squamous cell carcinoma, 4619
Stage I, p27, breast cancer, node dissection, estrogen receptor, progesterone receptor, 4401
Stage IB-IIB, cervical cancer, squamous cell carcinoma, concurrent chemoradiotherapy, locoregional recurrence, 1437
Staging laparoscopy, ovarian cancer, interval debulking surgery, optimal logistic regression, 4469
Staging, gastric cancer, lymph node dissection, prognosis, 2361
STAI test, form Y-2, cancer risk, breast cancer, anxiety, 1801
Stanniocalcin 1, prognostic factor, PCR, colorectal cancer, 325
STAT1, head and neck cancer, p38 MAPK, STAT3, phosphorylation, 3819
STAT3, head and neck cancer, p38 MAPK, STAT1, phosphorylation, 3819
Statins, prostate cancer, PSA, NSAID, thiazide diuretic, 1735
Stealth liposomes, PEG liposomes, 5-FU, locoregional chemotherapy, liver metastases, 147
Stealth liposomes, PEG liposomes, docetaxel, locoregional chemotherapy, liver metastases, hepatic arterial infusion, 153
Stem cell marker, wnt pathway, colorectal cancer, immunohistochemistry, LGR5, 263
Stem cells, breast cancer, pre-metastatic niche, metastasis, CD133, prognosis, 1315
Stem cells, notch, pancreatic cancer, signal pathway, natural agents, cancer therapy, drug resistance, review, 1105
Stem cells, sodium meta-arsenite, cancer cells, telomere length, telomerase activity, 4315
Steroid hormones, single nucleotide polymorphisms, estrogen pathway, mammographic breast density, breast cancer, review, 4369
Steroid sulfatase, aromatase inhibitors, anti-estrogens, breast cancer, tamoxifen, anastrozole, postmenopausal women, 1367
Stk11, *Lkb1*, hepatocellular carcinoma, nitrosamine, choline-deficient L-amino acid-defined diet, rat, 543
Striatum, intravenous curcumin, blood–brain barrier, post-traumatic sequelae, hippocampus, brain stem, 907
Subcellular distribution, non-seminomatous testicular cancer, PTEN, Akt, $p27^{Kip1}$, 3783
Subcellular localization, ovarian cancer, hyprocrellin B, hematoporphyrin monomethyl ether, intracellular metabolism, phototoxicity, 3229
Sudan, oral squamous cell carcinomas, toombak, genes, apoptosis, cell cycle regulation, intermediate filament proteins, 3345
Suicide genes, neural stem cells, prodrugs, invasive tumors, animal models, gene-directed enzyme prodrug therapy review, 1249
Sunitinib, antitumor, antimetastasis, *VEGF*, V*EGFR*, phosphorylation, mammary cancer, 1225
Sunitinib, *IDH1* mutation, glioma, cetuximab, bevacizumab, 4457
Sunitinib, metastatic renal cell carcinoma, sequential treatment regimen, tyrosine kinase inhibitor, mTOR inhibitor, 3507
Sunitinib, pneumatosis intestinalis, gastrointestinal stromal tumor, 3429
Surgery, colorectal cancer, liver metastases, biomarker, CD95-ligand, 4507
Surgery, pancreatic cancer, pancreatic neoplasms, long-term survivors, brain metastasis, 4599
Surgery, prostate cancer, patients' satisfaction, radiation, hormonal therapy, 3903
Surgical resection, HER2, non-small cell lung cancer, immunohistochemical staining, prognosis, 4631
Surgical tumor debulking, ovarian cancer, relapse, intraperitoneal, catumaxomab, operative morbidity, operative mortality, 2603
Surveillance, ulcerative colitis, colorectal cancer, 2499
Survival analysis, myeloid DC, dentritic cells, pancreatic cancer, prognostic factor, circulating dendritic cells, 3827
Survival probability, child's classification, hepatocellular carcinoma, liver cirrhosis, MELD-score, nonhepatic cancer, TNM classification, 2931
Survival, breast cancer, recurrence, operation, polychemotherapy, 277
Survival, cancer, immunotherapy, prediction, CD8, CD57, review, 639
Survival, colorectal cancer, adjuvant chemotherapy, *MTHFR C677T*, *MTR* A2756G, toxicity, 3057
Survival, endometrial cancer, prognosis, radiotherapy, chemotherapy, 3483
Survival, integrins, colorectal cancer, polymorphisms, single nucleotide polymorphisms, 1373
Survival, minichromosome maintenance proteins, MCMs, cyclin D3, CCND3, Hodgkin lymphoma, 3585

Survival, neutrophil-lymphocyte ratio, non-small cell lung cancer, 2995
Survival, non-small cell lung cancer, TIMP1, mRNA, DFI, blood plasma, 4031
Survival, polymorphism, *XRCC1*, Arg399Gln, Arg194Trp, *GSTP1* Ile104Val, *GSTT1*, *GSTM1*, gastric cancer, 705
Survival, prognosis, left colon, right colon, sigmoid, colon cancer, gender, 2347
Survival, prostaglandin E2 receptor, renal cell carcinoma, pathological features, immunohistochemistry, 597
Survival, quality control, brain tumor, pediatric neuro-oncology, 661
Survival, κ-actin, hepatocellular carcinoma, postoperative prognosis, 2037
Surviving fraction, human lung cancer cell lines, doubling time, radiobiology model, clonogenic assay, 1125
SVCAM-1, breast cancer, chemotherapy, dose-dense, sICAM-1, 2617
Swedish-type smokeless tobacco, cigarette smoking, Snus, ethanol, human normal cells, cell death, endothelial cells, fibroblasts, 1527
Synchronous, colorectal cancer, liver metastases, lung metastases, metachronous, 1049
Synergism, cisplatin, CTR1, bortezomib, drug combination, proteasomal degradation, drug uptake, drug resistance, 2757
Synergism, drug resistance, drug combination, quercetin, thymoquinone, cisplatin, oxaliplatin, 3789
Synergism, ovarian cancer, cisplatin, curcumin, EGCG, drug combination, 1131
Synergism, oxaliplatin, phytochemicals, ovarian cancer cell lines, cytotoxicity, 4283
T lymphocytes, nucleotide, insoluble protein, dendritic cell, immunotherapy, 881
T(10;17) translocation, endometrial stromal sarcoma, neuroectodermal, 2367
T(3;3)(q21;q26), Inv(3)(q21q26), breakpoint distribution, chromosomal abnormalities, fluorescent *in situ* hybridization, 3441
T0070907, PPARγ, breast cancer, PPARG, migration, invasion, 813
T47D cells, genistein, breast cancer, p90RSK, cell proliferation, 209
Taiwanese, *cyclin D1*, CCND1, polymorphism, lung cancer, smoking, 3601
T-ALL, HB-EGF, CRM197, doxorubicin, 2483
Tamoxifen, aromatase inhibitors, anti-estrogens, breast cancer, steroid sulfatase, anastrozole, postmenopausal women, 1367
Tamoxifen, breast cancer, anastrozole, radiotherapy, ipsilateral breast tumor recurrence, 367
Tamoxifen-resistance, insulin-like growth factor-1, IGF-1, oestrogen resistance, breast cancer recurrence, oestrogen receptor-alpha, *EGFR*, 23
Target, KRAP, *KRAS*, cancer, obesity, diabetes, review, 2413
Targeted therapy, NSCLC, methylation, MLPA, gene methylation, TKIs, smoking, *EGFR* mutation, 4647
Targeted therapy, ovarian cancer, HB-EGF, CRM197, 2461
γδ T-Cells, antigen presentation, cytotoxic T-cells, 2419
T-cell infiltration, SDF1β, RCC, grade, 2797
Tegafur, S-1, 5-fluorouracil, phase I, FBAL, FT, reversible dihydropyrimidine dehydrogenase, DPD, gimeracil, CDHP, solid tumors, 625
Telomerase activity, sodium meta-arsenite, cancer cells, stem cells, telomere length, 4315
Telomerase, indole, prostate cancer, diethylstilbestrol, cell viability, 3733
Telomere length, sodium meta-arsenite, cancer cells, stem cells, telomerase activity, 4315
TEM8, triple negative breast cancer, breast cancer, immunohistochemistry, lymph node metastasis, 3417
Temozolomide, anaplastic ependymoma, multifocal recurrence, 1023
Temozolomide, anaplastic gliomas, long-term administration, 3873
Temozolomide, diffuse intrinsic pontine glioma, chemotherapy, rofecoxib, bevacizumab, inflammatory processes, 2265
Temozolomide, glioma, *EGFR*, cell cycle, 3253
Temozolomide, glioma, PTEN, cell cycle, ionizing radiation, radiosensitivity, 1653
Temozolomide, ionizing radiation, immunogenicity, cell death, Hsp70, 3727
Temozolomide, metastastic melanoma, melanoma, brain metastases, whole-brain radiation, 4537
Temozolomide, mKate2, mCherry, glioblastoma model, intracranial, live imaging, 2161
Temsirolimus, chromophobe renal cell carcinoma, mTOR, sorafenib, interferon, 331
TENIS syndrome, thyroid neoplasms, thyroglobulin, iodine radioisotopes, 2109
2, 1, 3, 4-Tetrahydroisoquinolins, QSAR, tumor-specificity index, semi-empirical molecular-orbital method, artificial neural network, 4231
Tetramethylnaphthalene, HTLV-1, ATL, inhibitor, cell cycle, 2241
TFPI2, methylation, gastric cancer, 3835
TGF-α, silibinin, CD44, *EGFR*, EGF, MMP-9, breast cancer metastasis, 3767
TGF-β, cytoskeleton, paxillin, phosphatase, PP-1, 3159
TGF-β, epithelial to mesenchymal transition, lung cancer, potassium channels, Eag1, 1265
Therapy efficacy, circulating tumor cells, metastatic breast cancer, chemotherapy, 979
Therapy personalization, breast cancer, primary culture, chemotherapeutics, oncogramme, individualized tumour response testing, 139

Therapy response, hepatocellular carcinoma, ^{1}H MRI, apparent diffusion coefficient, extracellular space, benzamide riboside, angiography, motion effect, 2045
Thermal cancer therapy, hyperthermia, hepatic stellate cells, fibrosis, HCC, HepG2, 1583
Thermal cancer therapy, hyperthermia, hepatic stellate cells, fibrosis, HCC, transwell, co-culture, 3713
Thermal neutron irradiation, boron tracedrug, BODIPY, curcuminoid, neutron dynamic therapy, dynamic drug, BNCT, 2477
Thiazide diuretic, prostate cancer, PSA, statins, NSAID, 1735
6-Thioguanine, GLI2, PTHrP, osteolysis, breast cancer, 2705
Thioredoxin, non-small cell lung cancer, TXNDC5, protein disulphide isomerase, 1577
Thioredoxin, selenoprotein, colon cancer, glutathione, antioxidant enzyme expression, 2693
Thioridazine, multidrug-resistant cancer cells, MDR mouse T-lymphoma cells, ABCB1 transporter, P-glycoprotein, phenothiazines, apoptosis, 4201
Third-line treatment, non-small cell lung cancer, erlotinib, gefitinib, review, 649
Thoracic malignancy, carboplatin, cisplatin, hypersensitivity, antineoplastic, immunoglobulin E, 4525
Thrombin, colon cancer, vascular endothelial growth factor, vascular endothelial growth factor receptor-2, coagulation factor, angiogenesis, 843
Thrombosis, germ cell tumour, cisplatin, hypercoagulation, vascular toxicity, von Willebrand factor, 4501
Thromboembolism, breast cancer, chemotherapy, outcome, 2383
Thymic carcinoma, chemotherapy, ADOC, refractory, S-1, 299
Thymidine kinase, adenovirus, prodrug activation, HNSCC, ganciclovir, apoptosis, 3851
Thymidine kinase1, 5'(3')-deoxyribonucleotidase, fluorothymidine, proliferation, lung cancer, colon cancer, 2135
Thymidine phosphorylase, paclitaxel, doxifluridine, gastric cancer, chemotherapy, 287
Thymidylate synthase, 5-FU resistance, cyclooxygenase-2, etodolac, 2893
Thymidylate synthase, ERCC1, adenosine triphosphate, drug screening assay, colorectal neoplasm, 3843
Thymidylate synthase, gastric cancer, cetuximab, S-1, 3691
Thymidylate synthase, HGF, c-Met, *NK4*, CT26, 5-fluorouracil, Akt, Erk1/2, 2217
Thymidylate synthase, lung adenocarcinoma, 5-fluorouracil, dihydropyrimidine dehydrogenase, chemosensitivity, 4665
Thymidylate synthase, oral squamous cell carcinoma, dihydropyrimidine dehydrogenase, lymph node metastasis, KAI1/CD82, 3521
Thymoquinone, drug resistance, drug combination, synergism, quercetin, cisplatin, oxaliplatin, 3789
Thymus vulgaris L. (thyme), oral cavity squamous cell carcinoma OCSCC, head and neck squamous cell carcinoma HNSCC, natural product, pharmacogenomics, 81
Thyroglobulin, thyroid neoplasms, iodine radioisotopes, TENIS syndrome, 2109
Thyroid cancer, biomarker, diagnosis, sensitivity, specificity, metastasis, immunohistochemistry, 3433
Thyroid hormones, proliferation, PI3K, MAPK, 89
Thyroid malignant neoplasma, sialic fibronectin, lymph node metastasis, MoAb Jt-95, 1395
Thyroid neoplasms, thyroglobulin, iodine radioisotopes, TENIS syndrome, 2109
Tight junction regulation, HAVcR-1, tight junction, endothelial cells, 467
Tight junction, HAVcR-1, endothelial cells, tight junction regulation, 467
Time to castration resistance, castrate-resistant prostate cancer, predictors of survival, chemotherapy, advanced prostate cancer, 1475
TIMP, ADAM, MMP, solid cancer nest, invasive front, colorectal cancer, 1567
TIMP1, non-small cell lung cancer, mRNA, DFI, survival, blood plasma, 4031
TIP60, quantitative real-time PCR, gastric cancer, 77
Tissue engineering, high hydrostatic pressure, bone, revitalization, 1235
Tissue microarray, breast cancer, DAPK, 3633
Tissue microarray, cortactin, breast cancer, 293
Tissue microarray, cytokeratin 4, fascin, biomarker, squamous cell carcinoma, esophagus, 945
Tissue microarrays, non-small cell lung cancer, cancer stem cell antigens, biomarkers, prognosis, CD133, CD117, BCRP1, 4491
Tissue sections, renal cell carcinoma, chromophobe renal cell carcinoma, renal oncocytoma, fluorescence *in situ* hybridization, isolated nuclei, 3137
TKIs, NSCLC, methylation, MLPA, targeted therapy, gene methylation, smoking, *EGFR* mutation, 4647
T-lymphoblastoid leukemia, arsenic trioxide, arsenic acid, organic arsenicals, daunorubicin resistance, apoptosis, 4169
TMPRSS2:ERG, prostate cancer, microRNA, Fusion gene, 403
TNF-alpha, hepatoma, proteomics, 2-DE, LC-MS/MS, apoptosis, 2059
TNF-α, resveratrol, glioma, invasion, urokinase plasminogen activator, 4223
TNM classification, child's classification, hepatocellular carcinoma, liver cirrhosis, MELD-score, nonhepatic cancer, survival probability, 2931

Tobacco smoking, *EGFR*, mutation, methylation, lung adenocarcinoma, *FHIT*, RASSF1A, RUNX3, 1211
Tobacco-caused cancer, cigarette smoking, race, 3891
Tomotherapy, anal cancer, chemoradiation, image-guided radiotherapy, 4393
Tongue carcinoma, matrix metalloproteinases, gelatinase, green fluorescent protein, xenograft, peptide, 3659
Tongue, oral carcinogenesis, immunohistochemistry, beta-catenin, mice, 2805
Tonsillar cancer, base of tongue cancer, oropharyngeal cancer, head and neck cancer, HPV, revie, 1515
Toombak, oral squamous cell carcinomas, genes, apoptosis, cell cycle regulation, intermediate filament proteins, Sudan, 3345
Topotecan, cisplatin, small cell lung cancer, 3449
Total estrogen blockade, high-dose chemotherapy, leuprorelin, anastrazole, premenopausal breast cancer, *VEGF*, 671
Total testosterone (TT), prolactin (PRL), luteinizing hormone (LH), free testosterone (FT), prostate-specific antigen (PSA), prostate cancer, 3913
Total testosterone, luteinizing hormone, LH, TT, free testosterone, FT, prostate-specific antigen, PSA, prostate cancer, 1071
Toxicity, colorectal cancer, adjuvant chemotherapy, *MTHFR C677T*, *MTR* A2756G, survival, 3057
Toxicity, epigenetic modifiers, kidney, ROS, p66shc, mitochondria, 3267
Toxicity, LPS, endotoxin, oral administration, absorption, lipopolysaccharide, review, 2431
Toxicity, serum 25(OH)D, vitamin D, chemoprevention, 607
TP53, mutations, polymorphisms, *FHIT*, chronic esophagitis, esophageal carcinoma, 1685
TP53, ovarian cancer, gene mutations, BRCA 1/2, PI3K, AKT, *BRAF*, *KRAS*, review, 2661
TPS, uveal melanoma, metastasis, liver function tests, tumor markers, OPN, S-100β, MIA, 351
TPS, uveal melanoma, metastasis, tumor markers, OPN, S-100β, MIA, 345
TRAIL, apoptosis, liver metastases, invasion front, *FAS*, colorectal cancer, 1215
TRAIL, histone deacetylase inhibitor, LBH589, colon cancer, apoptosis, 3385
TRAIL, small cell lung cancer, paclitaxel, chemotherapy, 3193
Transarterial chemoembolization, hepatocellular carcinoma, miriplatin, 2983
Transarterial chemoembolization, liver directed therapy, metastatic colon cancer, irinotecan, DEBIRI, DC Bead, 4581
Transarterial chemoembolization, lymph node metastasis, hepatocellular carcinoma, resection, 3991
Transcriptional response, neuroblastoma, radiotherapy, neem leaf extract, apoptosis, 161
Transitional carcinoma, bladder cancer, lymphovascular invasion, upper tract transitional carcinoma, prognostic role, review, 3503
Translational research, *EGFR*, Ki-67, squamous cell carcinoma, head and neck cancer, 665
Transrectal ultrasonography, prostate cancer, contrast-enhanced ultrasonography, 1421
Transwell, hyperthermia, thermal cancer therapy, hepatic stellate cells, fibrosis, HCC, co-culture, 3713
Trastuzumab, breast cancer, neoadjuvant chemotherapy, pCR, 3041
Trastuzumab, HER2-positive, S-1, metastatic breast cancer, 3035
Treatment, panitumumab, metastatic colorectal cancer, bevacizumab, 1033
Treatment-free interval, ovarian cancer, consolidation chemotherapy, recurrent, salvage chemotherapy, paclitaxel, cisplatin, irinotecan, 4613
Trihaloacetylazulenes, QSAR, cytotoxicity, semiempirical molecular-orbital method, 515
Triphala, prostate cancer, cytotoxicity, gallic acid, Ayurvedic medicine, 3739
Triple negative breast cancer, TEM8, breast cancer, immunohistochemistry, lymph node metastasis, 3417
Triple negative, breast cancer, biomarker, 2389
Triple-negative, metastatic breast cancer, capecitabine, HER2-negative, prognostic factors, 1079
Triplet combination chemotherapy, paclitaxel, cisplatin, S-1, advanced gastric cancer, feasibility study, 3085
Triptolide, medicinal compounds, proteasome inhibitors, apoptosis, cancer therapy, 1
TS, colorectal cancer, pulmonary metastases, OPRT, ERCC1, BRCA1, MVD, adjuvant chemotherapy, 2763
TS-1, two-dimensional gel electrophoresis, LC-MS/MS, pancreatic cancer, proteomics, 2103
TT, luteinizing hormone, LH, total testosterone, free testosterone, FT, prostate-specific antigen, PSA, prostate cancer, 1071
Tubulin alpha-6 chain, HCV-HCC, proteomics, 2-DE, MS, 3331
Tumor cell proliferation, quinazoliniminium salts, Ki-67 expression, macromolecule syntheses, DNA interaction and fragmentation, multiple mitotic figures, nuclei, micronuclei, 2083
Tumor growth, MT477, NRF2, AURKA, 1181
Tumor location, colon cancer, microsatellite instability, age, early onset, 967
Tumor markers, colorectal cancer, biological activity, angiogenetic factors, metalloproteinases, adhesion molecules, 373

Tumor markers, growth factors, breast cancer, CA 15-3, CEA, IGF1, EGF, HGF, 4653
Tumor markers, renal failure, mesothelioma, N-ERC/mesothelin, osteopontin, 1427
Tumor markers, uveal melanoma, metastasis, liver function tests, OPN, S-100β, MIA, TPS, 351
Tumor markers, uveal melanoma, metastasis, OPN, S-100β, MIA, TPS, 345
Tumor models, immunotherapy, immunomodulation, natural killer cells, *Parapoxvirus ovis*, Orf virus, 4185
Tumor progression, hyperdiploid multiple myeloma, cytogenetics, 1599
Tumor progression, portal vein embolisation, liver hypertrophy, serum markers, 339
Tumor residual, ovarian cancer relapse, secondary cytoreductive surgery, predictive factor, complete tumor resection, 2583
Tumor response, rectal cancer, hyperthermo-chemo-radiation therapy, HCRT, distal margins, 3963
Tumor stage, soluble leptin receptor, colorectal cancer, 3381
Tumor suppressor gene, *FUS1*, sarcoma, RT-PCR, immunohistochemistry, growth inhibition, 11
Tumor suppressors, cell cycle arrest, DNA N-methyl transferase, ERK, 2723
Tumor volume, magnetic resonance imaging, micro-computed tomography, optical reflectance imaging, molecular imaging, GFP, RFP, 2907
Tumor, angiogenesis, cancer, CD105, endoglin, review, 2283
Tumor, cyclooxygenase, COX-2, breast cancer, prostaglandin, carcinogenesis, 4359
Tumor-associated proteins, neoadjuvant therapy, response prediction, squamous-cell esophageal cancer, 1769
Tumorigenesis, CD133, colon cancer, azomymethane, dextran sodium sulphate, 4273
Tumor-infiltrating lymphocytes, memory T- cell, CD44, melanoma, 4099
Tumor-specificity index, 1, 2, 3, 4-tetrahydroisoquinolins, QSAR, semi-empirical molecular-orbital method, artificial neural network, 4231
Tumour markers, breast cancer liver metastases, liver surgery, prognostic factors, differental diagnosis, benign liver lesions, 1447
Tumour markers, cervical cancer, artesunate, artenimol, clinical symptoms, 4417
Tumour markers, monoTotal, lung cancer, cytokeratins, 3107
Tumour regression, GLUT-1, rectal cancer, chemotherapy, radiotherapy, prognosis, 311
Tumour, microvesicles, chemokine, monocyte, 1329
TURBT, bladder cancer, radiochemotherapy, radiation therapy, 985
Two-dimensional gel electrophoresis, LC-MS/MS, pancreatic cancer, TS-1, proteomics, 2103
TXNDC5, non-small cell lung cancer, thioredoxin, protein disulphide isomerase, 1577
Type C, bening breast disease, personality, hopelessness, cancer risk, 4019
Type C, personality, commitment, cancer risk, 4013
Type I collagen, MMP-13, bone metastasis, integrin, MAPK, 1307
Tyrosine kinase inhibitor, sunitinib, metastatic renal cell carcinoma, sequential treatment regimen, mTOR inhibitor, 3507
Tyrosine kinase inhibitor, V*EGFR*2, drug resistance, angiogenesis, endothelial cells, HUVEC, 2787
Tyrosine kinase, hepatocellular carcinoma, liver resection, multidrug resistance, ABC proteins, 3883
Ubiquitin–proteasome system, extracellular proteasome, breast cancer, 2197
UC-associated colorectal cancer, leukocytapheresis, ulcerative colitis, 2547
Ulcerative colitis, colorectal cancer, surveillance, 2499
Ulcerative colitis, leukocytapheresis, UC-associated colorectal cancer, 2547
Ulcerative colitis, polymorphism, DNA methylation, CD14, p22PHOX, MBL, 933
Ultrasound, breast cancer, screening, mammography, automated 3D imaging, 2569
Ultrasound, mono-l-aspartyl chlorin e6, antitumor effect, sonodynamic therapy, sarcoma 180, colon 26, 501
Uncontrolled ascites, hepatocellular carcinoma, perioperative factors, hepatectomy, prognosis, 4545
U-PA, oncostatin M, interleukin-6, *VEGF*, prostate cancer, 3273
Upper tract transitional carcinoma, bladder cancer, transitional carcinoma, lymphovascular invasion, prognostic role, review, 3503
Upper tract urothelial cancer, CCND1 1722, *cyclin D1*, polymorphism, 1043
Upper urinary tract urothelial carcinoma, maspin, activin A, androgen receptor, prognosis, 1713
Urachal cancer, recurrence, gemcitabine, cisplatin, chemotherapy, 2335
Uridine phosphorylase, hybrid steroidal alkylators, *in silico* molecular docking, *in vitro* assay, mitrogen mustards, pancreatic cancer cells, 831
Urokinase plasminogen activator, resveratrol, glioma, invasion, TNF-α, 4223
Urothelial carcinoma, *hOGG1*, *XPD*, polymorphism, 3939
Urothelial lesion, BBN, gemcitabine, sirolimus, mice, 1637
Uterine cervical cancer, FDG-PET, lymph node, MRI, 3865
Uterobrush, cytology, endometrial brush, endometrial cancer, endometrial pathology, screening test, 3469

UVB, normal human keratinocytes, 18β-glycyrrhetinic acid, glabridin, ROS, 2209
Uveal melanoma, metastasis, liver function tests, tumor markers, OPN, S-100β, MIA, TPS, 351
Uveal melanoma, metastasis, tumor markers, OPN, S-100β, MIA, TPS, 345
V600E, *BRAF* mutation, *KRAS*, *EGFR*, ERBB2 mutation, lung cancer, adenocarcinoma, squamous cell carcinoma, SSCP, 4619
Vaccine, DC, whole tumor cell, IFN-γ, ELISPOT, 3995
Vaccine, Her-2/neu, peptide, B-cell epitope, antitumor effect, 3361
Valproic acid, apoptosis, celecoxib, cytotoxicity, neuroblastoma, 2231
Valspodar, isolated lung perfusion, sarcoma lung metastases, p-gp modulation, doxorubicin, cyclosporine, 2121
Vascular endothelial growth factor (*VEGF*), cysteine-histidine-rich protein (*PINCH*), colorectal carcinoma, epithelial mesenchymal transition (EMT), *FAS*, 4127
Vascular endothelial growth factor receptor-2, colon cancer, thrombin, vascular endothelial growth factor, coagulation factor, angiogenesis, 843
Vascular endothelial growth factor receptors, paclitaxel, bevacizumab, breast cancer, 3007
Vascular endothelial growth factor, alternative splicing, angiogenesis, autologous stem cell transplantation, chick chorioallantoic membrane assay, high-dose chemotherapy, placental growth factor, V*EGFR*1, 3115
Vascular endothelial growth factor, angiogenic factors, basic fibroblast growth factor, endostatin, cervical cancer, 2645
Vascular endothelial growth factor, colon cancer, thrombin, vascular endothelial growth factor receptor-2, coagulation factor, angiogenesis, 843
Vascular endothelial growth factor, *VEGF*, gene expression, anti-*VEGF* therapy, bevacizumab, epithelial ovarian cancer, 731
Vascular toxicity, germ cell tumour, cisplatin, thrombosis, hypercoagulation, von Willebrand factor, 4501
Vascular tube formation, angiogenic factor, cervical cancer, antiangiogenic therapy, 2609
Vascularisation, athymic mice, low-grade liposarcoma, soft tissue sarcoma, xenograft, 4061
Vascularity, CEUS, HCC, dysplastic nodule, characterization, cirrhosis, 3977
VEGF, angiogenic factors, cervical cancer, angiogenin, endoglin, 2589
VEGF, bevacizumab, safety, pediatrics, 3953
VEGF, mTOR, HIF-1α, angiogenesis, oral cancer, 4429
VEGF, oncostatin M, interleukin-6, u-PA, prostate cancer, 3273
VEGF, polymorphism, colorectal cancer, MMP2, HIF1A, SNP, 575
VEGF, sunitinib, antitumor, antimetastasis, V*EGFR*, phosphorylation, mammary cancer, 1225
VEGF, total estrogen blockade, high-dose chemotherapy, leuprorelin, anastrazole, premenopausal breast cancer, 671
VEGF, vascular endothelial growth factor, gene expression, anti-*VEGF* therapy, bevacizumab, epithelial ovarian cancer, 731
VEGF-C, breast cancer, lymphatic microvessel density, molecular classification, V*EGFR*-3, 1757
VEGF-C, lymphangiogenesis, lymphovascular invasion, liver metastases, colorectal cancer, 4605
V*EGFR*, sunitinib, antitumor, antimetastasis, *VEGF*, phosphorylation, mammary cancer, 1225
V*EGFR*1, alternative splicing, angiogenesis, autologous stem cell transplantation, chick chorioallantoic membrane assay, high-dose chemotherapy, placental growth factor, vascular endothelial growth factor, 3115
V*EGFR*2, tyrosine kinase inhibitor, drug resistance, angiogenesis, endothelial cells, HUVEC, 2787
V*EGFR*-3, breast cancer, lymphatic microvessel density, molecular classification, *VEGF*-C, 1757
Vessel identification, angiogenesis, breast cancer, image analysis, CD34, MVD, 4053
Vimentin, EMT, E-cadherin, gamma catenin, fibronectin, lung adenocarcinoma, 4451
Vimentin, quantitative methylation-specific PCR, hepatocellular carcinoma, 1289
Vincristine, drug delivery, cancer, liposome, folate receptor, drug targeting, 1521
Vincristine, glioma, oligodendroglioma, 1p19q, 1p, PAV, ACNU, procarbazine, chemotherapy, 4475
Vincristine, medulloblastoma, lomustine, apoptosis, chemotherapy, 1721
Vinorelbine, chemotherapy, carboplatin, paclitaxel, non-small cell lung cancer, 317
Vinorelbine, histoculture drug response assay, non-small cell lung cancer, class III β-tubulin, predictive marker, 999
Viral hepatitis, hepatocellular carcinoma, non-cirrhotic livers, 1055
Virotherapy, pancreatic cancer, chemoresistance, gemcitabine, PDAC, GFP, 1279
Vitamin D analog, prostate cancer, ZK191784, MMP-2, MMP-9, adhesion molecules, 4091
Vitamin D, 25-hydroxyvitamin D, breast neoplasms, case–control studies, epidemiology, meta-analysis, prevention, 2939
Vitamin D, colorectal cancer, breast cancer, prostate cancer, lung cancer, 3619
Vitamin D, serum 25(OH)D, toxicity, chemoprevention, 607
Voluntary running, metastasis, cytokines, mice, 3337

Von Willebrand factor, germ cell tumour, cisplatin, thrombosis, hypercoagulation, vascular toxicity, 4501
W-APC, cyclooxygenase, COX-2, right colon, left colon, colon cancer, 2191
Western blotting, estrogen receptor, breast cancer cell lines, flow cytometry, RT-PCR, 521
Whole tumor cell, DC, vaccine, IFN-γ, ELISPOT, 3995
Whole-brain radiation, metastastic melanoma, melanoma, brain metastases, temozolomide, 4537
Wilms' tumor 1 (WT1), myeloid dendritic cell, cancer vaccine, immunotherapy, 2447
WISP-1, esophageal cancer, CCN family, WISP-1v, 991
WISP-1v, esophageal cancer, CCN family, WISP-1, 991
Wnt pathway, colorectal cancer, immunohistochemistry, LGR5, stem cell marker, 263
Wnt pathway, multiple myeloma, signal transduction, myeloma, myeloma therapy, review, 725
Wnt, leukemia, notch, hedgehog, γ-secretase inhibitor, 893
WT1 peptide vaccine, immunotherapy, ovarian cancer, 2441
WU, human polyomavirus, BK virus, JC virus, hemotopoetic stem cell transplantation, cerebrospinal fluid, KI, 3489
XELIRI, bevacizumab, FOLFIRI, colorectal cancer, efficacy, safety, 1777
Xenograft model, (+)-spongistatin 1, anticancer, natural product, mitosis, 2773
Xenograft model, 3-Indole, cell cycle arrest, ATM, ATR, SMAD3, lung cancer cells, 203
Xenograft, athymic mice, low-grade liposarcoma, soft tissue sarcoma, vascularisation, 4061
Xenograft, breast cancer, ADAMTS1, amphiregulin, immunotherapy, 3839
Xenograft, heparan sulfate, proteoglycans, HepG2 cells, immunotherapy, liver cancer, 4067
Xenograft, hepatitis C virus, liver tumour, sarcomatoid tumour, cell line, culture, spectral karyotyping, 129
Xenograft, matrix metalloproteinases, gelatinase, tongue carcinoma, green fluorescent protein, peptide, 3659
Xenografts, ischemia, immunohistochemistry, phosphoproteins, pre-analytical variables, biopsy, 2073
Xenografts, radioimmunotherapy, HNSCC, SCID mice, radio-labeled monoclonal antibody, Cytokeratin 8, 3315
*Xho*I restriction site, EBV polymorphism, *Bam*HI W1/I1, EBV-associated gastric cancer, Latin America, 3607
XPD, *hOGG1*, polymorphism, urothelial carcinoma, 3939
X-ray repair cross-complementing group 1, *XRCC1*, polymorphism, DNA repair, skin cancer, meta-analysis, 3945
XRCC1, genetic polymorphisms, cancer susceptibility, DNA-repair genes, metabolizing genes, *CYP1A1*, *CYP1E1*, 1359
XRCC1, polymorphism, Arg399Gln, Arg194Trp, *GSTP1* Ile104Val, *GSTT1*, *GSTM1*, gastric cancer, survival, 705
XRCC1, polymorphism, *Helicobacter pylori*, gastric atrophy, intestinal metaplasia, *GSTP1*, *GSTT1*, *GSTM1*, 1459
XRCC1, X-ray repair cross-complementing group 1, polymorphism, DNA repair, skin cancer, meta-analysis, 3945
YB-1, non-Hodgkin's lymphoma, prognosis, immunohistochemistry, 2963
YT, myeloma, CD86, interleukin-2, cytotoxicity, 475
Zanthoxylum ailanthoides Sieb and *Zucc*., human colon adenocarcinoma cell, colo 205 cells, caspases, apoptosis, flavone, 1667
Zeranol, ACI rat serum, breast cancer, mitogenic activity, 481
Zeranol, cell proliferation, protein disulfide isomerase, mammary tumorigenesis, 1659
Zinc, clioquinol, *cyclin D1*, miR-302C, MCF-7 cells, 2739
ZK191784, prostate cancer, vitamin D analog, MMP-2, MMP-9, adhesion molecules, 4091

Authors Index

(Figures refer to page numbers)

Abbas A, 4637
Abbruzzese JL, 1417
Abdel-Nabi H, 411
Abdulkarim B, 3559
Abdullah A, 2017
Abe F, 2915, 4339
Abe T, 3463, 3535
Abo T, 4545
Abou-Elkacem L, 2907
Aboussekhra A, 1721
Abraham I, 1407
Absenger G, 1373
Abujamra AL, 2723
Abuzenadah A, 97, 2975, 4179
Acha-Sagredo A, 677
Ackermann H, 665
Acquati P, 1881
Adachi M, 2893
Adamo V, 1315
Addo J, 591
Adler S, 3733
Adoubi I, 4417
Advani PP, 335
Agatsuma T, 299
Agharahimi M, 3739
Agostini A, 3047
Aguirregaviria JI, 677
Aguirre-Urizar JM, 677
Ahmad A, 1105
Ahn SH, 4641
Aieta M, 1359
Akada JK, 3331
Akagi Y, 2517, 2541, 2547
Akaike M, 325
Akashi H, 763
Akaza H, 2065
Akazawa K, 1483
Akeda K, 4163
Akiba S, 3607
Akiyoshi K, 1653
Aklilu M, 255
Akrivos T, 3469
Aksoy-Sagirli P, 2225
Aktas B, 3623
Alamanis C, 1475
Al-Ayadhi B, 521
Al-Bader M, 521
Al-Benna S, 4061
Alberg AJ, 3891
Albisinni S, 1812
Albo G, 1880
Alcaraz JE, 2939
Al-Eisawi Z, 2757
Alessandro M, 1876
Alexander A, 3559
Alexander J, 785
Alexiadou A, 3469
Alexopoulou A, 1467
Alfaro R, 1599
Al-Ghamdi K, 4179
Al-Hindi H, 1721
Ali S, 209
Aliberti C, 4581
Al-Kofide A, 1721
Al-Maghrabi J, 97, 4179
Almhanna K, 4387
Al-Muhayawi S, 4179
Al-Qahtani M, 97, 2975, 4179
Al-Quran SZ, 3417
Al-Saad S, 1603
Al-Shail E, 1721
Al-Shibli K, 1603
Altherr K, 2797
Al-Thobaiti F, 2975
Al-Thubaity F, 97
Amano S, 3839
Amant F, 2367
Amaral L, 3285, 4201
Amatulli M, 2149
Ambrosio MR, 1865
Amellal N, 2271
Amend B, 3783
Amendola F, 4575
Amérigo J, 3019
Amirkhan RH, 4135
Amoroso D, 1061
An W-W, 1647
Anai H, 3909
Anastasiou I, 1475
Andergassen U, 2749
Andersen S, 1603
Andersen SN, 861
Anderson KM, 487
Ando M, 3449
Andratschke M, 3315
Andratschke N, 561
Andre T, 2271
Angelopoulou MK, 3585
Angiero F, 719, 4485
Anichini C, 3973
Anlasik T, 2197
Anthoine G, 281
Anthony B, 2813
Antonacopoulou AG, 1677
Antonelli A, 1922, 1924
Antonia SJ, 3193
Antoniolli SZ, 3913
Aoki M, 3991
Aoki S, 1685
Aoki T, 633
Aoki Y, 1437, 3527
Aomatsu K, 2787
Aomatsu N, 3369
Aoyama H, 2241
Aoyama M, 3353
Aoyama T, 1297
Apostolaki A, 3093
Aragona F, 4445
Arai M, 4169
Arany I, 3267
Arao T, 2787, 4561
Aravantinos G, 3007
Aravindan N, 161
Aravindan S, 161
Arbab AS, 3673
Arcoria D, 4553
Ardavanis A, 1033, 3093
Arena V, 4273
Ariad S, 913
Ariga T, 3527
Ariizumi T, 11
Arima N, 2241, 4251
Arisawa T, 705, 933, 1459
Arkins AM, 2073
Armakolas A, 4259
Armakolas N, 4259
Armentano R, 555
Arnes M, 2319
Arnold D, 1961
Arnolds J, 3151
Arnoldt J, 2012
Arrias-Herrera V, 849
Arthur G, 3809
Arthur JR, 2693
Asai K, 3353
Asaka S, 2989
Asanuma K, 4163
Asao T, 2847, 3963
Ashton J, 255
Astner ST, 3935
Ata M, 2975
Atasoylu O, 2773
Ater J, 2265
Aubard Y, 3865
Auge JM, 3107
Aung W, 1549
Avgerinou G, 2373
Avruch L, 3921
Awasthi V, 161
Ayabe T, 2995
Azmi AS, 1105
Azzarok A, 1961
Azzoni P, 2209
Baak JPA, 443
Baba E, 3995
Baba H, 991, 2983
Baba M, 2241
Babayeva SN, 2693
Babsky AM, 2045
Bachmann K, 1962
Bacigalupo B, 1061
Badisa RB, 3739
Badisa VLD, 2017
Bae SB, 3385
Bafaloukos D, 3007
Baggerly LL, 607
Baghi M, 665
Bahram F, 1527
Baj-Krzyworzeka M, 1329
Bakker J, 4043
Baldazzi V, 1870
Baldoli E, 3401
Balkin ER, 3143
Ballaré A, 1885
Ballester M, 4469
Bally MB, 2161
Balogh S, 3051
Bamias A, 1475
Bandapalli OR, 1215
Bando Y, 2389
Bansal N, 2045
Banys M, 4423
Barak V, 345, 351, 1962
Baran J, 1329

Barboro P, 1828
Bardin C, 2813
Barekati Z, 2623, 4267
Barinoff J, 2609, 2645, 2651
Barla G, 1033
Barlett B, 3747
Barnett CM, 973
Barsotti C, 3483
Barth S, 2907
Barth TFE, 2343, 4599
Bartnitzke S, 753
Baruch R, 351
Bas M, 3151
Basinko A, 3441
Ba-Ssalamah A, 2379
Bassi R, 2149
Basso SMM, 693, 3879, 3969
Basso U, 693
Bastian S, 3181
Bates V, 2661
Bau D-T, 221, 227, 745, 1043, 2395, 3511, 3601, 3629, 4301
Baxi S, 249
Beale P, 1131, 2757, 3789, 4283
Bechter K, 2343
Bechter O, 4407, 4439
Beckers S, 53
Bedke J, 3783
Beer TM, 973
Beldì D, 1909
Belge G, 753
Bellardita L, 1826
Bellastella G, 1847
Bellavita R, 1912, 1913
Bellyei S, 1769
Benali-Furet N, 427
Benassi L, 2209
Benbrook DM, 2739
Bendell JC, 255
Benea G, 4581
Benecchi L, 1860, 1911, 1912, 1914
Benedicenti S, 719
Benesova L, 4647
Benharoch D, 913
Bennett S, 2045
Beppu T, 2983
Berger G, 147, 153
Bergerat J-P, 1765
Berghmans T, 281
Bergmann C, 3151
Bergmeier S, 871, 1345
Bergner A, 849
Bergqvist M, 1125
Beris P, 3585
Berkkan H, 2225
Berkowitz JA, 427
Bernacki R, 411
Bernardo G, 3927
Bernreuther C, 591
Bernués M, 1599
Berremila S-A, 585
Bersani S, 3137
Bertazzoni G, 2209
Bertelli E, 1922
Bertini R, 1840
Bertucci F, 1079
Besalduch J, 1599
Bessette B, 139
Betz M, 4393
Bhattacharya A, 387
Bhayani MK, 2893
Bianchino G, 1359
Bieglmayer C, 3615
Biesterfeld S, 53, 2797
Bilal A, 1510
Billecke L, 1963
Birner P, 4605
Bischofs E, 3219
Bittman R, 3809
Blankenstein Th, 1963
Blau CA, 1189
Blau T, 561
Blobe GC, 255
Blohmer J-U, 2575, 2589, 2645
Bobek V, 1535, 3125
Bobos M, 3007
Boc M, 1777
Body G, 1783
Boix M, 4191
Bojic M, 2379
Bolikal S, 421
Bölling T, 3903
Bollito E, 1947
Bolotin A, 913
Boltetsou E, 3585
Bonanno A, 3069
Bondor C, 2637
Bonetta A, 1849, 1850, 1863, 1942
Borel Rinkes IHM, 1379, 4507
Borges KS, 1337
Borja-Cacho D, 1181
Borrelli D, 1903
Bortolato B, 1894, 1895
Bortolus R, 1941
Bouche O, 2271
Boulware D, 2191
Boumendjel A, 3213
Bournakis E, 1475
Bouteille C, 585
Boutonnat J, 3213
Bouvet M, 3125, 3665
Bovo C, 1007, 3441
Bowen KA, 1153
Bradley C, 1417
Brady PC, 243
Braicu EI, 2583, 2597, 2603, 2629, 2637
Braissant O, 2121
Branca G, 3069
Brand K, 1215
Brandau S, 3151
Brattström D, 1125
Braun S, 2657
Brausi M, 1817, 1819, 1834
Bravaccini S, 1864
Breidenbach M, 4039
Brekken RA, 843
Bremmer F, 1497
Bremnes RM, 1603
Brenner H, 1501
Brenner W, 2797
Brion N, 331, 3507
Brochez L, 3697
Brodin O, 1125
Brodt P, 3219
Bruckner T, 3219
Bruha F, 4647
Bruha J, 1447, 4031
Bruland ØS, 4053
Brunelli M, 3137
Brunello A, 693
Brunet B, 3559
Brunetti E, 89
Bruni E, 2209
Bruno P, 4207
Brunocilla E, 271, 3503
Bryan BA, 3645
Büchler MW, 3883
Buclin T, 2121
Budde U, 4501
Bufo P, 4211
Bugis A, 2975
Buhmeida A, 97, 2975
Buhr HJ, 147, 153
Bukac D, 1964
Bukholm IR, 861
Bullerdiek J, 753, 1541
Büntzel J, 1964, 1965
Buonocore G, 3973
Buonocore V, 1399
Burger CW, 4043
Burgkart R, 1235
Burke WM, 243
Busetto GM, 1399, 1845
Busund L-T, 1603
Byrne GJ, 2383
Byun H-S, 3809
Byun SJ, 4641
Cabanillas F, 1417
Cai FF, 4267
Cai J, 3897
Cakmakoglu B, 2225
Calì S, 4553
Calisti G, 3977, 4575
Camacho J, 1265
Camerini A, 1061
Cammarota F, 1863
Camoutsis C, 831
Camozzi V, 3969
Candeloro G, 671
Cangiarella J, 4401
Cao W, 39
Caparrotti P, 1898
Capellini C, 1061
Caraglia M, 1836
Cardinali M, 1889
Cardoso SV, 2805
Caredda E, 4273
Carlberg C, 1491
Carlotti Jr CG, 1337
Carlson D, 249
Carlsson G, 3057
Carmignani L, 1837
Carpenter MJ, 3891
Carrasquer CA, 3247
Carson DA, 725
Caruso B, 1071, 3913
Caruso MG, 555, 3381
Caruso ML, 555
Caruso R, 3069
Casati S, 3401
Castellano A, 3953
Casto BC, 3279
Catanzaro MA, 1827
Catlin T, 3193

Cattoretti G, 4485
Cavina M, 681
Cayre YE, 427
Ceausu R, 1757
Cerna M, 4653
Chabot S, 4083
Chacko J, 421
Chacon P, 3607
Chadalapaka G, 3799
Chammas R, 2805
Champelovier P, 3213
Chan C, 2757, 3789
Chandra KL, 2083
Chang CA, 3407
Chang C-H, 221, 745
Chang C-T, 1667
Chang EL, 2265
Chang K-W, 2037
Chang L-L, 1043
Chang S-J, 2203, 2821
Chang W-S, 221, 2395, 3511, 3601, 3629
Chanvorachote P, 193
Characiejus D, 639, 699
Chatelut E, 359
Chaudhary A, 97, 2975, 4179
Chauhan SC, 897
Chekerov R, 2603, 2657, 2669, 2679
Chen C-T, 3407
Chen C-Y, 3475
Chen F, 3165
Chen H, 3423
Chen H-W, 129
Chen Jung-Chou, 2821
Chen Jyh-Cheng, 3407
Chen P-J, 4007
Chen R, 4537
Chen T-C, 129, 2037
Chen TC, 1497
Chen WJ, 4267
Chen X, 243
Chen Y, 2231
Chen Y-J, 1713
Chen Y-R, 4239
Chen Y-Y, 1691
Cheng A-L, 4007
Cheng C-L, 3497
Cheng H-N, 221
Cheng L, 3137
Cheng Y-W, 3475
Cheong H-J, 3385
Chereau E, 4469
Chi A, 4393
Chiang J-H, 2821
Chiang P-H, 3407
Chiara F, 1911
Chiara GB, 3879
Chiba I, 2351
Chikaishi Y, 4451, 4631
Chikamoto A, 2983
Chilosi M, 3137
Chiou H-Y, 3939
Chiou S-H, 3407
Chiou S-M, 2203
Chirinos JL, 3607
Chiu C-F, 3629
Chiu S-J, 3407
Chiu SS, 907
Chiumento C, 1857
Cho CH, 2675
Cho DH, 4329
Cho GJ, 4223
Cho H, 33
Cho M-H, 1249
Cho YB, 3843
Choe J-H, 3767
Choi C-M, 3457
Choi DR, 3457
Choi Han Seok, 3301
Choi Hyeong Sim, 3301
Choi I, 3301
Choi J, 4223
Choi K-C, 1249, 2853
Choi SH, 3843
Choi WS, 4223
Choi YK, 3301
Chon CY, 4641
Chong K, 23
Chou A, 2037
Chou M-C, 3475
Chou S-E, 3633
Chou S-T, 1667
Chow H-HS, 2781
Choy E, 1115
Chrisofos M, 1475
Christodoulou C, 3007
Chu C-C, 3601
Chueh F-S, 2203
Chun F, 1965
Chun H-K, 3843
Chun YH, 4641
Chundong G, 1141
Chung HJ, 3843
Chung H-K, 1667
Chung J-G, 1667, 1691, 2203, 2821
Chung R, 421
Chunhacha P, 193
Cibei E, 1061
Cimpean AM, 1757
Cindolo L, 1935, 1937, 1938
Ciolino HP, 2699
Ciortea R, 2637
Cisternino A, 1833, 1856, 1859
Cittadini A, 1359, 4273
Cividini R, 1943
Clark JS, 3267
Classe J-M, 1783
Clemenson A, 585
Clouqueur E, 3047
Cocco C, 1071, 3913
Cochetti G, 1936
Coenegrachts L, 2367
Cohen D, 4393
Cohen L, 2141
Colaço A, 1637
Collan Y, 97
Collettini F, 2597
Collins S, 1627
Colombo R, 1852
Comoe KC, 4417
Comunale L, 1071, 3913
Conrad GR, 2109
Constantinides C, 1475
Conti G, 1952
Coombes RC, 1367
Cooperwood J, 2017
Copeland EM, 3417
Coppola C, 2291
Coppola D, 2191, 2957
Corbella F, 3727
Cordes T, 1495
Cormio L, 1931, 1934
Cornalba G, 3927
Cornuau M, 1783
Cortesi E, 4219
Cortez A, 4469
Corvalan AH, 3607
Cosio S, 3483
Costin N, 2637
Coutant C, 4469
Cova G, 1869
Covas DT, 2173
Cozza R, 3953
Crandon S, 961
Crepin M, 1321
Cricca A, 1947
Cristofani R, 3483
Cruz O, 953
Cseh J, 3051
Cseke L, 1769
Cstoth I, 281
Cufino V, 4273
Cui H, 39, 411
Cui L, 1279
Cui QC, 1
Cunningham AR, 3247
Cunningham SL, 3247
Curran JN, 3891
Curri V, 3213
Cushman S, 255
Cusi V, 953
Cusimano MD, 2283
Czejka M, 3573
D'Angelo L, 4211
Dahle J, 2113
Dahlmann B, 2197
Dai L-J, 3705
Dai Z, 2699
Daigeler A, 4061
Dailey Jr OD, 3165
Dalezis P, 831
Dalgleish AG, 3747
Dalianis T, 939, 1515, 3489
Dallara S, 4581
Dallol A, 2975
Dang D, 1205
Danilevičiūtė V, 639
Danilin S, 2705
Daraï E, 4469
Date H, 4619
Datler P, 2379
Daubine F, 4141
De Berardinis E, 1399, 1843, 1844
De Braekeleer E, 3441
De Braekeleer M, 1007, 3441
De Bruijn MT, 1379, 4507
De Cnodder T, 4417
De Cobelli O, 1894
De Faria PR, 2805
De Geest S, 1407
De Gramont A, 2271
De Grève J, 1407, 1753, 4457
De Ioris MA, 3953
De Laurentis C, 3953
De Manzoni G, 3543
De Marinis F, 649
De Nunzio C, 1811, 1812, 1813

De Pasquale MD, 3953
De Rosa A, 4211
De Sanctis V, 3555
De Sio L, 3953
De Stefano G, 2291, 3977, 4575
De Vogelaere K, 3579
De Vries A, 4407
De Witte O, 4457
Debald M, 1966
Debiec-Rychter M, 2367
Debski R, 1453
Decloedt J, 2367
Decoster L, 1753
Decosterd LA, 2121
Deeb D, 3673
Deevi D, 2149
Deguchi T, 3983
Deichert U, 753
Del Carmen Villa Cadenas M, 53
Delahunt B, 3137
Deliveliotis C, 1475
Dell'Atti L, 1811
Delle Cave A, 1851
Delmonte A, 3927
Delord J-P, 359
Delpeuch A, 1765
Delvaux G, 3579
Demars LC, 3337
Dempke WCM, 1966
Den Otter W, 639, 699
Denecke T, 2597
Dertimas V, 3469
Derwinger K, 2347, 3057
Desbordes C, 421
Desideri G, 671
Desitter I, 427
Desper J, 2083
Dessanti P, 1061
DeStefanis P, 1820, 1825, 1833, 1839
Deutsch I, 243
Devetzi M, 3093
DeVito N, 4537
Dhakal HP, 4053
Di Bartolo RM, 3973
Di Cesare P, 3927
Di Domenico M, 4211
Di Lallo A, 1864
Di Liberto R, 3727
Di Maggio EM, 4553
Di Sarno A, 2291, 3977, 4575
Di Silverio F, 1399, 1843, 1929
Di YP, 2877
Dian D, 451
Díaz-Delgado M, 3019
Dick Jr EJ, 2187
Dieckmann K-P, 4501
Diedrich K, 4359
Diehl P, 1235
Dienemann H, 4491
Dimitrakopoulos F-ID, 1677
Dimopoulos AM, 3007
Dimopoulos MA, 1475
Dimozi A, 4291
Ding H, 1521
Ding S, 3607
Ding W-Q, 2739
Ding Y-H, 4007
Dionisi F, 1874
Diorio C, 4369
Dirix L, 1407
Distel RJ, 427
Ditsch N, 451
Dittmer C, 4359
Dlaska M, 4439
Dobrovolskienė N, 699
Dohi S, 2441, 2447
Doi K, 2453, 2535
Doki Y, 507
Domanska G, 2629
Dong R, 3229
Donizy P, 711, 2963
Donnem T, 1603
Dono M, 1061
Dorff TB, 3897
Doroshow JH, 961
Dorr RT, 2781
Dosaka-Akita H, 263
Dou QP, 1
Doudican NA, 3259
Douet-Guilbert N, 1007, 3441
Dowell JE, 4135
Dowsett M, 1367
Drews N, 209
Driever PH, 661
Du Four S, 4457
Du P, 3205
Duan Z, 1115
Duchamp E, 3213
Duck L, 1407
Ducreux M, 2271
Duda V, 4039
Dudek AZ, 1181, 3945
Dudhgaonkar S, 379
Dulchavsky SA, 3673
Dumas I, 4369
Durán MA, 1599
Duranti E, 4207
Duret A, 359
Dürr S, 1966
Dutour A, 2813
Dziegiel P, 2833, 3027
Dziewanowska ZE, 2303
Ebara T, 2847
Eberle J, 807
Eberle N, 1541
Ebert AD, 2657
Ebi M, 3353
Eble JN, 3137
Eckardt A, 665
Eckardt AM, 2313
Eckert K, 1169
Eckhardt SG, 1093
Edamatsu T, 2733
Efferth T, 81, 185, 4417
Efstathiou E, 1475
Efstratiou I, 3007
Egami T, 1279
Egashira A, 3073
Egawa Y, 2499
Egawa-Takata T, 4513
Eggeman H, 2617
Eggen T, 2319
Eguchi K, 3449
Eichbaum C, 3219
Eichbaum MHR, 3219
Eichhorn T, 81, 185
Eichler C, 4039
Eidukevičius R, 699
Eijkemans MJ, 4043
Eisterer W, 4407, 4439
Eizuru Y, 3607
Elder DJE, 1577
Elgersma OE, 4043
El-Kum N, 1721
Eller J, 1431
Elling D, 2617
Elliott RL, 2899
El-Maghrabi J, 2975
Elsing C, 459
Elstner E, 2713
Ember I, 3051, 3267
Endo I, 1049, 1055
Endo M, 3775, 4075, 4519
Endo N, 11
Endo T, 725
Endoh M, 171, 1211
Engel JB, 1967
Enomoto T, 4513, 4613
Enrici RM, 3555
Erasmus E, 825
Erol E, 2679
Errico A, 1901, 1903
Escobar HM, 1541
Escudero JM, 1968
Eskelinen M, 739, 1065, 1801, 3101, 4013, 4019
Esposito F, 4211
Esposito V, 2291
Essa S, 1498
Esterni B, 1079
Estévez J, 4191
Etienne M-C, 359
Ettlinger D, 3573
Eucker J, 2713
Evers BM, 1153
Ewell L, 4393
Extra J-M, 1079
Faber TJE, 1968
Fabrini MG, 3483
Facoetti A, 3727
Fadlalla K, 233
Faiss S, 1969
Fakih M, 335, 975, 4637
Falandry C, 359
Faller DV, 2723
Fan W, 777
Fandella A, 1858, 1859
Fanti G, 3879
Fanucchi A, 3483
Farella N, 2291, 3977, 4575
Farkas R, 1769
Fassina A, 693
Faussner F, 1969
Fazio A, 2283
Fedele F, 3069
Fedeli F, 1061
Fehm T, 979, 4025, 4423
Fehr Y, 1970
Feldman D, 1493
Fellin G, 1815
Feng E, 481
Feng W, 443
Feng Y, 3595
Feola A, 4211
Ferda J, 339
Fermeaux V, 139, 3865

Fernando NH, 255
Fernando S, 3417
Ferraù F, 4553
Ferrera G, 1930
Ferro M, 1916, 1918, 1926
Ferro P, 1061
Fersching D, 1970
Festuccia C, 1821, 1822
Feyen O, 1971
Fichtl J, 339
Fiebig H-H, 4185
Fiegl M, 2949
Filiotou A, 1467
Finek J, 1447, 3619
Finek J, 1971
Fink D, 2161
Finn OJ, 3151
Fiorentini G, 4581
Fiorentino A, 1857
Fiorino C, 1931
Flamiatos JF, 973
Flessas I, 2373
Fletcher BS, 3417
Focan C, 1407
Fogelman DR, 1417
Folkerd EJ, 1367
Fontana A, 1906
Ford CHJ, 521
Ford ME, 3891
Forest F, 585
Forget F, 1407
Forman LW, 2723
Formenti SC, 4401
Fotiou S, 3469
Fotopoulou C, 2583, 2603, 2629, 2675
Fountzilas G, 3007
Fourie E, 825
Fraccon AP, 3543
Franceschini MC, 1061
Francescutti V, 3429
Francis I, 521
Franklin MJ, 3945
Frati L, 4219
Freibauer C, 3615
French CB, 607
Frenkel S, 345, 351
Freydanck MK, 1972
Freyer G, 359
Freyschlag CF, 1023, 3873
Frezza G, 1878
Fridrik MA, 4439
Friebe A, 4185
Friedrich M, 4359
Friedrich RE, 1972, 1973, 1974, 1975
Friese K, 451, 2749
Fryer RA, 3747
Fuchsova R, 1976, 3107, 3619, 4653
Fuerst F, 1373
Fujibayashi M, 2989
Fujieda A, 2733
Fujii H, 2999
Fujii Makoto, 4657
Fujii Masashi, 1019, 2339
Fujii S, 1055
Fujii T, 3963
Fujimoto T, 2413, 2453, 2535
Fujioka K, 1653, 3253
Fujioka M, 2733
Fujisaki M, 3983
Fujishima T, 1501
Fujita Hayato, 1279
Fujita Hiroshi, 705, 933
Fujita J, 113
Fujita M, 4513, 4613
Fujita Yoshihiko, 2787, 4561
Fujita Yoshimasa, 1741, 2297
Fujitani K, 3085
Fujiwara H, 67, 495, 2217
Fujiwara M, 1643
Fujiyama S, 2983
Fukada J, 3079
Fukai T, 501
Fukami T, 2461, 2483
Fukazawa T, 1197
Fukuda K, 3079
Fukunaga M, 2129
Fukusato T, 3691, 4147
Fukushima Takeo, 2527
Fukushima Toshihiro, 1741, 2297
Fulford AD, 2073
Fulton D, 3559
Fumaki T, 2553
Funada T, 2339
Funakoshi Y, 4665
Furák J, 1431
Fürst S, 1976
Furukawa A, 3361
Furukawa Takako, 1549
Furukawa Tatsuhiko, 4251
Furuta K, 2787
Furutani A, 67
Fury MG, 249
Fusch G, 2629
Futami K, 2499
Futawatari N, 2361
Fuyuhiro Y, 3369
Gadducci A, 3483
Gakis G, 2053
Galán P, 1599
Galle PR, 2797
Galleggiante V, 1893
Galosi A, 1938
Galustian C, 3747
Gansukh T, 711
Gao X, 3673
Gari M, 97, 2975, 4179
Garibaldi E, 1899
Garland CF, 607, 2939
Garrett-Mayer E, 3891
Garritsen HSP, 4267
Gasbarrini A, 4273
Gast S-M, 725
Gautam SC, 3673
Gazzaniga P, 4219
Gebauer B, 2597
Geers C, 3579
Geinitz H, 1735
Geleff S, 4605
Gellermann J, 2675
Gelli MC, 681
Gellrich N-C, 2313
Genazzani AR, 3483
Genet D, 3865
Geng F, 3229
Gentile V, 1399
George B, 2045
Georgoulias V, 807
Gerestein CG, 4043
Gerger A, 1373
Gerhardt TE, 4111
Germano IM, 959
Geromichalos GD, 831
Geromichalou E, 831
Ghimenton C, 1071, 3913
Ghosh S, 3559
Giannetti A, 2209
Gianni W, 4219
Giarnieri E, 4207
Giatromanolaki A, 1745
Giberti C, 1913, 1915
Gibson Wood W, 1667
Giffen C, 945
Gilabert M, 1079
Gildehaus FJ, 3315
Gil-Ibáñez B, 2583
Gill R, 2161
Giorgio A, 2291, 3977, 4575
Giorgio V, 2291, 3977, 4575
Giovagnoli MR, 4207
Giraud G, 3489
Giraud S, 139
Giri U, 33
Giudice S, 2209
Giuffrè G, 1315
Giuffreda P, 3401
Giulianelli R, 1814, 1815, 1835, 1836, 1837, 1881
Glehr M, 1373
Gnekow A, 661
Gobbo S, 3137
Gochman E, 1607
Gockel I, 2797
Goishi K, 4155
Goldnau C, 3623
Golzio M, 4083
Gomes MV, 1337
Gon Y, 2129
Gonçalves A, 1079
González-Cámpora R, 3019
González-Rodilla I, 4191
Goodman CB, 3739
Gopas J, 913
Gordanpour A, 403
Gordian E, 3757
Gorham ED, 2939
Gossmann A, 4039
Gotanda Y, 2517, 2541
Goto T, 77, 777, 1289, 1293, 2249, 2889, 3377, 3835
Gotsis AD, 1677
Gottschling S, 4491
Grabarska A, 565
Gradilone A, 4219
Graf C, 2797
Grant WB, 1502
Gray T, 4135
Greco C, 3483
Greco G, 3927
Green JA, 2661
Green S, 959
Greil R, 4439
Greiner J, 2343
Gremse F, 2907
Greve J, 3151
Grieco V, 1359
Grimm C, 2259
Grivas AA, 831
Gröber U, 1976

Grobmyer SR, 3417
Grondin JM, 2073
Groth S, 1977
Grünberger B, 4439
Grünberger T, 4605
Grünhage F, 1505
Gudlaugsson E, 443
Guéganic N, 1007, 3441
Guerra V, 3381
Guerrouahen BS, 427
Guinan P, 487
Gundling F, 2931
Gunning AC, 4507
Günthner-Biller M, 1977
Gunturu KS, 4397
Guo AM, 3673
Gustafsson B, 3489, 2347
Guth A, 4401
Gutierrez ME, 961
Gutwein LG, 3417
Gwin J, 209
Györffy B, 711
Ha CS, 33
Ha YJ, 4329
Haanpää ML, 3493, 4413
Haapasalo HK, 4413
Häberle L, 985
Habu S, 3361
Hachiman M, 4251
Hack R, 2949
Haddad R, 2173
Haese A, 1978
Haffty BG, 2327
Hagiwara Y, 1427
Hagström J, 3659
Hah Y-S, 4315
Halim H, 193
Halon A, 711, 2963
Hamada S, 1011
Hamada T, 4251
Hamasaki K, 4545
Hamasaki T, 2241
Hambek M, 665
Hambruegge C, 3903
Hamburger AW, 3129
Hamm B, 2597
Hamour O, 4179
Han J, 3767
Han K-H, 4641
Hanagiri T, 277, 619, 4631
Handzlik J, 3285
Hang L-W, 3601
Hanke St, 1979
Haque S, 249
Harada H, 4519
Harada Y, 2889
Haragâş D, 2637
Haraoka K, 2983
Harashima H, 2065
Harbeck N, 4039
Hare R, 3429
Hariri N, 1215
Harnack U, 475, 1169, 4195
Harrison GM, 467
Hartkopf AD, 979
Hartlapp J, 3903
Hase K, 1567
Hasegawa A, 3665
Hasegawa H, 3085
Hasegawa M, 3909
Hasegawa T, 2915, 3369, 4339
Hasegawa Y, 2893
Hashiguchi Y, 1567
Hashimoto K, 3073, 4481
Hashimoto S, 999, 2129
Hashimoto Y, 2241
Hassan NM, 1197, 1307
Hata K, 731
Hata T, 731
Hatae M, 3063
Hatooka S, 3535
Hatziolou E, 2373
Hauser J, 4061
Haussler MR, 1492
Havelund BM, 1559
Hawes D, 3897
Hayashi E, 1259
Hayashi K, 2927, 3665
Hayashi M, 543
Hayashi N, 991
Hayashi T, 597
Hayes M, 4135
Hayward R, 2023
Hazama S, 4569
Head JF, 2899
Heaney RP, 607
Hector J, 2669
Hedman M, 1125
Heesom KJ, 1577
Hefler L, 2259
Heidecke H, 2589, 2609, 2645
Heigener D, 1979
Heikkilä P, 3659
Heinze G, 2259
Heinzer H, 1979
Hejna M, 2379
Helm J, 2957
Helmke BM, 753
Helson L, 907
Henderson-Jackson EB, 2957
Hendler K, 345, 351
Hendruschk S, 3181
Henne-Bruns D, 4599
Hennenlotter J, 3783
Henry H, 2121
Hepp P, 1979
Herberger B, 4605
Herbstreit C, 2657
Herman TS, 161
Hermann TW, 2303
Hernando-Rodriguez M, 677
Herpel E, 4491
Herrmann T, 459
Herry A, 1007
Herth FJF, 4491
Herzog TJ, 243
Hetzel MR, 1577
Heubner M, 2197, 3623
Heusner T, 2645
Hewicker-Trautwein M, 1541
Hewitt SM, 945
Hibi K, 77, 777, 1289, 1293, 2249, 2889, 3377, 3835
Hidaka S, 4545
Hidalgo H, 3607
Hideghéty K, 1431
Hietaharju AJ, 4413
Higaki T, 3991
Higashi D, 2499
Higashiyama S, 4155
Hikita E, 4169
Hikita S, 2461, 2553
Hilbe W, 2949
Hino O, 1427
Hinrichs J, 1379
Hirahara N, 2733
Hirai Y, 999
Hirakawa K, 3369
Hirakawa M, 1437, 3527
Hirakawa T, 3369
Hirano T, 3839, 4169
Hirao M, 3085
Hirashima M, 2467
Hirashima T, 4525
Hirata I, 705, 933, 1459
Hirata Y, 3353
Hirooka S, 3827
Hirose K, 3839
Hirose Y, 1741
Hiroshige S, 4481
Hirota K, 2489
Hirota M, 1011
Hirsch J-M, 3345
Hitora T, 549
Ho C-Y, 3511
Ho M-R, 4239
Ho P-C, 789
Ho T-C, 1173
Ho WJ, 3237
Hochrath K, 1505, 1506
Hoellen F, 4359
Hoffman RM, 387, 1535, 2907, 3125, 3665
Hoffmann K, 3883
Hoffmann O, 2197, 3623
Hoffmann TK, 3151
Hofmann G, 1373
Holdenrieder S, 1980
Holick MF, 1491, 1504
Hollidt J-M, 1980
Holm PS, 2963
Holmberg AR, 4141
Holubec Jr L, 373, 1447, 3107, 3619, 4031
Holubec L, 1981
Holzer TR, 2073
Honda J, 2389
Honda K-I, 1271
Honda T, 2493
Hong DS, 3385
Hong JY, 421
Hönig A, 1982
Honoki K, 543
Hoogwater FJH, 4507
Hoopmann M, 4039
Hori H, 2477, 2489, 2561
Horiguchi J, 3041
Horiuchi S, 2553
Hornicek FJ, 1115
Horvath OP, 1769
Hoshiai H, 731, 3063
Hoshina A, 1471
Hoshino S, 633
Hosomi Y, 3449
Hotchkiss S, 2971
Hotta K, 2915
Hotta T, 11
Hou JC-T, 929
Hsia T-C, 1691, 3601
Hsiao K-H, 1043

Hsieh S-C, 4301
Hsieh Y-H, 4301
Hsu C-F, 227, 2395
Hsu C-H, 4007
Hsu N-Y, 3475
Hu N, 945
Hua C-H, 227, 2395
Huang Chao-Cheng, 293, 3633
Huang Chien-Chung, 4007
Huang C-L, 4619
Huang C-Y, 293, 3633
Huang Guangwu, 797
Huang Guohui, 3165
Huang K-C, 2773
Huang M, 2045
Huang S, 1321
Huang S-M, 203
Huang T-H, 3407
Huang X, 771
Huang Y, 3433
Huang Y-T, 1691
Huber K, 3273
Huber RM, 849
Hudacsko A, 2637
Huebner CA, 459
Hung C-F, 3497
Hunter TB, 3193
Huq F, 1131, 2757, 3789, 4283
Hurwitz HI, 255
Husøy T, 785
Huszár A, 3051
Hüttenberger D, 1982
Huylebrouck M, 4457
Hwang K-A, 2853
Hydock DS, 2023
Iacovelli R, 4219
Iavazzo C, 3469
Ibaragi S, 1307
Iberer F, 1583, 3713
Ibrahim SO, 3345
Icard P, 797
Ichikawa D, 67, 495, 2217
Ichikawa Y, 1049
Ichinose Y, 3449
Ieni A, 1315
Iida H, 1297
Iino T, 4163
Iizuka N, 3331
Ijichi K, 2893
Ikeda K, 1653, 3253
Ikeda M, 507
Ikeda T, 501
Ikoma H, 495
Ikonomidou C, 565, 3181
Imada T, 325
Imai K, 3361
Imai M, 2511
Imamura CK, 4561
Imamura Y, 991
Improta G, 1359
Inaba N, 1653, 3253
Inaba S, 3995
Inagaki D, 325
Inagaki Y, 535
Inagawa H, 2431, 2437, 2467, 2493
Inaji H, 367
Inamine M, 1437, 3527
Inghirami G, 4401
Inomata M, 4519
Inoue A, 2999
Inoue K, 3827
Inoue M, 2441, 2447, 2999, 4665
Inoue S, 2999
Inoue T, 2527
Inoue Y, 1653, 3253
Iori F, 1933
Iraha S, 3527
Isaka K, 3063
Isbir T, 2225
Ise N, 4155
Ishaq R, 2575
Ishibashi K, 77, 777, 1289, 1293, 2249, 3377
Ishibashi Y, 2499
Ishibe T, 1297
Ishida K, 1011
Ishiguro S, 3463
Ishihara M, 4231
Ishihara M, 515
Ishikawa D, 3361
Ishikawa H, 287, 4625
Ishikawa M, 4619
Ishikawa S, 991
Ishikawa T, 2483, 2553
Ishiko O, 1271
Ishinaga Y, 1427
Ishioka C, 3719
Ishitobi M, 367
Ishitsuka K, 2483
Ishizawa S, 3253
Ishizuka T, 705, 933, 1459
Ismaeel F, 2675
Isohata N, 2989
Isowa S, 1307
Ito H, 1011
Ito R, 3361
Ito S, 3463
Ito T, 3035
Ito Y, 3463
Itoh M, 781, 893
Iwabuchi Y, 3719
Iwadate Y, 4475
Iwagami S, 991
Iwaki H, 1297
Iwanami T, 1141, 4277
Iwao H, 1741, 2297
Iwasaki A, 2535
Iwase S, 1483, 3567
Iwase Y, 501
Iwashita A, 2499
Iwata M, 705, 1459
Iwatsuki M, 991
Iwazaki S, 287, 4625
Izawa S, 2999
Izumi K, 2389
Izumi M, 287, 4625
Izumi N, 2255
Jaakkola PM, 311
Jackson LN, 1153
Jacobs JJL, 639, 699
Jacobsen MB, 861
Jacquemier J, 1079
Jagota A, 2657
Jahnke K, 317
Jakob A, 825
Jakobsen A, 1559
Jalouli J, 3345
Jalouli MM, 3345
Jamnig H, 2949
Jang S, 4393
Jankevičius F, 699
Jankowska R, 2833
Jänne PA, 427
Janni W, 2749
Jansen FH, 4417
Jansen N, 4417
Janssen E, 443
Janzen E, 3873
Japink D, 1983
Jaramillo S, 3019
Jarkowski III A, 3429
Jasinski P, 1181
Javle M, 1417
Jaworska-Posadzy A, 1453
Jayaram HN, 2045
Jedinak A, 379
Jenkner A, 3953
Jensen BT, 2023
Jensen K, 4491
Jeon B-G, 4315
Jeon C-H, 1161
Jeon YJ, 4329
Jeong JY, 4223
Jeschke S, 2589
Jeschke U, 451, 1983
Jess P, 613
Jethon A, 2833, 3027
Jeung E-B, 1249, 2853
Ji B-C, 1691
Ji L, 11
Jia F, 3143
Jiang J, 687
Jiang L, 2327
Jiang M, 1321
Jiang WG, 303, 467, 1703, 3205, 4115
Jiang X-P, 2899
Jin D, 3859
Jin J, 2877
Joh T, 763, 3353
Johannsmeyer KD, 2657
Johannson V, 3315
Johnen H, 475
Johnson CS, 1497
Johnson M, 3559
Johnson RW, 2705
Jones G, 1493
Jones GL, 2095
Jonker DJ, 3921
Joone GK, 825
Joosens E, 1407
Joraku A, 2065
Joseph S, 3799
Joshi G, 3851
Ju S, 2045
Juchems M, 4599
Jueckstock J, 2749
Juncos LA, 3267
Jung A, 849
Jung H-K, 575
Jung JM, 575
Jung S-A, 575
Jutooru I, 3799
Juzeniene A, 1502
Kadomura T, 3983
Kadowaki T, 2467
Kage M, 2541
Kageyama S, 1297

Kahán Z, 1431
Kahkonen B, 2877
Kahlert C, 1215
Kai L, 3323
Kaiga T, 1019, 2339
Kaino S, 2103
Kaira K, 2763
Kaira K, 3775, 4075
Kaiser I, 459
Kaiserman I, 345, 351
Kajita Y, 1297
Kajiwara Y, 1567
Kakeji Y, 3073
Kakinohana Y, 3527
Kakinuma S, 287, 4625
Kalamanathan S, 2661
Kalanxhi E, 2113
Kalas W, 2869
Kalden M, 2675
Kaley K, 2971
Kalickman I, 345, 351
Kalinoglou N, 3469
Kalofonos HP, 1677
Kalogeris K, 1745
Kalso E, 3493
Kamano T, 705
Kamatani T, 2841
Kambara K, 881
Kamei R, 4569
Kametani Y, 3361
Kamigaki S, 3035
Kaminuma T, 2847
Kamiura S, 3063, 4513
Kamiya T, 3353
Kamiya Y, 705, 1459
Kamoshita N, 4625
Kan S, 4569
Kanai Y, 3775, 4075
Kanakura Y, 113
Kanamori N, 1019, 2339
Kanazawa A, 325
Kanda S, 597
Kane CJ, 2939
Kaneda H, 2787
Kanematsu S, 3517
Kanemitsu Y, 3463
Kanetake H, 597, 2335
Kang C-C, 129
Kang E-J, 4315
Kang H-Y, 1713
Kang M, 961
Kang M-J, 575
Kang N-H, 2853
Kang Seokmin, 4223
Kang SS, 4223
Kang Sumin, 113
Kanintronkul Y, 921
Kanitakis J, 807, 2373
Kanno A, 1011
Kano J, 529
Kanwar J, 1
Kanz L, 4025
Kao H-W, 4239
Kapapa T, 4599
Kaparelou M, 4259
Karagiannis A, 1033
Karameris A, 3093
Karapanagiotou EM, 649
Karashima R, 991
Karihtala P, 1411
Kashima S, 2173
Kashiwagi S, 3369
Kasimir-Bauer S, 2197, 3623
Kasuya G, 3527
Katada N, 2361
Katano I, 3361
Katano M, 2419, 2505, 3995
Kataoka H, 763, 3353
Katayose Y, 1011
Kates RE, 4039
Kato Ayako, 2915
Kato Ayu, 3983
Kato Takeshi, 4657
Kato Tomoyuki, 3463
Kato Toshihide, 3963
Kato Yukihiro, 3369
Kato Yutaro, 3983
Katsambas A, 2373
Katsifis A, 2883
Katsube T, 2989
Kaufmann Y, 215
Kaun C, 3273
Kauppila S, 1411
Kautiainen H, 3493
Kautio A-L, 3493, 4413
Kawabata H, 1741
Kawaguchi O, 3079
Kawaguchi T, 1483
Kawaguchi Y, 2999
Kawaguchi-Ihara N, 781
Kawahara A, 2517, 2541
Kawai K, 2065
Kawamura N, 3063
Kawasaki G, 3521, 4429
Kawase I, 4525
Kawase M, 4231
Kawashima H, 11
Kawate S, 287, 4625
Kaytan-Saglam E, 2225
Kazlauskaitė N, 639
Ke H-L, 221, 1043
Keese M, 2693
Keilholz U, 317
Kellermann U, 4195
Kelley MR, 379
Kelling K, 4359
Kellogg Parsons J, 2939
Kellokumpu-Lehtinen P-L, 4413
Kelly KW, 249
Kendler D, 4407
Kenmotsu H, 3775, 4075, 4519
Kenney B, 4397
Keohavong P, 2877
Ketonen L, 2265
Khaddage A, 585
Khafaga Y, 1721
Khamaisie H, 177
Khan M, 2699
Khan R, 4393
Khushalani N, 3429
Kichikawa K, 3909
Kieć-Kononowicz K, 3285
Kiełbus M, 565
Kiessling F, 2907
Kigawa G, 77, 777, 1289, 1293, 2249, 2889, 3377, 3835
Kijima K, 2889
Kikuchi M, 3041
Kikuchi R, 4619
Kikuchi S, 2361
Kilgore MW, 813
Kim BJ, 4111
Kim BS, 4329
Kim C-K, 3385
Kim DY, 4641
Kim Han Jo, 3385
Kim HC, 3843
Kim Hee Jin, 4329
Kim HN, 4347
Kim Ho Jin, 4307
Kim Hyun Joon, 4223
Kim Hyun Jung, 3385
Kim JC, 4329
Kim J-H, 3767
Kim JS, 3767
Kim JW, 3237
Kim KH, 3385
Kim N, 4223
Kim S, 3767
Kim S-E, 575
Kim Seung U, 1249, 2853
Kim Seung Up, 4641
Kim SH, 3385
Kim S-J, 3385
Kim S-W, 3457
Kim SY, 4329
Kim T-H, 575
Kim Y, 725
Kim Y-B, 1249
Kim Y-J, 4307
Kim YS, 4329
Kimmig R, 2197, 3623
Kimura Hideharu, 4561
Kimura Hiroaki, 3665
Kimura M, 1653, 3253
Kimura Tadashi, 4513, 4613
Kimura Toshihiro, 4513, 4613
Kinchington E, 2877
Kinoshita I, 263
Kinoshita S, 1395
Kinugasa T, 2517, 2541, 2547
Kioi M, 2893
Kirschenhofer A, 1984
Kirwan CC, 2383
Kishimoto H, 3665
Kisi T, 4339
Kisiel W, 843
Kiss A, 3573
Kiss I, 3051
Kiss R, 953
Kitagawa Y, 3079
Kitajima M, 3983
Kitamura K, 1483, 3567
Kitamura Y, 1289, 2249, 2889, 3377
Kittaka A, 1500
Kiura K, 3449
Kiyota A, 2505
Kiyota H, 4561
Kizir A, 2225
Kjellevold K, 443
Klapdor R, 1984, 1985, 1986
Klatka J, 565
Klein A, 3733
Klein MA, 3683
Kleinschmidt S, 1541
Kleiveland CR, 861

Klement RJ, 1987
Klimberg VS, 215
Kmiya Y, 933
Knobloch TJ, 2683
Knolle P, 4185
Knuth A, 3115
Knutsen HK, 785
Ko S-G, 3301
Ko Y-C, 1691
Kobayashi E, 4613
Kobayashi H, 1027
Kobayashi I, 4625
Kobayashi J, 287, 4625
Kobayashi Masashi, 4525, 4619
Kobayashi Mitsinobu, 287
Kobierzycki C, 3027
Kobunai T, 3691, 4147
Kochi M, 1019, 2339
Kodama S, 1307
Kodera Y, 1643
Koessner C, 3573
Koestenbauer S, 1583, 3713
Kofune H, 4251
Kohama H, 2065
Kohchi C, 2431, 2467
Kohler C, 2623, 4267
Kohyama K, 123
Koike M, 1643
Koizumi F, 2787
Koizumi M, 2477
Koizumi T, 299
Kojima M, 3983
Kokuba Y, 495
Kokudo N, 535
Kolb HC, 1987
Kolodziej B, 1453
Kolostova K, 1535, 3125
Komatsu H, 501
Komatsu S, 495
Komatsu Y, 299
Komiyama S, 495
Komoike Y, 367
Komori K, 3463
Kondo C, 3535
Kondo F, 2915
Kondo H, 2461, 2763, 3775, 4075
Kondo K, 4657
Kondo N, 2477
Kondo S, 2841
Kondo Y, 4525
Kong B, 3229
Kong X, 2327
Königsrainer A, 4407
Konishi T, 535
Kono K, 2999
Kono R, 549
Konrad K, 1583, 3713
Kontopidou F, 1467
Kontos M, 831
Kooi GS, 4043
Kopeckova M, 4647
Kopetz S, 1417
Kopij M, 2869
Kopp H-G, 4025
Koriyama C, 3607
Korkeila EA, 311, 4529
Korkolopoulou P, 3585
Korlach S, 2589, 2609, 2617, 2645, 2651
Kormunda S, 1447
Kornmann M, 4599
Kortmann R-D, 661
Koryllou A, 4291
Koskas M, 3047
Koskinas J, 1467
Koskinen MJ, 4413
Kotake T, 2255
Kothan S, 4067
Koto M, 33
Kotoula V, 3007
Kottorou A, 1677
Koukourakis MI, 1745
Kourea HP, 3007
Koutras A, 3007
Koutsilieris M, 4259
Kovacs K, 2283
Koya N, 2505
Koyama A, 4561
Koyama H, 367
Koyanagi M, 2453, 2535
Koyano T, 287
Kozako T, 4251
Kozawa E, 123
Kraemer B, 4423
Kramm CM, 661
Kranenburg O, 1379, 4507
Krasagakis K, 807
Kratzik C, 3615
Krause FS, 985
Krause R, 1502
Krauss K, 4025
Krawczyk N, 4423
Kresty LA, 2683
Kreuzberg B, 339
Krippl P, 1373
Krishnamoorthy S, 4397
Krockenberger M, 1987
Krohn V, 59
Kronenberger C, 2657
Kruck S, 2053
Krueger T, 2121
Krüger C, 1508
Krüger-Krasagakis S, 807
Krukemeyer MG, 3903
Krūmiņa G, 1421
Ku BM, 4223
Kuang Y, 427
Kubicka M, 1453
Kubo K, 299
Kubodera N, 1500
Kubota E, 105, 3353
Kubota K, 3983
Kubota T, 67, 2217
Kučera R, 3619
Kucera R, 4031, 4653
Kudaka W, 1437, 3527
Kudo C, 3719
Kudo K, 2787
Kudo S, 3449
Kudo T, 2255
Kuehs U, 3783
Kuemmel S, 2669
Kuemmerle A, 2121
Kuge T, 1647
Kuhara H, 4525
Kuhn C, 451
Kujawa K, 3027
Kulda V, 4031
Kuliczkowski K, 2963
Kulikowski GN, 1093
Kumamoto T, 1055
Kumar A, 897
Kumar BM, 4315
Kumar D, 1795
Kummar S, 961
Kümmel S, 2569, 2575, 2589, 2609, 2617, 2645, 2651
Kunami N, 2483
Kunisaki C, 325, 1055
Kupisz K, 565
Kuramitsu Y, 1259, 2059, 2103, 3331
Kurashige J, 991
Kurihara Y, 2841
Kurio N, 1197, 1307
Kuriu Y, 495
Kuroda J, 3983
Kuroda Y, 1483, 3567
Kurokawa T, 3991
Kurokawa Y, 3085
Kuroki H, 3995
Kuroki Masahide, 2453, 2425, 2461, 2483, 2499, 2527, 2535, 2553
Kuroki Motomu, 2425
Kushida T, 1241
Kusumoto T, 4481
Kusuzaki K, 4163
Kuttesch J, 2265
Kuwada E, 881
Kuwano H, 3963
Kuwata T, 4631
Kvols LK, 2957
Kwack D-O, 4315
Kwon A-H, 3517, 3827
Kydlicek T, 4653
Kyo S, 2441, 2447
Kyoda S, 1395
Kyrgias G, 1745
Kyrtopoulos SA, 4291
Kyrtsonis M-C, 3585
La Sala GB, 681
Laatio L, 1411
Labombardi V, 959
Lacetera V, 1917, 1925
Lackland DT, 3891
Lackner J, 3615
Lacola V, 3913
Lacquaniti S, 1848
Lage H, 711, 2963
Lahouassa R, 1509
Lai HC, 4111
Lai L-J, 1173
Lai M-W, 2037
Lai SY, 2893
Lai T-Y, 2821
Laino L, 4211
Lambaudie E, 3047
Lambert J, 3697
Lamerz R, 1988
Lan C, 4135
Lan J, 797
Lanciotti M, 1880
Landas S, 929
Landt S, 2569, 2575, 2589, 2609, 2617, 2645, 2651
Lane H-Y, 3511
Lang H, 825
Lang JC, 2683

Lang S, 3151, 3315
Langle F, 4605
Langsenlehner T, 1373
Langsenlehner U, 1373
Lanzi F, 1920
Lasano S, 4347
Lasaponara F, 1829
Latinwo LM, 2017
Lautrette C, 139
Lavoue V, 4469
Laytragoon-Lewin N, 1527
Le Bot R, 4141
Le Bris M-J, 1007, 3441
Le Mercier M, 4457
Lea MA, 421
Leber B, 1583, 3713
Lederle W, 2907
Lee C-C, 2037
Lee Dae Ho, 3457
Lee Dong Hoon, 4223
Lee EY, 1153
Lee H, 3475
Lee HJ, 2135
Lee H-S, 1161
Lee H-Z, 3601, 4301
Lee JE, 3767
Lee J-H, 2179
Lee J-S, 3457
Lee K-D, 1161
Lee KT, 3385
Lee KY, 4307
Lee LJ, 771, 1619
Lee N, 3385
Lee RJ, 771, 1521, 1619
Lee S-C, 3385
Lee SH, 4307
Lee SJ, 2135
Lee U, 105
Lee WY, 3843
Lee Y-H, 4007
Lee Y-J, 3407
Lee YK, 4223
Lee Y-M, 4315
Leers MPG, 1988
Lefranc F, 953
Lehner J, 1989
Lehnerdt G, 3151
Lehrer S, 959
Lekka C, 3469
Leminen A, 3493
Lemke J, 4599
Lemound J, 2313
Lenner P, 4267
Leobon S, 3865
Leong J, 481. 1659
Lerch T, 1989
Leszinski G, 1989
Levenson AS, 3323
Leveque D, 1765
Leveque J, 1783, 4469
Levidou G, 3585
Levy M, 373
Lewin F, 1527
Lewis MR, 3143
Li B, 1495
Li C, 2029
Li D, 529
Li F-J, 3511, 3629
Li G, 11
Li H, 2149
Li Jie, 3229
Li Jin, 1703
Li Junan, 2683
Li L, 3229, 3423
Li M, 3595
Li P-K, 2029
Li QQ, 3423, 3433
Li W, 3945
Li W-T, 3407
Li Xiaodong, 687
Li Xiaoyuan, 2327
Li Y, 1105
Liang H, 3433
Liang K-H, 2037
Liao S-K, 129
Liao Z, 2141
Lichtenegger W, 2583, 2589, 2645, 2651, 2679
Lien C-Y, 2023
Liguori G, 1873
Limmer A, 4185
Lin C, 3859
Lin C-C, 745, 2395, 3629
Lin Chih-Hsueh, 3511, 3601
Lin Chun-Hsuan, 3475
Lin H, 3433
Lin H-H, 221, 1043
Lin HQ, 2883
Lin H-Y, 2821
Lin J, 2029
Lin S-H, 481, 1659
Lin T-W, 4239
Lin W-C, 4239
Lin YC, 481, 1659
Lin Y-H, 3633
Lin Z-Z, 4007
Linares V, 3607
Lincet H, 797
Lindebjerg J, 1559
Lindhorst D, 2313
Linhardt RJ, 4067
Lipson BL, 249
Lisi D, 1399
Liska V, 339, 1447, 1990, 4031
Littlefield BA, 2773
Liu A, 2029
Liu C-J, 3601
Liu C-T, 3939
Liu D, 2265
Liu F-T, 2805
Liu H, 2713
Liu J, 2773
Liu J-Y, 481, 1659
Liu L-C, 3511
Liu M, 3859
Liu SV, 3897
Liu Xianzhe, 1115
Liu Xiaoping, 2877
Liu Xiyong, 3475
Liu Y, 3673
Liu Yan, 2029
Liu Y-F, 3629
Liu Ying, 1521
Liu Y-W, 3633
Liu YY, 1443
Liu Y-Y, 293
Ljungman P, 939
Lledo G, 359, 2271
Lloyd RV, 2283
Lo Monte AI, 1930
Lo Muzio L, 4211
Lo Rizzo C, 3973
Lo W-C, 221, 3601
Lo Y-H, 789
Loew JE, 2723
Löfdahl H, 2187
Löffler N, 2931
Lohr F, 1023, 3873
Lohri C, 3115
Longerich T, 3883
Longini M, 3973
Longo F, 1845, 4219
Lopes C, 1637
Lopes N, 1494
Lopez A, 2191
Lopez E, 3401
Lord R, 2661
Lorenz J, 3289
Lorusso D, 3381
Lorusso F, 1932
Lotrecchiano G, 1851
Loum E, 139
Loyola AM, 2805
Lu C-C, 2821
Lu D, 725
Lu H, 3705
Lu K-T, 203
Lu L, 1
Lu Y, 797
Lucarelli G, 1896
Lucianò R, 3069
Luckett M, 1577
Lucot JP, 3047
Luddy KA, 3193
Lüdecke G, 1991
Luebbers CW, 3315
Luethy A, 3115
Lüftner D, 317, 2617
Lui E, 907
Luisetto G, 3969
Luiten RM, 3697
Luk F, 1147
Lukas P, 4407
Luksch H, 565, 3181
Lumachi F, 693, 2923, 3879, 3969
Lunglmayr G, 3615
Luo G, 3595
Luo W, 2303
Luo Z, 3433
Luton D, 3047
Lv S, 4457
Lyer St, 1991
Lyn-Cook BD, 3171
Lyu P-C, 4239
Ma C, 481, 1659
Ma T, 2327
Mabuchi M, 763
Maccagnano C, 1854
Macchione N, 1839
Macdonald K, 1407
Macera CA, 2939
Machado HR, 1337
Macher-Göppinger S, 1215
Machida T, 2453, 2535
Maciejczyk A, 711
Mack B, 3315
Mack C, 4423
Madelenat P, 3047
Madroszyk A, 1079
Maeda H, 4665

Maeda Kazuhiko, 2553
Maeda Kazunari, 4569
Maeda M, 1427
Maeda N, 4569
Maeda Y, 4569
Maehara Y, 3073
Maekawa T, 2499
Maeng G-H, 4315
Maffezzini M, 1948
Mafune K-I, 535
Maggioni M, 1824
Magnani T, 1946
Magnoni C, 2209
Mahajan A, 2265
Mahajna J, 177, 1607
Maher DM, 897
Mahlstedt J, 1503
Mahner S, 1992
Maier JAM, 3401
Maindrault-Goebel F, 2271
Maines F, 1905
Maitra A, 907
Majeed M, 907
Makimura C, 4561
Makino T, 1241
Makishima M, 3839
Makita F, 287, 4625
Makuuchi H, 3361
Malafa M, 2191, 4387
Malaponte E, 4553
Malik R, 3921
Malizia M, 1919
Malki A, 871, 1345
Malo N, 2303
Manabe S, 2483
Mancini R, 4207
Mandai H, 1307
Mandato VD, 681
Mandic R, 59
Mangel L, 1769
Mangialardo C, 89
Mangolini A, 1816
Manimala NJ, 3193
Mankin H, 1115
Manoel-Caetano F, 1685
Manome Y, 1395, 1653, 3253
Mansel RE, 1703
Maráz A, 1431
Marchesi P, 2923
Marchioro G, 1907
Marek E, 3051
Marenghi C, 1944
Maresch J, 2379
Margari C, 1033
Marichalar-Mendia X, 677
Marin B, 3865
Mariniello A, 2291
Marino F, 693, 3879
Marino L, 1872, 1873, 1905
Marino R, 1948
Mariotta S, 4207
Markowski DN, 753
Marnerides A, 3585
Márquez M, 4141
Marschke KB, 2303
Marsh J, 2773
Martano M, 4211
Martignoni G, 3137
Martin G, 1877
Martin TA, 467
Martinesi M, 4091
Marton S, 1769
Martorana G, 271, 1949, 3503
Maruyama N, 705
Maruyama T, 2999
Marzahn J, 565, 3181
Masaki Y, 1741, 2297
Masamune A, 1011
Mascaux C, 281
Masieri L, 1879
Masin D, 2161
Mason MD, 467
Mastorakos G, 3469
Mastronuzzi A, 3953
Masuda M, 325
Masuda N, 3449
Masuda T, 2983
Materna V, 2963
Matheisen N, 1992
Matkowski R, 711
Matschke J, 591
Matsubara T, 4163
Matsui K, 3449
Matsui T, 2499
Matsumine A, 4163
Matsumoto G, 105
Matsumoto Kazuko, 2787, 4561
Matsumoto Kotaro, 3995
Matsumoto Kunio, 1279, 2217
Matsumura Akihide, 4665
Matsumura Atsushi, 2217
Matsuno Y, 263
Matsuo K, 1049
Matsuo T, 2335, 4465
Matsuoka H, 4561
Matsuoka J, 3369
Matsushita K, 4251
Matsutani T, 4475
Matsuzaki S, 4613
Matsuzaki T, 3369
Mattheis S, 3151
Maubon A, 3865
Maurer BJ, 961
Maurer G, 3273
Mauricas M, 639, 699
Mavropoulou S, 1745
May MT, 1577
Mayer F, 4025
Mayr D, 451
Mayrbaurl B, 4439
Mayrhauser U, 1583, 3713
Mazur G, 2963
Mazza M, 1902
Mazzeo F, 1407
Mazzini G, 3727
Mazzio E, 3739
Mazzotta M, 4211
McCollum CN, 2383
McDowell G, 2383
McLennan G, 2045
Meert A-P, 281
Meglasson MD, 2303
Meister M, 4491
Mekada E, 2553
Melchiorre F, 3927
Melegari S, 1896, 1897
Mendelson DS, 625
Menen RS, 3125
Meng Z, 2141
Merdad A, 97, 2975
Merger M, 2271
Meriaty H, 2883
Merkel AR, 2705
Merrouche Y, 359
Mesbah H, 1783
Meschenmoser K, 725
Meszarosova A, 4647
Metaxari M, 807
Meyer A-S, 3219
Michienzi S, 89
Michiura T, 3827
Michotte A, 4457
Micke O, 1993, 1994, 1995
Midasch O, 1507
Miele L, 1105
Migliorini F, 1071, 3913
Mihara Y, 1019, 2339
Mihu CM, 2637
Mihu D, 2637
Mikalsen LTG, 4053
Miki M, 1741, 2297
Milano G, 359
Milas L, 2141
Miliaras D, 3007
Milioudis N, 1745
Milk N, 913
Miller CP, 1189
Miller WH, 3143
Millington DJ, 3739
Mills M, 4393
Mimori K, 507
Mimura K, 2999
Min B-S, 2179
Minarik M, 4647
Minato N, 1027
Mininno M, 3213
Minniti G, 3555
Miotto D, 2923
Mirchandani D, 4401
Mirka H, 339
Misawa K, 3463
Mischo A, 3115
Misciagna G, 555
Mishima H, 4657
Misiti S, 89
Mitsudo K, 2893
Mittelmeier W, 1235
Miyagui J, 3607
Miyaki A, 2989
Miyako H, 3361
Miyamoto K-I, 4339
Miyamoto S, 2461, 2483, 2553
Miyashita A, 495
Miyashita K, 1427
Miyata K, 2553
Miyata Y, 597, 2335, 4465
Miyazaki J, 2065
Miyazaki T, 1019
Miyazawa M, 2989
Miyoshi Y, 4613
Mizokami A, 2927
Mizoshita T, 3353
Mizota A, 3535
Mizue Y, 2511
Mizukami H, 777, 1289, 2889
Mizuki M, 113
Mizumoto K, 1279

Mizumura K, 2129
Mizuno A, 3521, 4429
Mizushima T, 507
Moan J, 1502
Mochizuki H, 1567
Moerman P, 2367
Moertel S, 665
Mohr SB, 2939
Mohri K, 4231
Mok I, 1417
Mokbel K, 23, 4115
Molina R, 1995
Molina V, 1996
Molkentine D, 2141
Molls M, 3935
Molnár J, 1431, 3285, 4201
Moltrasio F, 4485
Mombelli G, 1924
Momose Y, 501
Monaco C, 1071, 3913
Monaco F, 1868
Monaco F, 3555
Moniri MR, 3705
Montagna B, 3927
Montanari M, 1860
Monteil J, 3865
Moon DH, 2135
Moon IH, 575
Moran MS, 2327
Mordelt K, 2651
Morel F, 1007, 3441
Morelli MP, 1093
Moreno CS, 403
Moreno DA, 1337
Mori M, 507
Mori Y, 3353
Moriggi G, 89
Moriguchi M, 3991
Morikawa T, 1395
Morimoto A, 4613
Morimoto J, 1225
Morimoto M, 2389
Morinaga S, 325
Morini D, 2209
Morioka T, 2351
Morisaki T, 2419, 2505, 3995
Morishita N, 4525
Morishita Y, 529
Morita A, 763
Morita H, 3963
Morita M, 3073
Morita S, 3035
Moriya T, 2389
Morse MA, 255
Mössner J, 3289
Motohashi N, 515
Motomura K, 367
Motoo Y, 2297
Motoyama T, 171, 1211
Motta R, 2923
Mousa SA, 411
Mouzaki A, 1677
Mucciardi G, 1941
Muecke R, 1996
Muermans K, 1407
Muggia F, 4401
Mukensnabl P, 4647
Mukudai Y, 2841
Muley T, 4491
Mulherkar R, 3851
Muller C, 3115
Müller CSL, 1509
Mundy CW, 2073
Mundy GR, 2705
Muñoz A, 1492
Muñoz A-B, 4191
Murakami H, 2763, 3775, 4075, 4519
Murakami K, 2103, 3353
Murata S, 2893
Murawa D, 711
Murayama M, 2989
Murayama S, 1437, 2351, 3527
Murayama Y, 495, 2217
Murgo AJ, 961
Muro K, 3535
Murohashi I, 781
Murotani K, 2547
Murtha A, 3559
Musa MA, 2017
Muszczynska-Bernhard B, 2833
Muto Y, 4481
Muzzio PC, 4581
Myojo S, 2447
Mytar B, 1329
Nagai T, 2787
Nagai Y, 991, 1437, 3527
Nagamatsu I, 2505
Naganaboina VK, 2083
Nagano Y, 1049, 1055
Nagao T, 2389
Nagaoka R, 3041
Nagarkatti M, 4099
Nagarkatti P, 4099
Nagasaka M, 705, 933, 1459
Nagata N, 4657
Nagata T, 495
Nagata Y, 4631
Nagayasu T, 4545
Nagumo T, 2841
Nagumo Y, 1483, 3567
Nair V, 2699
Naito K, 999
Naito T, 3775, 4075, 4519
Najajreh Y, 177
Nakagami K, 287, 4625
Nakagawa Kazuhiko, 4561
Nakagawa Kazuo, 4075
Nakagawa Makoto, 1141, 4631
Nakagawa Misako, 2389
Nakagawa Yoshihito, 705, 1459
Nakagawa Yoshinori, 2489
Nakahara S, 367
Nakai H, 731
Nakajima A, 1741, 2297
Nakajima H, 2297
Nakajima T, 2763, 3775, 4075
Nakajima Y, 3909
Nakamura K, 1259, 2059, 2103, 3331
Nakamura M, 705, 933
Nakamura Masakatsu, 1459
Nakamura Mitsunari, 3995
Nakamura O, 549
Nakamura S, 287
Nakamura Takahiro, 2217
Nakamura Takashi, 1297, 2065
Nakamura Takuji, 1741, 2297
Nakamura Tomoki, 4163
Nakamura Toshikazu, 2217
Nakamura Y, 4519
Nakanishi M, 495
Nakanishi T, 3063
Nakano T, 2847, 3963
Nakao A, 1643
Nakashima M, 4251
Nakashima Y, 3073
Nakata E, 2477, 2489
Nakata K, 2437
Nakata M, 535
Nakaya A, 2065
Nakaya K, 1647
Nakayama G, 1643
Nakayama T, 3035
Nakazawa H, 1027
Nam RK, 403
Nam SJ, 3767
Nam SO, 2553
Nambara D, 4155
Namiki M, 2927
Nanashima A, 4545
Nano R, 3727
Naomoto Y, 1197
Nara N, 781, 893
Narayanan B, 4347
Narayanan NK, 4347
Naritaka Y, 2989
Narsanska A, 339, 3619, 4653
Naruse T, 4429
Nasir A, 2073, 2191
Nasir NA, 2957
Nassiri F, 2283
Nassos P, 1745
Natarajan M, 161
Necozione S, 671
Negro-Vilar A, 2303
Nehme E, 4637
Nehoda H, 4407
Nemoto H, 77, 777, 1289, 1293, 2249 2889 3377, 3835
Nemoto M, 2361
Neri F, 1910, 1908
Nesi G, 1789, 2187, 4091
Nesland JM, 4053
Nessa MU, 3789
Neubauer A, 2343
Neuhaus P, 2583
Newbold RF, 4115
Newton-Bishop JA, 1498
Neyns B, 3579, 4457
Nezos A, 4259
Ng S-C, 2303
Nguyen MP, 2705
Nguyen NP, 4393
Nicol F, 2693
Nicolazzo C, 4219
Nicolle E, 3213
Nieder C, 561, 1735, 3935
Niho S, 3449
Nijkamp MW, 4507
Nilsson R, 2187
Nilsson S, 4141
Nimzyk R, 753
Nishi H, 501

Nishi K, 501
Nishi R, 2863
Nishida H, 2927
Nishiguchi H, 999
Nishijo K, 1297
Nishimaki T, 2351, 3527
Nishio K, 2787, 4561
Nishio M, 495
Nishiofuku H, 3909
Nishiyama H, 2065
Nitori N, 3983
Nitsios I, 2373
Nixon AB, 255
Noda S, 3369
Nogata H, 2999
Noguchi K, 881
Noguchi M, 529
Noguchi S, 3035
Nojiri K, 1049, 1055
Nolte I, 1541
Nomoto K, 2773
Nomura M, 1653, 3535
Nong J, 3705
Nonogaki S, 2805
Norberto L, 693
Norca J, 1783
Norton R, 1499
Norum J, 1735
Nose K, 2255
Notarnicola M, 555, 3381
Noto A, 4207
Nowak M, 725
Nowak-Markwitz E, 711
Nucciotti R, 1829
Nyberg P, 3659
O'Hanlon D, 1627
O'Sullivan GC, 1627
Obayashi Y, 4339
Oberhoff C, 3623
Obrist P, 4439
Ochiai K, 3063
Ochiai T, 495, 2217
Ock S-A, 4315
Ocsovszki I, 3285
Ocvirk J, 1777
Odagiri H, 1483, 3567
Odawara H, 3041
Odawara T, 2483
Oderda M, 1830, 1870
Odin E, 3057
Oehr P, 2013
Oertl A, 1997
Öfner D, 4407
Ogata T, 633
Ogawa Kazuhiko, 1437, 2351, 3527
Ogawa Kenji, 2989
Ogawa Tetsushi, 287
Ogawa Tetsuya, 2893
Ogino K, 3361
Ogino T, 2505
Ogose A, 11
Ohashi N, 1643
Ohba K, 597, 2335, 4465
Ohde Y, 2763, 4075
Ohga T, 3073
Ohi H, 763
Ohira M, 3369
Ohkura K, 2561
Ohlinger R, 4039
Ohmichi M, 3063
Ohmura T, 2527
Ohnishi T, 2389
Ohno S, 2441, 2447
Ohno Y, 2441
Ohori H, 3719
Ohta M, 4665
Ohta T, 2447
Ohta Yasuyuki, 2447
Ohta Yukinobu, 4513
Ohtsuka T, 1279
Ohuchida K, 1279
Oh-Uchida Y, 2983
Ohya T, 287, 4625
Oikonomopoulos G, 649
Oizumi H, 171, 1211
Oka M, 3331, 4569
Oka S, 4277, 4631
Okabe K, 543, 2983
Okabe T, 4625
Okada Akihiro, 3983
Okada Alan, 2511
Okada F, 1259
Okada H, 2511
Okada N, 2511
Okaichi K, 2255
Okamoto K, 67, 495, 2217
Okamoto M, 2241
Okamoto N, 4525
Okamoto T, 1395
Okamoto Y, 3353
Okamura H, 67
Okamura S, 67
Okamura Y, 999
Okazawa M, 4513
Oki E, 3073
Okita K, 3331
Okubo K, 4619
Okubo M, 705, 933, 1459
Okudaira K, 501
Okuhashi Y, 781, 893
Okui T, 1197
Okulicz K, 3151
Okumura M, 4665
Okumura T, 2763, 4075
Okuno Y, 2553
Okuyama Y, 4657
Oliveira PA, 1637
Ollonen P, 739, 1065, 1801, 3101, 4013, 4019
Olsen DR, 4053
Omi K, 4155
Omi Y, 105
Onaka K, 2477
Onda K, 4169
Onimaru M, 1279
Onishi H, 2419, 2505, 3995
Onishi T, 1471
Onitsuka T, 855, 1141, 2995
Onizuka S, 2489
Ono A, 4519
Ono F, 2511
Ono K, 2477
Onodera K, 501
Ørbo A, 2319
Ordonez P, 3607
Oremek GM, 1997
Origuchi N, 3983
Oriuchi N, 3775, 4075
Orlow SJ, 3259
Orrego A, 2187
Orsós Z, 3051
Ortega A, 421
Osada S, 4589
Osaka Y, 633
Oshima T, 325, 2915
Oskay-Özcelik G, 2583, 2679
Osti MF, 3555
Ota F, 999
Ota M, 1049
Ota T, 2453, 2535
Otsuji E, 67, 495, 2217
Otsuka Masatomo, 4561
Otsuka Masayasu, 113
Otsuki Y, 1225
Ott OJ, 985
Ottria R, 3401
Ou Y-C, 3497
Oura S, 999
Ouyang H, 1321
Ovarian Cancer (EKZE Berlin), 2583
Owston M, 2187
Oyama T, 1141, 3041, 3079
Paesmans M, 281
Paganin-Gioanni A, 4083
Pagano M, 4401
Palakurthi S, 897
Palazzo A, 4219
Palermo S, 1823
Pálföldi R, 1431
Pall G, 2949
Palloni T, 1882
Palma PVB, 2173
Palmeri R, 3069
Palmieri C, 1367
Palmieri F, 1823, 1834
Palminteri E, 1832
Palomino LF, 1637
Pan E, 4537
Pan Z-M, 3423
Panaia R, 1923
Panayiotidis P, 3585
Panebianco V, 1399, 4553
Pang H, 255
Pangalis GA, 3585
Pannone G, 4211
Panoussi A, 3469
Pantel K, 1997
Panteleakou Z, 4259
Panteliadou M, 1745
Paoli G, 3973
Paolini A, 3727
Papadaki H, 1677
Papadimitriou C, 3007
Papadopoulou A, 1745
Papageorgiou A, 831
Papageorgiou M-V, 1467
Papagerakis S, 4211
Papakostas P, 3007
Papaleo A, 1920
Papandreou CN, 3007
Papanikolaou G, 2603
Papazisis KT, 3007
Papp A, 1769
Pappagallo GL, 1872
Pappi V, 3585
Parisi A, 4553
Park B-W, 4315
Park HS, 3385
Park JB, 4307
Park JS, 4111

Park JY, 4641
Park SK, 3385
Parolini C, 3137
Parziani S, 1890
Pasi F, 3727
Pasini F, 3543
Passariello R, 1399
Pastore AL, 1837
Pašukonienė V, 639, 699
Patani N, 4115
Patel S, 3559
Patrinou-Georgoula M, 4291
Patsouris E, 3585
Patta A, 975
Pattanapanyasat K, 921
Paule B, 331, 3507
Pavlik R, 451
Pawade J, 1577
Paz K, 2149
Pazdiora P, 3619, 4653
Pázsit E, 3051
Pe'er J, 345, 351
Pecen L, 373, 1447, 3619, 4031, 4653
Pecher G, 4195
Pecher G, 475, 1169
Pectasides D, 1467, 3007
Pehl C, 2931
Pellucchi F, 1852, 1853
Pelofy S, 4083
Penate-Medina O, 3659
Peng H-Y, 1667
Penney R, 2971
Pentheroudakis G, 3007
Peoc'h M, 585
Pepe P, 4445
Perchellet EM, 2083
Perchellet J-PH, 2083
Perdonà S, 1918
Pereira MA, 3279
Perez J, 2813
Perillo L, 4211
Pernetti R, 271, 1849, 3503
Perrine SP, 2723
Perugia G, 1856
Pesek M, 3619, 4031, 4647
Pessin-Minsley MS, 959
Pesta M, 1447, 3107, 4031
Petracca A, 4219
Petraki K, 3007
Petralia G, 1842
Petrongari MG, 1928
Petrozziello A, 1071, 3913
Pettersen I, 2319
Pfab G, 2749
Pfister DG, 249
Pflüger H, 3273
Philippou A, 4259
Phillips L, 1577
Phillips PG, 411
Pi GE, 395
Pi Z, 1321
Piazze J, 671
Picozzi S, 1934
Pierantoni GM, 4211
Pietsch T, 661
Pietzner K, 2603, 2669, 2675, 2679
Pike JW, 1491
Pinney E, 3125
Pinski J, 3897
Pinterova D, 1535
Piotrowska A, 2833, 3027
Pircher A, 2949
Pirillo D, 681
Pirrelli M, 555
Pissimissis N, 4259
Pitts TM, 1093
Pizzirusso G, 1838
Pizzocaro G, 1940
Pletsa V, 4291
Plinkert PK, 81, 185
Pluschnig U, 2379
Plyta S, 3469
Pneumaticos SG, 4259
Podhorska-Okolow M, 2833, 3027
Poellinger A, 2597
Poggi G, 3927
Pogorzala M, 1453
Pohlen U, 147, 153
Polberg K, 565
Polo Padillo J, 3019
Polterauer S, 2259
Pommeri F, 4581
Pontoriero A, 1888
Porcaro AB, 1071, 3913
Poree P, 1783
Portugaller RH, 1583
Possinger K, 2713
Post S, 2693
Potenberg J, 2657
Poulain L, 797
Pozsgai E, 1769
Pradier C, 1783
Pramanik D, 907
Prati V, 1871
Prazakova M, 3107, 3619, 4031
Prewett M, 2149
Prezas P, 3093
Prezioso D, 1846
Pries R, 3819
Priftakis P, 3489
Procopio G, 1831
Proietti F, 3973
Pschowski R, 2629
Pudelko M, 711
Puget G, 1599
Puistola U, 1411
Pula B, 2833, 3027
Pultrone CV, 1884
Punt CJA, 1379
Purohit A, 1367
Pylväs M, 1411
Pyrhönen S, 311, 4529
Qamar S, 3247
Qin K, 3705
Qiu D, 2773
Qu X, 3229
Quaretti P, 3927
Quartier E, 4457
Quay E, 3259
Queiroz RG, 1337
Quon H, 3559
Raats DAE, 1379
Racchiusa S, 3069
Rack B, 2749
Radpour R, 2623
Rafinska-Kurylo B, 1453
Rahal P, 1685
Rahdon R, 1443
Raica M, 1757
Raimondi C, 4219
Rajah TT, 209
Rajendran S, 1627
Rajput A, 387
Raju U, 33, 2141
Rak J, 2869
Ramachandran K, 3757
Ramos DM, 1205
Ramos J, 4397
Ramqvist T, 1515, 3489
Rana M, 2313
Rancati T, 1927
Ranjan AP, 907
Rank A, 1998
Ranta T-M, 3659
Rapak A, 2869
Rashid G, 3733
Raspollini MR, 1921
Rau K-M, 1713
Ravage-Mass L, 625
Ravo V, 1866
Rayat S, 2083
Razis E, 3007
Rea S, 671
Rebersek M, 1777
Rebischung C, 359
Recchia COC, 671
Recchia F, 671
Reddavide R, 555
Reed MJ, 1367
Rega G, 3273
Regierer A-C, 2713
Reichrath J, 1498
Reifenberger G, 725
Reinke P, 2629
Reinthaller A, 2259
Renaudie J, 3865
Renner C, 3115
Renner W, 1373
Renninger M, 3783
Repana D, 3007
Restrepo-Angulo I, 1265
Reszka R, 147
Reunanen J, 3659
Reuter C, 2609, 2645
Rey-Barja N, 677
Reynolds CP, 961
Rezai M, 2569, 2575
Reznick AZ, 1607
Rho G-J, 4315
Ribatti D, 1757
Riccardi A, 3927
Ricci A, 4207
Richter E, 1998
Richter R, 2583, 2657, 2679
Riebe C, 3819
Riesterer O, 33
Rigal C, 2813
Ring A, 4061
Ríos-Moreno MJ, 3019
Ris H-B, 2121
Risatti CA, 2773
Roa W, 3559
Rob L, 1765
Rocca BJ, 1866
Rocchini L, 1853
Rocco B, 1883, 1884
Rochel N, 1492
Rödel C, 985

Rodrigues ES, 2173
Rodriguez-Tojo MJ, 677
Roh GS, 4223
Roh SA, 4329
Rokutanda N, 3041
Rolinski B, 1999
Romano M, 1071, 3913
Romeo A, 1877
Romeo K, 2517, 2541, 2547
Romeo P, 4553
Roncella S, 1061
Roppongi T, 287
Roscigno M, 1840, 1841, 1842
Rosell J, 1599
Rosen LS, 625
Rosenzweig KE, 959
Roses DF, 4401
Rossi T, 2209
Rothmund R, 979, 4423
Rotondo F, 2283
Rousseau R, 2813
Roux S, 3865
Rouzier R, 4469
Rozen WM, 1443
Ruan P, 1321
Ruat S, 3047
Rubenstein M, 487
Rubilotta E, 3913
Rubin J, 3489
Rubio CA, 1789, 2187
Ruchirawat S, 921
Ruegg C, 3115
Ruge F, 3205
Rullo R, 4211
Russ G, 4439
Russell Jr LH, 3739
Russo D, 1915
Rustum YM, 387
Ruthardt M, 177
Rutigliano M, 1892
Rutkowski S, 661
Rutqvist LE, 1527
Ryoo S, 2179
Ryozawa S, 2103
Rys J, 3027
Rytting M, 2265
Ryu J, 4223
Ryu Y, 2517, 2541, 2547
Rzeski W, 565
Saarto T, 3493, 4413
Sadahiro M, 1211
Sadones J, 4457
Saeki H, 3073
Saeki N, 4475
Safe SH, 3799
Safranek J, 3107, 4031
Safyan RA, 4401
Saga T, 1549
Sagara Y, 2335, 4465
Sager G, 2319
Saif MW, 625, 649, 1039, 2971, 4397
Saikawa Y, 3079
Saini SS, 3683
Saito Hidetsugu, 1653, 3253
Saito Hiroko, 2915, 4339
Saito J-I, 3963
Saito K, 625
Saito M, 77, 777, 1289, 1293, 2249, 2889, 3377, 3835
Saito Y, 1653, 3361
Sajjad M, 411
Sakagami H, 515, 1241, 4231
Sakaguchi H, 3909
Sakai Hideki, 597, 2335, 4465
Sakai Hiroshi, 3449
Sakai K, 2787
Sakai T, 1741, 2297
Sakaida I, 2103, 3331
Sakakura C, 495
Sakamoto A, 1395
Sakamoto I, 287, 4625
Sakamoto J, 3035, 4657
Sakashita S, 529
Sakata M, 2889
Sakuma S, 763
Sakuraba K, 77, 777, 1289, 1293, 2249, 2899, 3377
Sakuraba M, 1427
Sakurai K, 3839
Sakurai Y, 2477
Sakuramoto S, 2361
Salama S, 4179
Salehin D, 1494
Salmon I, 4457
Salo T, 3659
Samadder P, 3809
Samakoglu S, 2149
Samaras P, 3115
Samonigg H, 1373
Samuel T, 233
Samulitis BK, 2781
Samura H, 3527
San Martin ID, 387
Sanada Y, 77, 1289, 1293, 2249, 3377, 3835
Sánchez-León M, 3019
Sánchez-Torres C, 1265
Sand L, 3345
Sanders AJ, 303
Sanders JM, 2303
Sanguedolce F, 4211
Sano O, 2983
Sano T, 3463
Sanseverino R, 1908, 1909, 1911, 1940
Sant'Ana JM, 2805
Santi R, 4091
Santo M, 4525
Santoro A, 4211
Santos L, 1637
Sanui A, 2553
Sapkota D, 3345
Saraswati S, 1999
Saris PEJ, 3659
Sarkar FH, 1105
Sarkar S, 2723
Sartori Chr, 2000
Sasa M, 2389
Sasada S, 4525
Sasaki A, 1197, 1307
Sasaki Kanji, 549
Sasaki Kazunari, 2527
Sasaki Kenji, 3839
Sasaki S, 3361
Sasaki Takeshi, 1471
Sasaki Tomikazu, 4111
Sasazuki T, 2453, 2535
Sato Atsuko, 3719
Sato Ayako, 3041
Sato M, 2129
Sato T, 325, 529, 2297
Sato Y, 287, 2847, 4625
Satoh K, 1011
Satoi S, 3827
Satonaka H, 4163
Sauer R, 985
Sauter G, 2000
Sava T, 1071, 3913
Sawada D, 1501
Sawada T, 3369
Sawaki T, 1741, 2297
Scaldaferri F, 4273
Scardigno M, 3069
Scattoni V, 1861, 1862
Schade AE, 2073
Schaffran A, 4061
Schallier D, 1753
Scharf JP, 2657
Schatzl G, 3615
Schauwecker J, 1235
Scheckenbach K, 3151
Schefe J-H, 2713
Schefold JC, 2629
Scheithauer BW, 2283
Schemmer P, 3883
Schepp W, 2931
Schiavina R, 1949, 1950, 1951
Schill S, 561
Schilling1 G, 1963
Schimanski CC, 2797
Schindlbeck C, 2749
Schirmacher P, 1215
Schlenker T, 459
Schlomm T, 2001
Schmid P, 2589, 2617
Schmidt SC, 2603
Schmidt T, 2931
Schmidtler F, 2931
Schmidt-Wolf IGH, 725
Schmieder K, 1023, 3873
Schmitt B, 3315
Schmitt M, 1235, 2343
Schmitt S, 1
Schmittel A, 317
Schmitz I, 4061
Schmuck RB, 2675
Schnabel PA, 4491
Schnakenberg E, 2001
Schnapauff D, 2597
Schnegelsberg B, 1589
Schneider CM, 2023
Schneider J, 4191
Schneider T, 2001
Scholz C, 451, 2713
Schönknecht CE, 3935
Schoppmann A, 4605
Schoppmann SF, 2379, 4605
Schork NJ, 2303
Schramm M, 53
Schröder T, 4141
Schroeder JK, 2669
Schroeder KN, 3819
Schueller J, 3573
Schuler P, 3151
Schuller DE, 2683
Schulten H-J, 4179
Schulz C-O, 2713
Schumacher U, 1589

Schwab JH, 1115
Schwarzlose-Schwarck S, 2713
Schwidde I, 2609, 2651
Sciarra A, 1399
Scognamiglio U, 2291, 3977, 4575
Scopa C, 1677
Scorilas A, 3093
Scozzi D, 4207
Scrideli CA, 1337
Sculier J-P, 281
Seffert P, 585
Segala D, 3137
Sehouli J, 1387, 2569, 2575, 2583, 2589, 2597, 2603, 2609, 2629, 2645, 2651, 2657, 2669, 2675, 2679
Seidl H, 2931
Seiz M, 1023, 3873
Sekimoto M, 507
Sekine F, 2733
Selle F, 4469
Senda Y, 3463
Seo HS, 3301
Seo J, 2179
Sergeev IN, 1494
Serkova NJ, 1093
Serra A, 3953
Serretta V, 1817, 1818
Sertel S, 81, 185
Seshadri M, 387
Sesterhenn AM, 3959
Seth A, 403
Seto Y, 535
Seuter S, 1504
Sgambato A, 1359, 4273
Shao Y-Y, 4007
Shapiro O, 929
Sharif EA, 1507
Sharma A, 23
Sheen-Chen S-M, 293, 3633
Sheline CT, 3395
Shen C-H, 3939
Shen K-H, 3939
Shen R, 249
Shen Y, 687
Shen Y-J, 129
Sherman C, 403
Shi Y, 3595
Shiba A, 529
Shiba S, 2999
Shibaguchi H, 2425, 2527
Shibata H, 3719
Shibata M-A, 1225
Shibata T, 705, 933, 1459, 2361
Shibo L, 3883
Shibuya M, 3449
Shichinohe T, 263
Shigematsu N, 3079
Shigematsu Y, 4631
Shim K-N, 575
Shimada H, 1049
Shimakawa T, 2989
Shimazaki H, 1567
Shimizu T, 2995
Shimizu Y, 263, 3463
Shimo T, 1197, 1307
Shimoji H, 2351
Shimokawa H, 1141, 4277, 4631
Shimosegawa T, 1011
Shimura T, 3353
Shin YC, 3301
Shindo Y, 4569
Shinmura K, 2889
Shinoda M, 3535
Shinohara M, 633
Shinohara S, 4631
Shinohara Y, 2561
Shinozaki N, 4475
Shintani S, 2841
Shintani Y, 4665
Shinto E, 1567
Shinwari Z, 1721
Shiomi K, 1427
Shiomi S, 1427
Shioya M, 3963
Shiozaki A, 67, 495
Shiozawa M, 325
Shipp C, 2095
Shirahata A, 77, 777, 1289, 1293, 2249, 2889, 3377, 3835
Shirai T, 2927
Shiraishi M, 3527
Shirasawa S, 2413, 2453, 2535
Shiratsuchi I, 2517, 2541, 2547
Shirota K, 2553
Shirouzu K, 2517, 2541, 2547
Shitara K, 3535
Sho M, 3909
Shou J-Z, 945
Shukuya T, 3775, 4075, 4519
Siegfried JM, 2877
Siegling A, 4185
Sierko E, 843
Sifringer M, 565
Sigmundsdottir H, 1500
Signore A, 719
Silva AE, 1685
Silva SR, 1153
Silveira APF, 1685
Silvestri GA, 3891
Simak R, 3273
Simoni A, 4091
Sinclair A, 2017
Singal R, 3757
Singh H, 961
Singh NP, 4111
Singh-Ranger G, 1795
Sinha P, 2109
Sion-Vardy N, 913
Siracusano S, 1875
Sivridis E, 1745
Sixt SU, 2197
Skaane P, 2575
Skaland I, 443
Skalicky T, 339, 1447
Skelton IV WP, 395
Slewa A, 443
Sliva D, 379
Smerdely M, 3559
Smith III AB, 2773
Smith JA, 907
Smolczyk DR, 3873
Snoeren N, 4507
So T, 4631
Sogawa C, 1549
Sohail M, 1577
Sohn C, 3219
Søiland H, 443
Söletormos G, 613
Solomayer E-F, 4423
Soma G-I, 2431, 2437, 2441, 2467
Somasundaram K, 3851
Sommer H, 2749
Somura H, 1653
Song K, 3229
Song W, 39
Sonkoly E, 3151
Sonobe M, 4619
Sonoda H, 3073
Sonoyama T, 495
Sørby LA, 861
Søreide K, 967
Sørensen FB, 1559
Sorenson M, 209
Sorsa T, 3659
Sottotetti F, 3927
Southard RC, 813
Spaczynski M, 711
Spagnoletti G, 1885, 1886, 1887, 1926
Spechtenhauser B, 4407
Speeckaert M, 3697
Speeckaert R, 3697
Spengler G, 3285, 4201
Sperga M, 1421
Sperry JB, 2773
Spilotros M, 1892
Spindler K-LG, 1559
Spisakova M, 3107
Spitz J, 2002
Spratlin JL, 1093
Springer C, 3783
Sreevalsan S, 3799
Srivastava D, 3851
Sroka T, 4393
Stadlbauer V, 1583, 3713
Staebler A, 4025
Stambuk H, 249
Stamschror J, 209
Stanczyk FZ, 1367
Stanimirovic A, 403
Stanway SJ, 1367
Stathopoulos EN, 807
Staufner C, 3181
Stefanatou G, 3469
Stein A, 2002
Steinau H-U, 4061
Steinborn A, 3219
Steiner R, 3115
Steinhagen PR, 1387
Steinmeyer A, 4091
Steinstraesser L, 4061
Stelkens-Gebhardt R, 2569, 2575
Stella MG, 3927
Stenner F, 3115
Stenvold H, 1603
Stenzl A, 2053, 3783
Stepulak A, 565, 3181

Sterenczak KA, 1541
Sterlacci W, 2949
Sterling JA, 2705
Stewart D, 3921
Stieber P, 2003, 2004
Stiegler P, 1583, 3713
Stigliano A, 89
Stigliano E, 4273
Stio M, 4091
Stöblen F, 2569, 2575, 2589, 2617, 2645, 2651
Stokes C, 1506
Stopfer P, 2271
Story MD, 33
Stöver T, 665
Strakova M, 3619, 4653
Strassen I, 2931
Strazdiņa A, 1421
Street CA, 3645
Stricker I, 4061
Strimpakos AS, 2971
Strosberg J, 2957, 4387
Struss WJ, 4501
Strutt D, 2161
Strzadala L, 2869
Sturgeon C, 2004
Styczynski J, 1453
Su C-H, 3511
Subramanian A, 23
Suchi K, 67
Sudo A, 4163
Sueoka N, 3517
Suetsugu A, 3125
Sueyoshi S, 3909
Sugar L, 403
Sugiura H, 123
Sugiyama H, 2441, 2447
Suh C, 3457
Sumi T, 1271
Sun M-T, 1713
Sun X, 243
Sun XF, 4127
Sun X-Y, 3705
Sun Y, 3859
Sundström J, 311, 4529
Suñol M, 953
Sunose Y, 287, 4625
Suojanen J, 3659
Surarit R, 921
Surowiak P, 711, 2963
Sussan S, 177
Sutnar A, 339, 1447
Suto T, 3963
Suwanborirux K, 193
Suzuki H, 4525
Suzuki K, 1427
Suzuki S, 4251
Svacina S, 373
Svasti J, 921
Svendsen C, 785
Svobodova S, 373, 3107, 3619, 4653
Swarts JC, 825
Swiderek E, 2869
Syrigos KN, 649, 2971
Syrjänen K, 97, 311, 2975, 4529
Syro LV, 2283
Szántó E, 1431
Szatanek R, 1329
Szczuraszek K, 2963
Szewczyk M, 2005
Szigeti A, 1769
Szkandera J, 1373
Taba K, 2103
Tabata Y, 105
Tabe Y, 3963
Tada T, 2511
Tadaki T, 881
Tae N, 2179
Taflin H, 3057
Tagliaferri B, 3927
Taguchi O, 123
Taguchi T, 3035
Tahara T, 705, 933, 1459
Tai D-I, 129
Taiyoh H, 2217
Takagi Y, 633
Takahari D, 3535
Takahashi H, 2335
Takahashi H, 4465
Takahashi K, 1427
Takahashi M, 2389
Takahashi N, 2129
Takahashi S, 763
Takahashi Takao, 4589
Takahashi Takeo, 2847
Takahashi Toshiaki, 2763, 3775, 4075, 4519
Takahashi Tsunehiro, 3079
Takahashi Tsuyoshi, 4619
Takahashi Y, 2461
Takai C, 2389
Takaishi H, 3079
Takakura M, 2441
Takamatsu R, 2351
Takano F, 2447
Takano J, 3607
Takaoka M, 1197
Takashima M, 3331
Takashima T, 3035
Takashima Y, 2535, 2453
Takata D, 3041
Takayama T, 1019, 2339, 3991
Takayama Y, 1019
Takeda Kayoko, 263
Takeda Kazuhisa, 1055
Takeda Kazuyoshi, 501
Takeda Koji, 3449
Takeda M, 4561
Takemasa I, 507
Takemoto H, 4657
Takenaka M, 4631
Takeshita H, 4545
Takeuchi A, 2927
Takeuchi Hideya, 4481
Takeuchi Hiroya, 3079
Takeuchi M, 4339
Takeuchi R, 2489
Takeyama H, 1395
Takeyoshi I, 287, 3041, 4625
Takikita M, 945
Tal M, 177
Talieri M, 3093
Tamaki W, 2351
Tamamoto T, 3909
Tamandl D, 4605
Tamegai H, 1019, 2339
Tamesa T, 3331
Tamiya M, 4525
Tamura D, 2787
Tamura G, 171, 1211
Tamura K, 2483
Tamura S, 325
Tanabe K, 1027
Tanahashi Y, 287, 4625
Tanaka F, 855, 1141, 4277, 4451, 4631
Tanaka H, 2505
Tanaka Kanji, 3517
Tanaka Katsuaki, 325
Tanaka Kuniya, 1049, 1055
Tanaka Kyoko, 4561
Tanaka Mamoru, 763, 3353
Tanaka Masao, 1279, 1741, 2297
Tanaka N, 3063
Tanaka S, 4169
Tanaka Toshihiro, 3909
Tanaka Tsuneo, 2733
Tanaka Yoko, 2453, 2535
Tanaka Yoshihiro, 4589
Tanaka Yoshihisa, 1225
Tanaka Yoshimasa, 1027
Tang B-J, 3423
Tang N-Y, 1691
Tang R-P, 293, 3633
Tang W, 535
Tangney M, 1627
Tangoku A, 2389
Tanida S, 3353
Tanioka A, 1647
Tanzawa Y, 2927
Taran F-A, 2617
Tarpin C, 1079
Tavaré JM, 1577
Tavernarakis N, 807
Taylor PR, 945
Teerenstra S, 1379
Teissie J, 4083
Televantou D, 3007
Temme A, 3181
Tempfer C, 2259
Tendyke K, 2773
Teng L, 1521
Tentler JJ, 1093
Terada H, 2489
Terai K, 1181
Teramoto S, 1483
Terao K, 2511
Terkola R, 3573
Testoni N, 1943
Teugels E, 4457
Thaler J, 4439
Thall P, 2265
Thallinger CMR, 2379
Thasana N, 921
Theobald M, 2797
Theos A, 4259
Thiel E, 317
Thielemans K, 3579
Thiem U, 1507
Thill M, 1495, 2609, 2617, 2645, 4359
Thomas A, 4039
Thomas M, 4491
Thomé C, 1023, 3873
Thorpe PE, 843
Thorsteinsson M, 613
Thrum S, 3289
Thüroff JW, 2797

Thurzó L, 1431
Thymara I, 3585
Tian YF, 4127
Tilkorn D, 4061
Tilli M, 4581
Timotheadou E, 3007
Tiscione D, 1890, 1891, 1939
Tisnek N, 2113
Tiszlavicz L, 1431
Tjin EPM, 3697
Toda T, 3331
Todo M, 67
Todorova VK, 215
Toguchida J, 1297
Tohda S, 781, 893
Tohnai I, 2893
Toita T, 1437, 3527
Tokiniwa H, 3041
Tokuda Y, 3361
Tokuno K, 4569
Tol J, 1379
Tominaga H, 4657
Tominaga T, 4545
Tomita K, 3665
Tomita M, 2995
Tomiyasu S, 2983
Tomizawa N, 287, 4625
Tomomura A, 1241
Tomomura M, 1241
Tone LG, 1337
Toniolo P, 4267
Tonra JR, 2149
Tooker P, 2303
Topolcan O, 339, 373, 1447, 3107, 3619, 4031, 4653
Topolèan O, 2005
Topuz E, 2225
Torelli T, 1826
Torigoe S, 2893
Tortorella S, 4211
Tosca AD, 807
Toscano V, 89
Tosco L, 1936
Totaro A, 1936
Touloupidis S, 1745
Tousseyn T, 2367
Townsend Jr CM, 1153
Toyama M, 2241
Toyoda H, 4169
Toyokawa H, 3827
Tozuka K, 3041
Trafalis DT, 831
Traficante A, 1359
Tramacere F, 1889
Trellakis S, 3151
Trémezaygues L, 1509
Treska V, 339, 1447, 3619, 4031, 4653
Treskova I, 339, 3619, 4653
Treves C, 4091
Trigo-Sánchez I, 3019
Trump DL, 1496
Tsai C-H, 3633
Tsai C-W, 221, 227, 745, 1043, 2395, 3511, 3629
Tsai M-H, 227, 2395, 3629
Tsai R-Y, 221
Tsai S-J, 4301
Tsai Y-H, 2231
Tscheliessnigg K, 1583, 3713
Tschulakow A, 4417
Tseng C-J, 4301
Tseng H-C, 4239
Tseng S-H, 2231
Tsigris C, 831
Tsopra O, 3585
Tsou Y-A, 227, 745, 2395, 3629
Tsubaki K, 1647
Tsubota Y, 3517
Tsuchida A, 633
Tsuchiya H, 2927, 3665
Tsuda B, 3361
Tsujii M, 4163
Tsujinaka T, 3085
Tsujino I, 2129
Tsujioka H, 2461, 2553
Tsujiuchi T, 543
Tsukamoto H, 2841
Tsukiyama I, 2915, 4339
Tsunoda T, 2453, 2535
Tsuru H, 2425
Tsurutani J, 4561
Tsutsumi S, 3963
Tsuya A, 4519
Tübel J, 2006
Tubiana-Mathieu N, 3865
Tuccari G, 1315
Tuebel J, 1235
Tuettenberg J, 1023, 3873
Tujii R, 763
Tumor Bank Ovarian Cancer Network (TOC), 2583
Tung M-C, 3939
Tuohimaa P, 1503
Turesson I, 1527
Turner T, 233
Turowski SG, 387
Turski L, 565
Tutino V, 3381
Tzovaras AA, 1033
Uchida K, 1395
Uckermann O, 565, 3181
Ueda M, 1049, 1055
Ueda T, 2461, 2553, 2863
Ueda Y, 4513, 4613
Uejima D, 1297
Uemura M, 507
Uemura N, 3463
Uemura T, 4163
Uemura Y, 3517
Ueno H, 1567
Uesawa Y, 4231
Ueyama J, 2915
Ueyama Y, 1259
Uhmann A, 1499
Ulrich U, 2657
Ulsperger E, 2949
Um J-Y, 3301
Umebayashi M, 2505
Umeda M, 3521, 4429
Umehara H, 1741, 2297
Umehara S, 67
Umemura S-I, 501, 2527
Umezu H, 11
Unno J, 1011
Unno M, 1011
Uozumi K, 4251
Ura T, 3535
Uramoto H, 277, 619, 855, 1141, 4277, 4451, 4631
Urban N, 1189
Urtasun R, 3559
Uto Y, 2477, 2489
Utsumi H, 4169
Vala H, 1637
Valdagni R, 1945
Valente MG, 4485
Valentiner U, 1589
Valentini AM, 555
Valeriani M, 3555
Vallés A, 1599
Van De Winkel N, 3579
Van Den Broek M, 3115
Van Der Burg MEL, 4043
Van Geel N, 3697
Van Gele M, 3697
Van Hillegersberg R, 4507
Van Houdt WJ, 4507
Van Lierde M-A, 1407
Van Moorselaar RJ, 699
Van Pijkeren JP, 1627
Van Rensburg CEJ, 825
Vanderlinden K, 3579
Vangara KK, 897
Varin E, 797
Varkaris A, 1475
Vasconcelos-Nóbrega C, 1637
Vassilakopoulos TP, 3585
Vasta F, 4553
Vats T, 2265
Vavallo A, 1898
Vavassori A, 1900, 1901
Veeraraghavan J, 161
Veith J, 411
Veratti E, 2209
Vereczkei A, 1769
Verga Falzacappa C, 89
Vermaelen K, 3697
Verna V, 4191
Verreault M, 2161
Verzoni E, 1831
Vesely DL, 395
Vetvicka V, 47
Vetvickova J, 47
Viens P, 1079
Vieth R, 1496
Vilen S-T, 3659
Villani D, 1855
Villani L, 3927
Vincent EE, 1577
Vinh-Hung V, 4393
Virgolini I, 4407
Visconti C, 1867
Visconti D, 1847
Vishwanatha JK, 907
Vitale FV, 4553
Viveiros M, 3285, 4201
Vo RP, 4393
Vock J, 4393
Voest EE, 4507
Vogel RI, 1181
Vogel U, 3783
Vogel W, 4025
Volk H-D, 4185
Volmer DA, 1508
Volpe A, 1903, 1904
Von Eisenhart-Rothe R, 1235
Von Haehling S, 2629
Von Helden R. 1508
Vongchan P, 4067

Vorgias G, 3469
Voss A, 459
Vrzalova J, 339, 1447, 2006, 3107, 3619, 4031, 4653
Vycital O, 1447, 4031
Wada N, 3079
Wada T, 2733
Wagenblast J, 665
Wagner P, 979
Wagner W, 3903
Wakabayashi H, 515
Wakabayashi N, 543
Wakata K, 4545
Wakatsuki A, 4339
Walker F, 3047
Wallis NK, 813
Wallwiener D, 979, 4423
Walsh JE, 3159
Walsh WR, 1147
Walter B, 985
Wang Chaoyu, 945
Wang Chunrui, 3859
Wang CY, 929
Wang H, 3171
Wang H-C, 3511
Wang Li, 2141
Wang Lilin, 427
Wang N, 3219
Wang Q, 3423
Wang Q-H, 945
Wang S-C, 789
Wang Shusheng, 4111
Wang S-M, 3423
Wang Su, 2149
Wang Xi, 3165
Wang Xinmei, 1619
Wang Y-C, 203
Wang Y-H, 3939
Wang Yu, 303
Wang Yufeng, 2059, 3331
Wang YY, 4127
Wang Z, 1105
Ward R, 1367
Warm M, 4039
Warnock GL, 3705
Warth A, 4491
Wasa J, 123
Watanabe J, 3607
Watanabe Kazushi, 4339
Watanabe Koshiro, 3449
Watanabe Masahiko, 2361
Watanabe Masayuki, 991
Watanabe Megumu, 1019, 2339
Watanabe Michiko, 1395
Watanabe Mitsuaki, 2999
Watanabe S-I, 597, 4465
Watanabe T, 3691, 4147
Watanabe Y, 3063
Watanabe Y, 3991
Watanabe Y, 4569
Watanabe Y, 731
Waters AM, 2083
Watson A, 233
Watson K, 2095
Weber O, 4185
Wechsler J, 427
Wefstaedt P, 1541
Weghorst CM, 2683
Węglarczyk K, 1329
Wehler TC, 2797
Wehling M, 2589
Wei J, 3595
Weiss C, 985, 3873
Weiss G, 2007
Weiss HL, 1153
Weiss TW, 3273
Weissenbacher T, 451
Wells J, 3921
Wen S, 1475
Weng W-H, 129
Wenger RH, 3115
Wenz F, 3873
Werner JA, 59, 3959
Werynska B, 2833
West HC, 2109
Wettergren Y, 3057
White Y, 2241, 4251
Whiteside TL, 3151
Wide K, 3489
Wiedmann M, 3289
Wiegand S, 59, 3959
Wiest I, 2007
Wilgenhof S, 3579
Wilkinson N, 3429
Winayanuwattikun P, 921
Wingard DL, 2939
Winterhalter M, 2197
Witte L, 2149
Wittwer Chr, 2008
Wohlschlaeger J, 2197
Wojnar A, 3027
Wojta J, 3273
Wojtukiewicz MZ, 843
Wolf P, 2931
Wolff B, 661
Wolff JE, 661 2265
Wolff RA, 1417
Wöll E, 4407, 4439
Wollenberg B, 3315, 3819
Womastek I, 3615
Won J-H, 3385
Wong NS, 255
Woo S, 2265
Wood KB, 1115
Worayuthakarn R, 921
Word BR, 3171
Wright JD, 243
Wrobel T, 2963
Wu BM, 3237
Wu C, 687
Wu C-I, 3511
Wu C-Y, 221
Wu F, 2249, 3377
Wu H-C, 221, 745
Wu J-Y, 3475
Wu K-C, 2203
Wu RS-C, 2203
Wu S-H, 1691
Wu W-J, 1043
Wu Y, 771, 1619
Wullich B, 985
Wust P, 2597
Wutti-In Y, 4067
Wysocki M, 1453
Xiao Z, 3883
Xie K, 3433
Xie Y, 4135
Xiong S, 3897
Xu B, 687
Xu H, 535
Xu N, 687, 3595
Xu Q, 2773
Xu S, 1521
Xu X, 2343
Xu Y, 11
Xue W, 771
Yabana T, 1471
Yagi J, 1027
Yagublu V, 2693
Yajima R, 3963
Yalcin M, 411
Yamada H, 705, 933
Yamada K, 123
Yamada S-I, 3521
Yamada T, 4625
Yamada Takanobu, 325
Yamada Tatsuya, 287
Yamaguchi Kazuya, 4589
Yamaguchi Kentaro, 2989
Yamaguchi S, 3963
Yamaki S, 3827
Yamakoshi H, 3719
Yamamoto C, 3567
Yamamoto D, 1483, 3517, 3567
Yamamoto H, 507
Yamamoto I, 2493
Yamamoto Naoto, 325
Yamamoto Nobuyuki, 2763, 3775, 4075, 4519
Yamamoto Norio, 3665
Yamamoto S, 2489
Yamamoto Tetsuji, 549
Yamamoto Tomohisa, 3827
Yamamura S, 2983
Yamanaka T, 2983, 4561
Yamasaki A, 2419
Yamasaki LHT, 1685
Yamashita H, 705, 933, 1459
Yamashita K, 2361
Yamashita Y, 2477
Yamauchi K, 3665
Yamauchi T, 2863
Yamazaki S, 3991
Yan H, 2121
Yan J, 4135
Yan L, 3337
Yanagawa N, 171, 1211
Yanagimoto H, 3827
Yanagita M, 427
Yanamoto S, 3521, 4429
Yang C, 1115
Yang C-K, 3497
Yang DC, 2899
Yang H-C, 3423
Yang J-H, 3767
Yang Jia-Lin, 1147
Yang Jiun-Long, 1691
Yang J-S, 1667, 1691, 2203, 2821
Yang P, 2141
Yang Q, 2327, 3229
Yang S-T, 1667, 2821
Yang Yeongae, 4223
Yang Yong, 3205
Yang Z-J, 3423
Yano I, 2065
Yano S, 763
Yarom N, 3921
Yashiro M, 3369
Yasuda A, 2841

Yasui T, 1271, 1279
Yatabe Y, 3535
Yazbeck C, 3047
Ye L, 1703, 3205
Ye LI, 303
Ye W, 1659
Ye W-P, 481
Yeatman TJ, 2957
Yeh C, 2037
Yeh C-T, 2037
Yeh R-D, 2821
Yeh S-D, 3939
Yeh T-S, 2037
Yehualaeshet T, 233
Yellepeddi VK, 897
Yen Y, 3475
Yi B-R, 2853
Yi P, 1321
Yi SY, 575
Yin J, 2877
Ying T-H, 4301
Yokomizo K, 77, 777, 2889
Yokota T, 3535
Yokoyama T, 4613
Yokoyama Y, 3331
Yoneda M, 67
Yonei A, 2995
Yonemura J, 705, 933, 1459
Yoo H, 4307
Yoo K, 575
Yoon J, 3385
Yoon SN, 4329
Yoshida D, 2847
Yoshida H, 1271, 3517
Yoshida H, 3567
Yoshida Kanako, 2103
Yoshida Kazuhiro, 4589
Yoshida N, 2339
Yoshida T, 2517, 2541, 2547
Yoshida Y, 2453, 2535
Yoshidome K, 3035
Yoshihara K, 325
Yoshikawa Y, 4481
Yoshiki T, 1297
Yoshimasu T, 999
Yoshimi N, 2351
Yoshimitsu M, 4251
Yoshimura K, 4569
Yoshinari D, 4625
Yoshino K, 4513, 4613
Yoshino S, 4569
Yoshioka D, 705, 933, 1459
Yoshitomi I, 3521
Yoshiwara E, 3607
Yoshizato T, 2553
Yoshizawa A, 4619
Yoshizawa S, 2527
Yotsumoto F, 2461, 2483, 2553
Young MR, 3159
Yousef GM, 2283
Yu B, 771, 1619
Yu C-C, 2821
Yu C-S, 1691, 2203, 2821
Yu H, 2739
Yu JQ, 1131, 2757, 3789, 4283
Yu M, 4537
Yu Yan, 1147
Yu Yang, 3595
Yu Yinhua, 443
Yuan B, 4169
Yuan Z, 303
Yui R, 3827
Yumita N, 501
Yun SH, 3843
Yung B, 1521
Yunos NM, 1131, 4283
Zabernigg A, 4439
Zacherl J, 2379
Zago MA, 2173
Zagouri F, 2373
Zahm J, 4025
Zanella S, 693, 3969
Zang C, 2713
Zapala MA, 2303
Zaytseva YY, 813, 1153
Zebisch M, 2008
Zeidler R, 3315
Zeillinger R, 2259
Zeindl-Eberhart E, 849
Zeleniuch-Jacquotte A, 4401
Zelger B, 2949
Zembala M, 1329
Zergebel C, 625
Zerini D, 1869
Zervou M, 807
Zhan S, 3433
Zhang B, 4267
Zhang C, 1
Zhang Haijun, 3945
Zhang Haitian, 797
Zhang Hui, 443
Zhang Jinkun, 2303
Zhang JJ, 4267
Zhang Jun, 3595
Zhang LJ, 4127
Zhang N, 3125
Zhang P, 3229
Zhang R, 39
Zhang S, 3259
Zhang T, 3859
Zhang W, 3423
Zhang Xiaodong, 797
Zhang Xiulian, 1259, 2059, 2103
Zhang Y, 3129
Zhang Zhaoxia, 2683
Zhang Zhen, 2141
Zhang ZY, 4127
Zhao C, 1
Zhao Han, 1321
Zhao Huajun, 789
Zhao M, 1279
Zhao ZR, 4127
Zheng J, 2739
Zheng JI, 39
Zheng L, 3595
Zheng X, 687
Zhi X, 1271
Zhong S, 481, 1659
Zhong XY, 2623, 4267
Zhong Yin, 4099
Zhong Yuhua, 3433
Zhou H, 3129
Zhou J, 4099
Zhu J, 771, 1521
Zhu Z-P, 3739
Zimmermann AP, 3959
Zimmermann T, 2797
Zimnoch L, 843
Zittermann A 1503
Zografos G, 2373
Zorzetto M, 3927
Zuegel U, 4091
Zugor V, 2009, 2010, 2011
Zupa A, 1359
Zustin J, 591
Zweifel M, 3115
Zwirner M, 2011
Zwolak P, 1181

Errata

Volume 30, No. 9, page 3817:
The Authors' names should read:

GRAZIA ARTIOLI[1], SIMONE MOCELLIN[2], LUCIA BORGATO[1], ALESSANDRO CAPPETTA[1]
FERNANDO BOZZA[3], GIORGIO ZAVAGNO[2], STEFANIA ZOVATO[1],
ALBERTO MARCHET[2] and DAVIDE PASTORELLI[1]

Volume 30, No. 7, page 3015:
The name of the last Author should read:

ANDREW C. WOTHERSPOON

Volume 31, No. 5, page 1857:
The Authors' names of Abstract No 90 should read:

Costanza Chiumento, Alba Fiorentino, Anna Maria Mileo,
Rocchina Caivano, Mariella Cozzolino, Piernicola Pedicini
and Vincenzo Fusco

Volume 30, No. 5, page 1727:
The name of the second Author should read:

MANUEL TODOROVIC[2]

Volume 31, No. 6, page 2303:
The affiliation of the first Author, Dr. Wen Luo, should read:

[1]*Biomarker Discovery Service, Ligand Pharmaceuticals, San Diego, CA, U.S.A.;*

Volume 31, No. 7, page 2553:
The name of the third Author should read:

TATSUYA FUKAMI[1]

Volume 31, No. 9, page 2940, right column:
Lines 18-27 should read:

following cut-off points: 0-13.6 ng/ml; 13.7-20.9 ng/ml; 21.0-25.8 ng/ml; 25.9-32.9 ng/ml and ≥33 ng/ml. Odds ratios were then calculated for the association between each quintile of serum 25(OH)D and risk of breast cancer (39). Since raw cell frequencies were used from each study, the odds ratios calculated for the dose–response analysis were unadjusted for potential confounders. The medians of the quintiles were: 10, 16, 23, 31 and 38 ng/ml. The lowest quintile was used as the reference group. Confidence intervals were calculated using the method of Woolf, as for the Forest plots (36, 37).

Volume 31, No. 9, page 2975:
The name of the third Author should read:

JUDAH AL-MAGHRABI[3]

Volume 31, No. 9, page 3007, right column, lines 3, 5; and
page 3008, Patients and Methods: lines 31, 34:

The dose of bevacizumab should be 10 or 15 mg/kg (instead of μg/kg).

Volume 30 (2010), No. 6, page 1999, right column, line 27 should read:

identified a peptide of 22 amino acids, named GA3, which

Volume 30 (2010), No. 6, page 2000, Materials and Methods: first line should read:

Reagents. GA3 (WTIIQRREDGSVDFQRTWKEYK) was synthesized

Instructions to Authors

General Policy. ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts and Proceedings of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer, and (d) Announcements of awards and prizes.

The principal aim of AR is to provide for the prompt publication of original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works on the cancer problem that are not under consideration for publication by another journal, and that they will not be published again in the same form. All material submitted to AR will be subject to review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrantee due diligence in the creation and issuance of their work.

NIH Open Access Policy. The journal acknowledges that authors of NIH funded research retain the right to provide a copy of the final manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

Copyright. Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has passed from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without written consent of the Managing Editor Publisher.

Format. Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) short papers. Additionally, the Editors may invite review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the "Shorter Oxford English Dictionary".

Manuscripts. Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double - spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding four printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections:
(a) First page including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication "clinical", "epidemiological", or "experimental" study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) Abstract not exceeding 150 words, organized according to the following headings: Background/Aim - Materials and Methods/Patients and Methods - Results - Conclusion; (c) Introduction; (d) Materials and Methods/Patients and Methods; (e) Results; (f) Discussion; (g) Acknowledgements; (h) References. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

Figures. All figures (whether photographs or graphs) should be clear, high contrast, glossy prints of the size they are to appear in the journal: 8.00 cm (3.15 in.) wide for a single column; 17.00 cm (6.70 in.) for a double column; maximum height: 20.00 cm (7.87 in.). Graphs must be submitted as photographs made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated on the reverse side. Original karyotypes and photographs should be provided wherever possible, and not photographic copies. Colour plates are charged.

Tables. Tables should be typed double-spaced on a separate page, numbered with Roman numerals and should include a short title.

Nomenclature and Abbreviations. Nomenclature should follow that given in "Chemical Abstracts". Standard abbreviations will be preferable. If a new abbreviation is used, it must be defined at its first usage.

References. Citations for the reference sections of submitted works should follow the standard form of "Index Medicus" and must be numbered consecutively. In the text, references should be cited by number. Examples: 1 Sumner AT: The nature of chromosome bands and their significance for cancer research. Anticancer Res 1: 205-216, 1981. 2 McGuire WL and Chamnes GC: Studies on the oestrogen receptor in breast cancer. In: Receptors for Reproductive Hormones (O' Malley BW, Chamnes GC (eds.). New York, Plenum Publ Corp., pp 113-136, 1973.

Nomenclature and Abbreviations. Nomenclature should follow that given in "Chemical Abstracts", "Index Medicus", "Merck Index", "IUPAC –IUB", "Bergey's Manual of Determinative Bacteriology", The CBE Manual for Authors, Editors and Publishers (6th edition, 1994), and MIAME Standard for Microarray Data. Human gene symbols may be obtained from the HUGO Gene Nomenclature Committee (HGNC) (http://www.gene.ucl.ac.uk/). Approved mouse nomenclature may be obtained from http://www.informatics.jax.org/. Standard abbreviations are preferable. If a new abbreviation is used, it must be defined on first usage.

Clinical Trials. Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text. For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by "ISRCTN"). Please note that there is no space between the prefix "ISRCTN" and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by 'NCT'). Please note that there is no space between the prefix 'NCT' and the number. Example: NCT00001789.

Ethical Policies and Standards. CGP agrees with and follows the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals" established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 (www.icmje.org). Microarray data analysis should comply with the "Minimum Information About Microarray Experiments (MIAME) standard". Specific guidelines are provided at the "Microarray Gene Expression Data Society" (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human foetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

Submission of Manuscripts. Please follow the Instructions to Authors regarding the format of your manuscript and references. There are 3 ways to submit your article (NOTE: Please use only one of the 3 options. Do not send your article twice.):

1. To submit your article online please visit: IIAR-Submissions (http://www.iiar-anticancer.org/submissions/login.php)
2. You can send your article via e-mail to journals@iiar-anticancer.org. Please remember to always indicate the name of the journal you wish to submit your paper. The text should be sent as a Word document (*doc) attachment. Tables, figures and cover letter can also be sent as e-mail attachments.
3. You can send the manuscript of your article via regular mail in a USB stick, DVD, CD or floppy disk (including text, tables and figures) together with three hard copies to the following address:
   John G. Delinassios
   International Institute of Anticancer Research (IIAR)
   Editorial Office of ANTICANCER RESEARCH,
   IN VIVO, CANCER GENOMICS and PROTEOMICS.
   1st km Kapandritiou-Kalamou Road
   P.O. Box 22, GR-19014 Kapandriti, Attiki
   GREECE

Submitted articles will not be returned to Authors upon rejection.

Galley Proofs. Unless otherwise indicated, galley proofs will be sent to the first-named Author of the submission. Corrections of galley proofs should be limited to typographical errors.

Reprints. Twenty-five copies of each communication will be provided free-of-charge. Additional copies, PDF files, or/and Open Access may be ordered after the acceptance of the paper. Requests should be addressed to the Editorial Office.

Copyright© 2012 - International Institute of Anticancer Research (J.G. Delinassios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitter in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.

Editorial Staff
Managing Editor and Executive Publisher: J.G. DELINASSIOS, Athens, Greece

Assistant Managing Editor: S. AZOUDIS

Production Editor: E. ILIADIS, Athens, Greece

Editorial Office
International Institute of Anticancer Research,
1st km Kapandritiou-Kalamou Rd.,
Kapandriti, P.O.Box 22, Attiki 19014, Greece
Tel and Fax: +30-22950-53389

Please visit the IIAR websites: www.iiar-anticancer.org; www.iiarjournals.org

e-mails:
Editor: editor@iiar-anticancer.org; Journals: journals@iiar-anticancer.org; IIAR: iiar@iiar-anticancer.org

Publication Data: ANTICANCER RESEARCH (AR) is published monthly. Each annual volume contains twelve issues and index.

Copyright: Once a manuscript has been published in AR, which is a copyrighted publication, the legal ownership of all published parts of the paper passes from the Author to the Journal.

ANTICANCER RESEARCH is available in print (ISSN: 0250-7005) and online (ISSN: 1791-7530) through Stanford University's HighWire Press with access to full text/PDF articles from all previous volumes since January 1st, 2004. For online/print subscription rates, please visit the IIAR websites: www.iiar-anticancer.org; www.ar.iiarjournals.org

Annual Subscription Rates 2012: Institutional subscription online: Euro 1,650.00. Institutional subscription print: Euro 1,670.00. Institutional subscription online & print: Euro 1,700.00. Personal subscription online: Euro 780.00. Personal subscription print: Euro 800.00. Personal subscription online & print: Euro 830.00. Prices include rapid delivery and insurance. Previous volumes of Anticancer Research (Vol. 1-31, 1981-2011) are available at 50% discount on the above rates.

Subscription Orders: Orders can be placed at agencies, bookstores, or directly with the publisher. Cheques should be made payable to J.G. Delinassios, Executive Publisher of Anticancer Research, Athens, Greece and should be sent to the Editorial Office.

Correspondence: (subscription orders, reprint orders, change of address, disposition of submitted manuscripts, advertising rates requests, and general editorial matters) should be directed to Dr. J.G. Delinassios, Executive Publisher and Managing Editor, Editorial Office.

Advertising: Correspondence and rate requests should be addressed to the Editorial Office.

Book Reviews: Recently published books and journals should be sent to the Editorial Office. Reviews will be published within 2-4 months.

Articles in ANTICANCER RESEARCH are regularly indexed in all bibliographic services, including *Current Contents (Life Sciences), Science Citation Index, Index Medicus, Biological Abstracts, PubMed, Chemical Abstracts, Excerpta Medica, University of Sheffield Biomedical Information Service, Current Clinical Cancer, AIDS Abstracts, Elsevier Bibliographic Database, EMBASE, Compendex, GEOBASE, EMBiology, Elsevier BIOBASE, FLUIDEX, World Textiles, Scopus, Progress in Palliative Care, Cambridge Scientific Abstracts, Cancergram (International Cancer Research Data Bank), MEDLINE, Reference Update - RIS Inc., PASCAL-CNRS, Inpharma-Reactions (Datastar, BRS), CABS, Immunology Abstracts, Telegen Abstracts, Genetics Abstracts, Nutrition Research Newsletter, Dairy Science Abstracts, Current Titles in Dentistry, Inpharma Weekly, BioBase, MedBase, CAB Abstracts/Global Health Databases, Investigational Drugs Database, VINITI Abstracts Journal, Leeds Medical Information, PubsHub, Sociedad Iberoamericana de Información Cientifica (SIIC) Databases*.

Authorization to photocopy items for internal or personal use, or the internal or personal clients, is granted by ANTICANCER RESEARCH, provided that the base fee of $2.00 per copy, plus 0.40 per page is paid directly to Copyright Clearance Center, 27 Congress Street, Salem, MA 01970, USA. For those organizations that have been granted a photocopy license by CCC, a separate system of payment has been arranged. The fee code for users of the Transactional Reporting Service is 0250-7005/2010 $2.00 +0.40.

The Editors and Publishers of the journal ANTICANCER RESEARCH accept no responsibility for the opinions expressed by the contributors or for the content of the advertisements appearing herein.

Editorial Office
International Institute of Anticancer Research,
1st km Kapandritiou-Kalamou Rd.,
Kapandriti, P.O.Box 22, Attiki 19014, Greece
Tel and Fax: +30-22950-53389

PHOTOCOMPOSITION BY IIAR
PRINTED BY ENTYPO, GREECE
PRINTED ON ACID-FREE PAPER